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Abstract
Chapter 1. The Synthetic Chemistry of Platinum Anticancer Agents
Since the inception of cisplatin as a clinically approved anticancer agent, a large number of
platinum compounds have been synthesized with the aim of finding new, improved drugs. As a
result of these efforts, only two additional platinum-based drugs received FDA approval for the
treatment of cancer. Nevertheless, fundamental advancements in the synthetic chemistry of
platinum arose from these research endeavors. This chapter presents a comprehensive review of
synthetic methods for the preparation of classic and non-conventional platinum compounds with
therapeutic potential.
Chapter 2. Platinum(II) Complexes Bearing Fluorescent Di-2-Pyridylmethane Ligands
A strategy to investigate the cellular uptake and localization of platinum anticancer agents is to
label them with a fluorescent ligand. In pursuit of this strategy, three new platinum(II) complexes
with modified di-2-pyridylmethane (dpm) ligands, two of which are fluorescent, were prepared.
These new ligands contain either a non-fluorescent tosyl group (Ts-dpm) or fluorescent NBD or
dansyl group (NBD-dpm and dansyl-dpm). The photophysical and solution conformational
properties of the complexes [Pt(dpm')C12], where dpm' is one of the three ligands described
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above, are presented. The thermal and photolytic decomposition products and the hydrogen
peroxide oxidation products were investigated.
Chapter 3. Outer-Sphere Amide Bond Coupling Reactions for the Preparation of a
Fluorescent Platinum(IV) Redox Sensor
Because of the poor solubility, stability, and lack of structural similarity to clinically used
platinum anticancer agents of the complexes described in Chapter 2, synthetic strategies were
devised to prepare alternative fluorescent platinum compounds. The dangling carboxylic acid
groups of the platinum(II) complexes [Pt(edma)C 2] and [Pt(edda)C12], where edma =
ethylenediamine-N-acetic acid and edda = ethylenediamine-N,N'-diacetic acid, were
functionalized by amide bond coupling using benzyl amine. For [Pt(edda)C12], the resulting
product was a mixture of diastereomers owing to chirality at both coordinating nitrogen atoms.
Only [Pt(edma)C12] was further modified by coupling it to dansyl ethylenediamine to form
[Pt(edDS)C12], where edDs is the dansyl ethylenediamine-containing ligand. Upon oxidation of
this complex with iodobenzene dichloride, the emission of the dansyl fluorophore was
substantially quenched. By reducing the oxidized product [Pt(edDs)C14] with an excess of the
biological reducing agents glutathione, cysteine, and ascorbic acid in aqueous buffer, a 6.3-fold
turn-on in emission intensity was observed. This turn-on response suggests that [Pt(edDs)C14]
and its anologues may serve as fluorescent redox sensors to monitor the reduction of
platinum(IV) in living cells.
Chapter 4. In Vitro Anticancer Activity of Platinum(II) Complexes with p-Diketonate
Leaving Group Ligands
To investigate the role of the leaving group ligand on the anticancer activity of platinum(II)
complexes, five compounds with the general formula [Pt(NH3)2(p-diketonate)]* were prepared
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and characterized. The p-diketonate ligands were chosen to tune the lipophilicity and
electrophilicity of the resulting complexes. Three general synthetic protocols for preparing such
complexes were established. These compounds were tested for anticancer activity in a panel of
four different cell lines. Structure-activity relationships were derived, correlating high
cytotoxicity with increasing lipophilicity and decreasing donor strength of the p-diketonate.
Chapter 5. Acetate-Bridged Dinuclear Platinum(III) Complexes Derived from Cisplatin
The oxidation chemistry of a previously reported acetate-bridged dinuclear cis-
diammineplatinum(II) complex, cis-[Pt"(NH 3)2(p-OAc) 2Pt"(NH 3)2](NO 3)2, was explored.
Treatment of this complex with either PhICl2 or Br2 afforded the 2-electron oxidized halide-
capped dinuclear complexes, cis-[XPt"I(NH 3)2(t-OAc) 2Ptl"(NH3)2X](NO3)2, where X is either
bromine or chlorine. The platinum(II) and platinum(III) complexes were fully characterized by
X-ray crystallography and multinuclear NMR spectroscopy. The oxidation of cis-[Ptr(NH3)2(pt-
OAc) 2Pt"(NH 3)2](NO 3)2 with PhI(O2CCF3)2 and XeF2 was also explored. The use of
PhI(O2 CCF3 )2 gave the unexpected amido-bridged tetranuclear platinum(III) complex, cis-
[(O 2CCF3)Pt"'(NH3)2(pi-OAc) 2Pt1 (NH 3)(pt-NH 2)] 2(NO3)4, which was characterized structurally
by X-ray crystallography. From the analogous reaction using XeF2 instead of PhI(O 2 CCF3 )2 ,
yellow crystals were obtained, and the crystal structure revealed an infinite chain of acetate-
bridged dinuclear platinum units.
Chapter 6. Synthesis, Characterization, and Cytotoxicity of Platinum(IV) Dicarbamate
Complexes
The reaction of cis,cis,trans-[Pt(NH3)2Cl2(OH)2] with alkyl and aryl isocyanates (RNCO) in
DMF afforded dicarbamate complexes of the general formula cis,cis,trans-
[Pt(NH 3)2Cl 2(O 2CNHR)2]. The resulting complexes were fully characterized by X-ray
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crystallography, multinuclear NMR spectroscopy, and cyclic voltammetry. The anticancer
activities of these complexes were assessed in human lung cancer (A549) and human lung
fibroblast (MRC-5) cell lines. Although no clear structure-activity relationships could be
delineated, the complexes exhibited activity on the same order of magnitude as that of the
clinically established drug cisplatin. Therefore, the reaction of cis,cis,trans-[Pt(NH3)2Cl 2(OH)2]
with isocyanates provides a powerful new synthetic pathway to functionalize platinum(IV)
anticancer agents.
Appendix A. Aqueous Electrochemistry of a Platinum(IV) Prodrug
Electrochemical studies of cis,cis,trans-[Pt(NH3)2Cl2(OAc) 2] in aqueous media were carried out.
Cyclic voltammetry in pH 7.4 phosphate-buffered saline with glassy carbon and Pt disk working
electrodes gave substantially different peak potentials for the irreversible reduction feature.
Under these conditions, the glassy carbon electrode was plated with platinum metal derived from
the platinum(IV) complex, as determined by cyclic voltammetry and chronoamperometry
experiments. The bulk electrolysis of cis,cis,trans-[Pt(NH3)2Cl2(OAc)2] in aqueous solution at a
carbon felt working electrode was investigated by 1H NMR spectroscopy. These studies indicate
ligand loss upon reduction from both axial and equatorial sites of the platinum(IV) complex.
Appendix B. Targeting the Mitochondria with Platinum Anticancer Agents using
Mitochondria-Penetrating Peptides
Early results of a collaborative effort with the lab of Professor Shana 0. Kelley at the University
of Toronto to deliver platinum anticancer agents to the mitochondria are presented.
Succinylacetone (Hsuccac) was used as a leaving group ligand for a cis-diammineplatinum(II)
complex. The complex [Pt(succac)(NH 3)2 ](NO3), which contains a terminal, uncoordinated
carboxylic acid functional group, was prepared and fully characterized. This complex was
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conjugated to a mitochondria-penetrating peptide (MPP) using standard solid-phase coupling
chemistry. The anticancer activity of the Pt-MPP construct was tested in both wild-type and
cisplatin-resistant ovarian cancer cell lines, A2780 and A2780CP70. Although less potent than
cisplatin, the construct is equally toxic to both cell lines, thereby indicating that targeting the
mitochondria provides a viable strategy for circumventing resistance to platinum drugs.
Appendix C. Synthesis and Characterization of Several Novel Platinum Complexes
Throughout the course of this thesis work, several platinum complexes were synthesized and
characterized, but ultimately not fully pursued as potential anticancer agents. These species
include platinum compounds with dichloroacetate, 2,2'-bis(1-
methylimidazolyl)phenylmethoxymethane (BIPhMe), nitrogen mustard-containing, and
nitroimidazole-derivatized ligands. The syntheses and characterization of these compounds are
reported. Crystal structures are described for several of them.
Thesis Supervisor: Stephen J. Lippard
Title: Arthur Amos Noyes Professor of Chemistry
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Preface
Medicinal chemistry has long been the domain of the organic chemist. The seminal
discovery by Barnett Rosenberg in 1969 that cis-diamminedichloroplatinum(II), or cisplatin,
inhibits tumor growth in mice demonstrated the utility of metal compounds in medicine and
inspired subsequent generations of inorganic chemists to investigate medicinal applications of
their field. Several factors have contributed to the dominance of organic molecules in medicine.
One is the concern held by general public of toxicity associated with heavy metal ions, given
experience with mercury and lead, for example. Research has shown that the careful choice of
ligands can ameliorate toxic side effects of many metal ions. Another factor is the lack of general
synthetic methodologies for rationally preparing new metal complexes. Libraries of compounds
with minor structural differences are often necessary for medicinal chemistry studies where such
variations can have profound effects on the biological activity of a compound. Whereas hundreds
of reactions are at the disposal of an organic chemist for preparing a compound library, the
inorganic chemist is essentially limited to ligand substitution and redox reactions. A unifying
theme of the work in this thesis is the invention of general synthetic routes to anticancer platinum
drug candidates through variations of classical ligand substitution and redox strategies.
In Chapter 1 appears a comprehensive review of the different synthetic protocols for
preparing platinum complexes with known anticancer activity. This chapter classifies the
different types of ligands that have successfully been used in platinum anticancer complexes.
These ligands can be categorized as the leaving groups, non-leaving groups, and axial. The
leaving group ligands, typically halides or carboxylates, are those that are displaced from the
platinum coordination sphere and ultimately substituted by DNA, the biological target of
cisplatin and its analogues. The non-leaving group ligands, usually amines or N-heterocycles, are
those that remain within the platinum coordination sphere after binding to DNA. Axial ligands
are present only in octahedral complexes of platinum in the +3 or +4 oxidation state and are
situated orthogonal to the coordination plane composed of leaving and non-leaving group
ligands. As described below, the work in this thesis covers variations of all three ligand types.
Chapters 2 and 3 report platinum(II) complexes with modified non-leaving group ligands
containing fluorescent labels. In Chapter 2, variants of the di-2-pyridylmethane ligand were
prepared and purified using standard organic chemistry methodologies prior to coordination to
dichloroplatinum(II) centers. In contrast, the chemistry described in Chapter 3 allows for
modifications of the non-leaving group ligand while it remains coordinated to the platinum(II)
center. The platinum(II) complexes [Pt(edda)C 2] and [Pt(edma)C12], where edda = N,N'-
ethylenediamine diacetic acid and edma = N-ethylenediamine monoacetic acid, which both
contain free carboxylic acid groups, could be readily functionalized by amide bond coupling
chemistry. The utility of this method was demonstrated by attaching a dansyl fluorophore to a
platinum complex. An interesting feature of the dansylated platinum complex was that the
emission of the fluorophore was modulated by the oxidation state of the platinum center. The
straightforward and predictable amide coupling chemistry employed here enables the preparation
of a large number of variants, which may exhibit improved biological properties and be useful as
mechanistic probes.
Chapter 4 describes how modifications of the leaving group ligands of platinum(II)
anticancer complexes affect their biological activities. In particular, P-diketonates were selected
as leaving group ligands. Three different synthetic protocols for the preparation of cis-
diammine(p-diketonato)platinum(II) complexes are reported. The protocols were optimized to
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accommodate different solubilities of the resulting platinum complexes and the p-diketonate
ligands. The p-diketonates were selected because most are commercially available and contain
functional groups with different lipophilicities and electron-withdrawing properties. Structure-
activity relationships discovered here indicate that both properties are important in determining
the anticancer efficacy of the resulting cis-diammine(p-diketonato)platinum(II) complexes.
In the final two chapters, modifications of axial ligands in higher-valent platinum
complexes are investigated. Dinuclear platinum(III) compounds with metal-metal bonds are the
focus of Chapter 5. Because of the limited stability of these complexes to reducing agents, this
chapter primarily explores synthetic inorganic chemistry. It may be desirable, however, to use
dinuclear platinum(III) compounds as anticancer agents if they could be sufficiently stabilized to
tolerate biological conditions. Chapter 6 investigates an under-explored reactivity pathway for
the preparation of kinetically stable platinum(IV) complexes. In particular, the reaction of
cis,cis,trans-[Pt(NH3)2Cl2(OH)2] with aryl and alkyl isocyanates was investigated. The
nucleophilic hydroxo ligand of cis,cis,trans-[Pt(NH3)2Cl2(OH)2] readily attacks the electrophilic
isocyanates, forming stable platinum(IV) dicarbamates. As demonstrated in this chapter, such
compounds are cytotoxic. Therefore, this facile chemistry can be used to prepared a large
number of derivatives and attach platinum(IV) to various delivery or targeting devices via
carbamate linkages.
Appendices A, B, and C report the results of tangential work. Appendix A reports the
aqueous electrochemistry of a common platinum(IV) prodrug. Appendix B describes synthetic
methodologies for attaching peptides to leaving group ligands of platinum(II) complexes.
Appendix C contains synthetic protocols for and characterization of some miscellaneous
platinum complexes prepared during the course of this thesis, but not otherwise thoroughly
investigated.
Cisplatin has been in clinical use for over 40 years. During that period, many aspects
regarding its mechanism of action have been determined. New effective platinum-based drugs
should be optimized for increased cellular uptake, tumor selectivity, and transcription inhibitory
properties. The lack of chemical methods to prepare such constructs, however, is often a limiting
factor in the process of platinum-based drug development, despite the long history of platinum
coordination chemistry. The research presented in this thesis details several new and general
synthetic protocols for synthesizing a wide range of platinum compounds. As new synthetic
methodologies for platinum coordination compounds are unveiled, novel platinum anticancer
drug candidates with enhanced properties become available with the ultimate goal of improving
the treatment of patients and saving lives.
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Chapter 1
The Synthetic Chemistry of Platinum Anticancer Agents
26
1.1. Introduction
The demonstration in the 1960's that cis-diamminedichloroplatinum(II), or cisplatin,
inhibits cellular division of E. coli' led to the subsequent discovery that this simple coordination
compound is also an effective antitumor agent in mouse models.2 Continuing studies validated
cisplatin as an effective anticancer agent in humans as well,3 7 and FDA approval of cisplatin for
the treatment of metastatic ovarian and testicular cancers was granted in 1978.8 Its inception as a
chemotherapeutic agent significantly improved the survival outlook for many cancer patients; the
cure rate for testicular cancer before the approval of cisplatin was less than 10%, significantly
lower than the 90% cure rate attained with modem platinum chemotherapy.9"10
Cisplatin kills cancer cells primarily by cross-linking DNA and inhibiting transcription."
The chemical origin of this process begins when cisplatin enters the cell and undergoes an
aquation reaction via loss of one or both chloride ligands. The resulting platinum(II) aqua
complexes are potent electrophiles that readily react with a number of biological ligands with
loss of the bound water molecules. The purine bases of nucleic acids are strongly nucleophilic at
the N7 position. Thus, cisplatin binds readily to DNA, forming primarily bifunctional adducts
with loss of both chloride ligands. The major cisplatin-DNA adduct is the intrastrand 1,2-d(GpG)
lesion, which accounts for 60-65% of the bound platinum.12 The resulting Pt-DNA adducts,
which distort and bend the DNA structure,13- 5 impede transcription.16 The downstream effects of
transcription inhibition ultimately lead to cell death.
Despite its great curative success in testicular cancer, cisplatin is not universally effective
in other cancer types and induces a number of toxic side effects. 17-19 Additionally, certain cancers
are resistant to cisplatin therapy. This resistance is either intrinsic or developed during prolonged
treatment.20,21 To circumvent these problems, new platinum complexes have been pursued and
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investigated for their antitumor properties. Although well over a thousand complexes have been
prepared and tested thus far,2 only two other platinum drugs are approved for clinical use
worldwide, and three additional compounds are approved for regional use in Asia. These
complexes, displayed in Chart 1.1, operate with a mechanism of action similar to that of
cisplatin, which involves DNA binding and transcription inhibition.
o H 2
H3N CI H3N 0 N 0
Pt Pt Pt
H3N CI H3N 0 '"'" N O \0II O
o H 2
cisplatin carboplatin oxaliplatin
o CH3
H3N \0O O /.., NH 2 / NI 2 O
Pt Pt Pt
H3N 0 O NH 2 O NH2 00 o 0
nedaplatin heptaplatin lobaplatin
Chart 1.1. Chemical structures of the clinically used platinum-based anticancer drugs. The top
three complexes, cisplatin, carboplatin, and oxaliplatin, are approved for use worldwide. The
bottom three complexes, nedaplatin, heptaplatin, and lobaplatin, are approved for use in Japan,
Korea, and China, respectively.
In designing a new platinum anticancer agent, several structural features can be
strategically modified. As shown in Figure 1.1, three different ligand types generally comprise a
platinum anticancer complex. The non-leaving group ligands are typically nitrogen donors.
These are referred to as "non-leaving group" ligands because they form thermodynamically
stable bonds with platinum and are retained in the final platinum-DNA adduct. Modifications of
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these ligands directly affect the nature of the resulting platinum-DNA adducts24-26 and,
accordingly, the manner by which cellular repair pathways respond to those adducts. Complexes
that contain amine ligands different from those of cisplatin usually exhibit different spectra of
activity in cancer cell lines and are usually not cross-resistant with cisplatin.2 7 Oxaliplatin, with
its chelating and chiral diamine ligand trans-1R,2R-DACH (DACH = diaminocyclohexane), for
example, fits into this category. Modifications of the leaving group ligands, so named because
they are lost upon DNA-binding, can alter the overall reaction and aquation kinetics for a
platinum anticancer complex. Complexes that react quickly, such as those with labile nitrate
ligands, are generally more toxic because of their indiscriminate binding to off-target biological
nucleophiles.2 8 Carboplatin, on the other hand, contains a relatively stable chelating CBDCA
(CBDCA = 1,1-cyclobutanedicarboxylato) ligand as its leaving group. By comparison to
cisplatin, carboplatin can be administered at higher doses because of its lower toxicity
profile.2 9 ,30 Although less toxic, carboplatin has a similar spectrum of activity and exhibits cross-
resistance to cisplatin, which is a result of the same non-leaving group ammine ligands.2 7 ,11 A
third ligand category comprises the axial ligands. Axial ligands are present only in higher valent
platinum complexes, such as those of platinum(III) and platinum(IV). These ligands are
ultimately lost after biological reduction of the platinum complex and provide convenient points
for installation of tumor-targeting moieties or nanoparticle attachement units. Any of the three
ligand types can be modified in order to alter the lipophilicity and water solubility of the
resulting platinum complex. Both of these properties are important for the design of an effective
drug. The stereochemistry and the number of each respective ligand type can be altered as well.
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Non-Leaving Leaving Group
Group Ligands R Ligands
reaction kinetics
-nature of Pt-DNA adduct -Li - toxicity profile
resistance profile Pt lipophilicity
lipophilicity - Solubilitv
solubility
R
Axial Ligands
only present for Pt(IV)
additional targeting or biological properties
- lipophilicity
- solubility
Figure 1.1. Different components of platinum anticancer agents. Additional factors that can be
varied are the stereochemistry and the respective number of non-leaving and leaving group
ligands.
In this chapter, an overview of known synthetic strategies for making platinum anticancer
complexes is presented. Previous review articles have focused on the mechanistic details of
platinum-based drugs at the cellular level,32-37 the chemistry of platinum under biological
conditions,38,39 and new trends for the rational design of platinum anticancer agents.40 ~46 This
chapter provides a summary of strategies for the synthesis and purification of platinum
anticancer drug candidates, the subject that marks the main contribution of this thesis. There are
two major sections that describe, respectively, the synthesis of platinum(II) and platinum(IV)
complexes. These sections are further divided based on the nature and stereochemistry of the
target complexes. In each section, a short overview is provided of the anticancer properties of
these target complexes. Multinuclear platinum complexes, some of which are very good drug
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candidates, 4 7' 48 have been omitted from this review to focus on single-site reactivity. The
reaction schemes do not depict fully balanced chemical reactions, but rather show only the major
platinum-containing products. Two generic ligand types, L and X, are utilized, with ligands
symbolized by "L" representing either amine or N-heterocycle ligands. When "(L2)" is used, the
ligand is bidentate. Ligands depicted with "X" are monoanionic like halides or carboxylates.
1.2. Synthesis of Platinum(II) Complexes
All clinically used platinum drugs (Chart 1.1) contain this element in the +2 oxidation
state where square-planar coordination geometries are almost exclusively observed. The major
reaction pathways for platinum(II) and other square-planar d8 complexes involve associative
ligand substitution. These reactions proceed through five-coordinate trigonal bipyramidal
intermediates. The stereochemistry of the resulting products is dictated by the relative trans
effect of the ligands within the complex. Synthetic strategies discussed in the following sections,
therefore, rely heavily on the trans effect principle. For more detailed summaries of substitution
reactions of platinum(II) and other d8 complexes, as well as the trans effect, the reader is referred
elsewhere.4 9-51 An early review on the synthesis of monodentate amine complexes of
platinum(II) is also available.52
Synthesis of cis- and trans-[PtL2X2 ] Complexes. Cis- and transplatin, trans-
diamminedichloroplatinum(II), the trans stereoisomer of cisplatin, are representative members of
the class of complexes having the general formula, cis- and trans-[PtL2X2] where L is an
am(m)ine or N-heterocycle and X is a halide or other labile ligand. Both cis- and transplatin were
first prepared over 100 years ago by Peyrone and Reiset, respectively, 53,5 4 and were commonly
known as Peyrone's chloride and Reiset's second chloride. Cisplatin and transplatin, both yellow
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solids, were recognized to be isomers of Magnus' green salt, [Pt(NH 3)4][PtCl 4]. The structural
differences between these three species helped validate Werner's theory of coordination
chemistry.5 5
Since Peyrone's initial preparation of cisplatin, several different synthetic routes have
been described. The common starting material for these procedures is K2 [PtCl4], a water-soluble
salt, which can be prepared directly from platinum metal in two steps.56 As with Peyrone's initial
synthesis, several protocols for the synthesis of cisplatin involve the direct action of aqueous
ammonia on the tetrachloroplatinate ion. 57' 58 This reaction results inevitably in the formation of
Magnus' green salt and the trans isomer as undesired byproducts, which both must be removed
by additional purification steps.57' 58 Recently, the use of microwave irradiation for the synthesis
of cisplatin directly from K2PtCl4 and NH4OAc was reported. 59 The adaptation of this method
with flow chemistry techniques enables cisplatin to be synthesized on the gram scale in one step
with no impurities from Magnus' salt or transplatin.
The most widely used method for preparing cisplatin is that reported by Dhara in 1970.60
For this multistep reaction (Scheme 1.1), aqueous [PtCl 4 ]2- is first converted to [PtI4]2- upon
treatment with 4 equiv of KI. The addition of ammonium hydroxide to the dark brown solution
of [PtI]2- yields the yellow precipitate, cis-[Pt(NH 3)212]. The removal of the iodide ligands of
this complex with 2 equiv of AgNO 3 in water gives the diaqua cation, cis-[Pt(NH 3)2(OH 2)2]2 4 ,
from which isomerically pure cisplatin can be isolated as a yellow solid following treatment with
excess chloride ion. The absence of the trans isomer is attributed to the high trans effect of the
iodide compared to that of the chloride ligand. The key intermediate in the formation of cisplatin
from the tetrahaloplatinate ions is the monosubstituted complex, [Pt(NH 3)X 3] . When X is I, the
large trans effect ensures that the next NH 3 ligand substitutes trans to an iodide to give the
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desired cis isomer. When X is Cl, the lower trans effect of this ligand renders substitution trans
to NH3 kinetically competitive with substitution trans to chloride, thus yielding a small amount
of the trans isomer. This method has been adapted to prepare cis complexes with other amine or
N-heterocyclic ligands,6 1-63 cisplatin with 1N-labeled ammines, 64-66 and radiolabeled 19 smpt_
67 ceai68,69
cisplatin. When chelating diamines are used, this method is preferred as well. - In cases
where the desired amine or N-heterocyclic ligands are not water-soluble, an alternative synthetic
route involves the action of two equiv of the amine ligand on K 2 PtCl4 in a solvent mixture
comprising water and an alcohol at elevated temperatures. 70~ The use of DMF instead of
ethanol or methanol as a cosolvent for this reaction has also been reported.74
2-
Pt]
2-
+ 4KI
+ 2NH3
2-
Pt
H3N I
Pt
H3N I
H3N\ 1 1)2AgN 3  H3N Cl
x / 2) xs KCl N/
H3N I H3N Cl
Scheme 1.1. Synthesis of cisplatin using the method of Dhara. 60 All reactions
out in aqueous solution.
steps are carried
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Purification of cisplatin can be accomplished by recrystallization from hot water
containing either 0.1 M HCl or 0.9% NaC1. 6 '6 7 The high chloride concentration inhibits the
formation of platinum aqua or hydroxo complexes. The use of amide solvents to recrystallize
cisplatin is also an effective means of purification. 76 Dissolution of cisplatin in N,N-
dimethylacetamide (DMA) to a concentration of 18 mg/mL, followed by the addition of three
volume equiv of 0.1 N HCl and incubation in an ice bath, affords analytically pure compound.6 7
Alternatively, storing a concentrated solution (~22 mg/mL) of cisplatin in DMF at 3 'C
overnight yields yellow cube-like crystals of a DMF solvate, cisplatin-DMF. 7 Removal of DMF
from the crystal lattice under vacuum gives solvent-free cisplatin of very high purity.7 7 Care
should be taken when recrystallizing new complexes of the general formula, cis-[PtL2Cl2], from
hot solvents. Although not observed for cisplatin, several other complexes of this formula
isomerize upon recrystallization from hot acetone or DMF, giving instead the pure trans
isomer.78 -8 0 Thus, stereochemistry should be confirmed after each purification step.
A quick way to test for the presence of isomeric impurities in cis- and transplatin or
related [PtL2Cl2] complexes is the Kurnakow test.81 This test is carried out by adding an excess
of thiourea (tu) to an aqueous mixture of cis/trans-[Pt(NH3)2Cl2]. Transplatin transforms to the
white, water-insoluble powder, trans-[Pt(NH3)2 (tu) 2]C12, whereas cisplatin becomes the yellow,
soluble complex [Pt(tu) 4)]C12 (Scheme 1.2). The formation of different products from the two
isomers is a consequence of the high trans effect of thiourea. The first equiv of thiourea displaces
a chloride ligand. For cisplatin, this substitution places the thiourea trans to an ammine ligand,
whereas for transplatin the thiourea binds trans to a chloride. The ammine of cisplatin is
sufficiently labilized by the thiourea ligand such that it can be displaced. The ammines of
transplatin are never found trans to the thiourea ligand and therefore remain coordinated. The use
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of the Kurnakow test in conjunction with HPLC provides a powerful and sensitive method to
detect isomeric impurities. 8 2 ,83 In contrast to cis- and transplatin, the thiourea-coordinated
products exhibit significantly different retention times and contain stronger UV-vis absorbance
features, which make them amenable for HPLC analysis. NMR spectroscopy provides another
potential tool to distinguish between isomers. Unfortunately, the 195Pt NMR chemical shifts of
the cis and trans isomers are very similar. For example, 6 = -2104 ppm for cisplatin and -2101
ppm for transplatin. 84 The evaluation of 3-bond Pt-H coupling constants (3 JPtH) determined by
H NMR spectroscopy, however, revealed that these values are 8-14 Hz greater for cis isomer,85
indicating that the magnitudes of these coupling constant can be used to distinguish the two
isomers. A potential limitation to this method is the need for a low-field NMR spectrometer,
which decreases chemical-shift anisotropy effects of the 195Pt nucleus that broaden resonances
and obscure coupling.
NH2  CI
H3N CS H2N
Pt / + xs H ' t/ N2ylo
H3N PCI H2N NH2  
2N / Pt NH 2  water-soluble
cisplatin H2N )-NH2
H2N NH2 C1
H3N\/ C S H3N\ S white
C1Pt NH3 H2N NH2 -s Pt NH3 
water-insoluble
Cl N3  H2  NH2 S /NH 3
transplatin H2N -
Scheme 1.2. The use of the Kurnakow test to distinguish cis- and transplatin. Reactions with
thiourea are carried out in sub-boiling water.
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The discovery that transplatin lacks the biological activity of cisplatin influenced the
early structure-activity relationships derived for platinum-based anticancer agents. 2 8,8 6,87 in
contradiction to these structure-activity relationships, which prescribe cis geometry for activity,
it was later discovered that some trans complexes of general formula [PtCl 2L2] are cytotoxic
when L is an N-heterocycle like pyridine or thiazole.88-90 Several methods have been described
for the synthesis of these symmetric trans compounds from the [PtCl 4]2 - ion. To prepare
transplatin, excess ammonia is added to the [PtCl4]2 ~ anion to generate the complex cation,
[Pt(NH 3)4]2+. [Pt(NH 3)4]Cl2 forms colorless aqueous solutions from which transplatin can be
precipitated as a yellow solid after the addition of hydrochloric acid (Scheme 1.3).57 This
synthetic pathway also exemplifies the principles of the trans effect. After the treatment of
[Pt(NH 3)4]Cl2 with HCl, an ammine ligand is replaced by a chloride, forming [Pt(NH 3)3Cl]*. The
trans effect of chloride is greater than that of ammonia. Hence, the next incoming chloride ion
preferentially displaces the ammine trans to the coordinated chloride, selectively giving rise to
the trans isomer. This general scheme is applicable to other amine ligands and N-heterocycles as
well.90 Trans complexes can also be prepared directly from [PtL4]X 2 complexes without the use
of hydrochloric acid. Upon heating a [PtL 4]X2 as a suspension in an organic solvent or as a solid
under vacuum, the outer-sphere halides substitute the inner-sphere amine or N-heterocycle,
giving the trans isomer exclusively. 90-93 In an attempt to make trans-[PtL2Cl 2] where L is
imidazole, [PtL4]Cl 2 was treated with HCl. Instead of obtaining the expected product, trans-
[PtL2Cl 2], only platinum(IV) complexes were obtained. 61 The reaction of [PtL4]Cl 2 with excess
Et4NCl in refluxing DMF ultimately gave the desired trans complexes.6 1 Interestingly, for the
analogous complex where L is pyrazole, trans-[PtL2Cl 2] was obtained from [PtL4 ]C12 and HCl
without any reported difficulties. 94
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12- - +
ClClH 3N NH3
cl\Pt /'I + xs NH3 go 3 Pt/ H
Cl/ tCl L H3N NH3j
[ 2+
H3N \ NH 3  H3N Cl
I Pt I + xs HCl Pt
H3N NH 3J CI NH 3
Scheme 1.3. Synthesis of transplatin. 57 Reactions are carried out in water at elevated (50-100 'C)
temperatures.
As described in Section 1.1, the leaving group ligands can have profound effects on the
biological properties of the resulting platinum complexes. The importance of this behavior is
exemplified by the clinically used drugs, carboplatin and nedaplatin (Chart 1.1), which differ
from cisplatin only by the substitution of the chloride leaving groups by chelating ligands. The
chloride ligands of complexes of the general formula cis- and trans-[PtL 2Cl2], where L is an
amine or N-heterocyclic ligand, can readily be replaced by other desired ligands. A number of
different synthetic routes are available for substitution of the halides with other ligands. For the
synthesis of dicarboxylato species, these synthetic routes and their practical applications have
been reviewed in great detail." Here, we summarize these reactions schemes and reiterate some
practical aspects.
Typically, a water-soluble silver(I) salt, such as AgNO 3, is allowed to react with a
suspension of the platinum(II) complex in water. Silver chloride or iodide is formed as a white or
yellow solid, respectively, and removed by filtration. The filtrate contains the substitution-labile
complex [PtL2(OH 2)2] . The protonation state and charge on the complex cation depend on the
pH of the solution. At high pH, inert platinum(II) hydroxo compounds form. These species
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readily oligomerize to form equally unreactive multinuclear platinum(II) complexes containing
bridging hydroxide ligands.3 9 65 ,96 At slightly acidic pH, however, the aqua ligands are readily
displaced by other nucleophiles. Treatment of cis-[PtL2(OH 2)2]2+ in water with sodium salts of
anionic nucleophiles, NaNu, forms the complexes cis-[PtL2(Nu) 2] (Scheme 1.4a). This reaction
proceeds best when the resulting product is insoluble in water. The insoluble product can then be
isolated by filtration without the need to evaporate the solution to dryness. In cases where the
desired product is water soluble, contamination of the final product with NaNO 3 is a problem.97
In addition to preparing diamine dicarboxylato platinum(II) complexes, this reaction has been
used to synthesize platinum(II) diazido complexes, 98' 99 which are precursors to photoreactive
platinum(IV) prodrugs. 100 The platinum(II) dinitrato complexes, [PtL 2(ON0 2)2], can also be
prepared independently and isolated as solids. An efficient synthesis of cis-[PtL2(ON0 2)2] is
accomplished by treating cis-[PtL2I 2] with AgNO 3 in acetone.62,ioi The reaction proceeds
substantially faster in acetone compared to water. Solid cis-[PtL2(ON0 2)2] dissolves in water
with heating to form the diaqua species described above, which can then be used to install new
leaving group ligands.
An alternative reaction for preparing water-soluble complexes with modified leaving
groups utilizes a silver(I) salt of the desired new ligand. The silver(I) salts react directly with
cisplatin and related diaminedihalidoplatinum(II) complexes in water, yielding insoluble AgX as
the only byproduct (Scheme 1.4b). The resulting silver(I) halide can be removed by filtration,
leaving the soluble product to be recovered from the filtrate by evaporation of the solvent. This
strategy was employed for an optimized synthesis of radiolabeled 195mPt-carboplatin.102 In cases
where the silver(I) salt of a desired carboxylate ligand is not readily available, a one-pot strategy
can be employed, in which the diaminedihalidoplatinum(II) complex, Ag 2 CO3 , and the
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carboxylic acid are mixed together. 95 In another approach, the sulfate salt of [PtL 2(OH 2)2]2 +,
generated by the reaction of Ag2 SO 4 with [PtL2X2] in water, is used in conjunction with Ba(II)
salts of the carboxylates, usually formed in situ from Ba(OH)2, to synthesize the desired
platinum(II) carboxylate (Scheme 1.4c). 97,10 3 ,104 The byproduct of this reaction, insoluble BaSO 4,
can be easily removed by filtration. This reaction has been used to attach p-diketonatel 05 and
sulfonatel06 ligands to platinum(II). Another synthetic approach, which has not found widespread
use, requires a platinum(II) oxalate complex and the calcium salt of a ligand. The mixture of
these two species produces insoluble calcium(II) oxalate and the target complex, the latter of
which remains in solution (Scheme 1.4d). 0 6
L \ X L OH2 -H0 L Nu
(+) Pt AgNO 3  Pt + 2 NaNu ~ Pt
L/ X -2 AgX (s) L/ \OHJ -2 NaNO 3  L Nu
L X +H20 L \ N
(b) Pt + 2Ag. P/ \ -2 AgX (s) L \
L X H O L OH- H0 L Nu
(C) Pt + Ag2SO4 so Pt + Ba(Nu L)2 ~ Pt
-2 AgX (s) L/ OH - BaSO4 (s) L/ 'N
L O H0 L N
(d) Pt + Ca(N) 2  ~ . Pt
L/ O - Ca(oxalate)(s) L/ Nt
Scheme 1.4. Different synthetic routes to replace halide leaving group ligands.
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Various other interesting leaving groups have also been attached to platinum to generate
anticancer drug candidates. Platinum(II) diamine complexes with squarate, 107 selenite,107
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tellurate, 108 ascorbate, 109-111 and methyl sulfinyl carboxylate 1 2,11 3 leaving groups have been
prepared using the protocols described above. Additionally, the complex, [Pt(trans-1R,2R-
DACH)(B 20 5H2)] with a chelating borate ligand, was prepared from [Pt(trans-lR,2R-
DACH)(OH) 2] and a mixture of boric acid and tetraborate in water.1 4 These novel complexes
demonstrate the synthetic versatility of the methods described above for preparing new platinum
compounds with different leaving group ligands, some of which may have therapeutic potential.
Synthesis of cis- and trans-[PtLL'X 21, Complexes with Mixed Am(m)ine Ligands.
Platinum(II) complexes that bear two different amine or N-heterocyclic ligands have gained
importance in recent years as a new class of anticancer agents. The complexes cis-[Pt(NH 3)(2-
picoline)C12] (picoplatin) 11'16 and cis-[Pt(NH3)(cyclopentylamine)(hydroxybutanedioato)]
(cycloplatam) 17  (Chart 1.2), for example, have undergone clinical trials.23  Cis-
[Pt(NH 3)(cyclohexylamine)Cl 2] (JM-118) (Chart 1.2), an active metabolite of the clinically
investigated platinum(IV) complex satraplatin,1 ' 19 is another member of this class of
compounds. Trans platinum complexes of mixed amine or N-heterocyclic ligands are also of
importance. Some members of these "trans planar amine (TPA)" compounds with the general
formula trans-[Pt(NH 3)LX 2], where L is an N-heterocycle, exhibit potent anticancer activity and
are not cross-resistant with cisplatin. 20 Moreover, they serve as precursors for the preparation of
phototoxic platinum(IV) diazido complexes. 98,12 1
NH3
CH 3  Q N-Pt-O NH 3
N - P t- C l H0OO H
CI 0 'OH iO Cl
picoplatin cycloplatam JM-118
Chart 1.2. Structures of mixed amine platinum(II) complexes that have undergone clinical trials.
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The most obvious synthetic route to mixed amine platinum(II) complexes with cis
stereochemistry involves the use of the [PtLCl 3] anion as an intermediate. Treating this ion with
another amine or N-heterocycle, L', is expected to yield the complex cis-[PtLL'X 2]. A limitation
to this approach, however, is the difficulty in preparing am(m)inetrichloridoplatinate(II) ions.
Initial reports of the syntheses of K[Pt(NH 3)Cl 3] (Cossa's salt) appeared over a century ago.122,123
Since then, researchers have focused on finding straightforward, high yielding protocols for
obtaining this and related ions. The treatment of K 2PtCl4 with one equiv of L more readily
generates 0.5 equiv of the highly insoluble cis-[PtL2Cl 2] complex rather than the soluble salt
K[PtLC13]. An early, inefficient preparation of K[Pt(NH 3)Cl3] involved treatment of cisplatin
with hydrochloric acid in the presence of a catalytic amount of Pt metal at elevated
temperatures. 4 After removing unreacted cisplatin and Pt metal by filtration, the [Pt(NH 3)4]2 +
cation was added to precipitate the salt [Pt(NH 3)4][Pt(NH 3)Cl 3]2 . This salt was then treated with
K2PtCl4 , giving insoluble Magnus' salt, [Pt(NH 3)4][PtC4l4, and Cossa's salt, K[Pt(NH 3)Cl3], in
the filtrate. A typical yield was not reported for this method, but the large quantity of undesired
platinum-containing byproducts makes this method expensive and undesirable. The reaction was
later optimized to obtain Cossa's salt in 60% yield from cisplatin. 125 In this case, the salt was
isolated by anion-exchange chromatography and therefore did not require formation of the
platinum double salts. With careful control of temperature and reaction time, the ammonium salt
of [Pt(NH 3)Cl3] was reportedly isolated in 90% yield, similarly by the action of hydrochloric
acid on cisplatin, but in the absence of a Pt metal catalyst.12 6
An alternative, more commonly used route for the preparation of the [Pt(NH 3)Cl 3] anion
employs NN-dimethylacetamide (DMA) as the solvent.12 7 ,12 8 At high temperatures (100 C) with
a stream of nitrogen gas bubbling through the DMA solution, the direct reaction between an
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excess amount of tetraethylammonium chloride and cisplatin affords the desired anion, which
can be subsequently precipitated from an aqueous solution as the PPh 4* salt. 127 The use of other
cis-[PtL2Cl 2] complexes as starting materials in this reaction generally affords the corresponding
[PtLCl 3] ions. This transformation, however, is only successful if the leaving amine ligand is
sufficiently volatile, driving the reaction by the evaporation of the amine. Because of this
limitation, the anion [Pt(cyclohexylamine)C13]~ could not be prepared via this route.127 The high
temperatures employed for this method, which result in the eventual decomposition of cisplatin
to insoluble platinum black, restrict the overall yield and efficiency of the reaction. The
introduction of substoichiometric amounts of NH 4Cl (0.25 mol%) prevents formation of
platinum black (Scheme 1.5).129 The reported yield in this case was 58%, but unreacted cisplatin
could be recovered for later use.129 Water-soluble forms of the [Pt(NH 3)Cl3] ion as either its
sodium or potassium salt can be isolated using an ion-exchange resin,128,129 or metathesis with
either KPF6 130 or NaBPh4.m An HPLC method was described recently to assess the purity of the
potassium salt. 32 To prepare the analogous anions where L is an N-heterocycle instead of an
amine, direct reaction between K2PtCl4 and one equiv of L in DMF at 75 'C can be used. This
reaction also produces some of the disubstituted neutral product cis-[PtL2Cl 2] . The amount
of this undesired species formed depends on the steric bulk of the incoming heterocycle.13 4 For
example, much higher yields of the anion were afforded with 2,4-lutidine than with pyridine.
Presumably, the steric properties of the ortho methyl groups of 2,4-lutidine disfavor
simultaneous coordination of two such ligands to a single platinum center. The use of steric
effects to synthesize of [PtLCl 3] directly from K2PtCl4 in water, where L is an aliphatic amine,
has also been described.135 The sterically crowded amines, isopropyl and tert-butyl amine,
substantially retard the formation of cis-[PtL2Cl2], enabling isolation of K[PtLCl3] in 16-36%
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yields.' 5 For either reaction, the desired soluble anion can be separated from the insoluble
disubstituted complex by extraction into water.
The [PtLCl 3] ions are suitable precursors for the synthesis of mixed ligand complexes of
the type cis-[PtLL'X 2]. The reaction between L' and [PtLCl3] in water or DMF gives the mixed
amine complex with the expected cis stereochemistry. 12 7,136-138 Under these conditions, however,
a small amount of cis-[PtL' 2Cl2] can also be formed, presumably arising from [PtCl 4 ]2- impurities
in the starting material. 12 8 By analogy to Dhara's method for the synthesis of cisplatin, 60 the
preparation of cis mixed amine complexes was improved by first treating the [PtLCl3 anion
with two equiv of Nal or KI in water (Scheme 1.5).125 Multinuclear NMR spectroscopic studies
verified that the addition of two equiv of iodide, when L = NH 3, forms primarily the ion trans-
[PtI2Cl(NH3)]~, resulting from substitution of two chloride ligands.139 The large trans effect of
the iodide favors the amine substitution reaction. The addition of an amine to trans-
[PtI2Cl(NH3)]~ readily yields the mixed halide species cis-[PtLL'ClI]. In this case, some impurity
resulting from [PtCl 4]2~ is present in the form of cis-[PtL'212] is present. This impurity, however,
can be readily removed from the desired product by its dissolution in acetone. 12 8 The mixed
halide intermediate can then be converted to the dichloride by the removal of the iodide ligand
with Ag4 and the addition of Cl to the resulting platinum aqua complex (Scheme 1.5). In the
case where both L and L' are quinoline derivatives, the direct reaction [PtLCl 3] and L' in mixed
aqueous and organic solvent directly afforded the desired compound in its pure form without the
need to proceed through the mixed halide species. 14 0
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+ Et4 NCI 2) H+ ion exchange
then sat. KCl (aq)
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H20 10
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H3N 11) AgNO3, H20
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Scheme 1.5. Synthesis of cis-[Pt(NH3)LCl 2] starting from
as an intermediate.125,129
K I
H3N I
Pt
L/ \Cl
H3N\ /Cl
Pt
cisplatin using the [Pt(NH 3)Cl 3] ion
The other commonly used route for the synthesis of mixed cis amine platinum(II)
complexes utilizes iodido-bridged dimers, [PtLI(p-I)]2 , as intermediates. The reaction of cis-
[PtL2I2] with perchloric acid forms these species, which are generally insoluble and brown in
color (Scheme 1.6). 141 The scope of this reaction extends to a range of aliphatic 14 2 and aromatic
amines, 14 3 and N-heterocycles.144 For sterically hindered amines, such as tert-butyl amine, the
analogous iodido-bridged dimers form directly upon their reaction with K2PtI4 ; formation of the
expected product, cis-[PtL2 12], does not proceed, presumably due to the large steric hindrance of
the bulky amine ligands.14 2 The perchloric acid acts to remove an amine ligand from cis-[PtL2I 2]
by protonolysis. The vacant coordination site of the platinum(II) center is then filled by an iodide
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ligand of another complex. Because both the starting material and products are poorly soluble in
water, the reaction can take an exceedingly long time to reach completion; for cyclopropyl
amine, a reaction time of three weeks was necessary to achieve full conversion. 14 2 Furthermore,
the lack of solubility of both species makes it difficult to gauge the extent of the reaction. For
reactions that have not gone to completion, the final product may be contaminated by starting
material. The iodido-bridged dimers exist in two isomeric forms, syn and anti (Scheme 1.6),
depending on the disposition of the two amine ligands about the Pt-Pt vector. Solution NMR
spectra display resonances from both isomers, but in the solid-state only anti isomers have been
observed by X-ray crystallography.
14 2
,
145
Although several recent publications have reported that some of these iodido-bridged
dimers exhibit anticancer activity, 14 6"14 7 their primary use is for the synthesis of cis mixed amine
complexes. In this context, it should be noted that these iodido-bridged dimers can also serve as
precursors for the [PtLCl 3] anion discussed above. Treatment of [PtLI(p-I)] 2 with excess AgNO 3
in water, followed by the addition of excess KCl, provides another route to the [PtLCl 3] ion.148
More useful, however, is the direct reaction of these dimers with another amine or N-heterocycle
to form the mononuclear mixed amine complexes, cis-[PtLL'12] (Scheme 1.6).130'141 Despite the
presence of both anti and syn isomers in the iodido-bridged dimer starting material, only cis-
[PtL 212] is obtained from this reaction. The iodide ligands can be exchanged for other halides
using an appropriate silver(I) salt as described above. Analogous chlorido-bridged dimers can be
synthesized by the photolysis of trans-[Pt(ethylene)LCl2]. 14 9 Cleavage of these chlorido-bridged
dimers with another amine ligand, however, leads to formation of both the trans and cis isomers
of the mixed amine complex, 14 9 rendering this procedure less useful.
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L /I 70% HC1O 4, rt L \ I I L \ / I \ /
4 Pt Pt Pt + Pt Pt
L II I
anti syn
L \ I / H20,rt L I
Pt Pt + 2L' 0 2 Pt
syn + anti
Scheme 1.6. Synthesis of mixed amine complexes, cis-[PtLL'12], via iodo-bridged dimer
intermediates.3 0 14 1
When a bidentate oxygen ligand is desired as the leaving group instead of monodentate
halides, a different synthetic route can be used to access the mixed amine complex. The first step
in this pathway requires the synthesis of cis-[Pt(DMSO) 2(O 2Chel)], where O2Chel is a typically
anionic chelating ligand with oxygen donor atoms. This intermediate is prepared by the reaction
of cis-[Pt(DMSO) 2Cl2], which itself is obtained from commercially available K2PtCl4 and
DMSO, 5"0 and the disilver salt of the chelating ligand in water (Scheme 1.7).151 The first DMSO
ligand of cis-[Pt(DMSO) 2(O 2Chel)] can be substituted by an amine L at 40 'C in water to form
isolable complexes of the type cis-[PtL(DMSO)(O 2Chel)]. The addition of a different amine, U,
to this complex at higher temperatures (100 'C) in water enables substitution of the second
DMSO ligand to afford the mixed amine complex cis-[PtLL'(O2Chel) (Scheme 1.7). 151 The
difficulty in removing the second DMSO ligand is emphasized by the fact that even the use of
chelating diamine ligands requires heating to 100 'C to enforce bidentate coordination. For
bidentate N-heterocycles like 2,2'-bipyridine, lower temperatures (refluxing methanol) can be
used to substitute both DMSO ligands.152 The concentrations of the reactants are also important
because, when high concentrations of chelating diamine ligands are used, both the DMSO
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ligands and oxygen chelate get displaced, forming [Pt(L2 )2 ]2 +.15 3 Despite the apparent utility of
this method, it has not been widely applied.
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Scheme 1.7. Synthesis of mixed amine complexes with a
group.
0
O O
Pt)
L'\ /0
Pt oo
chelating oxygen donor leaving
The processes for preparing mixed amine complexes with trans stereochemistry are more
straightforward than those discussed above for cis complexes. These compounds, having the
general formula trans-[PtLL'C12], are of interest because many of them exhibit in vitro anticancer
activity superior to that of cisplatin, despite their trans stereochemistry.s 7 -1 62 Additionally, they
exhibit no cross-resistance with cisplatin. 157'158' 160 Their preparation begins with the complex cis-
[PtL 2Cl 2], the synthesis of which has been described earlier. The addition of greater than two
equiv of L' to a suspension of this complex in boiling water typically gives rise to a colorless
solution containing the salt, cis-[PtL2L' 2]Cl2 (Scheme 1.8). The solubility and color can vary
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slightly, depending on the hydrophobicity and electronic properties of the amine or N-
heterocycle ligands. Addition of concentrated hydrochloric acid to this salt at elevated
temperatures leads to substitution of one L and one L' ligand by chloride, forming trans-
[PtLL'Cl 2] (Scheme 1.8).157 The stereochemistry of the product is dictated by the kinetic trans
effect. The first chloride substitution can yield either of the intermediates, [PtL2 L'Cl] or
[PtLL'2Cl 2]. The larger trans effect of chloride compared to those of amines or N-heterocycles
ensures that the second chloride substitutes trans to the first chloride. Further substitution to form
[PtLCl3]~ or [PtCl4 ] is impeded by the low solubility of trans-[PtLL'C12], which precipitates
from solution as a yellow solid immediately upon its formation.
L Cl ~L L' Cl2
,+ x S H 20, 90-100 C L /
Pt + xLPt
L L' Cl 2 conc. HCl, 90-100 *C L Cl
Pt \ Pt
L L'Cl L'
Scheme 1.8. Synthesis of trans-[PtLL'C12]. 157
Synthesis of Monofunctional Platinum(II) Complexes. Platinum(II) complexes containing
only one substitution-labile ligand are described as monofunctional in contrast to cisplatin and
carboplatin, both of which contain two substitution-labile coordination sites and are referred to as
bifunctional. The earliest monofunctional platinum(II) complexes investigated for their potential
anticancer activity were [Pt(dien)Cl]C1 (dien = diethylenetriamine) and [Pt(NH 3)3Cl]Cl. The
observation that these two complexes are inactive helped establish the traditional structure-
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activity relationships for platinum therapeutics, which state that, among other requirements,
charge neutrality and bifunctionality are necessary for activity.28 163 In spite of their lack of
anticancer properties, these two monofunctional complexes have found use in modeling the
reactions of platinum anticancer agents with biologically relevant nucleophiles because the
presence of only one ligand exchange site simplifies the interpretation of results. 164-167
Optimized synthetic routes to these salts have been reported. 168'16 The synthesis of
[Pt(NH 3)3Cl]C1 commences by treatment of transplatin with one equiv of KI to form the mixed
halide complex, trans-[Pt(NH3)21Cl]. The addition of one equiv of AgNO 3 in water selectively
precipitates AgI and gives trans-[Pt(NH 3)2Cl(OH 2)](NO 3). Aqueous ammonia readily replaces
the labile aqua ligand, yielding [Pt(NH 3)3Cl]Cl as a colorless to pale yellow solid after
precipitation from the aqueous solution with a mixture of ethanol and diethyl ether (Scheme
1.9).168 The aqua intermediate, trans-[Pt(NH 3)2Cl(OH2)](NO3 ), could also conceivably used as a
synthon for complexes of the general type, trans-[Pt(NH 3)2LCl](NO3). The optimized
preparation of [Pt(dien)Cl]Cl utilizes the reaction of either cis/trans-[PtCl2(SMe 2)]1 70 or cis-
[Pt(DMSO) 2Cl2]1 50 with dien in refluxing methanol. Isolation of [Pt(dien)Cl]C1 as a white solid
in yields of >90% is accomplished by the addition of either CHC13 or CH 2Cl 2 to the resulting
methanolic reaction mixture. 169
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Scheme 1.9. Synthesis of [Pt(NH 3)3C]Cl. 168
More recently, a number of monofunctional platinum(II) complexes have been
discovered that break the traditional structure-activity relationships by exhibiting anticancer
properties. 11-175 The most thoroughly investigated members of this class are complexes of the
general formula cis-[PtL 2L'Cl]*, where L is a monodentate or bidentate amine and L' is either an
N-heterocycle,17 1 a sulfoxide,172 ,176,177 or a thiourea derivative (Chart 1.3).178
+0
// H2
-s N..,,
Pt
CI N2
H2
H2N NH 2
Pt
CI S
2+
Chart 1.3. Examples of cationic monofunctional platinum(II) complexes that exhibit anticancer
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For the sulfoxide and thiourea complexes, chelating diamines are used exclusively
because the strong trans effect of these ligands labilizes monodentate amines, leading to their
dissociation. Although we define the sulfoxide compounds, cis-[Pt(L2)(RR'SO)Cl]*, as
monofunctional because of the presence of only one labile Pt-Cl bond, these complexes form
bifunctional DNA-adducts.179 Rapid substitution of the chloride for water or nucleobases is
followed by the slow substitution of the sulfoxide ligand. The kinetics of the sulfoxide
substitution reaction are effectively modulated by the steric bulk of the sulfoxide. 17 2 ,176,17 9 The
synthesis of these complexes proceeds either by the addition of the chelating amine ligand to cis-
[PtCl2(RR'SO) 2] or the addition of one equiv of sulfoxide to cis-[Pt(L2)Cl2] (Scheme 1.10). The
latter reaction pathway is the preferred route; the use of cis-[PtCl 2(RR'SO) 2] as the starting
material in the former pathway gives variable amounts of cis-[Pt(L2)Cl2] as an undesired
byproduct.1 7 2
0 0
R-S S R
R' Pt + NH 2  NH2
R- - NH2 1
MeOH, rR' P
/Pt\ + -..- R L NH
Cl NH R
Scheme 1.10. Two different synthetic routes for the preparation of cis-[Pt(L2)(RR'SO)Cl] Cl.'7 2
Complexes of the type cis-[Pt(NH 3)2LCl]*, where L is an N-heterocycle, have attracted
significant attention since the initial discovery of their antitumor properties in 1989.171 In
contrast to the sulfoxide complexes discussed above, these cations bind to DNA and nucleobases
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in monofunctional manner with no indication of ammonia or N-heterocycle loss to form
bifunctional adducts. 180 Although the monofunctional lesions do not significantly bend
DNA,26,181 they still manage to effectively destabilize the structure of the double helix182-184 and
impede DNA replication 8 5 and transcription.26 ,is6 The characteristic monofunctional DNA
adducts may be responsible for the different spectrum of activity observed for these compounds
in comparison to those for clinically used bifunctional platinum drugs.1 87 A number of
derivatives of cis-[Pt(NH 3)2LCl]* have been synthesized, with L being a wide range of different
N-heterocycles. These N-heterocycles include derivatives of pyridine with different
substituents17 1 and fused aromatic rings, 188 pyrimidines,189 a fluorescently labeled pyridine, 190
steroid functionalized pyridines, 191 ,192 imidazothiazoles,193 9-aminoacridine, 194 the antimalarial
drug chloroquine,194 ethidium, 195 the anticancer drug 5-fluorouracil,196 and several antiviral
agents. 197'19 8 Of these drug candidates, the complex utilizing phenanthridine as its N-heterocyclic
ligand, termed phenanthriplatin, exhibits in vitro cytotoxicity greater than that of cisplatin across
a wide range of cell lines. 188 As phenanthriplatin illustrates, the judicious choice of the N-
heterocycle can give rise to very potent monofunctional complexes.
The synthesis of monofunctional complexes can be accomplished by stirring a mixture of
cisplatin and one equiv of the N-heterocycle in water at 50-60 'C for several days.m17 This
reaction proceeds by direct substitution of the chloride ligand for the N-heterocycle. This
method, however, typically gives low yields of impure compounds. The major impurity is the
disubstituted species, cis-[Pt(NH 3)2L2]Cl2 , which arises from substitution of both chloride
ligands. Pretreatment of cisplatin with one equiv of AgNO 3 in water to generate the reactive
monoaqua complex, cis-[Pt(NH 3)2Cl(OH 2)]*, followed by the addition of another ligand has also
been reported. 189 This method gave rise to a substantial portion of unreacted cisplatin and
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unidentified byproducts. The reaction mixture containing one equiv AgNO 3 and cisplatin in
water has been analyzed by 195Pt NMR spectroscopy. The monoaqua complex, cis-
[Pt(NH 3)2 Cl(OH2)]*, comprises 57% of the total platinum in solution, whereas the diaqua
complex, cis-[Pt(NH 3)2(OH 2)2]2+, and unreacted cisplatin account for 39 and 4%, respectively.1 71
The large quantity of the diaqua complex should lead to the formation of an equally large
proportion of the undesired disubstituted complex. Treating cisplatin with one equiv of AgNO 3
in DMF, however, gives a much more favorable product distribution; 79-86% of the total
platinum is in the monosolvated form cis-[Pt(NH 3)2Cl(solv)], where "solv" is either DMF or
nitrate, whereas only 9% and 9-12% of the platinum comprises disolvated species and unreacted
cisplatin, respectively. 17 1' 194 The preferred synthetic route to monofunctional complexes,
therefore, involves the reaction of cisplatin with one equiv of AgNO 3 in DMF followed by the
addition of the N-heterocyclic ligand (Scheme 1.11).171,199 Care must be taken to purify the final
monofunctional product from unreacted cisplatin and disubstituted byproducts. Because cisplatin
is not soluble in methanol, it can be removed by filtration after dissolving the crude product in
this solvent. A final recrystallization step from either dilute HCl or methanol is necessary to
separate the monofunctional complex from disubstituted byproducts. The mononitrato species,
cis-[Pt(NH 3)2Cl(NO3)], has reportedly been isolated as a solid by evaporation of an aqueous
solution containing a 1:1 mixture of cisplatin and AgNO 3.19 8 This complex was then used as a
precursor for new monofunctional complexes. Only CHN analyses were presented as
characterization for cis-[Pt(NH 3)2Cl(NO 3)]; it is most likely that the isolated solid comprised the
mixture of species found in solution by 195Pt NMR spectroscopic studies, as discussed above.
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Scheme 1.11. Synthesis of cis-[Pt(NH 3)2LCl]NO3 7118 8
Another important class of monofunctional platinum anticancer agents contains
complexes of the general formula cis-[Pt(L2)Cl(tu)]*, where L2 is a chelating diamine ligand and
tu is a derivative of thiourea, coordinated through the sulfur atom (Chart 1.3, right side).20 0 20'
Although the first generation analogues of these complexes with underivatized thiourea ligands
exhibit only poor to moderate in vitro cytotoxicity, 2 0 2 the second generation compounds with
acridine-functionalized thioureas are typically more cytotoxic than cisplatin. 173,203,204 These Pt-
acridinylthiourea, or PT-ACRAMTU, conjugates form hybrid DNA adducts;20 5 the Pt center
binds preferentially to N7 of guanine bases and the acridine intercalates between base pairs. In
contrast to the monofunctional sulfoxide complexes discussed above, the thiourea ligand does
not get displaced by nucleobases and therefore only monofunctional covalent DNA adducts are
formed.2 0 2 The unique hybrid DNA-binding motif of these complexes gives rise to a profile of
activity in a wide range of cancer cells substantially different from those of cisplatin and related
platinum anticancer drugs.178 The synthesis of PT-ACRAMTU complexes follows a protocol
similar to that used for the monofunctional cis-diammine complexes. A 1:1 mixture of cis-
[Pt(L2)C12] and AgNO 3 are stirred in DMF, and the filtrate is treated with one equiv of the
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thiourea ligand (Scheme 1.12).216 This reaction fails when monodentate amine ligands are used;
the addition of thiourea induces full substitution of the monodentate amine ligands, forming
[Pt(tu)4 ] ,206 consistent with the expected results of the Kurnakow test, as discussed above.
H2 N\ N2  _ F(NO 3)H2N+ AgNO DMF, rt H2N / NH 2
CI C 
- AgCI (s) Cl / SolvI
(NO3 ) (NO 3 )
2N NH2 R2N NR 2 DMF, rt H2N\/ H 2
Pt + Pt
Cl Solv S Cl S
R 2N NR2
Scheme 1.12. Synthesis of monofunctional, thiourea platinum(II) complexes.20 6
Platinum(II) Complexes Synthesized by Ligand-Based Reactivity. The synthetic strategies
discussed in the previous sections all rely on ligand substitution reactions at the platinum(II)
center. Alternative synthetic pathways involve the use of outer-sphere, ligand-based reactivity.
These reactions are facilitated by the ability of transition metal ions to activate coordinated
ligands, making them more susceptible to certain reactivity pathways that would otherwise be
inaccessible to them in the unbound form. This section covers several examples of these
reactions that have been utilized to synthesize of novel platinum anticancer drug candidates.
Iminoether complexes of platinum(II) of general formula [Pt(iminoether) 2Cl2] display
potent anticancer activity both in vitro and in vivo. As for traditional platinum anticancer agents,
this activity is proposed to arise from DNA binding.207 For the trans isomers, monofunctional
adducts 20 s,2 09 and protein-DNA cross-links 21 0 are invoked as the predominant cytotoxic lesions.
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The trans isomers tested initially proved to be more active than their cis congeners, although
some recent studies have reported the opposite observation for new members of this class of
compounds.m2 12 ,21  The cis and trans structure-activity relationships for these compounds,
therefore, depends on the exact chemical nature of the iminoether ligand. In addition to the
stereochemistry at the square-planar platinum center, the iminoether ligands can exist in either E
or Z configuration, depending on the orientation of the substituents about the C-N double bond.
As a result, six isomers exist for [Pt(iminoether) 2Cl 2] complexes, neglecting rotational isomers
involving the Pt-N vector (Chart 1.4). For both cis and trans isomers, the stereochemistry of the
ligand had a substantial effect on the biological activity of the complex.2 ,214 Therefore, precise
synthetic control over the total stereochemistry of the final complex is important for further
biological applications.
R OR' R'O R R'O RC_ \ .Cl i CI
H-N-Pt-Cl H-N-Pt-Cl H-N-Pt-Cl
H,/ H, H,
'N N N
R OR' R OR' R'O R
cis-ZZ cis-EZ cis-EE
R OR' R'O \ R *C H R'Oj R __/ 1 H
.P,H - H\\ / ,
H-N-Pt- N H-N-Pt-N H N
C1 R'O R Cl R'O R Cl R OR'
trans-ZZ trans-EZ trans-EE
Chart 1.4. Depiction of the six different stereoisomers of [PtCl2(iminoether)2]. The terms cis and
trans refer to the stereochemistry at the platinum(II) center, whereas E and Z denote the
stereochemistry at the C-N double bond of the iminoether ligands.2 n
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The nitrile complexes, cis- and trans-[PtCl2(NCR)2], are precursors for the synthesis of
cis- and trans-[PtCl 2(iminoether) 2] complexes. The reaction of cis- or trans-[PtC 2(NCR)2] in
alcohols 215 or alcohol-dichloromethane mixtures 2 16 with a catalytic amount of KOH affords the
iminoether complexes by nucleophilic attack of the alkoxide on the coordinated nitrile ligand
(Scheme 1.13). Formation of the iminoether occurs with retention of the starting stereochemistry
of the platinum complex, but generally a mixture of E and Z ligand-based isomers are obtained.
Formation of the Z iminoether is kinetically preferred; isomerization to the E isomer occurs in
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the presence of catalytic amounts of base, which is present under the reaction conditions.
Carrying the reaction out at low temperature (0 C) also significantly impedes isomerization to
the E isomer, giving predominantly Z isomers. 2 1 8 The ZZ, EZ, and EE isomers can be separated
on the basis of solubility differences by fractional crystallization or silica gel column
chromatography.21
ROR'
C1 R'OH, 0-20 *C R-{ I'
RCN-Pt-C cat. KOH H-N-Pt-Cl
RC H, 4RCN c HN
R OR'
mixture of EE, EZ, and ZZ isomers
ROR'
Cl R'OH, 0-20 *C R ,H
RCN-P--LNCR N H-N-Pt--N
cat. KOH
R'O
mixture of EE, EZ, and ZZ isomers
Scheme 1.13. Synthesis of cis- (top) and trans-[PtCl 2(iminoether)2] (bottom).2 21
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Mixed iminoether-ammine platinum(II) complexes of fonnula [PtCl2(NH3)(iminoether)]
also exhibit in vitro and in vivo anticancer activity. 2 18 21 9 These complexes are prepared from
mixed ammine-nitrile complexes by the attack of an alkoxide on the coordinated nitrile ligand
under conditions similar to those employed for the bis(iminoether) complexes described above.
The synthetic protocols for the precursor complexes, cis- and trans-[PtCL2(NH3)(NCR)], are
similar to those described for mixed amine platinum(II) complexes described above. To prepare
trans-[PtCl2(NH3)(NCR)], cis-[Pt(NH 3)2 2] is treated with two equiv of AgNO 3 in water to form
the diaqua complex, from which cis-[Pt(NH 3)2(NCR)2] can be formed by addition of a large
excess of nitrile at 70 'C. Excess aqueous KI displaces two ligands; the large trans effect of
iodide enforces trans stereochemistry in the final product, trans-[PtI2(NH3)(NCR)] .219 The iodide
ligands can be replaced by chlorides via sequential treatment with AgNO 3 and KCl. The
synthesis of cis-[PtCl 2(NH3)(NCR)] is accomplished more simply by action of a large excess of
nitrile on Cossa's salt, K[Pt(NH3)Cl 3].2 18
In addition to alcohols and alkoxides, platinum(II) nitriles are also activated for
nucleophilic attack by amines to form amidine complexes. Amidine complexes of formulas cis-
and trans-[PtCl2(amidine)2], cis- and trans-[PtCl2(NH3)(amidine)], and trans-
[Pt(amine) 2(amidine) 2]Cl2 have been investigated for anticancer potential, both in vitro and in
vivo. 0-22' Like their iminoether analogues, these complexes generally show good activity in
both cisplatin-sensitive and -resistant cell lines. Additionally, both metal- (cis or trans) and
ligand-based (EE, EZ, or ZZ) stereoisomers are possible, as for the related iminoether complexes.
The syntheses of cis- and trans-[PtCl 2(amidine) 2], like those for the analogous iminoether
complexes, begin with cis- and trans-[PtC 2(NCR)2]. Low temperature reactions (-10 C) of the
bisacetonitrile complexes with secondary or primary amines in CH 2Cl 2 affords the amidine
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complexes (Scheme 1. 14).226 For the cis isomer, five equiv of the amine are required, whereas
for the trans isomer 50 equiv of amine are required for complete conversion to the diamidine
product.2 27 The metal stereochemistry is initially retained in both cases, but in pure water these
22
complexes isomerize, forming an equilibrium mixture of cis and trans species.228 This
isomerization is prevented in the presence of 100 mM NaCl. 22 8 The stereochemical outcome of
the amidine ligand (E vs Z) appears to be dictated by the nature of the coordinated nitrile ligand
and the nucleophilic amine. In the reaction with the bisacetonitrile or bis(benzylcyanide)
platinum complexes, primary amines selectively give ZZ isomers and secondary amines give EE
isomers. 2 22 ,2 2 9 When the coordinated nitrile is benzonitrile, a mixture of EE and ZZ isomers is
230 220
obtained. Preparative TLC can be used to separate and isolate some of these isomers.
The action of ammonia on both cis- and trans-[PtCl2(NCR)2] has also been
investigated.22 1' 23 ' For cis dinitrile complexes, addition of aqueous ammonia in THF affords the
expected diamidine species.2 21 When gaseous ammonia is bubbled through a CH 2 Cl2 solution of
the trans dinitrile complex at -10 'C, the major product is trans-[PtCl(NH 3)(amidine) 2]Cl, which
results from substitution of a chloride ligand by ammonia in addition to the expected attack on
the coordinated nitrile.231 This complex is also the major product when the trans dinitrile
complex is treated with aqueous ammonia in THF.22 At room temperature and with 24 h
reaction times, both chlorides of trans-[PtCl2(NCR)2] can be substituted by aliphatic amines or
ammonia to form the salts, trans-[Pt(amine) 2(amidine)2]C12 (Scheme 1. 14),32 which also exhibit
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anticancer activity. The greater tendency of the trans dinitrile complex to lose its chloride
ligands in comparison to that of the cis is proposed to be a consequence of the greater solubility
of the intermediate diamidine complex, trans-[PtCl2(amidine)2], which makes it susceptibility to
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further reactivity with the nucleophilic amines. For the cis complex, the diamidine complex
precipitates from solution, thus impeding further substitution reactions.
H
CH2 C12, -10 *C RIN RICl
RCN-Pt-Cl + xs R'NH 2  - H-N-Pt--Cl
RCN H,/
RN
R N'R'
H
H
Cl CH2Cl2, -10 *C R/ , '1 H
RCN- Pt--NCHR + xs R'NH2 No H -N - Pt--N
ClR''N R
H
- H~
,Cl CH2Cl 2, rt, 24 h R N H2N'-RH
RCN-Pt-NCHR + xs R'NH2  H-N-Pt-N
ClI SR R''N}R
H2  H
Scheme 1.14. Synthesis of cis- (top) and trans-[PtCl2(amidine)2] (middle).22 6 Room temperature
conditions and extended reactions times lead to the formation of primarily trans-
232[Pt(NH2R')2(amidine) 2] from trans-[PtCl2(NCR)2] (bottom).
Using the abovementioned amidine-forming reactions, new analogues of the
monofunctional PT-ACRAMTU complexes, discussed above, were prepared.233 These
complexes have the general formula, cis-[PtCl(L 2)(amidine)](NO 3), where L2 is either two
ammine ligands or a chelating diamine, and the amidine ligand is tethered to an intercalating
acridine unit. These complexes exhibit excellent activity against non-small cell lung cancer
(NSCLC) cell lines without displaying cross-resistance to cisplatin.233 Furthermore, compared to
first generation thiourea analogues, these amidine complexes react less readily with cysteine
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sulfur,23 4 yet bind more rapidly to DNA.23 By comparison to cisplatin, these complexes display a
significantly larger degree of intracellular accumulation and DNA platination.23 6 The syntheses
of such species is accomplished by first treating cis-[PtL2(NCR)Cl]Cl with one equiv of AgNO 3
to exchange the outer-sphere chloride with a nitrate counterion, followed by the addition of an
acridinyl amine to a DMF solution of the complex at -10 'C (Scheme 1.15).23 Acidic workup
with HNO3 yields the product in its protonated form. The low temperature conditions employed
during the addition of the amine is presumably necessary to prevent it from displacing the
chloride ligand. The mononitrile precursor complex, cis-[PtL2(NCR)Cl]Cl, is synthesized by
refluxing a mixture of cis-[PtL2Cl 2] and excess nitrile in dilute HCl (Scheme 1.15).233,237 This
straightforward, amidine-forming reaction has recently been applied to combinatorially screen a
number of new platinum complexes that differ in the starting nitrile ligand and the acridinyl
amine. 23 8 This method was used to delineate some structure-activity relationships for this new
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class of platinum anticancer complexes.
L Pt L + xs RCN dil. HCI (pH 4), 60 
*C L
C /Cl Cl NCR
L L CI DMF, rt L L NO3
Pt j+ AgNO 3  LPtC
ci /NCR - AgCi (s) CI NCR
~(NO3)2
LL
H H Pt
L Pt L 3+ R'N N DMF, -10 *C CI NH
Cl NCR |-N Acidic work-up R ' N "H
(HNO3) ]' 
-NH
Scheme 1.15. Multi-step synthetic scheme for the preparation of monofunctional platinum-
amidine complexes.233
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In addition to nitriles, amines and ammonia are also activated for novel reactivity
pathways when coordinated to platinum. Such ligands can engage in condensation reactions to
form coordinated imines or iminates. For example, reactions of [Pt(NH3)6]4* and [Pt(en) 3]4* with
acetylacetone afford p-diketiminate complexes. 2 39,2 40 Additionally, both cis and transplatin react
with 2-pyrdinecarbaldehyde to form [Pt(pmpa)Cl] where pmpa = N-(2-picolyl)picolinamide),
presumably by condensation of the coordinated NH 3 group with the aldehyde (Scheme 1.16).241
Ammine insertion into a carbon-carbon double bond of the axial ligand of a platinum(IV)
complex has also been observed.24 2 Acetonimine complexes of platinum(II), cis and trans-
[PtX2(acetonimine) 2] where X = Cl or I, were synthesized by the reaction of cis and trans-
[Pt(NH 3)2X2] with acetone in the presence of KOH (Scheme 1.16).243 These complexes are of
therapeutic interest because they display good in vitro anticancer activity against a panel of
human cancer cell lines without exhibiting cross-resistance to cisplatin.24 3 Cis- and transplatin
react more slowly with acetone than their corresponding iodide analogues, and the complexes of
cis stereochemistry are more reactive than the trans complexes. Based on these observations, the
ligand trans to the ammines is proposed to modulate the condensation reactivity, which occurs
first by deprotonation of the ammine to form a nucleophilic amido ligand. Higher trans effect
ligands lower the ammine pKa by stabilizing the anionic amido ligand. Another route to
bis(acetonimine) platinum(II) complexes was also reported; direct ligand substitution reaction of
[PtL2Cl 2] (L in this case is a phosphine) by [Ag(acetonimine) 2]Cl0 4 affords such species.24 4
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H3N Cl
H3N \ Cl \
+ 2'H20,40 *C \ N\ /+r N O Pt\orN
Cl NH 3  H
3Pt \C
H3N CI
H
H3N X Pt
Pt N X
H3N X Acetone, MeOH, KOH H
rt, 24 h
or D or
X NH 3  H
Pt X N=
H3N X Pt
H
Scheme 1.16. Condensation reactions involving the coordinated ammine ligands of cis- and
transplatin, as well as their diiodo analogues.24 1 ,2
Ligand-based reactivity does not necessarily require activation by platinum coordination.
If the ligand has a functional group that is not in direct interaction with the platinum ion, this
functional group can display its typical reactivity, provided that the reaction conditions or
byproducts do not lead to decomposition of, or ligand dissociation from, the platinum complex.
The platinum(II) complexes [Pt(edma)C 2] and [Pt(edda)C12], where edma =
ethylenediaminemonoacetic acid and edda = ethylenediamine-N,N'-diacetic acid, can engage in
reactions associated with their free carboxylic acid groups (Scheme 1.17). The reaction of
[Pt(edma)C12] with thionyl chloride in methanol converts the acid to a methoxy ester group,
presumably through an intermediate acid chloride.245 Furthermore, the carboxylic acids of both
[Pt(edma)C12] and [Pt(edda)C12] can be converted to amides after activation with 1,1'-
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carbonyldiimidazole (CDI) and treatment with an amine. In both cases, the platinum
coordination sphere remains unaffected. Platinum(II) complexes of a chelating diamine ligand
having a pendant azide have also been synthesized.24 8 The azide functional group was employed
for the Cu(I)-catalyzed click reaction with terminal alkynes. This chemistry was used to attach a
number of different groups to the platinum complex (Scheme 1.17). Notably, the coordination
sphere of the platinum(II) core remained intact in the presence of the Cu(I) catalyst.24 8
Platinum(II) complexes with thiol-reactive maleimide derivatives attached to both the non-
leaving249 and leaving group ligands2 5 0 were prepared. As expected, the maleimide moiety
readily reacted with thiols. This reaction was used to link carboplatin derivatives to human serum
albumin for improved tumor delivery. 25 0
OH OINH2N NH MeOH, reflux H2N NH-> CH3
Pt 0 + SOC12  / Pt \
C.I CI CI CI
H
\ OH \y N,
H2 N\ /NH 0 H2N\ PNH 'R
Pt 0 Pt O
CI CI CDI, DMF CI CI
or + 1 or 2 RNH2 - * or
H H
HOx. 0I N... f--\ N,
HO HN NH I R N HN NH NR
0 Pt 0 0 Pt 0
C/ \CI Cl/ C'l
H2N CuSO4 , CuH, DMF X H2N NN
Pt N3  + R_ ~~~- Pt N
X H2N X H2N R
\Pt / R-SH, pH 7.4 buffer Pt O S
H3N \0 -( H3N \0 o R
Scheme 1.17. Outer-sphere ligand-based reactivity pathways of several platinum(II)
complexes.2 45 2 so
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1.3. Synthesis of Platinum(IV) Anticancer Complexes
Several platinum(IV) complexes have undergone clinical trials, but to date none has been
approved for use. Examples include iproplatin, tetraplatin, and satraplatin (Chart 1.5).23 An
advantage of platinum(IV) complexes over their platinum(II) analogues is their six-coordinate
octahedral coordination geometry. The introduction of two additional ligands allows for further
tuning of the properties and confers the ability to attach functional or targeting groups.
Moreover, being complexes of d6 octahedral metal ions, platinum(IV) compounds are
substantially more inert than those of platinum(II). Thus, undesirable side reactions with proteins
or intracellular thiols can generally be avoided using platinum(IV) complexes. The kinetic
inertness of satraplatin is most likely the reason why it was deemed suitable for oral
administration in contrast to all other platinum drugs, which are delivered intravenously.
OH 0 4 C1
H2 H2
N.,"P,.C W*H 3N..," Pt..Cl N..,"P 11 ,.Cl
OH O Cl
iproplatin satraplatin tetraplatin
Chart 1.5. Examples of several clinically investigated platinum(IV) anticancer agents.
Because platinum(IV) complexes are inert, they usually undergo reduction to
platinum(II) before binding to their ultimate intracellular target, DNA.52 Reduction of
platinum(IV) occurs with loss of two ligands, giving a square-planar geometry for the
platinum(II) product. It has generally been assumed that the two ligands lost upon reduction are
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located trans to each other and that both derive from the axial positions. This longstanding notion
has been challenged by number of recent studies, which show that the composition of the
reduced platinum(II) products depends on the nature of the reducing agent.232 Furthermore,
the kinetics of intracellular platinum(IV) reduction depend both on the cell type 25 7 and the
ligands that define the coordination sphere of the complex. 258 The precise synthetic control over
new platinum(IV) anticancer drug candidates is critical for discovering new therapeutic agents
and for further elucidating structure-activity relationships.25 9
Oxidation of Platinum(II). A common synthetic route to complexes of platinum(IV) proceeds
via two-electron oxidation of an appropriate platinum(II) precursor. For potential platinum(IV)
anticancer agents, the most widely used oxidizing agents are hydrogen peroxide2 60 and
chlorine. 2 6 1 These two molecules react with platinum(II) to give trans oxidative addition products
(Scheme 1.18). The equatorial ligands of the resulting platinum(IV) complex are generally
retained with the stereochemistry of the starting platinum(II) compound. For some diamine
dicarboxylato platinum(II) complexes, however, the action of chlorine leads to undesired
displacement of the carboxylate groups to form diaminetetrachloridoplatinum(IV) compounds.2 62
Platinum(IV) dihydroxo compounds, obtained by oxidation of platinum(II) complexes in
water, are important starting materials for the synthesis of further derivatized platinum(IV)
compounds (vide infra). The treatment of a yellow-orange suspension of cisplatin in water with
10-100 fold excess of H20 2 at 50 'C gives rise to a pale-yellow suspension comprising
cis,cis,trans-[Pt(NH3)2Cl2(OH)2] .263 This reaction is general for related cis and trans platinum(II)
complexes.264 When isolated directly from the mother liquor, this complex crystallizes with a
molecule of hydrogen peroxide that forms hydrogen bonds with the hydroxo ligands.26 s
Hydrogen peroxide is also retained in the crystal lattice of the related complex, cis,cis,trans-
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[Pt(1PrNH2)2Cl 2(OH) 2] (iproplatin). 2 66 The observation that these complexes are able to cleave
DNA 267,26 is a consequence of hydrogen peroxide in the lattice rather than the platinum(IV)
complex. The hydrogen peroxide can be removed by recrystallization from pure water.263 26 4 For
the all trans isomer, trans,trans,trans-[Pt(NH3)2Cl2(OH)2], which does not contain lattice-bound
hydrogen peroxide, recrystallization from water leads to isomerization, giving trans,cis,cis-
[Pt(NH 3)2Cl 2(OH)2].264 Diphenyl phosphate (DPP) can also be incorporated into the crystal
lattice of trans-platinum(IV) hydroxo compounds.2 69 In these crystals, the diphenyl phosphate
forms strong hydrogen bonds with the coordinated hydroxide or water ligands. 2 69 The DPP
adducts exhibit improved aqueous solubility. Thus, the use of an appropriate co-crystallization
agent may enhance the pharmacological properties of the complex. The abovementioned results
point to a large degree of complexity for the H 2 0 2 oxidation of anticancer platinum(II)
complexes. Care should be taken to avoid co-crystallized molecules that themselves might have
biological activity. Additionally, isomerization may impede purification attempts.
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Scheme 1.18. Oxidation of a platinum(II) complex with chlorine (top)2 6 1 and hydrogen
peroxide263 (bottom). The products obtained for the hydrogen peroxide oxidation are dependent
on the solvent used. 70'27
The mechanism of platinum(II) oxidation by hydrogen peroxide and chlorine has
important implications for the composition of the isolated products. Studies of hydrogen
peroxide oxidation of platinum(II) complexes using 180-labeled water revealed that only one of
the hydroxide ligands on the platinum(IV) complex originates from hydrogen peroxide; the other
comes from water.2 Recently, the oxidation of [Pt(cis-1,4-DACH)Cl 2] (DACH =
diaminocyclohexane) by chlorine gas was investigated in several different solvents.27 3 By NMR
spectroscopy, an intermediate corresponding to the addition of one solvent molecule and one
chloride ligand, fac-[Pt(cis-1,4-DACH)(solv)Cl 3]*, was detected. The remaining outer-sphere
chloride counterion then substitutes the labile solvent molecule, giving the expected tetrachlorido
species. 3 ,2 4 Further support for this mechanism comes from the crystal structure of a mixed
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trans-chloridoaqua complex obtained by the aqueous chlorine oxidation of a platinum(II)
oxazole complex.27 s Some early studies report the observation of a transient red or orange color
upon oxidation of cisplatin or [Pt(en)C12] with chlorine.26 1 276 The color then changes to the
characteristic yellow of the tetrachloride complexes.26 1 276 In our lab, we observed similar
behavior following the oxidation of cisplatin and related platinum(II) complexes with
hypervalent iodine reagents. The transient red color has been tentatively proposed to arise from
dinuclear metal-metal bonded platinum(III) complexes, some of which are also red and readily
277,278diueaform tetrachloroplatinum(IV) complexes by disproportionation. These dinuclear
intermediates probably only occur at high platinum concentrations.
The use of coordinating solvents enables isolation of mixed trans oxidative addition
products. For example, oxidation of platinum(II) in alcohols with H 2 0 2 gives trans hydroxo-
alkoxo complexes (Scheme 1.18).270-272,279-281 An optimized protocol for the synthesis of
cisplatin analogues of these species, cis,cis,trans-[Pt(NH3)2Cl2(OH)(OR)], utilizes high dilution
conditions in neat alcohol and oxidation with 50% aqueous H2 0 2 .2 71,28 1 The use of 50% rather
than 30% H20 2 presumably minimizes the amount of water in solution, which can compete with
the alcohol for coordination to platinum. Addition of hydrogen peroxide to a platinum(II)
complex with a 9-fluorenylidenepropanedioate (fpd) ligand in refluxing methanol afforded a
complex with two axial methoxide ligands instead of the expected mixed hydroxo-methoxo
complex. 2 7 9 The formation and stability of the dimethoxo complex is proposed to arise from an
intramolecular stabilizing interaction between the methoxide and fpd ligands, 2 79 and therefore
this reaction is probably not general for most platinum(II) complexes. The use of ethyleneglycol
as a solvent for the hydrogen peroxide oxidation of platinum(II) affords a trans hydroxo-
ethyleneglycolato complex. 2 80 The terminal alcohol group of the ethyleneglycolate ligand can
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presumably be further functionalized by electrophiles, but such reactions have not yet been
investigated.
The hydrogen peroxide oxidation of platinum(II) complexes in the presence of carboxylic
acids has also been explored. The oxidation of [Pt(CBDCA)(DPDA)] (DPDA = 2,2-dimethyl-
1,3-propanediamine) in acetic acid with hydrogen peroxide gave the unexpected cis diacetate
282complex, cis-[Pt(CBDCA)(DPDA)(OAc) 2]. In contrast, the use of acetic anhydride mixed
with a small amount of acetic acid, present due to hydrolysis of the anhydride, as a solvent
selectively afforded the trans diacetate complex, trans-[Pt(CBDCA)(DPDA)(OAc) 2] (Scheme
1.19).282 The mechanistic details and reasons for the isomeric preferences of these reaction
products have not yet been elucidated. The oxidation of the platinum(II) dihydroxo compound,
[Pt(DPDA)(OH) 2], with hydrogen peroxide in carboxylic acids at room temperature gave an
unexpected species of general formula and stereochemistry, fac-[Pt(DPDA)(OH)(O 2CR)3]
(Scheme 1.19).283 In our lab, we also explored the oxidation of cisplatin with hydrogen peroxide
in neat formic acid. The major product obtained is the diformate complex, cis,cis,trans-
[Pt(NH 3)2Cl 2(O2CH)2] (Scheme 1.19).284
Recently, the oxidation of oxaliplatin with hydrogen peroxide in the presence of greater
than 40 equiv of carboxylic acid in a minimum volume of THF was reported.28 s The major
products, observed were the monocarboxylato species, trans-[Pt(trans-1,2-
DACH)(oxalate)(OH)(O 2CCR)].285 When bromoacetic acid was used, however, a large quantity
of the dicarboxylato species was obtained.2 8 s This observation was rationalized based on the
lower pKa of bromoacetic acid (2.9) compared to those of the other acids screened (~ 4.8). With
its greater acidity, the bromoacetic acid can protonate the second hydroxo ligand and displace it,
as discussed below. Unlike hydrogen peroxide oxidations carried out in alcohols where one
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alkoxide and hydroxide are added, there is a greater tendency to add at two carboxylate ligands
when the oxidation is performed in organic acids. The species initially formed are most likely
mixed hydroxo-carboxylato complexes, analogous to the mixed chloride-solvento species
observed in chlorine oxidations.273 The highly acidic conditions, not present in alcohol solutions,
lead to protonation and subsequent substitution of the hydroxide ligand by a carboxylate, as
discussed below. The relative pKa values of the hydroxo ligands and carboxylic acids most likely
dictate whether the major product will be the mono or dicarboxylato complex. Another strategy
to prepare mixed hydroxo-acetato complexes employs a different oxidant and solvent
mixture.2ss,28s Oxaliplatin and trans-[PtLL'C 2] complexes, suspended in a 1:1:1 mixture of
DMF, CH 2 Cl 2 , and acetic acid, can be oxidized with tert-butyl hydroperoxide (in decane) to
afford trans- [Pt(trans- 1,2-DACH)(oxalate)(OH)(OAc)] and trans, trans, trans-
[PtLL'C12(OH)(OAc)] .258,285 The use of entirely non-aqueous solvent and peroxide for these
reactions prevent formation of the dihydroxo compound. These complexes can serve as
precursors for the synthesis of mixed dicarboxylato species.
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Scheme 1.19. Peroxide oxidations of platinum(II)
solvents. 258,282,
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complexes in various acidic
Oxidation with hydrogen peroxide can also be used to increase the denticity of a ligand.
Platinum(II) complexes with the formulas, [Pt(edma)C12], [Pt(edda)C12], and [Pt(edta)C12]
contain one, two, and four uncoordinated carboxylic acid groups, respectively. Upon oxidation of
[Pt(edma)C12] with H20 2, the carboxylate coordinates and the ligand binds in a facial, tridentate
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manner, forming fac-[Pt(edma)C 2(OH)] (Scheme 1.20).245 Similarly, both carboxylates of
[Pt(edda)C12] coordinate upon oxidation with H2 0 2 .245 ,286 For [Pt(edta)C12], only two of the four
free carboxylates bind upon oxidation.2 87 The remaining two carboxylates can potentially be
functionalized by standard amide-bond coupling chemistry, as for the platinum(II) analogues
described above. These ring-closing reactions provide a general synthetic route to stable
platinum(IV) complexes with multidentate ligands. The design of ligands for platinum(II)
complexes with strategically placed donors can facilitate such reactions upon oxidation.
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Scheme 1.20. Ring-closing oxidation reactions of [Pt(edma)C12] (top),24s [Pt(edda)C12]
(middle), and [Pt(edta)C12] (bottom).
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Apart from chlorine and hydrogen peroxide, few other oxidants have been explored for
the synthesis of platinum(IV) anticancer agents. One such alternative oxidant is the
dithiobis(fornamidinium) cation. The dichloride salt of the dithiobis(formamidinium) cation
oxidized cisplatin, adding a thiourea and a chloride to the axial positions (Scheme 1.2 1).288 The
oxidation of transplatin with this reagent afforded initially the all trans isomer, tt,t-
[PtCl 2(NH3)2(tu)Cl], but over time it isomerized to give the same product obtained by the
oxidation of cisplatin, cis,cis,trans-[Pt(NH3)2Cl2(tu)Cl] .289 Notably, the tetrafluoroborate salt of
the dithiobis(formamidinium) cation does not give any oxidation products, thus highlighting the
important role of the coordinating chloride counterion in facilitating the oxidative addition.2 88 289
Bromine, like chlorine, also oxidizes diamine platinum(II) complexes, generally forming trans
dibromo complexes (Scheme 1.21) 290 The bromine oxidation of several dichloro platinum(II)
complexes, however, failed to give the expected trans dibromo products; instead, a mixture of
complexes with different ratios of chloride and bromide ligands was obtained.2 4 7,2 91 For
diphosphine complexes, this halide scrambling reaction is initiated by light.292 Oxidation of
cisplatin with KMnO42 93 or ozone 294 in water reportedly both lead to the formation of the
dihydroxo compound, cis,cis,trans-[Pt(NH3)2Cl2(OH)2], which is also obtained by oxidation with
hydrogen peroxide. The use of peroxydisulfate, S208 2~, as an oxidant, primarily gives trans
hydroxo-sulfato platinum(II) complexes.293 29s The reaction of diamine diamidate complexes of
platinum(II) with NaOCl yields the corresponding trans hydroxo-chloro platinum(IV) complexes
(Scheme 1.2 1).296 The tetrachloroaurate ion, [AuCl 4 ]-, can also oxidize platinum(II). The
complex cis-[Pt(NH 3)2(1-methylthymine) 2] was oxidized by NaAuCl 4 to afford cis,cis,trans-
[Pt(NH3)2(1-methylthymine) 2(OH)(OH 2)] .297 The addition of two ligands originating from water
was unexpected and rationalized on the basis of steric crowding at the axial sites by the 1-
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methylthymine ligands. In contrast, the oxidation of a platinum(II) terpyridine complex by
AuCl4- added two chloride ligands to the resulting platinum(IV) coordination sphere. 2 9 8 Nitrogen
dioxide gas can also oxidize cisplatin in an aqueous solution containing one equiv of KCl
(Scheme 1.21 ).299 The product, [PtCl3(NO 2)(NH 3)], which could not be isolated as analytically
pure material, comprised primarily the facial isomer, as determined by NMR spectroscopy.
Analysis by X-ray diffraction revealed a disordered mixture of facial and meridional isomers.2 99
Potassium dichromate, K2 Cr 2O 7, and potassium chlorochromate, KCrO3 Cl, can also oxidize
cisplatin.300 On the basis of spectroscopic data, the products were proposed to be a dimetallic
heteronuclear Pt-Cr complex and a trimetallic Pt-Cr2 complex, respectively, with oxo ligands
bridging the metal centers (Scheme 1.21).300 Similarly, cisplatin was oxidized by iron(III)
complexes of the general formula, cis-[Fe(bpy') 2(CN)2](NO 3) where bpy' is derivative of 2,2'-
bipyridine, to form trinuclear cyanide-bridged complexes (Scheme 1.21).301,302 The
photochemistry of these complexes was explored, and in some cases the release of aquated
cisplatin as a photoproduct occurred3 0 1 3 02 thus signifying the potential use of such complexes as
photoactivated anticancer agents.
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288-Platinum(JV) complexes using different oxidizing agents.-
Hypervalent iodine species are a class of powerful oxidizing agents with utility in organic
synthesis. Iodobenzene dichloride (PhICl2),3 03 which can be isolated as a crystalline solid, acts as
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C1
an easy-to-handle surrogate for chlorine gas. It efficiently converts cisplatin and related
diaminedichloridoplatinum(II) complexes to their corresponding tetrachloridoplatinum(IV)
analogues (Scheme 1.22). 246,247 A recent report describes the action of PhICl 2 on an organoamide
platinum(II) complex in a mixture of acetone and basic water.3 0 4 A mixed trans hydroxo-chlorido
platinum(IV) complex is obtained (Scheme 1.22),304 consistent with a solvent-assisted
mechanism, similar to that observed for oxidations by chlorine and hydrogen peroxide.
The oxidations of cis- and trans-[Pt(NH 3)(NH 2Cy)C12], where NH 2Cy is
cyclohexylamine, with PhI(OAc)2 in dichloromethane have been investigated.3 0 s The major
products derive from the oxidative addition of two acetate ligands in a cis orientation. For cis-
[Pt(NH 3)(NH 2Cy)C12], the major product is cis,cis,cis-[Pt(NH3)(NH2Cy)Cl2(OAc) 2], whereas,
when the starting material is trans-[Pt(NH3)(NH2Cy)Cl2], the major product is cis,trans,cis-
[Pt(NH 3)(NH 2Cy)Cl 2(OAc)2] (Scheme 1.22). In addition to the major product, minor products
mer-[Pt(NH 3)(NH 2Cy)Cl(OAc) 3] andfac-[Pt(NH 3)(NH 2Cy)(OAc)Cl 3] also form upon PhI(OAc)2
oxidation of cis-[Pt(NH 3)(NH 2Cy)Cl2], indicative of intermolecular ligand substitution reactions.
The apparent limitations of using PhI(OAc) 2 in contrast to PhICl2 are the formation of products
without predictable stereochemistry and unexpected ligand stoichiometries. Given the large
number of hypervalent iodine complexes in the literature, further investigations of their reactivity
with platinum(II) complexes is certainly warranted, for they may lead to new, valuable synthetic
routes to novel platinum(IV) complexes.
77
DMF, rt
+ PhICI9
R 1 equiv Bu4NOH
N+ C NI 5% H2O in acetone
Pte fN + PhlC12I
R
Pt"C, + PhI(OAc) 2  CH 2Ca, rt ,
CyH 2N Cl
Cl--," Pt*,..NH 3 + PhI(OAc) 2  CH2CI2 , rt
CyH 2NO *Cl
Cl
H3N..,,1 I%.Cl
H3N ICI
C1
R OH
tIN
R CI kzk
C]
H3N.,"Pt,..Cl1Pt,
CyH 2N | OAc
OAc
major product
OAc OAc
H3N.." I Cl H3N,"I ..Cl
CyH2N OAc CyH 2N* ICl
OAc CI
minor products
Cl
H3N..,Pt,,*,.OAc
CyH 2N | OAc
Cl
Scheme 1.22. Oxidation of platinum(II) complexes with hypervalent iodine reagents.304,30s
Outer-Sphere Ligand-Based Reactivity. Outer-sphere ligand-based reactivity pathways for the
preparation of new platinum(IV) complexes is a valuable synthetic route because their kinetic
inertness limits the utility of ligand substitution reactions. A reaction of key importance in this
regard is that of Pt(IV)-hydroxo compounds with electrophiles. The coordinated hydroxide
ligand of platinum(IV) complexes is sufficiently nucleophilic to enable such transformations.
The acetylation of cis,cis,trans-[Pt(PrNH2)2Cl2(OH)2] with trifluoroacetic anhydride to form
cis,cis,trans-[Pt(PrNH 2)2Cl2(O 2CCF3)2] was first demonstrated in 1983.306 This chemistry was
78
H3N..,,, , ,.IC
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further expanded to include a broader range of acid anhydrides, pyrocarbonates, and isocyanates
as electrophiles to afford dicarboxylate, dicarbonate, and dicarbamate platinum(IV) complexes,
respectively.128 In all cases, retention of the stereochemistry of the starting dihydroxo
platinum(IV) compound is observed. For acetylation of trans,trans,trans-
[Pt(NH 3)(NH 2Cy)Cl 2(OH)2] with acetic anhydride, however, light-induced isomerization of the
initial product, trans,trans,trans-[Pt(NH3)(NH 2Cy)Cl2 (OAc)2], to trans,cis,cis-
[Pt(NH 3)(NH 2Cy)Cl 2(OAc) 2] occurred.30 s
Since the initial report, a wide variety of trans platinum(IV) dicarboxylate complexes
have been synthesized in this manner. The carboxylate ligands have significant effects on both
the lipophilicity and reduction potentials of the resulting platinum(IV) complexes.307-310
Furthermore, the ubiquitous nature of the carboxylate functional group in many different organic
molecules enabled the synthesis of platinum(IV) complexes bearing biologically active ligands,
311-314
attached via the carboxylate. Different protocols have called for the use of excess
18128 66,307 315,316
anhydride, either neat, or together with acetone,128 dichloromethane,, acetonitrile, or
DMSO 17' 31 8 as the solvent (Scheme 1.23). Similarly, tetracarboxylato platinum(IV) complexes,
some of which exhibit anticancer activity when administered orally,3 1 9 can be synthesized from
cis-[PtL2(OH) 4] 290,30,320 and excess anhydride in dichloromethane (Scheme 1.23).305,321 This
reaction demonstrates that equatorial cis hydroxide ligands also display nucleophilic properties.
Acyl chlorides also react with trans dihydroxo platinum(IV) complexes to form dicarboxylates.
A difficulty in this reaction, noted early on, 12 8 is the formation of hydrochloric acid as a
byproduct, which can remove the hydroxo ligands of platinum(IV) by protonation. Optimized
reaction conditions utilize refluxing acetone as a solvent and an excess of pyridine as a base to
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sequester the HCl that is formed (Scheme 1.23).322,23 Aromatic carboxylate ligands can be
installed on platinum(IV) with this method as well.3 n1 3 4
A third route to trans platinum(IV) dicarboxylates utilizes the ring opening reactions of
the platinum(IV) hydroxo complexes with cyclic anhydrides. Succinic, 153,325,326 maleic, 153,2 4 2
glutaric,15 3,32 7 phthalic,324 and naphthalic 328 anhydrides have all been used in this reaction,
together with the traditional Chinese medicine cantharidin.m Early protocols for this reaction
involved the treatment of a platinum(IV) hydroxo compound with the cyclic anhydride in
refluxing dichloromethane for two days.15 3,327 Currently, the most commonly used method
utilizes either DMF3 2 6 or DMS0 325 as solvent at 50-80 'C for 6-24 h (Scheme 1.23). Activating
carboxylic acids with an appropriate coupling reagent has also been an effective means of
forming trans dicarboxylate complexes. For example, the reaction of a platinum(IV) analogue of
oxaliplatin, trans-[Pt(trans- 1,2-DACH)(oxalate)(OH) 2], with 3 equiv of carboxylic acid,
triethylamine (TEA), and the coupling reagent 0-benzotriazol-1-yl-N,N,N-
tetramethyluronium tetrafluoroborate (TBTU) readily yields the dicarboxylato complex, trans-
[Pt(trans-1,2-DACH)(oxalate)(O 2CR) 2] (Scheme 1.23).285 This one pot procedure may provide a
useful alternative to the abovementioned methods because it avoids the need to prepare
anhydrides or acyl chloride as intermediates.
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The synthesis of mixed platinum(IV) carboxylate complexes can introduce greater
molecular complexity and provide a means of installing different functional or targeting groups.
The reaction of a platinum(IV) dihydroxo complex with a mixture of different anhydrides gives
rise to a statistical mixture of symmetric and asymmetric platinum(IV) dicarboxylates that can be
separated by silica gel chromatography. 12 8 Similarly, mixed tetracarboxylates were synthesized
by the reaction of a platinum(IV) tetrahydroxo complex with different ratios of anhydrides. 3 29
The resulting products required purification by either silica gel chromatography or preparative
reverse-phase HPLC.3 2 9 Another, more elegant pathway to mixed platinum(IV) dicarboxylates
requires the isolation of a trans mixed hydroxo-carboxylato platinum(IV) complex. The
remaining hydroxo ligand could then be derivatized with a different carboxylate ligand. The
synthesis of several mixed hydroxo-carboxylato complexes by the peroxide oxidation of
platinum(II) in the presence of an excess of carboxylic acid was described above, as shown in
Scheme 1.19.258,285 These complexes can react with another acid anhydride to yield a mixed-
dicarboxylate complex. The selective acetylation of a single hydroxo ligand is another potential
strategy. One way to accomplish this selective reaction is with steric control. Initially, the
acetylation of a platinum(IV) analogues of sterically hindered picoplatin, cis,cis,trans-
[Pt(NH3)(2-pic)Cl 2(OH)2], with acetic anhydride was reported to be unsuccessful because the
ortho methyl group of the picoline ligand impedes the hydroxo nucleophilic attack. 144 It was later
shown, however, that the acetylation of this complex can be successfully executed with a number
of different anhydrides to give symmetric dicarboxylate complexes. 3 30 Thus the steric effects of
the 2-picoline ligand did not successfully favor formation of the monohydroxo complex. The
platinum(IV) complex cis,cis,trans-[Pt(en')C2(OH)2], where en' is NN-
dimethylethylenediamine, is selectively acetylated at only one of the hydroxo ligands in the
82
presence of excess succinic anhydride (Scheme 1.24).331 The inability to form the dicarboxylate
was attributed to steric repulsion induced by the additional methyl groups on the
ethylenediamine ligand.331 Although this reaction demonstrates that steric effects can be used to
selectively obtain mixed hydroxo-carboxylato complexes, it is unlikely, because of those same
steric effects, that this complex could be further acetylated with an additional anhydride to form
a mixed dicarboxylate complex. The isolation of other mixed hydroxo-carboxylato platinum(IV)
complexes as synthons for mixed dicarboxylates was described recently.32 8 These complexes
were obtained by careful control of the reaction conditions. The room temperature reactions of
platinum(IV) dihydroxo complexes with an acid anhydride in DMSO were used to increase the
yield of the desired monocarboxylate complexes with respect to that of the dicarboxylate species
(Scheme 1.24). These reaction conditions were employed to prepare complexes with axial
aromatic carboxylates 32 8 and succinate 255 ,3 3 2 . In general, the desired mixed hydroxo-carboxylato
complexes are insoluble in acetone, thereby enabling the undesired dicarboxylate complexes to
be removed by dissolution in this solvent.128 An alternative procedure utilizes a carboxylic acid
preactivated by N,N-dicyclohexylcarbodiimide (DCC).28 s The one pot reaction of a trans-
[Pt(trans-1,2-DACH)(oxalate)(OH) 2] with only slightly greater than one equiv of DCC and a
carboxylic acid in DMF at rt preferentially gave the monocarboxylato species (Scheme 1.24).285
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In addition to acid anhydrides and acid chlorides, several other electrophiles react with
platinum(IV) hydroxo complexes. The reactivity of platinum(IV) hydroxides with
pyrocarbonates and isocyanates to form platinum(IV) carbonates and carbamates has been
known for over 15 years. 128 The reactions of cis,cis,trans-[Pt(NH3)2Cl2(OH)2] with both alkyl
and aromatic isocyanates were recently investigated in detail,33 as described in Chapter 6. The
optimal conditions utilized 4 equiv of the isocyanate and DMF as the solvent at room
temperature for several hours (Scheme 1.25). The action of trimethylsilyl chloride (TMSCl) on
the tetrahydroxo complex, cis-[Pt(DPDA)(OH) 4] has also been explored.320 At room temperature
in THF with TEA as a base, the main reaction product is the trans disiloxide complex,
cis,trans,cis-[Pt(DPDA)(OSiMe3)2(OH)Cl], whereas refluxing conditions afforded cis,trans,cis-
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[Pt(DPDA)(OSiMe 3)2C 2] (Scheme 1.25).320 The substitution of the hydroxide ligands most
likely arises from the HCl byproduct, which acts as the source of protons to labilize the
hydroxide ligands and as the source of the nucleophilic chloride ligands.
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The additional axial ligands available in platinum(IV) but not platinum(II) complexes can
be selected for introducing reactive organic functionalities. For example, the ring-opening
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reaction of platinum(IV) hydroxides with cyclic acid anhydrides yields platinum(IV) complexes
with free terminal carboxylic acids. The terminal carboxylic acids can undergo amide and ester
coupling reactions with the octahedral platinum(IV) center remaining intact (Scheme 1.26).
These reactions have been used to covalently modify platinum(IV) complexes with estrogen, 325
peptides, 3 34 -337 and nano-delivery devices. 271,3 38 -3 4 4 Additionally, a wide variety of amines and
alcohols have been coupled to such platinum(IV) complexes in order to systematically adjust
their lipophilicities. 2 81 ,32 6,34 5 -350  For coupling reactions carried out in DMF, N,N'-
diisopropylcarbodiimide (DIPC),m O-(7-azabenzotriazol-1-yl)-NN,N',N-tetramethyluronium
hexafluorophosphate (HATU), 33 8 and 1,1'-carbonyldiimidazole (CDI) 32 6 were all used with
success, whereas for aqueous coupling reactions the combination of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) (EDC) and N-hydroxysuccinimide (NHS) works
wel332,334,337
Two platinum(IV) complexes with axial ligands containing aldehyde and ketone
functional groups have also been reported recently. 3 2 The reaction of these functional groups
with organic hydrazines and hydroxylamines leads to the formation of hydrazones and oximes,
providing a new convenient method to conjugate platinum(IV) to different units (Scheme 1.26).
This strategy has already been employed to attach platinum(IV) to a short peptide35 2 and a
polymeric nanoparticle. 3 5 1 A platinum(IV) complex containing an axial carboxylate ligand with a
pendant azide has also recently been described.28 s In the presence of Cul, the azide ligand reacts
with an alkyne to form the expected triazole, and the intact platinum(IV) complex can be isolated
by preparative HPLC in approximately 50% yield (Scheme 1.26).285 A possible limitation of this
reaction for use in the preparation of other platinum(IV) complexes could be undesired reduction
of the platinum(IV) center by the Cu(I) ion. In another recent report, a thiol-reactive maleimide
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functional group was installed in the axial positions of two platinum(IV) complexes via
carbamate linkages.3 s3 The maleimide was used to attach the platinum(IV) complex to human
serum albumin at its single exposed cysteine residue (Scheme 1.26).35
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Ligand Substitution Reactions. Because of the inert nature of platinum(IV) complexes, direct
ligand substitution reactions are generally very slow and require harsh conditions. As a result,
such reactions are rarely employed to prepare anticancer platinum(IV) prodrugs. Complexes of
the type [Pt(L2)Cl 4] where L2 is a chelating diamine ligand, however, can be synthesized by the
reaction of the [PtC16]2~ anion with L2 in water, usually under refluxing conditions.1 43 5-3 For
more complicated structures, different strategies can be utilized to facilitate ligand substitution of
platinum(IV), as discussed below.
Hydroxide ligands bound to platinum(IV) complexes can be substituted under acidic
conditions. A popular synthetic route to cis-[Pt(NH3)2Cl4] and other diamine tetrachlorido
complexes utilizes cis,cis,trans-[Pt(NH3)2Cl2(OH)2] as a platinum(IV) starting material.
Treatment of this compound with hydrochloric acid affords the tetrachloride (Scheme 1.27).307
This reaction most likely proceeds via protonation of the hydroxo ligands, converting them to
labile water ligands, followed by their displacement by the nucleophilic chloride ion. This
reaction also works for hydrobromic acid to substitute bromide for hydroxide ligands. 35 9 When
hydrochloric acid is added to the tetrahydroxo compound, [Pt(trans-1,2-DACH)(OH) 4], all four
hydroxides are replaced by chloride ligands. 360 In contrast, suspending [Pt(trans-1,2-
DACH)(OH)4] in neat carboxylic acid affords the trisubstituted species, fac-[Pt(trans-1,2-
DACH)(OH)(O 2CR)3] (Scheme 1.27).360 It is hypothesized by the authors of these studies that
the pKa of the last hydroxide ligand is too low to be protonated by a carboxylic acid (pKa ~ 5),
but not lower than that of the stronger acid HCl. This hydroxo ligand, however, still retains its
nucleophilic character as it can be acetylated with other carboxylic anhydrides to rationally make
mixed carboxylate complexes.36 ' When trifluoroacetic anhydride is added to these tricarboxylate
complexes in the absence of a base, the unexpected product cis,cis,cis-[Pt(trans-1,2-
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DACH)(O 2CR)2(O2CCF3)2] is obtained (Scheme 1.27).362 The hydroxide is most likely initially
acetylated by trifluoroacetic anhydride, releasing the strong acid, trifluoroacetic acid, as a
byproduct. Trifluoroacetic acid can then protonate and release a coordinated carboxylate ligand
and bind to the platinum(IV) center. Consistent with this hypothesis is the observation that
adding a base with the trifluoroacetic anhydride gives rise only to the expected complex, fac-
[Pt(trans-1,2-DACH)(O 2CCF 3)(0 2CR)3], presumably by neutralizing the trifluoroacetic acid
byproduct.3 62
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Scheme 1.27. Ligand substitution reactions facilitated by acidic conditions.
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Just as acidic conditions favor ligand substitution reactions in platinum(IV) complexes by
protonolysis, basic conditions can also induce ligand substitution, albeit by a different
mechanism. Under basic conditions, platinum amine complexes can undergo ligand substitution
363-365
via the base hydrolysis mechanism.3- In general, these reactions result in the net substitution
89
of a chloride by a solvent ligand. The first step is the deprotonation of an amine ligand to form an
amido ligand. The high trans effect of the amido ligand favors dissociation of a trans chloride
ligand, yielding a five-coordinate intermediate. The addition of a solvent molecule to this five-
coordinate intermediate results in the observed product. In the realm of platinum-based
anticancer agents, this reaction mechanism has been proposed, albeit without supporting kinetic
data, for the formation of several new derivatives of satraplatin.3 0s,3 66 The reaction of
cis,cis,trans-[Pt(NH3)(NH2Cy)Cl2(0 2CC3H7)2] with sodium methoxide in methanol resulted in
substitution of the chloride trans to the cyclohexylamine for a methoxide ligand, forming
cis,cis,trans-[Pt(NH3)(NH2Cy)C(OMe)(0 2CC3H7)2] (Scheme 1.28).366 Similarly, in basic water
ciscis,trans-[Pt(NH 3)(NH 2Cy)Cl2(O 2CCH 3)2] converts to the monohydroxide complex,
cis,cis,trans-[Pt(NH 3)(NH 2Cy)C(OH)(O2CCH 3)2], where the hydroxide ligand is also trans to
the cyclohexylamine (Scheme 1.28).30s In DMA containing 2 M LiCl, the addition of TEA as a
base to cis-[Pt(NH3)(NH2Cy)(OAc) 4] afforded the monochloro complex mer-
[Pt(NH 3)(NH 2Cy)Cl(OAc) 3] (Scheme 1.28).30s In this case, the base hydrolysis route was able to
substitute an acetate ligand rather than a chloride. This reaction also demonstrates that, if a non-
coordinating solvent is used, other ligands besides solvent can be added to the platinum(IV)
complex.
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1.4. Concluding Remarks
The chemistry of cisplatin and its isomers was first explored over one hundred years ago.
The discovery of its anticancer properties in 1969 motivated further exploration into its
coordination chemistry and that of related species, 3 67,3 68 with the ultimate goal of finding new
complexes with improved therapeutic properties. The development of new synthetic
methodologies can give access to new platinum complexes with novel structures and possibly
novel modes of biological activity. This chapter summarizes the known reactivity patterns and
synthetic strategies for a range of platinum anticancer complexes. Notably, much of this
chemistry has only been developed within the last 20 years. Thus, as long as the need for new
platinum anticancer agents persists, new chemistry will be developed and investigated in order to
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obtain such compounds. The following chapters in this thesis address these needs by surveying
new synthetic methods for the preparation of novel platinum anticancer complexes.
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Chapter 2
Platinum(II) Complexes Bearing Fluorescent Di-2-
Pyridylmethane Ligands
Reproduced in part with permission from Wilson, J. J.; Lopes, J. F.; Lippard, S. J. Inorg. Chem.
2010, 49, 5303-5315. Copyright 2010 American Chemical Society.
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2.1. Introduction
There is still much uncertainty regarding the mechanism of uptake and cellular
distribution of cisplatin and related platinum-based anticancer drug candidates. 1-3 Reliable
methods to image cisplatin in living cells will most likely aid in the understanding of these
processes. Synchrotron x-ray spectroscopic techniques have been used to visualize cisplatin and
4-8its derivatives in cells. These methods, however, are limited by the availability of synchrotron
radiation and the resolution of the images that they produce. An alternative strategy is the use of
fluorescence microscopy, a relatively non-invasive technique, which can be used to image living
cells with high resolution.9 Unfortunately, most clinically relevant platinum anticancer agents are
not intrinsically fluorescent, thereby preventing use of this technique.
To make fluorescence microscopy a viable method for investigating platinum anticancer
agents, many researchers have attached fluorescent ligands to platinum complexes that are
structurally similar to the established drugs.1012 A potential problem with this strategy, however,
is that the fluorophore rather than the platinum ion may dictate the localization and uptake
properties of the complex, as has been observed for other metal-fluorophore conjugates.13 The
design of entirely new platinum structural motifs that are both cytotoxic and fluorescent is
another area of research.14-1 9 As new drug entities, these types of complexes can be imaged
without the concern of altered localization properties induced by an external fluorophore.
In this chapter, we report the preparation of three new ligands based on di-2-
pyridylmethane. Two of these ligands contain the fluorescent dansyl and 7-nitro-1,2,3-
benzoxadiazole (NBD) units. The initial goal of this research was to prepare new anticancer
platinum complexes with intrinsic fluorescent properties. As demonstrated here, however, the
resulting platinum(II) dichloride complexes of these ligands (1-3, Chart 2.1) are not soluble in
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water, are thermally and photolytically unstable, and poorly emissive. In spite of these
shortcomings, full synthetic details and characterization of these complexes is reported in this
chapter. Additionally, some preliminary studies involving the oxidation of these complexes are
described as well.
CH3  H3C'N'CH3
NO2
N
02S NH 02 NH HN N-
.Pt-Pt* Pt'Cl 'Cl C1' 'Cl Cl 'Cl
1 2 3
Chart 2.1. Structures of [Pt(Ts-dpm)C12] (1), [Pt(Ds-dpm)C12] (2), and [Pt(NBD-dpm)C12] (3),
the syntheses and characterizations of which are presented in this chapter.
2.2. Experimental Methods
General Considerations. Di-2-pyridylmethanamine was prepared from commercially available
di-2-pyridyl ketone by a reported method.20 K2PtCl4 , purchased from Strem Chemicals, was used
to prepare cis-[Pt(DMSO) 2Cl 2]. 21 [Pt(dpk)C12]2 2 and 4-amino-7-nitro-2,1,3-benzoxadiazole
(NBD-NH 2)23 were also prepared by literature procedures. Other reagents were used as received
from commercial vendors. Methanol (MeOH) and acetonitrile (CH 3CN) were used without prior
degassing or drying. Tetrahydrofuran (THF) was saturated with argon and purified by passage
over two columns of A12 0 3 prior to use.
Physical Measurements. NMR measurements were recorded on a Bruker DPX-400
spectrometer in the MIT Department of Chemistry Instrumentation Facility. 1H and 13C NMR
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spectra were referenced internally to residual solvent peaks, and chemical shifts are expressed
relative to tetramethylsilane (SiMe 4; 6 = 0 ppm). 195Pt NMR spectra were referenced externally
using a standard of K2PtCl4 in D20 (6 = -1628 ppm). Optical absorption spectra were recorded
with a Cary 1E spectrophotometer. Emission spectra were obtained with a Photon Technology
International QM-4/2003 fluorimeter. Quantum yields for emission were measured using either
fluorescein in 0.1 M NaOH (D = 0.95)24 for NBD-containing compounds or quinine sulfate in
0.1 M H2SO 4 ((=0.58)25 for dansyl-containing compounds as references and by exciting samples
at their wavelengths of maximum absorbance. Electrospray ionization mass spectrometry (ESI-
MS) measurements were acquired on an Agilent Technologies 1100 series LC-MSD trap.
Elemental analyses were carried out by a commercial analytical laboratory.
Synthesis of N-(Di-2-pyridylmethyl)tosylamide (Ts-dpm). To a mixture of di-2-
pyridylmethanamine (0.706 g, 3.80 mmol) and Na 2CO 3 (1.21 g, 11.4 mmol) in 25 mL of CH 3CN
was added dropwise a solution of tosyl chloride (0.703 g, 3.70 mmol) in 5 mL of CH 3CN. The
resulting mixture was stirred at room temperature for 12 h and then filtered. The colorless filtrate
was concentrated in vacuo to a volume of approximately 10 mL, at which point Ts-dpm
separated from the solution as a white crystalline solid. This solid was collected by vacuum
filtration. An additional crop was collected by further concentration of the filtrate to yield 0.551
g (44%) of Ts-dpm. Mp: 143-144 0C. 1H NMR (400 MHz, CDCl 3): 6 (ppm) 8.41 (2H, d, J= 4.7
Hz), 7.59 (2H, d, J= 8.0 Hz), 7.50 (2H, t, J= 7.6 Hz), 7.28 (3H, in), 7.08 (4H, in), 5.68 (1H, d, J
= 5.8 Hz), 2.28 (3H, s). 13C{ 1H} NMR (100 MHz, CDCl3): 6 (ppm) 158.1, 148.9, 143.2, 137.1,
137.0, 129.5, 127.4, 122.8, 122.3, 62.1, 21.6. ESI-MS: m/z 340.0 ([M+H]+, calcd. 340.1), 338.0
([M-H]~, calcd. 338.1). Anal. Calcd. for Ts-dpm, C18H17N30 2S: C, 63.70; H, 5.05; N, 12.38.
Found: C, 63.71; H, 5.06; N, 12.55.
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Synthesis of N-(Di-2-pyridylmethyl)dansylamide (Ds-dpm), To a mixture of dansyl chloride
(3.60 g, 13.4 mmol) and Na 2CO 3 (7.10 g, 67.0 mmol) in 20 mL of CH3CN was added dropwise
di-2-pyridylmethanamine (2.75 g, 14.8 mmol) in 5 mL of CH 3CN. The resulting mixture was
stirred at room temperature for 12 h and then filtered. The orange filtrate was concentrated to
dryness under vacuum to give a thick oil, which was purified by silica gel column
chromatography, eluting with 9:1 CH 2Cl 2/MeOH. After chromatography, the product was
initially obtained as a thick yellow-green oil. Upon recrystallization with 1:1 MeOH/Et 2O, pure
Ds-dpm was obtained as a pale-yellow crystalline solid (4.20 g, 75%). Mp: 101-104 "C. 'H
NMR (400 MHz, CDCl 3): 6 (ppm) 8.34 (1H, dt, J= 8.7 and 0.8 Hz), 8.30 (1H, dt, J= 8.4 and 1.0
Hz), 8.23 (2H, in), 8.12 (1H, dd, J= 7.3 and 1.3 Hz), 7.50 (1H, app t), 7.40 (1H, d, J= 6.5 Hz),
7.34-7.30 (3H, in), 7.11 (2H, d, J= 7.2 Hz), 7.07 (1H, dd, J= 7.32 and 0.8 Hz), 6.93-6.90 (2H,
m), 5.57 (1H, d, J = 6.5 Hz), 2.78 (6H, s). "'C{'H} NMR (100 MHz, CDCl 3): 6 (ppm) 157.8,
151.7, 148.7, 136.6, 134.9, 130.3, 130.0, 129.64, 129.62, 128.3, 123.1, 122.5, 122.0, 119.5,
115.1, 62.5, 45.6. ESI-MS: m/z 419.1 ([M+H]+, calcd. 419.2); 441.0 ([M+Na]*, calcd. 441.1);
859.2 ([2M+Na]*, calcd. 859.3). Anal. Calcd. for Ds-dpm, C23H22N4 0 2S: C, 66.01; H, 5.30; N,
13.39. Found: C, 65.80; H, 5.16; N, 13.44.
Synthesis of N-(Di-2-pyridylmethyl)-7-nitro-2,1,3-benzoxadiazole-4-amine (NBD-dpm). To
a mixture of di-2-pyridylmethanamine (0.802 g, 4.33 mmol) and K2CO 3 (3.00 g, 22.0 mmol) in
15 mL of THF was added dropwise a 10 mL THF solution of 4-chloro-7-nitro-2,1,3-
benzoxadiazole (NBD-Cl; 0.900 g, 4.50 mmol). The mixture was stirred at room temperature for
12 h and then filtered. The dark-brown filtrate was concentrated to dryness in vacuo, and the
resulting residue was partitioned between 50 mL of CH 2 Cl2 and 50 mL of 1 M HCl. The organic
layer was separated, and the aqueous layer was further extracted with two 25-mL portions of
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CH2 Cl 2 . The organics were combined, washed with 50 mL of saturated NaCl, and dried with
MgSO 4. Pure NBD-dpm was obtained after silica gel chromatography (5% MeOH in CH 2Cl 2) as
a brown solid (0.714 g, 46%). Mp: 188-192 0C (dec). 1H NMR (400 MHz, CDCl3): 6 (ppm) 9.15
(1H, bs), 8.65 (2H, d, J= 4.8 Hz), 8.35 (1H, d, J= 8.6 Hz), 7.65 (2H, t, J= 7.7 Hz), 7.40 (2H, d,
J = 7.9 Hz), 7.26 (2H, t, J = 6.1 Hz, overlaps with residual CHCl 3 peak), 6.13 (1H, d, J = 8.6
Hz), 6.02 (1H, bs). 13C{H} NMR (100 MHz, CDCl3): 6 (Ppm) 157.1, 149.4, 144.8, 144.1, 142.5,
137.9, 136.5, 124.7, 123.7, 122.0, 100.9, 63.2. ESI-MS: m/z 349.1 ([M+H]*, calcd. 349.1); 370.9
([M+Na]', calcd. 371.1); 718.8 ([2M+Na]*, calcd. 719.2). Anal. Calcd. for NBD-dpm,
C17H 12N 6 0 3: C, 58.62; H, 3.47; N, 24.13. Found: C, 58.13; H, 3.44; N, 24.02.
Synthesis of [Pt(Ts-dpm)C 2] (1). Ts-dpm (0.270 g, 0.800 mmol) in 10 mL of MeOH was
added to a suspension of cis-[Pt(DMSO) 2Cl2] (0.330 g, 0.780 mmol) in 10 mL of MeOH. After
stirring for 12 h at room temperature, the reaction mixture was filtered to collect 1 as a white
solid. The solid was washed sequentially with 10 mL of MeOH and 10 mL of Et20 before being
dried in vacuo to obtain 0.417 g (88%) of 1. 1H NMR (400 MHz, DMF-d 7), endo conformer: 6
(ppm) 9.54 (1H, d, NH), 9.23 (2H, d), 8.13 (2H, t), 7.90 (2H, d), 7.60 (2H, t, overlapped by exo
conformer peaks), 7.78 (2H, d), 7.34 (2H, d, overlapped by exo conformer peaks), 6.15 (1H, d,
py 2CHNHR), 2.39 (3H, s, CH 3); exo conformer: 6 (ppm) 10.15 (1H, d, NH), 9.13 (2H, d), 8.19
(2H, t), 7.87-7.84 (4H, m), 7.60 (2H, t), 7.36 (2H, d), 6.79 (1H, d, py 2CHNHR), 2.34 (3H, s,
CH 3). "Pt NMR (86 MHz, DMF-d7): 6 (ppm) -2082 (endo), -2198 (exo). ESI-MS: m/z 603.9
([M-H]-, calcd. 604.0). Anal. Calcd. for 1, C18H17Cl2N30 2SPt: C, 35.71; H, 2.83; N, 6.94.
Found: C, 35.71; H, 2.87; N, 6.96.
Synthesis of [Pt(Ds-dpm)C12] (2). By following the procedure described for 1 using 1.14 g
(2.69 mmol) of cis-[Pt(DMSO)2Cl2] and 1.50 g (3.58 mmol) of Ds-dpm, 2 was obtained as a
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yellow solid (1.75 g, 95%). 'H NMR (400 MHz, DMF-d), exo + endo: 6 (ppm) 10.40 (d, NH,
exo), 9.65 (d, NH, endo), 9.14 (d, o-py, endo), 9.08 (d, o-py, exo), 8.62 (d, exo), 8.53 (d, endo),
8.47 (d, exo), 8.36 (d, exo), 8.20 (d, endo), 8.02-7.98 (m, exo + endo), 7.75-7.48 (m, exo +
endo), 7.29 (d, exo), 7.18 (d, endo), 6.82 (d, py2CHNHR, exo), 6.30 (d, py2CHNHR, endo), 2.85
(s, N(CH 3)2, endo), 2.83 (s, N(CH 3)2), exo). 19'Pt NMR (86 MHz, DMF-d7): 6 (ppm) -2105
(endo), -2199 (exo). ESI-MS: m/z 682.8 ([M-H]-, calcd. 683.0). Anal. Calcd. for 2,
C23H22Cl2N40 2 SPt: C, 40.36; H, 3.24; N, 8.19. Found: C, 40.40; H, 3.36; N, 8.30.
Synthesis of [Pt(NBD-dpm)C121 (3). By following the procedure described for 1 using 0.106 g
(0.250 mmol) of cis-[Pt(DMSO)2Cl2] and 0.100 g (0.290 mmol) of NBD-dpm, 3 was obtained as
an orange-brown solid (0.109 g, 7 1%). 'H NMR (400 MHz, DMF-d 7), endo conformer: 6 (ppm)
10.40 (1H, d, NH), 9.31 (2H, d), 8.63 (1H, d), 8.40-8.35 (4H, m), 7.73 (2H, t), 7.17 (1H, d,
py 2CHNHR), 7.00 (1H, d); exo conformer: 6 (ppm) 10.44 (1H, d,NH), 9.28 (2H, d), 8.77 (1H, d),
8.31 (2H, t), 8.18 (2H, d), 7.70 (2H, t), 7.60 (1H, br, py 2CHNHR), 7.13 (1H, d). '95Pt NMR (86
MHz, DMF-d): 6 (ppm) -2057 (endo), -2196 (exo). ESI-MS: m/z 612.8 ([M-H]-, calcd. 613.0).
Anal. Calcd. for 3, C17H12Cl2N6O3Pt: C, 33.24; H, 1.97; N, 13.68. Found: C, 33.28; H, 2.04; N,
13.44.
Preliminary Oxidation Chemistry of 1. To a suspension of 1 (0.050 g, 0.083 mmol) in 10 mL
of glacial acetic acid was added 30% H 20 2 (66 pL, 0.58 mmol). The resulting suspension was
stirred at room temperature for 12 h and then filtered to collect 0.029 g of an off-white solid,
which was washed with 10 mL of Et20. The 1H NMR spectrum of this material freshly dissolved
in DMSO-d revealed the presence of a single compound formulated to be the Cs-symmetric
meso-[Pt(K3-Ts-dpm)Cl 2(OH)], a result inconsistent with the lack of symmetry observed in the
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isolated crystal, 1.. After several days standing in solution, the 1H NMR spectrum revealed the
presence of at least two different compounds.
Preliminary Oxidation Chemistry of 3. To an orange suspension of 3 (0.020 g, 0.043 mmol) in
5 mL of glacial acetic acid was added 30% H2 0 2 (34 pL, 0.30 mmol). After stirring at room
temperature for 12 h, acetic acid was removed under reduced pressure from the resulting red
suspension. A 10-mL portion of Et 2 O was added to the red residue, and the dark-red solid that
resulted was collected by filtration and washed with 20 mL of Et2O. The yield was 0.022 g. The
'H NMR spectrum of this material indicated the presence of at least two different compounds.
No attempts were made to isolate and characterize these compounds.
Thermal and Photochemical Reactions. Photochemical reactions were performed using a 1000
W high-pressure Hg/Xe arc lamp (Oriel). Compounds 2 and 3 were irradiated in standard
borosilicate NMR tubes. Because of the low absorptivity of 1 in the visible region, it was
irradiated in a quartz NMR tube to allow better UV light penetration. Thermal reactions were
conducted by placing NMR tubes covered with aluminum foil in a temperature-controlled oil
bath. The temperature was maintained between 60 and 65 'C. Dioxygen- and water-free samples
were prepared in a nitrogen-filled glovebox with dimethylformamide (DMF)-d 7 that had been
dried over 4 A molecular sieves for 48 h. NMR tubes were sealed with rubber septa and
electrical tape.
X-ray Crystallographic Studies. Single crystals were mounted in paratone oil on a cryoloop
and frozen under a 110 or 100 K KRYO-FLEX nitrogen cold stream. Data were collected on a
Bruker APEX CCD X-ray diffractometer with graphite-monochromated MoKa radiation (k =
0.71073 A) controlled by the APEX2 software package.26 Empirical absorption corrections were
applied using SADABS. 2 7 The structures were solved using direct methods and refined on F2
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with the SHELXTL-97 software package.28 29 Structures were checked for higher symmetry
using PLATON. 3 0 All non-hydrogen atoms were located and refined anisotropically. In general,
all hydrogen atoms were placed in idealized locations and given isotropic thermal parameters
equivalent to either 1.5 (methyl hydrogen atoms) or 1.2 times the thermal parameter of the atom
to which they were attached. For NBD-dpm and 2, the amine and sulfonamide hydrogen atoms
(H3N) were located on the difference Fourier map and refined with constrained H-N bond
distances (0.88 A) and isotropic thermal parameters (1.2 times the thermal parameter of the
attached nitrogen atom).
Table 2.1. X-Ray Crystallographic Data Collection and Refinement Parameters for Ds-dpm and
NBD-dpm.
Ds-dpm NBD-dpm
formula C2 3 H2 2N 4 0 2 S C 17H 12N 60 3
fw 418.51 348.33
space group Pbca C2/c
a, A 10.4517(9) 13.9662(10)
b, A 15.8232(13) 10.6609(8)
c,A 24.852(2) 21.2035(15)
a, deg
p, deg 101.7580(10)
,y, deg
V, A3  4109.9(6) 3090.8(4)
Z 8 8
Pcaic, g/cm 3  1.353 1.497
T, 0C -163(2) -163(2)
p(Mo Ka), mm1  0.186 0.108
0 range, deg 1.64-26.37 1.96-28.70
total no. of data 55468 31855
no. of unique data 4194 3998
no. of params 276 238
completeness to E (%) 100.0 100.0
Ra (%) 4.41 4.53
wR 2 b(%) 9.45 10.93
GOFC 1.033 1.024
max, min peaks, e/A3 0.312, -0.378 0.438, -0.318
a RI = 1llFoI - IFeII/EIFol. b wR2 = {E[w(F 2 - Fe2)2]/E[w(Fo2)2] } 2. c GOF = {E[w(Fe2 -Fe2 ]/(n
-p)}1/2 where n is the number of data and p is the number of refined parameters.
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X-ray-quality crystals of the ligands Ds-dpm and NBD-dpm were grown by evaporation
from 1:1 MeOH/Et2O and CH2 Cl2 solutions, respectively. X-ray-quality crystals of the platinum
complexes 1-3, lo, and 3., were grown by vapor diffusion of diethyl ether into DMF solutions.
Compound 2 crystallized with a well-ordered molecule of DMF in the asymmetric unit.
Compound 3 crystallized with half a molecule of disordered diethyl ether in the asymmetric unit,
with the central oxygen atom occupying a crystallographic inversion center. This molecule of
diethyl ether was refined anisotropically with the help of similarity restraints on bond distances
(SADI) and anisotropic thermal parameters (SIMU and DELU). In addition, 3 crystallized as a
disordered mixture of the exo and endo conformers. Restraints to enforce planarity (FLAT) and
similarity (SAME, SIMU, and DELU) were used in the refinement of the disordered NBD rings.
The thermal parameters of C6 and its disordered component C6A were constrained to be
identical with the use of the EADP command. Both 1., and 3,, afforded only small, low-quality
crystals. Refinement suffered from several unreasonable thermal ellipsoids. The ellipsoid of the
oxygen atom of the hydroxo ligand in 1, failed the Hirschfeld rigid-bond test.31 The Pt-O bond
separation was around 2.1 A, which is 0.1 A longer than most Pt-hydroxo bond lengths. These
two results suggest some occupational disorder between a chloride and an oxygen atom. A
hydrogen-bonding interaction is present between the sulfoxide oxygen (02) and the coordinated
oxygen (03, 2.96 A) suggesting that the modeled stereochemistry is most likely the most
prevalent in the crystal structure. The thermal ellipsoid of C6 in 3., became nonpositive definite
upon the initial anisotropic refinement and was therefore subsequently constrained to equal that
of its neighbors. Additionally, large solvent-accessible voids that contained heavily disordered
electron density were present in both cases, thus affecting the overall weighting factor of the
refinement. Because of these problems, only the probable atomic connectivity is discussed for
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these structures. A summary of the crystallographic data and refinement information for the
ligands and 1-3 is presented in Tables 2.1 and 2.2, respectively. Because the crystal structures of
lx and 3ox were not refined to completion, only the space group and unit cell parameters are
given in Table 2.3.
Table 2.2. X-Ray Crystallographic Data Collection and Refinement Parameters for 1-3.
1
C 18 H 17Cl 2N 30 2Pt
605.40
2-DMF
C26 H29Cl2N 5O3PtS
757.59
3-0.5Et2O
C 19H 1 7Cl 2N 60 3.50
651.38
space group
a, A
b,A
c, A
a, deg
P, deg
y, deg
V, A3
z
Pcalc, g/cm 3
T, C
p (Mo Ka), mm-1
0 range, deg
total no. of data
no. of unique data
no. of params
completeness to E
Ra (%)
wR2 b (%)
GOFc
max, min peaks,
Cc
11.4122(12)
13.2503(14)
13.7957(19)
112.456(2)
1927.9(4)
4
2.086
-173(2)
7.683
2.47-28.28
18845
4712
246
100.0
2.24
4.46
1.006
1.424, -0.767
a RI = IIFol - IFj/IIFol. b wR2= {E[w(F=2
-p)}l12 where n is the number of data and p
PI
9.3238(12)
10.2881(13)
16.284(2)
74.290(2)
79.220(2)
65.939(2)
1367.8(3)
2
1.839
-173(2)
5.439
1.30-26.51
24234
5667
350
99.5
2.87
6.22
1.055
1.450, -1.758
PT
8.5263(4)
11.3987(6)
11.9663(6)
86.0360(10)
85.1820(10)
69.5230(10)
1084.67(9)
2
1.994
-163(2)
6.752
1.71-26.37
19570
4436
435
100.0
2.50
5.16
1.092
1.086, -0.606
- Fe 2)2]/y[w(F0 2)2 ] 1/2. c GOF = {I[w(F2 - Fe2 2]/(n
is the number of refined parameters.
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formula
fw
Table 2.3. Space Group and Unit Cell
lox 3 ox
space group PI Pbca
a, A 7.4999(5) 14.3561(9)
b, A 11.6437(7) 15.0452(9)
c,A 13.9301(9) 23.5886(15)
a, deg 95.2240(10)
p, deg 95.0050(10)
y, deg 92.5160(10)
V, A3  1205.15(13) 5094.9(5)
Z 2 2
T, OC -163(2) -163(2)
2.3. Results and Discussion
Ligand Synthesis and Characterization. The three ligands were prepared in moderate to good
yields from di-2-pyridylmethanamine and the corresponding sulfonyl (Ts-dpm and Ds-dpm) or
aryl (NBD-dpm) chloride in the presence of a carbonate salt as a base to neutralize the
hydrochloric acid byproduct, as shown in Scheme 2.1. Di-2-pyridylmethanamine is a convenient
starting material for the synthesis of these new fluorescent ligands. The primary amine group is
readily functionalized by a number of amine-specific fluorescent labeling reagents, while the two
pyridyl arms remain available for metal coordination. This property is demonstrated here by our
use of dansyl and NBD, both well-known fluorophores. Because platinum complexes containing
similar ligands display cytotoxic activities similar to that of cisplatin, 32-34 we hypothesized that
platinum complexes utilizing our modified dpm ligands would similarly be cytotoxic.
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Parameters of 1o. and 3ox.
CH3
TsCl, Na2CO3  02S.NH Ts-dpm
CH3CN N H N_
H3CXCHCR3
NH2
N N 
_ 
_ DsCL, Na2CO 3
CH 3CN 02S'NH Ds-dpm
I UNTN
0 2N N-0
NBD-Cl, K2C0 3
THF N NH NBD-dpm
Scheme 2.1. Syntheses of modified di-2-pyridylmethane (dpm) ligands.
The three ligands were characterized by 1H and 13C NMR spectroscopy and by ESI-MS.
Both Ds-dpm and NBD-dpm were structurally characterized by X-ray diffraction as well. The
NMR spectra of the ligands are consistent with the structures depicted in Scheme 2.1. The 13C
NMR spectra displayed characteristic resonances for the methine carbon atoms (py2 CINHR) at
62-63 ppm for all three ligands. The proton resonance of this methine carbon atom appeared as a
doublet near 5.6 ppm in the 'H NMR spectra of Ts-dpm and Ds-dpm. In NBD-dpm, this
resonance was a broad singlet at 6 ppm.
The molecular structures of Ds-dpm and NBD-dpm as determined by X-ray
crystallography are shown in Figure 2.1. Both structures reveal an intramolecular hydrogen bond
between N2 of the pyridine ring and N3 of the sulfonamide. The N- -N distance is 2.73A for Ds-
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dpm and 2.60 A for NBD-dpm. Ds-dpm exhibits no other noteworthy intra- or intermolecular
interactions in the solid state. In contrast, NBD-dpm engages in a long range intermolecular n-
stacking interaction along the crystallographic c axis. This stacking interaction occurs in a
BBABB-type pattern, where the pyridine ring (A) is flanked on either side by two consecutively
stacked NBD heterocycles (B). The interplanar distance between the NBD heterocycles is 3.37
A, and the spacing between the NBD heterocycle and pyridine ring is 3.23 A.
6iom
M4)
03 NO 02
M412
//D
Ds-dpm NBD-dpm
Figure 2.1. Solid-state molecular structures of Ds-dpm (left) and NBD-dpm (right). Ellipsoids
are drawn at the 50% probability level. Unlabeled grey ellipsoids and green open circles
represent carbon and hydrogen atoms, respectively.
Syntheses and X-Ray Crystal Structures of the Platinum Complexes. The platinum
complexes 1-3 were prepared by treatment of a suspension of cis-[Pt(DMSO) 2Cl 2] in MeOH
with a methanolic solution of the ligand, as shown in Scheme 2.2. This general synthetic route
for the preparation of diiminedichloroplatinum(II) compounds has been used previously.3 s-3 9 The
platinum complexes were isolated as analytically pure solids in yields of greater than 70%. These
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compounds were characterized both in the solid state by X-ray diffraction and in solution by
NMR spectroscopy.
I I
N, N
N. N
MeOH, rt C1'"Pt-C1
cis-[Pt(DMSO) 2C 2] + RNH-dpm ' c
1, R=Ts
2, R=Ds
3, R = NBD
Scheme 2.2. Syntheses of platinum(II) complexes 1-3.
The molecular structures of 1-3 are shown in Figure 2.2. Selected interatomic distances
and angles are displayed in Table 2.4. As anticipated, the ligands adopt a bidentate coordination
mode through the nitrogen atoms of the pyridine rings. The typical square-planar geometry for
platinum(II) is observed for 1-3 with only minor deviations from the ideal 900 L-Pt-L
interatomic angles. These values range from 87.6' to 92.0' in the three complexes. The Pt-L
bonds have the expected distances of about 2 A for Pt-Npy and 2.3 A for Pt-Cl. In the solid
state, these compounds are asymmetric. For 1 and 2, the tosyl and dansyl groups are positioned
over a coordinating pyridine ring. In 3, the NBD heterocycle is tilted to one side, thus destroying
a potential mirror plane containing Ptl, C6, and N3.
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3
Figure 2.2. Solid-state molecular structures of 1-3. Ellipsoids are drawn at the 50% probability
level. Unlabeled grey ellipsoids and green open circles represent carbon and hydrogen atoms,
respectively. Solvent molecules and the disorder of 3 is omitted for clarity.
Unlike the related diimine ligands 2,2'-bipyridine and 1,10-phenanthroline, which form
five-membered planar chelate rings, dpm and the analogues studied here give rise to six-
membered chelate rings that are not planar. As observed in the structures of 1-3, the chelate
rings adopt a boat-like conformation. Because the bridging methine carbon atom is bound to two
inequivalent substituents in addition to the pyridine rings, two different conformational isomers
exist. These conformers, exo and endo, are depicted in Scheme 2.3.
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Table 2.4. Selected Interatomic Distances (A) and Angles (0) for 1-3.a
1 2-DMF 3-0.5Et 2O
Ptl-Cl 2.2980(13) 2.2917(9) 2.2851(10)
Ptl-C2 2.2903(11) 2.2943(9) 2.3044(9)
Ptl-N1 2.032(4) 2.015(3) 2.015(3)
Ptl-N2 2.020(3) 2.018(3) 2.009(3)
N1-Ptl-N2 87.93(14) 87.71(11) 87.64(11)
N1-Ptl-Cll 178.33(10) 178.70(8) 177.48(8)
N1-Ptl-Cl2 90.90(10) 90.39(8) 90.47(8)
N2-Ptl-Cl 90.65(11) 91.09(8) 89.92(9)
N2-Ptl-C12 178.73(11) 177.41(8) 178.11(9)
Cll-Ptl-Cl2 90.52(4) 90.83(3) 91.98(4)
a Numbers in parentheses are the estimated standard deviations of the
last significant figures. Atoms are labeled as indicated in Figure 2.2.
RHN H
H NHR
Pt NCl Ptoo'Cl
exo endo
Scheme 2.3. Depiction of the two conformational isomers of 1-3.
Compound 1 crystallizes exclusively as the endo conformer, 2 as the exo conformer, and
3 as a disordered mixture of the two. The occupancy factors of the disordered components of 3
were allowed to refine freely, and a final value of 66% was obtained for the exo conformer. The
two disordered components of 3 are shown in Figure 2.3.
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exo endo
Figure 2.3. Disordered components of 3. Both exo (left) and endo (right) isomers were present in
the crystal lattice.
Another noteworthy feature in the structures of 1-3 is a close Pt -- H interaction observed
for the hydrogen atoms of the methine carbon (C6) in the exo conformers and the hydrogen atom
of amine or sulfonamide nitrogen (N3) of the endo conformers. For 1 and the endo conformer of
3, the hydrogen atom of N3 is 2.88 and 2.90 A from the Pt center, respectively. The
corresponding N-H-Pt angles are 102.40 and 110.90. These values, however, should be
interpreted with caution because the hydrogen atoms were placed at calculated positions rather
than being freely refined. The hydrogen atoms could not be freely refined because they were not
located on the difference map. Similar Pt --H distances are observed in the exo conformers. For
the exo conformer of 3, the hydrogen atom of C6 is at distances of and 2.67 A from the platinum
atom with a C-H-Pt angle of 97.44. These values also are derived from a hydrogen atom placed
at a calculated location. For 2, which crystallizes in the exo conformer, the hydrogen atom of the
methine carbon could be located on the difference map and freely refined. In the final model,
however, this hydrogen atom was placed at a calculated position. The Pt-- H distance for the
freely refined model is 2.92(4) A, whereas for the model with the calculated position it is 2.79 A.
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The corresponding C-H-Pt angles are 87.7 and 95.50 for the freely refined and calculated
models, respectively. The disparity in these values emphasizes the potential shortcomings in
using X-ray diffraction data to interrogate distances between heavy metals and hydrogen atoms.
The nature of similar axial M --H interactions of less than 3 A in d8 square-planar
complexes has previously been investigated by us 4 0 and by others.4143 These studies examined
whether such interactions should be considered agostic. Authentic agostic interactions are
characterized as covalent 3-center-2-electron interactions.4 In all of the studies, these particular
d8 square-planar interactions were characterized as purely electrostatic in nature and therefore
not agostic. In the cases of 1-3, the close Pt---H distances are most likely a consequence of the
ligand-binding geometry. However, the NMR data discussed below are consistent with the
presence of weak electrostatic interactions.
NMR Spectroscopic Characterization of 1-3. The three platinum complexes are insoluble in
nonpolar organic solvents and water. The compounds are very soluble in DMSO and DMF.
Given the propensity of DMSO to interact with platinum(II) by ligand substitution reactions, 4 5-4 7
DMF-d 7 was chosen as the solvent for conducting NMR spectroscopic studies of 1-3. The 'H
NMR spectra of 1-3 in DMF-d7 at 20 'C displayed two distinct sets of resonances of unequal
intensity corresponding to the inequivalent exo and endo conformers. At temperatures above 65
0 C, the signals coalesce as interconversion rapidly occurs and the different conformers become
indistinguishable on the NMR time scale, as shown in Figure 2.4 for 1. Similar behavior was
observed for 2 and 3. This process is reversible through several temperature cycles. However,
prolonged exposure of these compounds to elevated temperatures does eventually lead to
decomposition (vide infra).
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Figure 2.4. Variable-temperature 1H NMR spectra of 1 in DMF-d. The signal marked with an
asterisk is from a monoprotic impurity in the deuterated DMF.
Proton resonances were assigned using 2D NMR spectroscopic techniques. Selected 1H
and 195Pt NMR chemical shifts are displayed in Table 2.5. The resonances of the protons ortho to
the coordinating nitrogen atoms of the pyridine rings fall between 9.0 and 9.3 ppm for the three
complexes in both conformations. These resonances are 0.6-1.0 ppm downfield from the
corresponding values in the free ligands, consistent with coordination to the Pt center. In the 'H-
13 C HSQC spectra, the amine and sulfonamide protons could be identified as the only resonances
not correlated to a carbon nucleus. These proton chemical shifts are farthest downfield, with
values ranging from 9.5 to 10.4 ppm. The large downfield shifts of these protons are attributed in
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part to hydrogen-bonding interactions with the highly polar DMF solvent. The methine proton
resonances (C6 in Figure 2.2) were identified based on coupling to the NH resonances (observed
by 1H-1H COSY) and by coupling to carbon atoms near 65 ppm (observed by 'H-13 C HSQC).
These resonances occur between 6.3 and 7.2 ppm in complexes 1-3.
Table 2.5. Selected 1H and
Compound 6 ' 9'Pt, ppm
exo-1 -2198
endo-1 -2082
exo-2 -2199
endo-2 -2105
exo-3 -2196
endo-3 -2057
195Pt NMR Chemical Shifts for the Conformers of 1-3.
6 'H, ortho-py, ppm 6 1H, N-H, ppm 6 'H, methine H, ppm
9.13 10.15 6.79
9.23 9.54 6.15
9.08 10.40 6.82
9.14 9.65 6.30
9.28 10.44 7.60, broad
9.31 10.40 7.17
'H-1H NOESY experiments identified the exo conformer as the major species in solution
for all three compounds. Especially diagnostic is the presence of an NOE cross-peak between the
NH proton and the protons at the 3 position of the pyridine rings only in the major set of signals.
A similar cross-peak was observed between the methine proton and the protons at the 3 position
of the pyridine ring in the minor set of signals, corresponding to the endo conformer. Negative
phase cross-peaks between analogous protons of the exo and endo conformers were also
observed, indicating that interconversion between the conformers occurs within the 400 ms
mixing period of the experiment. Figure 2.5 shows a 1H- H NOESY NMR spectrum of 1 as a
representative example.
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NH NH CH CHH (eo) (endo) (exm) (endo)
H -
32
4 N'PtI*C
56
exo ff 0
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H X
NHR -H 2
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6 endo 1
Figure 2.5. 1H- H NOESY NMR spectrum of 1 in DMF-d7 at 20 'C. Positive-phase cross peaks
are in green and negative-phase cross-peak are in turquoise. Cross-peaks in squares are due to
NOE interactions between the CH methine proton and the protons at the 3-position of the
pyridine ring of the endo isomer. Cross-peaks in circles are due to NOE interactions between the
sulfonamide NH proton and the protons at the 3-position of the pyridine ring of the exo isomer.
The turquoise cross-peaks between NH and methine protons of the two isomers are indicative of
chemical exchange within the 400 ms mixing time of the experiment. The cross-peak marked
with a cross is an instrumental artifact due to folding over of the NMR spectrum.
The methine proton resonances of the exo conformers 1-3 occur about 1 ppm downfield
from those in the endo conformers. This downfield shift is consistent with a weak electrostatic
interaction between the methine proton and the Pt center, as observed in the crystal structures an
discussed above. Agostic interactions, on the other hand, would shift these resonances upfield.4
195 Pt NMR spectra for 1-3 were recorded at 20 *C in DMF-d7. As expected, two distinct
resonances are observed for each compound, corresponding to the two conformers (Figure 2.6).
The observed chemical shifts (-2057 to --2199 ppm) for these complexes are in the range
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expected for platinum(II) with an N2 Cl 2 coordination environment. 4 8-50 For all three complexes,
the exo conformer resonance occurs upfield from that in the endo conformer, indicating greater
shielding of the Pt nucleus in the former. In the three complexes, the chemical shifts of the exo
conformers all fall within 3 ppm of -2198 ppm. This similarity is remarkable given the large,
15,000 ppm window for the 195Pt nucleus. The chemical shifts of the endo conformers span a
wider range. The shifts are -2082, -2105, and -2057 ppm for 1-3 respectively. This wider range
in shifts reflects the fact that the endo conformations position the different functional groups of
the ligands closer to the Pt center than the exo conformations.
3
1
-1900 -20 -2100 0-230
5/ppm
Figure 2.6. 195Pt NMR spectra of 1-3 in DMF-d 7 at 20 'C. Signal are observed for the both the
exo (major) and endo (minor) conformers.
From the VT-NMR experiments, thermodynamic data could be obtained by exploring
how the relative ratios of the exo and endo conformers vary with temperature. From this data
van't Hoff plots were constructed to afford values of AH', AS', and AG' (at 298 K) for the
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conversion of the exo conformer to the endo conformer. These parameters are collected in Table
2.6. The larger size of the dansyl group may influence the greater thermodynamic preference for
the exo conformer in 2, relative to 1 and 3. In general, these energy differences are quite small,
consistent with the presence of both conformers in the solid-state and solution.
Table 2.6. Thermodynamic Parameters for the exo to endo Conversion of 1 - 3 in DMF
Solution.
Compound AH*, kcal-mol-' AS0, cal-K' -mol' AG' (298 K), kcal-molr
1 +1.38 ±0.05 -2.4 ±0.2 +2.09 ±0.07
2 +2.10 ±0.07 -3.9 ±0.2 +3.25 ±0.09
3 +1.31 0.05 -2.5 ± 0.1 +2.06 ± 0.06
Photophysical Properties. Relevant photophysical properties for the ligands and compounds 1-
3 in a DMF solution are summarized in Table 2.7, and optical absorption spectra are shown in
Figure 2.7. Emission spectra of the compounds are provided in Figure 2.8. A pyridine-localized
1 1-2* transition appears in all three ligands around 270 nm. For Ts-dpm, this is the only spectral
feature observed. The band at 340 nm and the absorptions at 330 and 468 nm of Ds-dpm and
NBD-dpm, respectively, can be assigned to 'n-n* transitions localized in the naphthalene ring
system and fused heterocycle of the two ligands. Ts-dpm is nonemissive. Both Ds-dpm and
NBD-dpm emit in the green region of the visible spectrum at 521 and 524 nm with quantum
yields of 0.30 and 0.32, respectively. These values are similar to those reported for other
compounds conjugated with dansy151 -53 and NBD'54 55 in organic solvents. This result indicates
that the pyridine rings do not induce significant quenching of the fluorophores.
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Table 2.7. Electronic Absorption and Emission Data for Ligands and Platinum Complexes in
DMF Solution.
Compoun Absorption Xmax, nm (s x 10-, M-'-cm-') Emission lem, nm (0)
Ts-dpm 268 (5.04) -
Ds-dpm 269 (18.7), 340 (4.90) 521 (0.30)a
NBD-dpm 270 (8.80), 330 (6.30), 468 (22.0) 524 (0.32) b
1 270 (10.00), 310 (5.10) -
2 266 (16.30), 312 (8.50) 440 (0.019) a
3 270 (19.0), 388 (13.60), 476 (sh, 25.80), 496 (28.20) 545 (0.003) b
a Referenced to quinine sulfate (D = 0.58 in 0.1 M H2 SO 4 ) b Referenced to fluorescein ((D = 0.95
in 0.1 M NaOH)
E
300 350 400 450 500
Wavelength (nm)
550 600 650
Figure 2.7. UV-vis absorption spectra for Ts-dpm (-), Ds-dpm (red
(blue m), 2 (maroon *), and 3 (purple o) in DMF at room temperature.
o), NBD-dpm (green x), 1
128
1.00- 1-00
0.75- /> ~075 /
0.50- 0.o 0
0.25- f02
0.00 * 0,00
350 400 450 500 550 600 850 450 500 550 800 650 700
Wavelength (nm) Wavelength (nm)
Figure 2.8. Room temperature normalized emission spectra of Ds-dpm (red .) and 2 (maroon *)
(left), and NBD-dpm (green x) and 3 (blue o) (right) in DMF. Spectra were obtained by exciting
compounds at their wavelengths of maximum absorption.
Upon coordination to platinum(II), the absorption features of the ligands are altered. The
pyridine-localized ln-n* transitions occur at nearly the same wavelength but with a 2-fold
increase in the extinction coefficients in the platinum complexes. For 1, a new band at 310 nm is
observed that is not present in the free ligand. For 2, the band at 340 nm in the free ligand is
shifted to higher energy, appearing at 312 nm. The major bands of NBD-dpm are red-shifted
significantly to 388 and 496 nm when coordinated to platinum in 3.
Platinum coordination also affects the emission properties of the ligands (Figure 2.8).
Like Ts-dpm, 1 is not emissive. The platinum complexes 2 and 3 exhibit broad, unstructured
emission bands similar to those of the free ligands. The emission band of 2 is centered at 440 nm,
which is 80 nm (3500 cm-) higher in energy than the free ligand. In contrast, the emission band
of 3 is centered at 545 nm, 20 nm (740 cm-1) lower in energy than the free ligand.
The measured quantum yields for fluorescence of 2 and 3 are 0.019 and 0.003,
respectively, indicating large quenching of the ligand fluorescence. This effect most likely arises
from the close proximity of the Pt center to the fluorophores. Heavy atoms can increase the rates
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of spin-forbidden radiation-less transitions in aromatic systems, thus lowering the overall
quantum yield of fluorescence.56'57 Fluorescence quenching of a dansyl fluorophore by
platinum(II) occurs in a series of compounds with different-sized linkers between the metal atom
and fluorophore. 58 As expected, the fluorescence was quenched to a larger extent when the
dansyl group was closer to the Pt center. The large quenching effect observed for 2 and 3 is
undesirable for potential cellular imaging applications. For future ligand design, longer and more
rigid alkyl chains as spatial linkers may be necessary to position the fluorophores farther away
from the Pt center to avoid quenching by the heavy-atom effect.
Thermal and Photochemical Reactivity. Compounds 1-3 are stable for over 4 weeks in a DMF
solution when kept in the dark at room temperature. To assess the stability of these compounds
under elevated temperatures and exposure to light, controlled thermolytic -and photolytic
reactions were monitored by 1H and 195Pt NMR spectroscopy. At 60 'C in the dark, air-
equilibrated solutions of 1 in DMF slowly decompose. Several new resonances appear in the 1H
NMR spectrum, and the solution color changes gradually from almost colorless to pale yellow.
The thermal reaction is slow; after 85 h at 60 'C, only 25% of the starting compound is
consumed. The decomposition products are numerous and were not conclusively identified.
Irradiation of 1 at room temperature led to no observable changes in the 1H NMR spectrum.
An air-equilibrated solution of 2 in DMF is stable at 60 'C for at least 60 h, with no
noticeable change in the 1H NMR spectrum or solution color. However, upon irradiation, the
pale-yellow color of a solution of 2 turns dark red over the course of several days. The
conversion is complete after 80 h, as monitored by 1H NMR spectroscopy. The 'H NMR
spectrum of the photoproduct displays resonances consistent with the presence of a dansyl group
and two equivalent pyridine rings. Neither the sulfonamide nor the methine proton was observed,
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indicating their absence in this photoproduct. A signal at -2177 ppm was present in the 19 5Pt
NMR spectrum. This value is within the range expected for platinum(II) having an N 2Cl 2
coordination environment. 48 ~50 Attempts to crystallize the major photoproduct of 2 were
unsuccessful. Additional attempts to characterize the compound by ESI-MS were also
unsuccessful; no diagnostic peaks were observed in the MS spectrum in either positive- or
negative-ion mode. Our current working hypothesis for the identity of this photoproduct is that a
dichloroplatinum complex ligated by a sulfonylimine analogue of Ds-dpm forms, as illustrated in
Scheme 2.4. This formulation is consistent with the lack of methine and NH protons in the 1H
NMR spectrum.
H3C' N' CH3  H3C'N'CH3
[PtN2C 2]
02S'NH hv, 02, trace H20 02S, N 19 5Pt 5= -2177 ppm
DMF_
D M F I I ''D ark R ed
PC~ Pt-C1' 'Cl C1 'Cl
Pale Yellow
Scheme 2.4. Proposed photolytic decomposition pathway of 2.
. Thermolysis of 3 at 60 'C for 80 h leads to its complete conversion to several new
compounds, as monitored by 1H NMR spectroscopy. Two of the newly formed products were
conclusively identified as [Pt(dpk)C12] and NBD-NH 2. Figure 2.9 shows the 1H NMR spectrum
of 3, its thermolysis products, and authentic samples of [Pt(dpk)C12] and NBD-NH 2 in DMF-d 7.
The resonances marked with circles correspond to [Pt(dpk)C12] and the resonances marked with
crosses to NBD-NH 2 . Further support for these assignments comes from 19'Pt NMR
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spectroscopy and ESI-MS. At 40 h into the thermolysis reaction, a 195Pt NMR spectrum was
obtained of the reaction mixture. In addition to the two signals observed for the conformational
isomers of 3, a new signal a -1958 ppm appeared. This value matches the 195Pt chemical shift of
[Pt(dpk)Cl 2] measured independently, thus supporting its assignment in the 1H NMR spectrum.
ESI-MS studies of the reaction mixture revealed a peak at m/z 178.9 in the negative-ion mode.
This value matches that calculated for NBD-NH-, m/z 179.0. The doublets at 8.8 and 7.3 ppm
and the broad peak at 7.8 ppm in the 1H NMR spectrum are not assigned but most likely
correspond to another NBD-containing compound.
0
0
NO 2
SN
0
N J
NH2
Compound 3 after 80 h at 60 *C
0
to 9 6P 8 7
Figure 2.9. From bottom to top: 1H NMR spectra of 3, 3 after thermolysis at 60 *C for 80 h,
NBD-NH 2, and [Pt(dpk)C12] in DMF-d7 . Resonances marked with circles are assigned to
[Pt(dpk)C12], and resonances marked with crosses are assigned to NBD-NH 2. The doublets at 8.8
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and 7.3 ppm and the broad singlet at 7.8 ppm are currently unassigned. The sharp singlet at 8
ppm in all spectra marked by an asterisk is from the solvent.
Decomposition of 3 to [Pt(dpk)C12] and NBD-NH 2 also proceeds photochemically, as
depicted in Scheme 2.5. Irradiation of 3 at room temperature produces the same changes in the
H NMR spectrum as those observed for the thermal reaction. The photochemical reaction,
however, is much slower. After 85 h of irradiation at room temperature, only 50% conversion of
3 occurs.
NO2
S hvorA, 0 2 ,trace H20 0 NO2
HN N- 0  DMF .--_N
N. NN :t- C1 Cf
CPtPt NH2C1'1 'Cl
Scheme 2.5. Thermolytic and photolytic decomposition pathways of 3.
For 1-3, the same thermal and photochemical conditions were applied under dioxygen-
and water-free conditions by using samples prepared in a nitrogen-filled glovebox in septa-sealed
NMR tubes. Neither irradiation with light nor heating at 65 'C for up to 72 h produced
noticeable changes in the 1H NMR spectra. It is therefore clear that dioxygen and at least trace
amounts of water are necessary to promote the photochemical and thermal transformations
reported here.
Preliminary Oxidative Reactivity Studies. Compounds 1 and 3 could be successfully oxidized
to their platinum(IV) analogues by a procedure recently described for the oxidation of
platinum(II) pyridylazido complexes. 59 Suspensions of the complexes in acetic acid were treated
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with H20 2 to afford the oxidized products. The anticipated products of these reactions were
platinum(IV) hydroxoacetato species, but the observed products were generally more complex.
In the case of 1, a 1H NMR spectrum of the freshly isolated solid indicated the presence of a
single compound. The 1H NMR spectrum was consistent with a complex of Cs symmetry
containing no sulfonamide proton. Additionally, coupling to the 195Pt nucleus was observed for
protons ortho to the coordinating nitrogen atoms of the pyridine rings (JPtH= 27.2 Hz) and, more
surprisingly, to the methine (C6, Figure 2.2) proton (JPtH = 20.4 Hz). Upon standing in solution,
however, this compound undergoes chemical transformations to at least two new species over the
course of several days, as monitored by 1H NMR spectroscopy. The red material isolated from
the oxidation reaction of 3 was also investigated by 1H NMR spectroscopy. The 1H NMR
resonances reveal the presence of at least two different compounds.
Attempts to crystallize these oxidized products for structural characterization afforded
small, weakly diffracting crystals from the reactions of both 1 and 3. Because several issues were
encountered with data collection and refinement (see the Experimental Section), only the
probable connectivity is considered here. The structures of these oxidized compounds, 1. and
3.,, are shown in Figure 2.10. The chemical formulas of 1, and 3.,, as postulated from the
crystal structures are rac-[Pt( 3-Ts-dpm)Cl2(OH)] and [Pt(K3-NBD-dpm)C13]. A common feature
between the two structures is the change in the coordination mode of the dpm ligands from K2 to
K3 upon oxidation. A third binding atom of the dpm ligands is provided by the deprotonated
anionic sulfonamide or amine nitrogen (N3, Figure 2.10). In this coordination mode, the methane
proton is only three bonds from the Pt center, thus accounting for the Pt-H coupling observed in
the 1H NMR spectrum described above. It is also noteworthy that 1. lacks the pseudo-C,
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symmetry that is observed in 1-3 and in the initial oxidation product of 1 as observed by NMR
spectroscopy, thus indicating that the complex isomerizes in solution from the meso isomer (both
chlorides trans to pyridine) to the rac isomer. Also of interest are the three chloride ions in the
coordination sphere of Pt in 34.. Given that no additional chloride source was present in the
reaction mixture, the additional chloride ion of 3,, must have been provided by another platinum
complex. Although the characterization of these oxidation products is incomplete, these
preliminary results demonstrate that the dpm-based ligands can bind in a tridentate manner.
- ~ 0031
~~2 031
lox x
Figure 2.10. Ball-and-stick structures of 14. and 3. as determined by X-ray crystallography
demonstrating atomic connectivity. Carbon and hydrogen atoms are not labeled. The hydrogen
atom of 0(3), a proposed hydroxide ligand, in 14 was not located on the difference map.
2.4. Summary and Conclusions
The synthesis and characterization of three new ligands and their corresponding platinum
complexes was reported. Two of the ligands are fluorescent. Use of di-2-pyridylmethanamine as
a starting material provides access to fluorescent ligands by using any fluorescent amine-labeling
reagent. These ligands can bind in either a bidentate or tridentate coordination mode, a property
of relevance to their chemistry with platinum(IV) and other transition metals that form
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octahedral complexes. Coordination of platinum to the ligands induces significant fluorescence
quenching. Such quenching is undesirable for cellular imaging applications. The platinum
complexes exhibit interesting oxygen-dependent photo- and thermochemical behavior. Although
the products of these reactions for 1 and 2 have not been unambiguously characterized, the final
products for such reactions of 3 were identified as [Pt(dpk)C 2] and NBD-NH 2 . A combination of
the lack of aqueous solubility, poor stability to light and heat, and low emission quantum yields
of 1-3 precludes their use in biological or simulated biological studies.
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Chapter 3
Outer-Sphere Amide Bond Coupling Reactions for the Preparation
of a Fluorescent Platinum(IV) Redox Sensor
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3.1. Introduction
The ability to systematically modify potential platinum anticancer agents by predictable
and readily controlled chemistry is of value for the synthesis of new drug candidates having
novel properties. In recent years, this principle has been applied to generate platinum(IV)
prodrugs. For example, the free carboxylic acid groups of the platinum(IV) compound
cis,cis,trans-[Pt(NH3)2Cl2(succinate)2] can engage in amide bond coupling reactions.1
Functionalization of this compound via amide bond formation has led to the synthesis of many
new platinum(IV) complexes that were tested for biological activity.1-8 This predictable
chemistry has also been used to attach platinum(IV) prodrugs to peptides9-12 and various nano-
delivery devices 1 3-19 for improved anticancer efficacy.
As discussed in Chapter 1, platinum(IV) prodrugs must first be reduced intracellularly to
form platinum(II) complexes that can bind to DNA. 20 There remains some uncertainty about this
21process. It is not clear how quickly, by what means, and where such reduction occurs in living
systems. X-ray fluorescence and absorption spectroscopy has been used to address these
questions. - These methodologies, however, are not applicable to living cells and generally
require synchrotron radiation.
The Introduction of Chapter 2 described some advantages of using fluorescence
microscopy as an imaging technique. Although fluorescence microscopy, unlike X-ray methods,
cannot directly provide information about the oxidation state of metal ions, it is possible to install
ligand systems in which the fluorescence intensity is modulated depending on the oxidation state
of the coordinated metal.2 6 27 Such a system, involving the Pt(IV)/Pt(II) redox couple, has
recently been described,28 in which analogous platinum(II) and platinum(IV) complexes were
coordinated to fluorescent coumarin ligands by means of an aniline functional group on the dye.
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The authors reported a 7-fold greater emission intensity for the platinum(II) compared to the
platinum(IV) complex in DMF solution. Furthermore, confocal fluorescence microscopic
imaging analyses revealed strong localization of the complexes in the cytosol and lysosomes.
The free coumarin ligands localize in a manner similar to that of the complexes, thus raising the
possibility that the coumarin ligands are displaced from platinum in the cell. Similar systems
with strongly coordinated bidentate ligands may be able to provide information about
platinum(IV) reduction in live cells.
In this chapter, outer-sphere amide bond coupling chemistry that is analogous to that
described above for the platinum(IV) complex cis,cis,trans-[Pt(NH3)2 Cl2(succinate)2] is reported
for the platinum(II) complexes [Pt(edda)C12] and [Pt(edma)C12] where edda = ethylenediamine-
N,N'-diacetic acid and edma = ethylenediamine-N-monoacetic acid, which contain two and one
uncoordinated carboxylic acid groups, respectively. In both cases, benzylamine is used as a
substrate for these reactions. For [Pt(edma)C12], the fluorescent amine, dansyl ethylenediamine
(Ds-en) is used as well to form the resulting fluorescent platinum(II) complexes [Pt(edDs)C12].
The platinum(IV) analogue of this compound, [Pt(edDs)C14], is substantially less emissive than
[Pt(edDs)C12]. Upon reduction of [Pt(edDs)C14], a fluorescent turn-on is observed. Hence, the
studies reported in this chapter describe both a modular synthetic route to new platinum(II)
complexes, and the use of such chemistry to design a prototypical fluorescent platinum(IV)
redox sensor. The compounds reported and investigated in this chapter are shown in Chart 3.1.
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Chart 3.1. Structures of compounds 1-6.
3.2. Experimental Methods
General Considerations. All reactions were carried out under normal atmospheric conditions.
Solvents were used as received without additional drying or purification. The compounds,
[Pt(edma)C12],2 9 [Pt(edda)C12],30 dansyl ethylenediamine (Ds-en),3 1 and iodobenzene dichloride 3 2
were synthesized as previously described.
Physical Measurements. NMR spectra were recorded on a Bruker DPX-400 spectrometer in the
MIT Department of Chemistry Instrumentation Facility at 20 0 C. 'H and 13C {'H} NMR spectra
were referenced internally to residual solvent peaks, and chemical shifts are expressed relative to
tetramethylsilane, SiMe 4 (6 = 0 ppm). 195 Ptf'H} NMR spectra were referenced externally to
K 2PtCl4 in D20 (6 = -1628 ppm). Electrospray ionization mass spectra (ESI-MS) were acquired
on an Agilent Technologies 1100 series LC MSD trap. Fourier transform infrared (FTIR) spectra
were recorded with a ThermoNicolet Avatar 360 spectrometer running the OMNIC software.
Samples were prepared as KBr disks. Optical absorption spectra were recorded with a Cary 1E
spectrophotometer. Emission spectra were obtained with a Photon Technology International
QM-4/2003 fluorimeter. Quantum yields for fluorescence were measured using quinine sulfate in
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0.1 M H 2 SO 4 (<D = 0.58) as the reference 33 over a range of at least five different absorbance
values. For measuring these values in phosphate buffered saline (PBS), the samples were diluted
from DMF solutions to give aqueous solutions containing less than or equal to 1% DMF. For all
photophysical measurements, the sample temperature was maintained at 25.0:± 0.5 0C using a
circulating water bath. Elemental analyses were carried out by a commercial analytical
laboratory.
Synthesis of [Pt(edBz)C12] (1). A solution of 1,1'-carbonyldiimidazole (CDI, 0.230 g, 1.42
mmol) in 10 mL of DMF was added to a solution of [Pt(edma)C12] (0.535 g, 1.39 mmol) in 10
mL of DMF. The resulting mixture was heated at 60 'C for 10 min, and then sparged with N2 for
5 min. Benzylamine (0.152 g, 1.42 mmol) in 15 mL of DMF was added dropwise to the solution
containing the activated platinum complex. After stirring for 12 h, the solution was concentrated
to 10 mL under reduced pressure and elevated temperature (60 C), and then filtered through
Celite. The addition of 10 mL of water afforded the desired compound as a pale yellow solid,
which was isolated by filtration and washed sequentially with 5 mL of water, 2 x 5 mL of
ethanol, and 2 x 5 mL of diethyl ether before being dried in vacuo. Yield: 0.268 g (40%). M.p.
298-300 'C (dec). 1H NMR (400 MHz, DMF-d7): 5 8.60 (t, 1H), 7.35-7.26 (m, 5H), 6.15 (br s,
1H), 5.48 (br s, 2H), 4.43 (d, 2H), 4.27 (d, 1H), 3.71 (dd, 1H), 3.12-3.07 (br m, 1H), 2.82-2.72
(br m, 2H), 2.57-2.55 (br m, 1H). 13C{'H} NMR (100 MHz, DMF-d 7): 6 168.2, 139.4, 128.6,
127.7, 127.2, 57.8, 55.1, 47.3, 42.8. 195 Ptf'H} NMR (86 MHz, DMF-d 7): 6 -2339. IR (KBr, cm-
): 3335 m, 3274 s, 3202 m, 2940 w, 1654 vs, 1576 m, 1545 s, 1455 w, 1436 m, 1425 m, 1392
vw, 1279 w, 1243 m, 1168 w, 1116 w, 1091 w, 1041 w, 967 w, 758 m, 702 s, 611 w, 572 w, 525
w. ESI-MS (negative-ion mode): m/z 509.4 ([M+Cl]~ , calcd. 508.0), 944.6 ([2M-H]~, calcd.
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945.1), 980.9 ([2M+Cl] , calcd. 981.0). Anal. Calcd. for 1, CnIH17Cl 2N3OPt: C, 27.92; H, 3.62;
N, 8.88. Found: C, 28.30; H, 3.65; N, 8.85.
Synthesis of [Pt(edDs)C12] (2). A solution of CDI (0.206 g, 1.27 mmol) in 20 mL of DMF was
added to a solution of [Pt(edma)C12] (0.469 g, 1.21 mmol) in 16 mL of DMF, and the resulting
mixture was stirred at 60 'C for 10 min. The solution was sparged with N 2 for 5 min, and then
Ds-en (0.372 g, 1.27 mmol) in 20 mL of DMF was added dropwise. After stirring at rt for 12 h,
the mixture was concentrated to 10 mL under vacuum and increased temperature (60 *C), and
then filtered through Celite. Water (10 mL) was added to the filtrate to precipitate the desired
compound. The pale yellow solid was isolated by filtration, and washed sequentially with water,
ethanol, and diethyl ether. Yield: 0.471 g (59%). M.p. 258-262 'C (dec). 'H NMR (400 MHz,
DMF-d 7): 6 8.55 (d, 1H), 8.39 (d, 1H), 8.28 (t, 1H), 8.20 (d, 1H), 7.97 (br t, 1H), 7.68 (t, 1H),
7.62 (t, 1H), 7.30 (d, 1H), 6.03 (br s, 1H), 5.44 (br s, 2H), 4.12 (d, 1H), 3.49-3.45 (m, 1H), 3.29
3.26 (m, 2H), 3.01-2.96 (m, 3H), 2.88 (s, 6H), 2.69 (br m, 2H), 2.44 (br m, 1H). 13C{'H} NMR
(100 MHz, DMF-d 7): 6 168.4, 152.2, 136.6, 130.01, 129.99, 129.8, 128.9, 128.2, 123.9, 119.7,
115.6, 57.7, 55.1, 47.3, 45.2, 42.5, 39.6. '95Pt{H} NMR (86 MHz, DMF-d7): 8 -2345. IR (KBr,
cm-1): 3351 m, 3270 m, 3192 m, 3141 m, 2946 w, 1659 vs, 1571 w, 1547 w, 1318 s, 1144 s,
1095 w, 788 s, 629 w, 576 w. ESI-MS (negative-ion mode): m/z 657.8 ([M-H]-, calcd. 658.1).
Anal. Calcd. for 2, Ci8 H27Cl2N50 3PtS: C, 32.78; H, 4.13; N, 10.62. Found: C, 32.92; H, 4.12; N,
10.77.
Synthesis of [Pt(edBz 2)C 2] (3). A solution of CDI (0.465 g, 2.87 mmol) in 50 mL of DMF was
added to a suspension of [Pt(edda)C12] (0.619 g, 1.40 mmol) in 16 mL of DMF. The resulting
mixture was heated at 60 'C for 10 min, at which point a yellow solution resulted, and then
sparged with N2 for 5 min. Benzylamine (0.307 g, 2.87 mmol) in 40 mL of DMF was added in a
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dropwise manner to this solution containing the activated platinum complex. After stirring for 12
h, the solution was concentrated to 15 mL under reduced pressure and elevated temperature (60
C). The addition of 20 mL of water afforded the desired compound as an off-white solid, which
was isolated by filtration and washed sequentially with 5 mL of water, 2-5 mL of ethanol, and 2
x 5 mL of diethyl ether (Et 2O) before being dried in vacuo. Yield: 0.594 g (68%). M.p. > 280 OC
(gradual browning), 302-307 *C (dec into black liquid). 1H NMR (400 MHz, DMF-d): R,R/S,S
+ R,S diastereomers (1:1) 6 8.64 (2H, two overlapping triplets, amide NH), 7.36-7.24 (multiplet,
10H, aromatic protons), 6.22 + 6.15 (2H, broad singlets, coordinating NH), 4.48-4.38 (m, 4H,
benzyl CH 2), 4.31-4.16 (2H, two doublets, CH adjacent to amide), 3.80-3.62 (two doublet of
doublets, 2H, CH adjacent to amide), 3.21-3.11 (broad multiplet, 2H, CH2 ethylenediamine
backbone), 2.72-2.66 (broad multiplet, 2H, CH 2 ethylenediamine backbone). "C{ 1H} NMR
(100 MHz, DMF-d 7): R,R/ SS + R,S diastereomers (1:1) 6 168.1 + 168.0, 139.50 + 139.48,
128.7, 127.82, 127.79, 127.3, 55.6 + 54.7, 55.1, 42.91. 195Pt{'H} NMR (86 MHz, DMF-d):
R,R/S,S + RS diastereomers (1:1) 6 -2347, -2362. IR (KBr, cm 1): 3340 m, 3165 m, 3111 m,
2949 w, 1685 m, 1662 s, 1555 m, 1496 w, 1452 w, 1419 m, 1358 w, 1261 m, 1078 w, 1025 w,
986 w, 860 w, 748 w, 695 w, 581 w, 453 w. ESI-MS (negative-ion mode): m/z 582.9 ([M-2H-
Cl]-, caled. 583.1), 619.0 ([M-H]- , calcd. 619.1), 1239.1 ([2M-H]-, calcd. 1239.2). Anal. Calcd.
for 3, C20H26Cl2N40 2Pt: C, 38.72; H, 4.22; N, 9.03. Found: C, 38.71; H, 4.13; N, 8.96.
Synthesis of [Pt(edBz)C14] (4). [Pt(edBz)C12] (0.120 g, 0.250 mmol) was dissolved in 10 mL of
DMF with gentle heating at 60 'C. To this solution, iodobenzene dichloride (0.072 g, 0.26
mmol) in I mL of DMF was added dropwise. The solution changed color immediately from pale
yellow to bright yellow. After stirring 3 h at rt, a 25-mL portion of diethyl ether was added, and
the resulting bright yellow solid was collected by filtration. It was further washed with diethyl
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ether and then dried in vacuo. Yield: 0.086 g (63%). M.p. 188-198 'C (dec). 1H NMR (400
MHz, DMF-d): 6 8.90 (t, 1H), 7.92 (br s, unresolved 195Pt satellites, 1H), 7.68 (br s, unresolved
19 5 Pt satellites, 1H), 7.39-7.27 (m, 5H), 7.10 (br s, 2 JPtH = 56 Hz, 1H), 4.51-4.43 (m, 3H), 3.93-
3.83 (m, 1H), 3.36-3.20 (br m, 3H), 2.88 (br m, lH). 13C{ 'H} NMR (100 MHz, DMF-d 7): 6
166.7, 139.2, 128.7, 127.8, 127.4, 59.2, 54.5, 47.8, 43.2. 195Pt fH} NMR (86 MHz, DMF-d7): 6 -
382. IR (KBr, cm 1): 3224 m, 3075 m, 3027 m, 2961 w, 1656 vs, 1571 m, 1496 vw, 1453 w,
1409 w, 1329 w, 1298 w, 1266 w, 1203 vw, 1131 vw, 1098 w, 1048 w, 750 m, 701 m, 662 w,
613 w, 595 w, 575 w. ESI-MS (negative-ion mode): m/z 542.5 ([M-H]-, calcd. 542.0), 1086.6
([2M-H]~, calcd. 1086.9). Anal. Calcd. for 4, CuH17Cl4N3OPt: C, 24.28; H, 3.15; N, 7.72.
Found: C, 24.66; H, 3.36; N, 7.43.
Synthesis of [Pt(edDs)CL4] (5). A solution of iodobenzene dichloride (0.107 g, 0.390 mnol) in 2
mL of DMF was added dropwise to a solution of [Pt(edDs)C12] (0.250 g, 0.379 mmol) in 16 mL
of DMF. The color of the solution changed immediately from pale yellow to pale orange. After
stirring 12 h at rt, 80 mL of diethyl ether was added to form a sticky residue on the flask bottom.
The diethyl ether and DMF were decanted, and 30 mL of water was added to the residue. The
resulting solid was collected by filtration. It was suspended sequentially in water, methanol, and
diethyl ether before being dried in vacuo. Yield: 0.103 g (33%). M.p. 245-254 'C (dec). 1H
NMR (400 MHz, DMF-d 7): 6 8.57-8.53 (m, 2H), 8.41 (d, 1H), 8.23 (d, 1H), 8.01 (t, 1H), 7.90
(br s, 1H), 7.71-7.61 (m, 3H), 7.32 (d, 1H), 6.92 (br s, 2JPtH= 58 Hz, 1H), 4.35-4.30 (m, 1H),
3.74-3.68 (m, 1H), 3.37-3.29 (m, 3H), 3.16-3.05 (m, 5H), 2.89 (s, 6H). 13C{ 1H} NMR (100
MHz, DMF-d 7): 6 166.7, 152.0, 136.6, 130.0, 129.9, 129.8, 128.9, 128.2, 123.9, 119.8, 115.6,
58.9, 54.3, 47.7, 45.2, 42.3, 40.0. 195Pt{1H} NMR (86 MHz, DMF-d7): 6 -386. IR (KBr, cm-1):
3346 s, 3307 m, 3185 m, 3075 m, 2956 w, 2872 w, 2790 w, 1688 vs, 1613 w, 1573 m, 1543 m,
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1480 w, 1450 m, 1431 m, 1412 m, 1316 s, 1254 w, 1234 w, 1158 s, 1141 vs, 1085 m, 1063 m,
1041 m, 960 m, 942 m, 910 w, 839 w, 814 m, 788 s, 681 w, 627 s, 574 s, 554 w, 499 w. ESI-MS
(negative-ion mode): m/z 728.5 ([M-H]~, calcd. 728.0), 1458.6 ([2M-H]-, calcd. 1459.0) . Anal.
Calcd. for 5, C18H27Cl4N5O3PtS: C, 29.60; H, 3.73; N, 9.59. Found: C, 29.55; H, 3.71; N, 9.36.
Synthesis of [Pt(edBz 2)C 4] (6). To a suspension of [Pt(edBz 2)Cl2] (200 mg, 0.322 mmol) in 5
mL of DMF, a solution of iodobenzene dichloride (91 mg, 0.33 mmol) in 1 mL of DMF was
added in a dropwise manner. The suspension became a bright yellow solution, which was
allowed to stir at rt for 1 h. The solution was filtered and 200 mL of Et 20 was added. After 10
min, a fine yellow solid deposited. This solid was isolated by vacuum filtration, washed twice
with 10 mL of Et20, and then dried under vacuum. Yield: 0.108 g (49%). M.p. > 200 0C (gradual
browning), 255-265 'C (dec into black char). 1H NMR (400 MHz, DMF-d): R,R/S,S + R,S
diastereomers (3:1) 6 8.95 + 8.92 (triplets, 2H, NH amide), 7.39-7.28 (overlapping multiplets,
12H, 5H aromatic + NH), 4.50 + 4.45 (doublets, 4H, benzyl CH2), 4.23-3.80 (multiplets, 4H,
CH 2 adjacent to amide), 3.60-3.20 (broad multiplets, 4H, CH2 ethylenediamine backbone).
13 C {1H} NMR (100 MHz, DMF-d7): R,R/S,S + R,S diastereomers (3:1) 6 166.6 + 166.5, 139.2 +
139.1, 128.7, 127.8, 127.4, 57.4 + 57.2, 55.0 + 54.3, 43.3 + 43.2. ' 95Pt{1H} NMR (86 MHz,
DMF-d7): R,R/S,S + R,S diastereomers (3:1) 6 -370 (minor), -378 (major). IR (KBr, cm 1): 3440
m, 3294 m, 3153 w, 3105 w, 2924 w, 2876 w, 1657 s, 1584 w, 1571 m, 1495 vw, 1450 w, 1384
w, 1410 w, 1324 w, 1277 w, 1216 vw, 1068 w, 758 m, 704 m, 508 w. ESI-MS (negative-ion
mode): m/z 580.9 ([M-4H-3Cl]-, calcd. 581.1), 616.9 ([M-3H-2Cl] , calcd. 617.1), 652.9 ([M-
2H-Cl]~, calcd. 653.1), 689.0 ([M-H]-, calcd. 689.0), 1381.1 ([2M-H]~, calcd. 1380.9). Anal.
Calcd. for 6, C20H26Cl4N40 2Pt: C, 34.75; H, 3.79; N, 8.10. Found: C, 34.70; H, 3.66; N, 8.20.
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X-Ray Crystallography. Single crystals of 1 DMF and 4-DMF were grown by vapor diffusion
of diethyl ether into DMF solutions. Single crystals of 3 and 6 were grown by slow evaporation
of a DMF solution and vapor diffusion of water into a DMF solution, respectively. Single
crystals were mounted in Paratone oil on cryoloops and frozen under a 100 K KRYO-FLEX
nitrogen cold stream. In general, data were collected on a Bruker APEX CCD X-ray
diffractometer with graphite-monochromated Mo Ka radiation (k = 0.71073 A) controlled by the
APEX2 software package. For crystals other than those of 3, absorption corrections were
applied using SADABS. The structures were solved using direct methods and refined on F2
with the SHELXTL-97 software package. Structures were checked for higher symmetry using
PLATON. 3 6 All non-hydrogen atoms were located and refined anisotropically. Hydrogen atoms
were placed in idealized locations and given isotropic thermal parameters equivalent to either 1.5
(terminal CH 3 hydrogen atoms) or 1.2 times the thermal parameter of the atom to which they
were attached. X-ray crystallographic data collection and refinement parameters are presented in
Table 3.1.
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Table 3.1. X-Ray Crystallographic Data Collection and Refinement Parameters for 1-DMF, 3,
4-DMF, and 6.
1-DMF 3 4-DMF 6
formula C 14H 24Cl2N 40 2Pt C 20H 26Cl2N 40 2Pt C 14H 24Cl4N 40 2Pt C 20 H 26Cl4N 40 2Pt
fw
space group
a, A
b, A
c, A
a, deg
p, deg
y, deg
v, A
Z
Pcalcd, g-cm-3
T, 0 C
pt(Mo Ka), mm-1
0 range, deg
total no. of data
no. of unique data
no. of parameters
completeness to
(%)
R1a (%)
wR2b (%)
R1a (%) for I > 2ay
wR2b (%) for I > 2cy
GOFC
546.36
P2 1/c
13.7730(9)
12.6440(8)
11.2843(7)
102.6200(10)
1917.6(2)
4
1.892
-173(2)
7.608
1.52-29.61
41701
5382
210
0 99.8
2.49
3.95
1.77
3.72
1.074
620.44
Pi
9.2382(10)
12.9438(14)
18.045(2)
80.2930(17)
88.9920(18)
90.0000(16)
2126.5(4)
4
1.938
-173(2)
6.874
1.60 to 25.06
58892
7479
518
99.4
8.00
12.58
4.93
11.07
1.024
617.26
P2 1/c
14.4637(8)
11.2251(6)
13.3621(8)
109.8980(10)
2039.9(2)
4
2.010
-173(2)
7.418
1.50-25.05
31699
3604
228
99.8
3.42
6.98
2.81
6.66
1.086
691.34
P4 32 12
11.3811(3)
18.4022(11)
2383.63(17)
4
1.926
-173(2)
6.360
2.10 to 28.71
50603
3092
142
99.9
2.42
4.11
1.92
4.11
1.058
max, min peaks, eA- 3  1.123, -0.447 4.783, -2.435 2.011, -0.894 0.817, -0.558
Flack parameter -0.012(7)
a RI = IllFol - IFel1/IIFo. b wR2 = {2[w(F2 - Fc2)2]/[w(F2)2]}1/2 c GOF ={[w(Fo 2 - Fel)']/(n
-p)}/2 where n is the number of data and p is the number of refined parameters.
Crystals of 3 all displayed signs of non-merohedral twinning in the form of split
reflections. After full data collection, the program CELLNOW37 was used to look for additional
domains. Two domains were found that accounted for 97% of the harvested reflections. The
second domain was rotated by 6.8' about the c* axis. The data were integrated over both
domains using SAINT. 3 8 An absorption correction was applied with the program TWINABS. 3 9
The corrected data were then analyzed for systematic absences and higher metric symmetry with
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XPREP40 to determine the space group. The structure was solved with the SHELXTL-97
software package and refined using data from both domains. The second domain refined to a
scale factor of 8.33%. Two molecules of 3 are present in the asymmetric unit in the space group
P1. Restraints on the directionality and size of the thermal displacement parameters of the
nitrogen and carbon atoms of the ethylenediamine backbone of one of the molecules in the
asymmetric unit were applied. The largest electron density peak and hole are 4.78 and -2.44
e-A 3, located 1.19 A from Pt2 and 0.78 A from Ptl, respectively. This large residual density
might in part be due the presence of additional twin domains. It should also be noted that the
space group utilized was P 1. Both b and c are close to 900, suggesting that a higher metric
symmetry monoclinic space group might be more appropriate to describe the structure.
Furthermore, the presence of two molecules of 3 in the asymmetric unit also raises concerns as to
whether these two species are symmetry-related in a monoclinic space group. Structure solution
in P21/c gave basic atomic connectivity. During refinement, however, thermal ellipsoids attained
unreasonable sizes and many became non-positive definite upon anisotropic refinement, a
problem not encountered in P 1. Furthermore, the merging and refinement statistics and the
standard deviations of the bond distances and angles for the P21/c solution and refinement were
substantially worse than those in the triclinic space group. The two molecules in the asymmetric
unit in the P I solution exhibit only one obvious conformational difference. In particular, the
tilting of the five-membered chelate rings is different, as discussed in more detail below.
Searches for higher symmetry space groups with PLATON on the P I solution were
unsuccessful.
Theoretical Calculations. Density functional theory (DFT) calculations were performed with
the GAUSSIAN 03 (Rev.DO1) software package. 41 All calculations were carried out using the
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B3LYP functional. 42 ,43 The LANL2DZ basis set and effective core potential 44 was used for the Pt
atom and the 6-3 1++G(d,p) basis set4 5 was used for all other atoms. Geometries of 2 and 5 were
optimized in the gas phase and established as local minima by frequency calculations, which
revealed no imaginary values. The conductor-like polarizable continuum model (CPCM) 46 was
applied for subsequent molecular orbital and time-dependent DFT (TDDFT) calculations to
simulate solvation of the compounds in water. The TDDFT calculations were used to determine
the natures, energies, and oscillator strengths of the 50 lowest energy singlet excited states.
3.3. Results and Discussion
Synthesis and Characterization. The platinum(II) complexes, 1 and 2, were prepared by an
amide coupling reaction between [Pt(edma)C12 ] and benzylamine or Ds-en, respectively.
Similarly, using two equiv of the necessary coupling reagents, benzylamine was coupled to the
dicarboxylic acid complex [Pt(edda)C12] (Scheme 3.1). This amide coupling reaction can
potentially be used to tether other desired amines to the core platinum(II) moieties. It is
analogous to the amide coupling chemistry that has been employed to conjugate chemical
moieties to the platinum(IV) complex, c,c,t-[Pt(NH 3)2Cl 2(O2CC 2H4CO 2H)2], a derivative of
cisplatin.1, 2 Similar platinum(II) and platinum(IV) complexes bearing ethylenediamine-N,N'-
diester ligands have been reported previously.47  In these cases, however, the esterified ligands
were prepared prior to metallation. For a series of platinum(II) peptide conjugates that were
synthesized on a solid-phase support, it was necessary to protect the platinum-chelating unit
during the synthesis of the peptide fragment.5 2 The advantage of performing the coupling
reaction directly on the coordinated ligand, as demonstrated here, is that it eliminates the need
for protecting groups during organic or peptide synthesis. We envision that this synthetic
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approach will be general and provide access to a range of interesting functionalized platinum(II)
complexes.
I equiv benzylamine /~ \
rt H2)N..,, ,O..NH HN
C1 C H
[Pt(edBz 2 )C12 ]
H2N N OH lequiv 1,1'-carbonyldiimidazole. 60 *C
CI '*C] DMF 0
[Pt(edma)CI,] I equiv Ds-en / N
rt H2N.. WNH N S
Cl *C H o-
[Pt(edDs)C12 ]
2
1) 2 equiv 1,'-carbonyldiimidazole, 60 0C oOg/HN 2)2 equiv benzylamine, rt HNHN
HOr / tI OH q NH Pe HC1o VCl DMF C100 CI
[Pt(edda)C12 ] [Pt(edBz 2)C12 ]3
Scheme 3.1. Syntheses of 1-3.
The oxidation of the platinum(II) complexes with iodobenzene dichloride in DMF
cleanly afforded the expected diaminotetrachloroplatinum(IV) analogs (Scheme 3.2).
Alternatively, the use of Br2 as an oxidant for 3 gave rise to a mixture of
diaminotetrahalidoplatinum(IV) complexes varying in respective ratios of chloride to bromide.s3
Previously described methods to generate diaminotetrachloroplatinum(IV) complexes utilize a
two-step reaction sequence. 54 The first step is formation of a trans-hydroxo complex by oxidation
with aqueous H20 2 . The following step is the ligand substitution of the hydroxide ligand carried
out by hydrochloric acid. The use of iodobenzene dichloride to access
diaminotetrachloroplatinum(IV) complexes in a single step, described here, is advantageous.
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0
R'= H, R = 4
R' R R'\ -C R 0 H -
HN .. NH PhICl2, rt HN.,," t ,NH R'=H,R= /N2 5
C t DMF C, C5C04 'CI CI0" tC H N
C1
0
R=R'= 6
Scheme 3.2. Oxidation of 1-3 with iodobenzene dichloride (PhICl2).
Verification of successful amide bond formation for 1-3 is provided in part by IR
spectroscopy. The strong stretching frequency of the free carboxylic acid near 1720 cm- present
in the starting materials is absent in the amide-containing products. Instead lower energy C=O
stretching frequencies are present at 1654, 1659, and 1662 cm-1 for 1-3, respectively, which
correspond to the newly formed amides. The platinum(IV) complexes, 4-6, display similar IR
spectroscopic features. New Pt-Cl stretching modes, which typically range between 300 and 400
cm-', expected for these complexes could not be observed within the window of the spectrometer
used (4000-400 cm-1). Elemental analysis and ESI-MS further validate the proposed
compositions and structures of 1-6.
The 1H and 13C NMR spectra obtained in DMF-d 7 of 1, 2, 4, and 5 are consistent with the
proposed structures. The aliphatic regions of the 1H NMR spectra are characterized by complex
splitting patterns due diastereotopic protons on and near the ethylenediamine backbone. The
proton of the amide group resonated between 8.2 and 9.0 ppm in the four complexes as a triplet.
Upon formation of the platinum(IV) complexes, resonances due to the coordinated NH and NH2
groups shift downfield, consistent with oxidation of the platinum center (Figure 3.1).
Additionally, the NH resonances of the coordinated secondary amine in the platinum(IV)
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complexes display satellites arising from coupling to the '95Pt nucleus (I = 1/2, 33%), with 2JPtH
= 56 and 58 Hz for 4 and 5, respectively. Platinum(IV) complexes give rise to well-resolved Pt
satellites, unlike those of platinum(II)." The "C NMR spectra display all anticipated resonances.
NH (amide) NHNH2
NHH
NH (amide)N
NHNH
-- 2IPtH =56 Hz
9 8 7 6
6(ppm)6
Figure 3.1. 'H NMR spectra in the aromatic region of 1 (top in red) and 4 (bottom in blue)
recorded in DMF-d 7 at 20 *C with a field strength of 400 MHz. The asterisk marks the signal due
to a protic impurity in the solvent.
For 3 and 6, NMR spectroscopy in DMF-d7 revealed the presence of two species in
solution. Because both coordinating nitrogen atoms of 3 and 6 are chiral, both the enantiomeric
R,R/S,S and meso R,S diastereomers exist. The two distinct, yet chemically similar, species
observed in solution are assigned as these two diastereomers. The ratio of these diastereomers for
3 observed by NMR spectroscopy is 1:1, whereas for 6 it is 3:1. As for 1, 2, 4, and 5 amide
protons resonate between 8.5 and 9.0 ppm. The NH resonances of the coordinated amine ligand
in the 'H NMR spectrum are shifted downfield relative to those of 3 and are largely obscured by
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overlapping resonances of the aromatic protons. This overlap prevents observation of 195Pt
coupling to the NH protons, as was detected for 4 and 5.
The 195Pt NMR spectra of 1 and 2 reveal resonances at -2339 and -2345 ppm,
respectively. For 3, two peaks, corresponding to the two diastereomers, are present in a 1:1 ratio
at -2347 and -2362 ppm. These values are typical for platinum(II) in an N2 Cl 2 coordination
environment,56 and the similarity between them indicates that the peripheral substituents on the
amide do not significantly affect shielding at the platinum nucleus. Upon oxidation, a large
downfield shift occurs as expected. Compounds 4 and 5 resonate at -382 and -386 ppm,
respectively. The signal of the major diastereomer of 6 is at -378 ppm in the 19 5Pt NMR
spectrum, whereas that of the minor diastereomer resonates if found at -370 ppm. As with the
platinum(II) complexes, the close proximity of all the resonances indicates that the coordination
environments of the platinum centers are substantially the same with almost no effect due to the
peripheral amide substituents.
X-Ray Crystal Structures. Single crystals of 1-DMF, 3, 4-DMF, and 6 were analyzed by X-ray
diffraction and structurally characterized. Selected interatomic distances and angles for 1-DMF
and 3 are collected in Table 3.2. These structures are shown in Figure 3.2. Both 1 and 3 attain a
square planar coordination geometry as expected for platinum(II). The platinum(II)-ligand
distances are typical as well. A molecule of DMF is in the crystal lattice of 1 and forms a
hydrogen bonding interaction with the NH group of the amide linkage, with ODMF---Namide = 2.83
A. Also present in the lattice of both 1 and 3 are short intermolecular Pt---Pt interactions, marked
by Pt- --Pt distances of 3.30 and 3.38 A, respectively. The X-ray crystal structure of the analogous
compound, [Pt(en)C12] (en = ethylenediamine), has been determined for two distinct
polymorphs. 57' 58 A careful crystal packing analysis of these polymorphs revealed close Pt-.Pt
155
intermolecular interactions, similar to those observed for 1 and 3. In the orthorhombic form of
[Pt(en)C12], 57 the Pt...Pt separation is 3.38 A, whereas the Pt---Pt separation in the triclinic
polymorph 58 is 3.42 A. These Pt.-Pt interactions are partially supported by hydrogen bonds
between the chloride ligands and coordinated amine protons of the neighboring molecules. As
mentioned above, 3 exists as two possible diastereomers in solution. Both molecules of 3 in the
asymmetric unit are meso-R,S diastereomers as conveyed by their nitrogen centers. A significant
difference between them is the canting of the five-membered chelate ring. The conformation of
non-planar five-membered chelate rings produces two different chiral orientations of the ligand,
referred to as X and 6 (Figure 3.3).59 One of the molecules in the asymmetric unit has the X
chelate ring conformation, whereas the other displays a 6 chelate ring conformation. No disorder
occurs in the ethylenediamine backbone, confirming that the two molecules are
crystallographically distinct and not symmetry related.
1 3
Figure 3.2. Solid-state molecular structures of 1 and 3. Ellipsoids are drawn at 50% probability
levels. The DMF molecule in the lattice with 1 is omitted. The other molecules of 3 in the
asymmetric unit is not shown.
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Table 3.2. Selected Interatomic Distances (A) and Angles (0) for 1 and 3.'
1-DMF 3b
Ptl-C11 2.3142(5) 2.310(2)
Ptl-C12 2.3246(6) 2.303(2)
Pt1-N1 2.024(2) 2.060(8)
Ptl-N2 2.0425(18) 2.061(8)
N1-Pt--N2 84.14(7) 84.3(3)
N1-Pt1-Cll 90.87(5) 94.1(2)
N1-Ptl--C2 174.38(5) 175.2(2)
N2-Ptl--Cll 174.97(6) 178.3(2)
N2-Pt1-Cl2 90.28(6) 90.9(2)
Cll-Pt1-C12 94.72(2) 90.74(9)
a Atoms are labeled as indicated in Figure 3.2. Numbers in parentheses are estimated standard
deviations of the last significant figures. b Two structurally similar molecules of 3 are present in
the asymmetric unit. The distances and angles of only one of those are presented in this table.
N-- -N
N ----- --- N..
Figure 3.3. Depiction of the X and 6 isomers of 3 found in the asymmetric unit. Hydrogen atoms
and phenyl rings are omitted for clarity.
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The platinum(IV) complexes 4 and 6 attain expected octahedral coordination geometries,
as shown in Figure 3.4. Selected interatomic distances and angles for these complexes are
collected in Table 3.3. The coordination spheres are comprised of four chloride ligands and the
chelating diamine. Compound 4, like 1, crystallizes with a molecule of DMF. This DMF
molecules also hydrogen bonds to the amide proton with ODMF---Namide = 2.81 A. The platinum
atom of 6 resides on a crystallographic 2-fold symmetry axis in the chiral space group P432 12.
The 2-fold axis requires that both coordinating nitrogen atoms attain the same stereochemistry,
and for the crystal studied the complex is the SS enantiomer. The fact that the Flack parameter
refined to a value near zero confirms this choice. The conformation of the chelate ring is 6.
4
Figure 3.4. Solid-state molecular structures of 4 and 6. Ellipsoids are drawn at 50% probability
levels. The DMF molecule in the lattice with 1 is omitted.
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Table 3.3. Selected Interatomic Distances (A) and Angles (0) for 4 and 6.a
4 6
Pt1-Ni 2.017(4) N2-Ptl-Cll 173.63(15) Ptl-N1 2.083(2)
Ptl-N2 2.109(6) N2-Ptl--Cl2 94.22(14) Ptl-Cll 2.3091(7)
Ptl-Cll 2.3041(15) N2-Ptl-Cl3 91.87(14) Ptl-Cl2 2.3061(7)
Ptl-C2 2.3216(14) N2-Ptl-Cl4 85.70(14)
Ptl-C3 2.3065(14) Cl1-Ptl-Cl2 91.43(5) N1-Ptl-N1A 84.28(14)
Ptl-Cl4 2.3189(14) Cl1-Ptl-C3 91.06(6) N1-Ptl-Cl 89.69(8)
Cll-Ptl--Cl4 91.05(5) N1-Ptl-Cl2 177.07(7)
N1-Ptl-N2 83.30(18) C2-Ptl-Cl3 90.09(5) N1-Ptl-ClA 88.20(8)
N1-Ptl-Cll 91.12(12) C2-Ptl-Cl4 93.27(5) N1-Ptl-Cl2A 92.79(7)
N1-Ptl-Cl2 177.20(12) C3-Ptl-C4 175.99(5) Cl1-Ptl-C12 90.21(4)
N1-Ptl-Cl3 88.69(13) Cll-Ptl-CllA 177.15(5)
N1-Ptl-Cl4 87.86(13) C2-Ptl-Cl2A 90.14(4)
a Atoms are labeled as indicated in Figure 3.4. Numbers in parentheses are estimated standard
deviations of the last significant figures.
Photophysical Properties of 2 and 5. The absorption and emission properties of the fluorescent
compounds 2, 5, and Ds-en were measured in both DMF and phosphate-buffered saline (PBS) at
pH 7.4. The results are summarized in Table 3.4. In DMF, the absorption and emission maxima
of the three compounds are nearly identical. This result is expected because the optical properties
of both compounds are dominated by relatively intense n-n* transitions of the dansyl
fluorophore. In moving from DMF to water, the absorption maxima of the three compounds are
blue-shifted by 10 nm, and the emission maxima are red-shifted by approximately 40 nm. As
seen in Table 3.4, the emission quantum yields depend on both the presence of the platinum
center and its oxidation state, as well as the solvent. In DMF, the platinum(II) center of 2 slightly
quenches the emission, with the quantum yield dropping to 27% from the 40% value measured
for free Ds-en. The relatively high quantum yield of 27% is in contrast to the results described in
Chapter 2 in which the presence of a platinum(II) center lowered the quantum yield of the
dansylated di-2-pyridyl(methane) ligand by a factor of 15. In the previous system, however, the
dansyl fluorophore was positioned much more closely to the platinum(II) center. Quenching of
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dansyl fluorescence by platinum(II) through the heavy-atom effect has been shown to depend on
the spatial separation between the two moieties.6 0 The higher quantum yield of 2 most likely
derives from the long distance of the dansyl fluorophore from the platinum(II) center. The
emission quantum yield of the platinum(IV) complex, 5, in DMF is only 1.6%, significantly less
than that of 2. This result indicates 5 to be a good candidate for displaying the desired
fluorescence turn-on response upon reduction to Pt(II).
Table 3.4. Photophysical Properties of 2, 5, and Ds-en in DMF and Buffered Aqueous Solution.
Compound DMF PBS DMF PBS
Xma (nm), Xmx (n), X), nm), ( Xm (1un), (F
S X 10-3 (M-1-cm-1) F, X 10-3(M_'-cm1)
2 339, 4.8 328, 4.6 520, 0.27 560, 0.033
5 333,5.19 325, 5.1 520,0.016 560,0.0027
Ds-en 333, 4.7 328, 4.6 520, 0.40 555, 0.032
In moving from DMF to PBS, significant fluorescence quenching occurs for all three
compounds. The quantum yields of Ds-en and 2 drop to values of 3.2% and 3.3%, respectively.
This result is expected because the emission of the dansyl fluorophore depends strongly on
solvent polarity. Importantly, the increased quenching effect of the platinum(IV) compound, 5,
carries over to the aqueous environment where the 0.27% quantum yield for emission is still
much lower than that of 2. In water, 5 will therefore elicit a fluorescence turn-on response when
reduced to platinum(II), as described below.
DFT Calculations. Time-dependent DFT (TDDFT) calculations were performed to gain an
understanding of the origin of the decreased emission of 5 relative to that of 2. The frontier
molecular orbital diagrams of 2 and 5 are shown in Figure 3.5. The HOMO for both complexes
is a dansyl-based a orbital. The LUMOs of 2 and 5 are different, however. In the case of 2, the
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LUMO, like the HOMO, is a dansyl-based 7E orbital. In 5, the octahedral coordination geometry
shifts the energies of the dxy and dz2 metal orbitals to an energy that lies between those of the
dansyl-based occupied and unoccupied orbitals, resulting in a LUMO that is metal-based. To
understand how these molecular orbitals affect the photophysical properties of the complexes,
the 50 lowest energy singlet excited states were computed for both 2 and 5. Both compounds are
computed to have an identical, dansyl-based excited state in the visible region (3.32 eV, 373 nm,
S3 for 2, S16 for 5) with a large oscillator strength (f = 0.1741), corresponding to the HOMO-
LUMO transition for 2 and the HOMO-LUMO+2 transition for 5 (Figure 3.5). Because this
excited state transition is the only one that is strongly allowed following irradiation with visible
light (k > 310 nm, f > 0.01) and is localized entirely on the dansyl moiety, it is therefore
responsible for emission as it relaxes to the ground state. If lower-energy excited states are
available, however, relaxation can occur non-radiatively through them. In 2, only two excited
states, both ligand field (d-d) in character, are lower in energy than the allowed HOMO-LUMO
transition. Compound 5, on the other hand, has 15 excited states that are lower in energy than its
allowed HOMO-LUMO+2 transition. Of these 15, the first and second lowest-energy excited
states can be described as a (dansyl) -> d * (Pt) charge-transfer states (Si, HOMO-LUMO and
S 2, HOMO-LUMO+1). As shown on the right side of Figure 3.5 by the black downward arrows,
these excited states provide plausible non-radiative decay pathways that can be rationalized
based on molecular orbital energies alone. These competing non-radiative pathways lower the
overall quantum yield for emission of 5, relative to that of 2.
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-2
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dxy
Lr
hv = 3.325 eV
f=0.1741
L n
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Figure 3.5. Frontier Kohn-Sham molecular orbital diagram for 2 and 5. The high oscillator
transition of the dansyl group, calculated by TDDFT, is indicated.
Response to Reducing Agents. Figure 3.6 displays the emission turn-on response induced by
treatment of 5 with a 10-fold excess of glutathione in PBS at pH 7.4. Substitution of other
biological reducing agents, cysteine and ascorbic acid, for glutathione afforded nearly identical
results. The magnitude and speed of the turn-on response is the same for the three reducing
agents. Within a minute after addition of the reducing agents, the turn-on response is complete,
with no further increase in emission for up to 15 min. The kinetic behavior of this turn-on
response is consistent with the ability of ascorbic acid to rapidly reduce a similar compound,
[Pt(en)C41]. 62 The turn-on response upon reduction affords a 6.3-fold increase in integrated
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emission intensity. Control experiments were carried out in which 5 was treated with the non-
reducing amino acid glycine, and the platinum(II) complex, 2, was similarly treated with glycine
as well as the three biological reducing agents. The emission of 2 did not change upon
introduction of any of the four compounds, as anticipated. When 5 was treated with glycine, a
1.2-fold increase in emission was observed after several scans and minutes. In an additional
control experiment, 5 alone in buffer showed a similar emission increase after several scans in
the fluorimeter. This small but noticeable emission increase most likely arises from
photoreduction of 5 in the fluorimeter. Such photoreduction of the metal center is consistent with
the proposed fluorescence quenching mechanism by which non-radiative relaxation occurs
through the population of metal-based orbitals.
1.00-
S 0.75-
W 0.50 -
z 0.25-
450 500 550 600 650 700 750 800
Wavelength (nm)
Figure 3.6. Emission spectra of 5 before (solid black) and after (dashed red) the addition of 10
equiv of glutathione in pH 7.4 phosphate-buffered saline. The small peak at 680 nm arises from
scattered excitation light (kex = 340 nm).
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3.4. Summary and Conclusions
The platinum(II) complexes [Pt(edma)C12] and [Pt(edda)C12] can be readily coupled to
amine functional groups through amide bond formation at the non-coordinating carboxylic acid
moieties of the ligands, as demonstrated here in the syntheses of 1 and 3 from benzylamine. The
convenient amide coupling chemistry employed for their syntheses can be used to access many
different derivatives with the goal of either making effective anticancer agents or complexes that
act as mechanistic probes. Fluorophore-labeled construct 2 was prepared as just such a probe by
using this synthetic strategy. The clean oxidation of these three complexes was demonstrated
with the hypervalent iodine reagent iodobenzene dichloride. The fluorescent
platinum(II)/platinum(IV) pair, 2 and 5, are useful for investigating the reduction of
platinum(IV) complexes. Compound 5 elicits an emission turn-on response upon reduction to 2.
Compound 5 therefore has the potential to serve as a mechanistic probe to monitor the reduction
platinum(IV) complexes in biology. In theory, such a turn-on response should enable both spatial
and temporal resolution of the platinum(IV) reduction event by fluorescence microscopy.
Unfortunately, the practical applicability of this complex in living cells is limited by its low
quantum yield in water and the rapid rate of reduction. As a first generation platinum(IV) redox
sensor, however, 5 provides a proof of concept and starting point for the design of more effective
sensors of the properties of platinum(IV) complexes in biological milieu.
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Chapter 4
In Vitro Anticancer Activity of Platinum(II) Complexes with p-
Diketonate Leaving Group Ligands
Reproduced in part with permission from Wilson, J. J.; Lippard, S. J. J. Med. Chem. 2012, 55,
5326-5336. Copyright 2012 American Chemical Society.
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4.1. Introduction
As described in Chapter 1, the administration of cisplatin produces toxic side effects,' the
amelioration of which inspired the discovery of the second-generation chemotherapeutic agent,
carboplatin (Chart 4.1). Cisplatin and carboplatin operate by the same mechanism. Labile ligands
in the coordination sphere, chloride for cisplatin and 1,1 -cyclobutanedicarboxylate (CBDCA) for
carboplatin, are displaced by water or other nucleophiles, and the activated cis-
diammineplatinum(II) moiety binds to purine bases in nuclear DNA.2 The resulting platinum-
DNA adducts, chiefly 1,2-intrastrand cross-links, ultimately lead to the death of cancer cells
through transcription inhibition and downstream effects.3 Because cisplatin and carboplatin bear
the same NH3 nonleaving group ligands, the resulting DNA adducts are identical,4 and the drugs
therefore exhibit the same spectrum of activity.5 Carboplatin, however, is significantly less toxic
than cisplatin. The typical patient dose for carboplatin is approximately ten times greater than
that of cisplatin (400 mg/m 2 versus 40 mg/m2), and the dose-limiting toxic side effect of
carboplatin is myelosuppression in contrast to nephrotoxicity for cisplatin.6 These important
clinical differences reveal that the leaving group ligands can play an important role in
modulating toxic side effects. Further modification of these units may therefore be of value in the
search for new platinum anticancer drug candidates.
As anticipated, the properties of carboplatin spurred the design of cisplatin analogues
having other leaving groups. 7-20 The departing ligands of platinum anticancer agents influence
not only the aquation rate but also the lipophilicity of the resulting complex. Both parameters, as
exemplified by carboplatin, influence overall pharmacokinetic properties. Leaving group
modifications have been applied to a class of cytotoxic platinum(II) complexes in which the
remaining ligands have trans stereochemistry.2 1 Exchange of the original halide leaving groups
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of these trans platinum(II) compounds with carboxylates led to new complexes with improved
aqueous solubility, hydrolytic stability, and cellular 
uptake.22-26
Acetylacetonate (acac) and related p-diketonates form a diverse class of ligands with
many applications in inorganic chemistry. The primary 0,0' bidentate chelating mode of these
ligands is analogous to that of the CBDCA ligand of carboplatin, thus warranting consideration
of their use as leaving group ligands for novel platinum anticancer drug candidates. Although p-
diketonates have been used as supporting ligands for titanium(IV) 27,28 and organometallic
ruthenium(II) anticancer agents, 2 9-32 few studies describe their potential utility in platinum-based
therapeutic agents. In an early investigation, the complex [Pt(1,2-
diaminocyclohexane)(acac)](N03) was synthesized, but it displayed poor antitumor activity in
vivo.3 1 On the basis of the structure-activity relationships at the time,34 the authors attributed this
poor activity to the positive charge of the complex. More recently, the complex, [Pt(0,0'-
acac)(y-acac)(dimethylsulfide)], was investigated for its anticancer properties.35-39 This
nonconventional anticancer platinum complex apparently exerts its biological properties through
a mechanism other than DNA binding. Only the y-coordinated acac ligand behaves as a leaving
group.
Chapters 2 and 3 have focused on strategies to modify the non-leaving group ligands of
platinum(II) complexes. In this Chapter, this trend is shifted to exploring the modifications of
leaving group ligands. As alluded to above, $-diketonates are explored as leaving group ligands
for platinum(II) anticancer complexes. Five such cis-diammineplatinum(II) complexes bearing
different p-diketonates were prepared and characterized (Chart 4.1). The particular variations on
the p-diketonate ligands were selected to systematically modify the electronic properties and
hydrophobicity of the resulting platinum complexes through the use of trifluoromethyl and
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phenyl groups, respectively. We discovered that both of these properties have a direct effect on
the overall cytotoxicity of the resulting complexes in cancer cells.
o o
CI CI 0
Pt Pt
H3N NH 3  H3N NH3
cisplatin carboplatin
H3C CH3  H3C CF3
SPt (SO4)0.5 Pt (SO 4)0.5t t
H3N NH 3  H3N NH 3
1 2
CH3 CF3
CH3 (NO 3) (NO3)
o OPt O0
H3N NH 3  L H 3N NH 3
3 4
O O (NO3)
Pt /
H3N NH3
5
Chart 4.1. Structures of cisplatin, carboplatin, and P-diketonate compounds 1-5 described in this
Chapter.
4.2. Experimental Methods
General Considerations. All synthetic procedures were performed under normal atmospheric
conditions without exclusion of oxygen or moisture. Cisplatin and Ba(acac) 2 -H20 were
purchased from Strem Chemicals and used as received. The p-diketonate ligands were obtained
from Alfa Aesar and used as received. Distilled water and analytical grade DMF were employed
as solvents.
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Physical Measurements. NMR measurements were recorded on a Bruker DPX-400
spectrometer in the MIT Department of Chemistry Instrumentation Facility at 20 0C. 11 and
13C {H} NMR spectra were referenced internally to residual solvent peaks, and chemical shifts
are expressed relative to tetramethylsilane, SiMe 4 (6 = 0 ppm). 195 Ptf 1H} and 19F{ 1H} NMR
spectra were referenced externally using standards of K 2PtCl 4 in D2 0 (6 = -1628 ppm relative to
Na2PtCI6) and trifluorotoluene (6 = -63.72 ppm relative to CFCl3), respectively. Fourier
transfonn infrared (FTIR) spectra were recorded with a ThermoNicolet Avatar 360
spectrophotometer running the OMNIC software. Samples were prepared as KBr disks.
Electrospray ionization mass spectrometry (ESI-MS) measurements were acquired on an Agilent
Technologies 1100 series LC-MSD trap. Graphite furnace atomic absorption spectrometry
(GFAAS) was carried out using a Perkin-Elmer AAnalyst600 GFAAS. Elemental analyses were
performed by a commercial analytical laboratory.
Synthesis of [Pt(acac)(NH 3)2](SO 4)o.5 (1). A suspension of cisplatin (0.500 g, 1.67 mmol) and
Ag2 SO 4 (0.499 g, 1.60 mmol) in 15 mL of water was stirred at room temperature in the dark for
12 h. The resulting solids were filtered to remove white AgCl, and to the filtrate, a 10 mL
aqueous solution of Ba(acac)2 -H20 (0.268 g, 0.800 mmol) was added dropwise, inducing the
precipitation of insoluble BaSO 4. This suspension was stirred at room temperature for 3 h and
then filtered. The orange-brown filtrate was concentrated to dryness under reduced pressure at
60 'C to afford a brown residue. The residue was dissolved in 5 mL of MeOH at 65 'C and
filtered through Celite to remove an insoluble impurity. Treatment of this MeOH solution with
15 mL of Et20 yielded the desired compound as a white solid, which was isolated by
centrifugation and washed an additional two times with 10 mL of Et 20 before drying in vacuo.
Yield: 0.438 g (70%). Mp >140 *C (gradual darkening and decomposition). 1H NMR (400 MHz,
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MeOD-d 4): 6 5.58 (s, 1H), 1.85 (s, 6H). "C{ 1 H} NMR (100 MHz, MeOD-d 4): 6 185.6, 103.3,
26.1. 195 Pt 'H} NMR (86 MHz, MeOD-d4): 6 -1593. IR (KBr, cm'): 3446 m, 3179 s, 3134 s,
3075 m, 1564 s, 1525 vs, 1427 w, 1382 m, 1331 w, 1304 m, 1284 w, 1194 w, 1112 vs, 1024 w,
951 w, 938 w, 869 w, 831 w, 772 vw, 659 m, 619 m, 541 w, 480 w. ESI-MS (pos. ion mode,
MeOH): m/z 328.1 ([M]+, calcd. 328.1). Anal. Calcd. for 1, C5HI3 N2 0 4 PtSo.5 : C, 15.96; H,
3.48; N, 7.44. Found: C, 15.82; H, 3.51; N, 6.94.
Synthesis of [Pt(tfac)(NH 3)2](SO 4)0 .5 (2). A suspension of cisplatin (0.500 g, 1.67 mmol) and
Ag2 SO 4 (0.499 g, 1.60 mmol) in 15 mL of water was stirred at room temperature in the dark for
12 h. The resulting suspension was filtered to remove white AgCl, and to the filtrate, a 10 mL
hot (70 'C) aqueous solution of Ba(OH)2-8H 20 (0.252 g, 0.800 mmol) and Htfac (0.246 g, 1.60
mmol) was added dropwise, inducing the precipitation of insoluble BaSO4. The yellow
suspension was stirred at room temperature for 3 h and then filtered. The bright yellow filtrate
was concentrated to dryness under reduced pressure at 60 'C to afford the desired compound as a
yellow solid. The yellow solid was resuspended in 5 mL of cold H20 (~ 4'C), filtered, and
washed sequentially with 5 mL of cold H20 and twice with 5 mL of Et2O before being dried in
vacuo. Yield: 0.314 g (44%). Mp >190 'C (gradual darkening and decomposition). 'H NMR
(400 MHz, MeOD-d 4): 6 6.10 (s, 1H), 2.00 (s, 3H). 19F{1H} NMR (376 MHz, MeOD-d 4): 5
-76.43. 195Pt{'H} NMR (86 MHz, MeOD-d 4): 6 -1497. IR (KBr, cm-1): 3341 m, 3101 s, 2917 w,
1592 s, 1526 m, 1458 w, 1367 w, 1304 vs, 1240 m, 1194 m, 1138 vs, 876 w, 805 w, 743 w, 668
w, 618 m, 448 w. ESI-MS (pos. ion mode, MeOH): m/z 382.0 ([M]+, calcd. 382.0). Anal. Calcd.
for 2, C5 HioF 3N2 0 4 PtSo.5 : C, 13.96; H, 2.34; N, 6.51. Found: C, 13.81; H, 2.48; N, 6.41.
Synthesis of [Pt(bzac)(NH 3)2](NO 3) (3). A mixture of cisplatin (0.500 g, 1.67 mmol) and
AgNO 3 (0.553 g, 3.25 mmol) in 10 mL of water was stirred in the absence of light for 12 h at
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room temperature. The resulting suspension was filtered to remove white AgCl, and a hot
aqueous solution (70 'C, 10 mL) of Hbzac (0.264 g, 1.63 mmol) and NaOH (0.065 g, 1.6 mmol)
was added dropwise to the filtrate, forming a yellow suspension, which was allowed to stir at
room temperature for 4 h. The mixture was concentrated in vacuo at 60 'C to a volume of 8 mL
and then filtered to collect the desired compound as a pale yellow solid. This solid was
suspended in 10 mL of Et20 and isolated by centrifugation twice to remove an ether-soluble
impurity, before being dried in vacuo. Yield: 0.400 g (53%). Mp 160 'C (gradual darkening),
210-215 'C (dec). 1H NMR (400 MHz, MeOD-d4): 5 7.95 (d, 2H), 7.55 (t, 1H), 7.41 (app t, 2H),
6.31 (s, lH), 2.00 (s, 3H). 13C{ 1H} NMR (100 MHz, MeOD-d 4): 6 187.5, 178.2, 138.0, 132.7,
129.9, 128.4, 100.3, 26.7. 195Pt{1H} NMR (86 MHz, MeOD-d4): 6 -1572. IR (KBr, cm '): 3435
w, 3279 s, 3200 m, 3116 m, 1599 w, 1584 m, 1548 s, 1514 vs, 1490 m, 1451 m, 1397 s, 1383 s,
1341 vs, 1312 vs, 1221 w, 957 w, 878 w, 779 m, 713 m, 689 w, 671 w, 580 vw, 483 vw. ESI-MS
(pos. ion mode, MeOH): m/z 390.1 ([M]+, calcd. 390.1), 842.0 ([2M+NO 3]+, calcd. 842.1).
Anal. Calcd. for 3, CioH 15N30 5Pt: C, 26.55; H, 3.34; N, 9.29. Found: C, 26.30; H, 3.26; N, 9.20.
Synthesis of [Pt(dbm)(NH 3)21(NO 3) (5). Cisplatin (750 mg, 2.50 mmol) and AgNO 3 (828 mg,
4.87 mmol) were stirred in 6 mL of DMF at room temperature for 12 h in the absence of light.
The resulting suspension was filtered to remove AgCl. The pale yellow filtrate was added
dropwise to Na2CO 3 (321 mg, 3.00 mmol) and Hdbm (560 mg, 2.50 mmol) in 5 mL of DMF.
This mixture was stirred at room temperature for 3.5 h and then filtered. The filtrate was
concentrated to dryness under vacuum at 60 'C to obtain an orange oily residue. This residue
was dissolved in 10 mL of MeOH and filtered. The addition of Et20 (40 mL) afforded the
desired product as a yellow solid, which was isolated by filtration, washed with cold H20 (4 'C,
20 mL) and Et20 (20 mL), and dried under vacuum. Yield: 0.306 g (24%). Mp 221-229 *C
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(dec). 'H NMR (400 MHz, MeOD-d4): 6 8.07 (d, 4H), 7.60 (t, 2H), 7.47 (t, 4H), 6.96 (s, 1H).
"C{'H} NMR (100 MHz, MeOD-d4): 6 179.9, 138.5, 132.9, 130.0, 128.4, 97.5. 195Pt{'H} NMR
(86 MHz, MeOD-d4): 6 -1528. IR (KBr, cm-1): 3438 w, 3278 m, 3198 m, 3058 w, 1589 m, 1530
vs, 1487 s, 1454 m, 1385 s, 1318 s, 1237 m, 1075 w, 1024 w, 999 w, 945 w, 827 w, 757 m, 706
m, 670 m, 596 vw, 559 vw. ESI-MS (pos. ion mode, MeOH): m/z 452.0 ([M]+, calcd. 452.1),
965.8 ([2M+NO 3]+, caled. 966.2). Anal. Calcd. for 5-H20, C15 H19N30 6Pt: C, 33.84; H, 3.60; N,
7.89. Found: C, 34.17; H, 3.24; N, 7.99.
X-ray Crystallography. Vapor diffusion of diethyl ether into methanol solutions afforded single
crystal of 3 and 4. The single crystals were mounted in Paratone oil on a cryoloop and frozen
under a 110 or 100 K KRYO-FLEX nitrogen cold stream. Data were collected on a Bruker
APEX CCD X-ray diffractometer with graphite-monochromated Mo-Ka radiation (k= 0.71073
A) controlled by the APEX2 software package. 4 0 Absorption corrections were applied using
SADABS. 4 1 The structures were solved using direct methods and refined on F2 with the
42,43SHELXTL-97 software package. Structures were checked for higher symmetry using
PLATON. 4 4 All non-hydrogen atoms were located and refined anisotropically. Hydrogen atoms
were placed in idealized locations and given isotropic thermal parameters equivalent to either 1.5
(terminal CH3 or NH3 hydrogen atoms) or 1.2 times the thermal parameter of the atom to which
they were attached. Crystallographic data collection and refinement parameters are provided in
Table 4.1.
174
Table 4.1. X-Ray Crystallographic Data
3 4
formula CioH 15N 30 5Pt CioH 12F 3N 30 5Pt
fw 452.34 506.32
space group Pca21  P21/c
a, A 9.4898(12) 18.336(2)
b, A 15.218(2) 7.1871(9)
c,A 8.9436(12) 7.1871(9)
P, de 100.556(2)
v, A 1291.6(3) 1400.5(3)
Z 4 4
pcalcd, g-cm-3  2.326 2.401
T, 0 C -173(2) -173(2)
(Mo Ka), mm-1  10.884 10.081
0 range, deg 2.53-29.06 2.26-28.48
total no. of data 25499 26078
no. of unique data 3436 3530
no. of parameters 176 201
completeness to 0 99.8 99.4
(%)
R1a(%) 1.44 2.78
wR2 (%) 2.89 3.91
R1a (%) for I > 2y 1.31 1.94
wR2 (%) for I > 2a 2.85 3.67
GOFC 1.062 1.045
max, min peaks, eA- 3 0.879, -0.532 0.959, -0.765
Flack parameter 0.011(7)
a RI = IIFoI - IFcII/EIFoI. b wR2 = {E[w(F 2 - Fe2)2]/E[w(Fo2 )2 1 1 2 . c GOF = {E[w(F 2 -Fe2)2]/(n
-p)} 1/2 where n is the number of data and p is the number of refined parameters.
Solution Stability Measurements. The platinum complexes were dissolved in water or pH 7.4
PBS containing 10% D20 to a concentration of -1 mM. The solutions were transferred to NMR
tubes and incubated in a 37 'C water bath. 1H and 19F NMR spectra were obtained at various
type points during the incubation. A small amount of 1,4-dioxane (6 = 3.75 ppm) was included in
the samples as an internal standard for referencing 1H NMR spectra and a sealed capillary
containing aqueous KF (6 = -120.46 ppm) was used for referencing 19F NMR spectra. The
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Refinement Parameters for 3 and 4.Collection and
methyl group of 2 in the 1H NMR spectra was integrated relative to the 1,4-dioxane reference at
different time points and used for kinetic analyses. The trifluoromethyl group of 4 in the 19F
NMR spectra was integrated relative to the KF standard at different time points and used for
kinetic analyses. Under the assumption of first-order kinetics, approximate half-lives were
determined by fitting a line to a plot of In[Pt] versus time and using the integrated first-order rate
law, In[Pt] = -kt + [Pt]0 and the relationship, t112 = ln 2/k, where [Pt]o is the starting concentration
of complex, k is the pseudo-first-order rate constant, t is time, and t112 is the half-life. Water
suppression for 1H NMR spectra was accomplished with presaturation. The pH of the solutions
was measured at the beginning and end of the desired incubation time using a DG- 111 -SG glass
electrode calibrated with standard buffers.
Partition Coefficient Measurements. Water or PBS were stirred vigorously with n-octanol for
24 h and then centrifuged for 5 min to obtain octanol-saturated water and water-saturated
octanol. The platinum complexes were dissolved in the octanol-saturated water, or PBS for
cisplatin, to a typical concentration of 0.03 to 3 mM and then mixed with water-saturated octanol
in volumetric ratios of 1:1, 1:2, and 2:1 in duplicate. The mixtures were vortexed for 0.5 h and
then centrifuged for 5 min. The layers were separated carefully using a fine-gauge needle and
then analyzed for Pt content by GFAAS. The partition coefficient was taken as a ratio of the
concentration of platinum in the octanol layer to that in the aqueous layer (P = coct/cwater). The
reported error is the standard deviation of the six measurements obtained from this protocol.
Calculated ligand log P values were obtained from the online program ALOGPS 2.145
available at the Virtual Computational Chemistry Laboratory.46'47 Only the keto tautomeric form
of the protonated ligand was used for these calculations. In addition to using the ALOGPS
algorithm, this program also calculates log P values using several other algorithms for
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comparison. The values presented here are the average log P values computed for all the
algorithms, and the errors reported are the standard deviation of these values.
Cell Lines and Culture Conditions. HeLa (human cervical cancer), A549 (human lung cancer),
U2OS (osteosarcoma), and MCF-7 (human breast cancer) cells were grown as adherent
monolayers in growth medium consisting of Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cultures
were grown in 25-cm2 flasks in an in an incubator at 37 'C with a humidified atmosphere
composed of 5% CO 2.
Cytotoxicity Assays. The colorimetric MTT assay was used to determine the cytotoxicity of
cisplatin and the p-diketonate platinum complexes. Trypsinized cells were seeded into a 96-well
plate at a cell density of 2000 cells/well in 200 piL of growth medium and incubated for 24 h.
The medium was then removed, and 200 ptL of new growth medium containing various
concentrations of the platinum complexes was added. After 72 h, the medium was removed, 200
piL of a 0.8 mg/mL solution of MTT in DMEM was added, and the plate was incubated further
for 4 h. The DMEM/MTT mixture was aspirated, and 200 ptL of DMSO with 10% pH 10.5
glycine buffer was added to dissolve the resulting purple formazan crystals. The absorbance of
the plates was read at 555 nm. Absorbance values were normalized to the platinum-free control
wells and plotted as [Pt] versus % viability. IC50 values were interpolated from the resulting
curves. The reported IC5 0 values are the averages from at least three independent experiments,
each of which consisted of six replicates per concentration level. Dilutions of the platinum
complexes in growth medium were made from concentrated (1-3 mM) solutions in distilled
water for p-diketonate platinum complexes or pH 7.4 PBS for cisplatin.
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Compound 4 was submitted to the National Cancer Insitute (NCI) in July 2011 for single-
dose testing in the NCI-60 tumor cell screen. These tests were carried out by the NCI using their
established protocols.4 8
Cellular Uptake Studies. The total platinum uptake per cell was determined using slight
modifications of a previously described protocol.49 In two 6-well plates, 3 x 105 HeLa cells per
well were seeded in 3 wells with 2.5 mL of growth medium. In one of the plates, the additional 3
wells were filled with 2.5 mL of growth medium to act as blanks for nonspecific platinum
adsorption on the surface of the well. After incubating for 48 h, each well in the plate containing
both cells and cell-free medium was treated with 0.278 mL of a 100-pM solution of the desired
compound to give an exposure concentration of 10 tM. The cells and cell-free blanks were
incubated with the Pt complex for 4 h. Meanwhile, the cells in the other plate were counted with
trypan blue after detachment with trypsin in order to obtain the number of cells per well. After
the 4-h incubation period, the growth medium was aspirated, and all six wells were washed twice
with 3 mL of pH 7.4 PBS and then treated with exactly 0.5 mL of hot (~ 90 'C) concentrated
nitric acid for 2 h. This solution was analyzed by GFAAS to determine the total Pt content per
well. The amount of Pt per cell was calculated by subtracting the average amount of Pt found in
the blank wells from the average amount of Pt found in the cell-containing wells and normalizing
to the average number of cells per well.
Intracellular DNA Platination Measurements. Five million HeLa cells were seeded in a 100
mm Petri dish containing 9 mL of growth medium. On the following day, the cells were treated
with the platinum complex at 100-pM concentration for 4 h. The growth medium was then
replaced with platinum-free medium, and the cells were incubated for an additional 16 h. Cells,
both floating and attached, were collected and combined. Trypsin (2 mL) was used to detach the
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cells. The combined cells were centrifuged for 5 min at 4 'C, and the resulting cell pellet was
washed twice with 3 mL of ice-cold PBS. DNAzol (1 mL, genomic DNA isolation reagent,
MRC), containing 100 pg/mL RNase A, was used to lyse the cell pellet. DNA was precipitated
with 0.5 mL of absolute ethanol, washed with 75% ethanol (2 x 0.75 mL), and redissolved in 200
gL of 8 mM NaOH. The DNA concentration was determined by UV-visible spectroscopy, and
platinum was quantified by GFAAS. The reported values are the average of at least three
independent experiments with the error reported as the standard deviation.
4.3. Results
Synthesis and Characterization. The platinum p-diketonate complexes were synthesized by
three different routes using cisplatin as a common starting material (Scheme 4.1). In all three
approaches, cisplatin was first activated by treatment with the appropriate Ag(I) salt to remove
the chloride ligands as insoluble AgCl and generate reactive solvated cis-diammineplatinum(II)
cations. Subsequent treatment with the appropriate salt of the p-diketonate ligand afforded 1-5
(Scheme 4.1). The disparate solubilities of the p-diketonate ligands and the final platinum(II)
complexes necessitated the use of the three slightly different routes shown in Scheme 4.1, as will
be described in more detail in Section 4.4 below.
Characterization of the complexes was achieved by NMR and IR spectroscopy,
electrospray ionization mass spectrometry (ESI-MS), and elemental analysis. The presence of
nitrate as the counterion for 3-5 was verified both by the characteristic N-O stretching band in
the IR spectrum near 1383 cm-1 and by an ESI-MS m/z peak corresponding to the nitrate adduct,
[2M + N0 3]+. In the mass spectra of 1 and 2, only the molecular ion arising from the cationic
platinum complex was observed. The IR spectra of 1-5 are consistent with O,O'-coordination of
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the p-diketonate ligands. Vibrational frequencies between 1560 and 1590 cm-1 correspond to
C=O stretches5 0 and indicate a decrease in C=O bond order, consistent with a electron
delocalization through the six-membered chelate ring. Elemental analyses are in agreement with
the anticipated molecular formulas.
H3C R
0 0
0.5 Ba
H3N, ,CI H20 O H3N. ,OH2 ,(SO4 ) R >CH 3
,t+ Ag2SO4  r a Pt r3
H3N CI 2 AgCI(s) H3N 'OH 2] - BaSO 4 (s)
Na
H3N ,CI H20 H3N ,OH2 (NO 3)2  01
Pt + 2 AgNO 3  W Pt J R Ph
H3N CI - 2 AgCI(s) H3N 'OH 2  - NaNO3 (aq)
Na
O' 'O0
H3N, ,CI DMF H3N DMF (NO 3)2
Pt + 2 AgNO 3  Do Pt Ph Ph
H3N CI - 2 AgCi(s) H3N DMF - NaNO3
H3N R (SO 4)0.5
Pt ( R = CH3 , 1
H3N O~~' R 3, 2
CH3 j RC 3
[H3N .- R (NO3)
I Pt~ 2
H3N 0 
L Ph
Pl1 (NO3)H3N, ,O..I Pt 2)
H3N 'O**I
L Ph
R = CH3 ,3
R = CF3 , 4
5
Scheme 4.1. Syntheses of 1-5.
The complexes were also studied by multinuclear NMR spectroscopy. The low solubility
of 2 in aqueous and organic solvents precluded acquisition of its 13 C NMR spectrum. For the
other complexes, all expected resonances were observed in the 13 C NMR spectra. The
trifluoromethyl groups of 2 and 4 appear at -76.43 and -76.17 ppm, respectively, in the 19F
NMR spectra. The 'H NMR spectra display the expected resonances except for the protons of the
coordinated NH 3 ligands, which are not observed, presumably due to rapid exchange with
deuterons of the methanol-d 4 NMR solvent. Protons at the gamma position of the P-diketonate
ligands resonate between 5.58-6.94 ppm in the five complexes, as summarized in Table 4.2. The
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195Pt NMR spectra of the complexes are marked by a single peak that ranges from -1593 to
-1454 ppm depending on the p-diketonate ligand (Table 4.2).
Table 4.2. Selected 'H, 13C, 19F, and 195Pt NMR Chemical Shifts (ppm) for 1-5.
compound 6 'H, y positiona 6 "C, y positiona 6 195Ptb 6 19FC
1 5.58 103.3 -1593
2 6.10 n.d.d -1497 -76.43
3 6.32 100.3 -1572
4 6.72 96.5 -1454 -76.17
5 6.96 97.5 -1528
a Referenced to SiMe 4 at 6 = 0 ppm. b Referenced to Na 2PtCl 6 at 0 ppm. c Referenced to CFC13 at
0 ppm. d Not determined.
Single crystals of 3 and 4 were obtained by vapor diffusion of diethyl ether into methanol
solutions of the compounds, enabling their structures to be determined by X-ray crystallography.
The results are presented in Figure 4.1, with relevant bond lengths and angles reported in Table
4.3. The structures confirm the expected square planar coordination geometries of the
platinum(II) center and the 0,O'-coordination mode of the p-diketonate ligands. The nitrate
counterions are engaged in hydrogen bonding interactions with the protons of the coordinated
NH 3 ligands (not shown).
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N2~
I N1
3 4
Figure 4.1. Solid-state molecular structures of the complex cations of 3 and 4. Ellipsoids are
drawn at the 50% probability level. Gray shaded ellipsoids represent carbon atoms, orange
shaded ellipsoids fluorine atoms, and open green circles hydrogen atoms. The identities of the
other atoms are denoted.
Table 4.3. Selected Interatomic Distances (A) and Angles (0) for 3 and 4.'
Ptl-N1
Ptl-N2
Ptl-01
Ptl-02
01-Ptl-02
01-Ptl-N1
01-Ptl-N2
02-Ptl-N1
02-Ptl-N2
N1-Ptl-N2
a Atoms are labeled as shown in Figure
deviations of the last significant figures.
3
2.034(2)
2.030(2)
1.9956(17)
1.9907(18)
95.20(7)
86.81(8)
177.62(9)
177.79(8)
85.37(8)
92.65(9)
4.1. Numbers
4
2.017(3)
2.015(2)
2.005(2)
1.988(2)
94.69(9)
88.69(10)
176.19(10)
176.54(10)
86.12(10)
90.55(11)
in parentheses are estimated standard
Lipophilicity. To quantify the lipophilicity of the new platinum complexes, water-octanol
partition coefficients (P) were measured using the shake-flask method. The resulting log P
values are reported in Table 4.4 and graphically compared in Figure 4.2. The measured log P of
cisplatin is -2.21, consistent with literature values.5 1 The most lipophilic complex is 5, with a log
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P value of 0.0 ± 0.1. The overall order of lipophilicity follows the sequence 5 > 4 > 3 > 2 > 1.
The phenyl groups in 3, 4, and 5 have a larger effect on the lipophilicity than the trifluoromethyl
groups of 2 and 4. Substitution of a phenyl for a methyl group on the p-diketonate ligand leads to
an increase of lipophilicity by approximately 1 log P unit, whereas the analogous substitution for
a trifluoromethyl group leads to an increase of approximately 0.3 log P units.
The log P values of the free p-diketonate ligands in the keto form were calculated using
the online program ALOGPS 2.141 available at the Virtual Computational Chemistry
46,47 vLaboratory. The values are displayed in Table 4.4. The calculated ligand log P values are
linearly proportional to the experimentally measured complex log P values (Figure 4.2). As
expected, more lipophilic ligands give rise to more lipophilic complexes.
Table 4.4. Experimentally Measured Complex and Computed Ligand Log P Values.
compound measured complex log P calculated ligand log Pb
1 -2.67 ± 0.08 0.09 ± 0.35
2 -2.28 ± 0.07 0.72 ± 0.24
3 -1.30 ±0.09 1.47 0.43
4 -0.98 ±0.03 2.15 0.54
5 0.0 0.1 3.08 0.33
cisplatin -2.21 0.06 n.d.c
a Errors are estimated from the standard deviations of repeated experiments. bErrors are the
standard deviations obtained from the use of seven different computational algorithms as
employed by ALOGPS 2.1. 'Not determined.
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Figure 4.2. (a) Graphical representation of experimentally measured log P values of 1-5 and
cisplatin. (b) Plot of calculated ligand log P (Clog P) values versus experimentally measured
complex log P values. The line represents the best fit to a linear regression analysis of the data.
The slope and intercept of this line are 0.90 ± 0.06 and -2.8 ± 0.1, respectively. The R 2 value is
0.98.
Aquation and Anation Rates. The stabilities of 1-5 in water and phosphate-buffered saline
(PBS), pH 7.4, at 37 *C were determined by NMR spectroscopy. The compounds bearing
nonfluorinated p-diketonate ligands, 1, 3, and 5, exhibited no changes in their 1H NMR spectra in
either medium for up to 25 d. Compounds 2 and 4, which both have a trifluoromethyl group in
the ligand backbone, slowly decomposed in water and PBS. In water, the 1H NMR chemical shift
at 2.00 ppm of the methyl group of 2 decayed with a half-life of 58 d and concomitant
appearance of a new resonance at 2.22 ppm. Over the course of this reaction, the pH changed
from 7.5 to 6.3. For 4, the rate of decomposition was faster. The 19F NMR chemical shift at
-74.4 ppm of 4 disappeared with a half-life of 29 d, accompanied by the appearance of a new
resonance at -76.6 ppm. The aliphatic region of the 1H NMR spectrum at this final time point is
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marked by a sharp singlet at 2.67 ppm, which is not observed upon the initial dissolution of the
complex. The pH of this solution remained at 7.5 for the duration of the experiment.
In pH 7.4 PBS, the rates of decomposition increased. The half-lives of 2 and 4 in this
medium are 3.4 and 1.8 d, respectively. For 4, the final product is the same as that observed
following aquation in non-buffered water as characterized by a 19F NMR chemical shift at -76.6
ppm and a sharp singlet in the 'H NMR spectrum at 2.67 ppm. Complex 2 displays more
complex reactivity in PBS. Although the major final product is the same as that observed for
aquation in pure water ('H 6 = 2.22 ppm), two other minor products were observed by 'H NMR
spectroscopy having CH 3 proton resonances at 1.91 and 1.56 ppm. In addition, an intermediate
with a CH 3 proton resonance at 2.25 ppm was apparent.
With the goal of characterizing the aquation and anation products of 2 and 4, the NMR
spectra of the free ligands of these complexes in PBS were investigated. Initially, the 'H NMR
spectrum of sodium trifluoracetylacetonate, Na(tfac), in PBS displayed a CH 3 resonance at 2.25
ppm. Upon further incubation at 37 'C for 6 d, this resonance at 2.25 ppm decayed and was
replaced by a major resonance at 2.22 ppm and two minor resonances at 1.91 and 1.56 ppm.
Because these signals are the same as those observed during the aquation and anation of 2, we
propose that the free tfac ligand is displaced from the platinum center as an intermediate with a
chemical shift of 2.25 ppm and then undergoes ligand decomposition reactions. For the ligand of
4, 4,4,4-trifluorobenzoylacetone (Htfbz), two peaks in its 19F NMR spectrum at -76.37 and
-86.7 ppm were initially observed. These two signals possibly correspond to the keto and enol
tautomers of the compound. After 6 d at 37 'C, the major species in solution is a compound
characterized by a singlet in the 'H NMR spectrum at 2.67 ppm and a signal in the 19F NMR
spectrum at -76.41 ppm. These spectroscopic signals are consistent with the major species
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observed after the aquation and anation of 4. Thus, as for 2, dissociation from the platinum
center precedes ensuing hydrolytic decomposition of the fluorinated p-diketonate ligand.
Cancer Cell Cytotoxicity. The antiproliferative activities of 1-5 and cisplatin were determined
in HeLa (human cervical cancer), A549 (human lung cancer), U2OS (human osteosarcoma), and
MCF-7 (human breast cancer) cell lines by the MTT assay. The cells were treated continuously
for 72 h. The resulting 50% growth inhibitory concentration (IC 50) values are summarized in
Table 4.5 and graphically depicted in Figure 4.3. For the four cell lines tested, 1 is the least
cytotoxic of the five complexes, with IC50 values ranging from 24 to 76 pM. The IC50 values of 3
vary between 7 and 33 pM, indicating slightly greater cytotoxicity than 1. Complexes 2, 4, and 5
exhibit cytotoxicities comparable to that of cisplatin. The IC50 values for these compounds are
generally <10 gM, except for 2 in MCF-7 cells where the ICso is 15 pM.
Table 4.5. IC50 Values of 1-5 and Cisplatin in HeLa, A549, U2OS, and MCF-7 Cell Lines and
Cellular Uptake in HeLa Cells.
IC50 (pM)a
compound HeLa A549 U2OS MCF-7 HeLa cellular uptake
(ng Pt/10 6 cells)b
1 32 5 28 9 24 ±2 76 ±2 6± 2
2 2.9 0.7 2.2 0.6 4.1± 0.8 15 ±2 29+9
3 24 4 7 2 8 2 33 ±6 83± 8
4 3 1 1.3 0.2 1.6 0.5 4.3 ±0.3 160±20
5 6.7 ±0.7 1.3 0.3 2.7 0.7 3.1 ±0.5 520 ±80
cisplatin 2.1 ±0.1 3.2 0.6 5 2 14 ±3 14± 2
aErrors are standard deviations determined from at least three independent experiments. "The
errors are determined by error propagation equations, as described in ref 49.
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Figure 4.3. Graphical representation of IC 50 values for 1-5 and cisplatin in HeLa, A549, U2OS,
and MCF-7 cell lines.
Because 4 is on average the most cytotoxic of the five complexes, it was submitted to the
NCI for evaluation in the NCI-60 tumor cell panel screen.52 In this screen, a single-dose
cytotoxicity measurement is performed in 60 cell lines with distinctive drug sensitivity profiles.
This process can identify drug candidates with unique anticancer activity spectra based on which
cell lines are sensitive or resistant to a compound of interest. Using the COMPARE algorithm,
activity spectra can be quantitatively correlated with those of other compounds in the NCI
database. Pearson correlation coefficients are used to evaluate similarities in activity spectra.
Correlations coefficients close to one indicate compounds with similar mechanisms of action and
resistance profiles. The average cell growth percentage of the 60 cell lines after 48 h of treatment
with 10 [tM 4 was 89.65%, indicating slight growth inhibitory action. Compound 4 showed the
greatest efficacy against central nervous system (CNS) cancer, where the average cell growth
was 64.52%. Results of the COMPARE algorithm are summarized in Table 4.6.
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Table 4.6. Results of COMPARE Analysis of 4.
Compound
PCCa NSC no.
0.589 95466
0.569 750
0.559 301739
0.534 355644
0.506 178248
0.501 357704
0.495 3088
0.491 132313
0.489 119875
0.485 353451
correlation coefficient.
4 (NSC No. 761186) COMPARE Analysis
name biological mechanism of action
PCNU alkylating agent
busulfan type II topoisomerase inhibitor
mitoxantrone type II topoisomerase inhibitor
anthrapyrazole alkylating agent
chlorozotocin alkylating agent
cyanomorpholino-ADR alkylating agent
chlorambucil alkylating agent
dianhydrogalactitol alkylating agent
cisplatin alkylating agent
mitozolamide alkylating agent
"Compound identification number utilized by the NC.
Cellular Uptake. The uptake of cisplatin and 1-5 by HeLa cells after a 4 h exposure time at 10
ptM concentration was measured by GFAAS. The results are tabulated in Table 4.5. The cellular
uptake correlates with the lipophilicity of the compound in an exponential fashion (Figure 4.4).
The most lipophilic complex, 5, is taken up to the greatest extent (520 L 80 ng Pt/10 6 cells),
whereas the least lipophilic complex is taken up the least (6 ± 2 ng Pt/106 cells). All complexes
except 1 have larger accumulation in HeLa cells than cisplatin under similar conditions.
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Figure 4.4. Plot of complex log P versus cellular uptake in HeLa cells. The blue line is an
exponential fit of the data.
Intracellular DNA Platination. Because platinum-based drugs exert their cytotoxic effects by
the formation of DNA crosslinks, the extent to which 1-5 bind to intracellular DNA was
measured. HeLa cells were treated with 100 pM of the platinum complexes for 4 h and then
incubated for an additional 16 h in platinum-free growth medium. The nuclear DNA was
isolated, and the quantity of bound platinum was measured by GFAAS. The results of this study
are shown in Table 4.7. The extent of DNA platination follows the order 5 ~ 4 > cisplatin > 3 ~ 2
> 1.
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Table 4.7. Intracellular DNA Platination in HeLa Cells Induced by Cisplatin and 1-5.a
compound Pt/DNA (pmol/pg)
cisplatin 1.58 ± 0.97
1 0.063 ±0.012
2 0.30 ± 0.07
3 0.35 ± 0.24
4 14 3
5 23 10
aReported errors are the standard deviations from at least three experiments.
4.4. Discussion
The use of p-diketonate ligands as leaving groups for traditional cis-
diammineplatinum(II) anticancer agents is relatively unexplored. Here, we investigated the
physical properties and anticancer efficacy for a small set of compounds in this class. The five p-
diketonate ligands chosen for this study were systematically varied, by addition of either a
phenyl ring or a trifluoromethyl group (Chart 4.1). Such variations allowed us to monitor how
alterations of the hydrophobicity and electron-withdrawing properties of the leaving group ligand
translate into differences in anticancer efficacy in vitro.
The three synthetic methodologies employed to prepare 1-5 are outlined in Scheme 4.1.
For 1 and 2, the sulfate salt of the cis-diamminediaquaplatinum(II) cation was utilized. The
treatment of this cation with Ba(acac) 2 or Ba(tfac) 2 produced 1 or 2, each of which was
subsequently isolated from the aqueous solution, and BaSO4 as an insoluble white solid. For the
syntheses of 3 and 4, the nitrate salt of the cis-diamminediaquaplatinum(II) cation was treated
with Na(bzac) or Na(tfbz). The NaNO 3 byproduct of the reaction was washed away using cold
water with little product loss because 3 and 4 are only sparingly soluble in water. The low
aqueous solubility of the ligand Hdbm necessitated the use of NN-dimethylformamide (DMF) as
the solvent. Activation of cisplatin in DMF with AgNO 3 followed by treatment of Na(dbm)
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afforded 5 after the appropriate reaction workup, albeit in lower yields. The preparation of the
analogous hexafluoroacetylacetonate (hfac) complex was also attempted. None of the three
synthetic methodologies described here provided access to the desired platinum-hfac complex.
After reaction workup, unidentified green-blue residues were obtained. We propose that the
difficulties associated with obtaining this complex may arise from the lability of the strongly
electron-withdrawing hfac ligand.
Characterization data including ESI-MS, elemental analysis, IR spectroscopy, and
multinuclear NMR spectroscopy are consistent with the proposed structures and elemental
compositions of 1-5. Of particular interest are the 195Pt NMR chemical shifts of the new
complexes. This parameter is very sensitive to the platinum coordination environment and can
span a region of >13,000 ppm. 3-ss In the present case, the 195Pt NMR chemical shifts of 1-5
range over 139 ppm (Table 4.2), indicating that peripheral substituents on the p-diketonate
ligands influence the electron density at the platinum center. Complex 1 has the most shielded Pt
nucleus, which resonates at -1593 ppm, whereas 4 is most deshielded with the 195Pt chemical
shift appearing at -1454 ppm. The chemical shift for this class of compounds appears to depend
on the electron-withdrawing strength of the ligand. The trifluoromethyl substituents of 2 and 4
deshield the Pt nucleus by approximately 100 ppm relative to their analogues, 1 and 3, which
lack trifluoromethyl groups. The phenyl groups of 3, 4, and 5 also deshield the Pt nucleus, but to
a lesser degree than the trifluoromethyl groups. Compared to their analogues having no phenyl
groups, 3, 4, and 5 are deshielded by 20-44 ppm. The solid-state molecular structures of 3 and 4
display the expected coordination geometries (Figure 4.1). The complexes are structurally
similar, with comparable interatomic distances and angles (Table 4.3). A related compound,
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[Pt(acac)(trans-1R,2R-diaminocyclohexane)](acac), has also been structurally characterized,56
and its bond metrics resemble those of 3 and 4.
An important physical property that affects the biodistribution of a drug candidate is its
lipophilicity. The lipophilicity of a compound can be quantitatively evaluated by its log P values,
where P is the water-octanol partition coefficient. More positive log P values correspond to
more lipophilic complexes, whereas more negative log P values correspond to more hydrophilic
ones. The log P values for cisplatin and 1-5 are given in Table 4.4 and Figure 4.2. The addition
of lipophilic groups to the p-diketonate ligands increases the log P values of the resulting
complex. Thus, the lipophilicity can be tuned with the appropriate choice of functional groups.
For comparison, the log P values of the free ligands in their diketo forms were computed with an
online program. A linear correlation exists between the calculated log P values of the ligands and
the experimentally measured log P values of the complexes, as shown in Figure 4.2. The slope of
the best-fit line is 0.90. This value, which is close to 1, indicates that coordination of the p-
diketonate ligand to the cis-diammineplatinum(II) moiety affects its lipophilicity in an additive
manner, consistent with the additive properties of substituent hydrophobicity constants. 57 The
intercept of the best fit line is -2.8, which can be interpreted as the substituent hydrophobicity
constant for the [Pt(NH3)2]* moiety in this class of compounds.
After establishing that different substituents on the p-diketonate ligands have a
predictable and significant effect on the lipophilicities of 1-5, we investigated how these
substituents can modulate the reactivities of the complexes. The stabilities of 1-5 in water and in
pH 7.4 phosphate-buffered saline at 37 0 C were assessed by NMR spectroscopy. In either water
or PBS, there was no sign of decomposition for 1, 3, and 5 for up to 25 d. Compounds 2 and 4
decomposed in water with half-lives of 58 and 29 d, respectively, and in PBS with half-lives of
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3.4 and 1.8 d, respectively. The observation that the non-fluorinated complexes, 1, 3, and 5,
appear to have an indefinite lifetime in water and aqueous buffer indicates that the strongly
electron-withdrawing properties of the trifluoromethyl groups in 2 and 4 are responsible for the
increased reactivities of these complexes. In this context, however, it should be noted that 2 and
4 are still significantly more inert than cisplatin, which has an aqueous solution half-life of 2 h.58
In PBS, which contains 137 mM NaCl and 10 mM Pi, the half-lives of 2 and 4 decrease to 3.4
and 1.8 d indicating that the high ion concentration plays a role in their reactivities. Carboplatin,
which is stable for up 60 d in water,59 has increased reactivity in the presence of high phosphate
and chloride ion concentrations, the chemistry proceeding by direct anion attack on the complex
and not requiring an aqua intermediate.60 A similar process most likely explains the increased
rates of decomposition of 2 and 4 in PBS relative to pure water as the solvent.
The antiproliferative activities of the complexes were assessed in four human cancer cell
lines. IC50 values are displayed in Table 4.5 and graphically compared in Figure 4.3. The general
trend of cytotoxicity among the four cell lines follows the order 1 < 3 < 2 ~ 4 ~ 5. Compounds 2,
4, and 5 have IC 50 values comparable to or lower than those of cisplatin. The differences in
observed cytotoxicities among the five complexes can be attributed to variations in lipophilicity
and reaction kinetics conferred by the p-diketonate leaving group ligands because the DNA-
binding cis-diammineplatinum(II) fragment is the same in all five complexes as well as cisplatin.
The cellular uptake properties of the five complexes and cisplatin were measured in HeLa
to see whether this parameter might be the dominant factor in determining cytotoxicity. The
results are summarized in Table 4.5. As shown in Figure 4.4, the cellular uptake is a function of
lipophilicity of the platinum complex. This correlation suggests that these complexes are
dependent on a passive diffusion uptake mechanism. Given that these complexes are cations,
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they may also take advantage of organic cation transporters for selective transport into cancer
cells, like oxaliplatin.6 1 No direct correlation, however, was observed between cellular uptake
and IC50 values for the five complexes. This result indicates that the reaction kinetics of the
complexes must also play a role in their biological activities. Consistent with this hypothesis is
the observation that the fluorinated complexes, 2 and 4, exhibit comparable or better
cytotoxicities than 5 despite the fact that over twice as much 5 is taken up by cells. The increased
reactivities of 2 and 4 in water and buffer are probably why they display comparable cytotoxicity
to 5, even though they are present at significantly lower concentrations within the cell. A similar
correlation between aquation rates and activity is observed in a series of carboplatin derivatives
bearing fluorinated CBDCA leaving group ligands.13 There is rapid aquation of the fluorinated
CBDCA relative to that of the nonfluorinated ligands, which is most likely responsible for the
increased cytotoxic activity of the fluorinated derivatives relative to underivatized carboplatin.13
The amount of platinum found on the DNA of HeLa cells treated with cisplatin and 1-5
(Table 4.7) is not directly correlated with the IC50 values of the complexes, although the least
active complex, 1, does induce the least amount of DNA platination. However, for determination
of the IC50 values the cells were treated for a continuous 72 h period, whereas for the DNA
platination measurements, cells were treated at a high concentration for 4 h and then allowed to
incubate for an additional 16 h in the absence of platinum. During this 16 h post-treatment
period, efflux of platinum complexes out of the cell might become an important factor.
Additionally, cellular targets other than DNA could modulate in part the cytotoxic activities of
1-5. The balance between lipophilicity and reactivity in the formation of Pt-DNA adducts is still
apparent, however. Complexes 2 and 3 platinate DNA to a similar extent (~ 0.3 pmol Pt/pg
DNA), as do complexes 4 and 5 (14-23 pmol Pt/pig DNA). Cellular accumulation studies
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indicate that 3 and 5 are taken up to a much greater extent than 2 and 4, owing to their greater
lipophilicities. The similar DNA platination levels of these complexes probably reflects the
higher reactivities of the fluorinated complexes 2 and 4, which compensates for their lower
intracellular abundance.
Among the compounds studied, 4 has the optimal balance of lipophilicity and reactivity.
The average IC5 0 value of this complex in the four cells lines tested is 2.6 tM, the lowest among
the five complexes tested. For this reason, 4 was submitted to the National Cancer Institute for
testing in the NCI-60 tumor cell panel screen. As described above, the NCI-60 tumor cell panel
screen utilizes 60 different cell lines with distinct sensitivity profiles and measures the cell
growth inhibitory action of a compound of interest, initially at a single dose. Differential cell
growth inhibition among the 60 cell lines indicates the compound's spectrum of activity, which
can be quantitatively compared to that of other compounds in the database via the COMPARE
algorithm. For 4, the average cell growth percent among the 60 cell lines after a single dose (10
pM) treatment was 89.65% relative to the complex-free control. The apparent lower activity of 4
in the NCI-60 tumor cell screen compared to that observed in our laboratory is most likely the
result of different experimental conditions. 48 The shorter incubation time (48 h), the use of RPMI
as culture medium, different initial cell densities, and use of the sulforhodamine B (SRB) assay
by the NCI screen are plausible reasons for the difference. In fact, higher IC50 values are
typically measured with the SRB compared to the MTT assay because the former measures total
protein content instead of mitochondrial activity.62 The COMPARE algorithm was utilized to
investigate how the spectrum of activity of 4 matches that of other anticancer agents in the NCI
database. Table 4.6 lists the ten anticancer compounds with the highest correlation coefficients
with the spectrum of activity of 4. Eight of these ten compounds are known DNA alkylating
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agents. Cisplatin is one of the top ten with a Pearson correlation coefficient of 0.489. These
correlations indicate that 4 and the related p-diketonato complexes act, as anticipated, by binding
DNA, with the p-diketonate ligands serving as the leaving groups. The relatively high correlation
with the activity of cisplatin is consistent with the formation of similar DNA cross-links. The
Pearson correlation coefficient comparing the spectra of activity of cisplatin and carboplatin is
0.7985 and is therefore much greater than that for 4 and cisplatin. The p-diketonate ligand of 4
apparently has a larger influence on the cell line selectivity than the CBDCA ligand of
carboplatin. This observation may have important implications in the design of new cisplatin
analogues, which differ only by the nature of their leaving group ligands.
4.5. Summary and Conclusions
This Chapter describes the first systematic study of the physical properties and in vitro
anticancer efficacy of a series of cis-diammineplatinum(II) complexes with p-diketonate leaving
group ligands. Our results indicate that modifications of the p-diketonate ligands predictably
affect both the lipophilicity and reactivity of the resulting platinum complexes. The lipophilicity
of these compounds is important because it dictates the degree of cellular uptake, whereas
optimal reactivity kinetics ensure that a significant amount of platinum can bind to DNA or other
cellular targets within the biologically relevant time frame. Of the compounds presented here, 4
exhibited the greatest cytotoxicity on average. The trifluorobenzoylacetonate (tfbz) ligand of 4
carries both a phenyl and trifluoromethyl group. These two groups appear to provide an optimal
combination of lipophilicity and reactivity for biological activity. The NCI-60 tumor cell screen
revealed 4 to have a spectrum of activity similar to that of other alkylating agents, a category that
often includes cisplatin. Like carboplatin, which has a similar spectrum of activity as that of
196
cisplatin and is used as a less toxic alternative, the present p-diketonate complexes may find
similar roles in future pharmaceutical applications.
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Chapter 5
Acetate-Bridged Dinuclear Platinum(III) Complexes Derived from
Cisplatin
Reproduced in part with permission from Wilson, J. J.; Lippard, S. J. Inorg. Chem. 2012, 51,
9852-9864. Copyright 2012 American Chemical Society.
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5.1. Introduction
Chapters 2-4 focused on the chemistry of platinum in the +2 oxidation state, presenting
modifications of both leaving and non-leaving group ligands. Beginning in this Chapter and
continuing in Chapter 6, higher valent platinum complexes are explored. Multinuclear platinum
complexes in the rare +3 oxidation state are described. It is well established that platinum
typically attains oxidation states of 0, +2, or +4. The +3 oxidation state, however, is much less
common for mononuclear complexes of this element, and only few such species are known. 1-4 In
contrast, platinum(III) compounds with metal-metal bonds are more common.5- 7 The unpaired
electrons of the platinum(III) units couple to form a metal-metal a bond, thus eliminating any
radical character and increasing the stability of the platinum(III) centers.
Early interest in dimeric and oligomeric platinum(III) complexes was motivated by the
discovery that such species are a component of the deeply colored class of compounds known as
the platinum blues,' 10 some members of which display anticancer properties.1 1 "2 Since then, a
large array of ligand-bridged dinuclear platinum(III) complexes have been synthesized and
characterized, 5 ~7 as well as several unbridged platinum(III) dimers with unsupported metal-metal
bonds.1-18 In addition to their potential utility as anticancer agents, 19-2 2 dinuclear platinum(III)
complexes have found use as photoluminescent materials23-25 and catalysts. 2 6
In this chapter, the previously reported dinuclear platinum(II) complex cis-[Pt11(NH3)2(p1-
OAc)2Pt"(NH 3)2](NO 3)2, [1](N0 3)2,27 is utilized as a synthon for new platinum(III) species. Full
structural and multinuclear NMR spectroscopic characterization of [1](N0 3)2 and its two-
electron oxidation products, cis-[ClPt"'(NH 3)2(p-OAc) 2Pti(NH3)2 Cl](N03)2 , [2](NO 3)2, and cis-
[BrPt"'(NH 3)2(pt-OAc) 2Pt1 (NH3)2Br](NO 3)2, [3](NO 3)2, are presented. Electrochemical studies
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of these complexes are also reported. Lastly, the oxidation of [1](N0 3)2 with PhI(O2CCF3)2 and
XeF2 was explored.
5.2. Experimental Methods
General Methods and Materials. Cisplatin was purchased from Strem Chemicals and used as
received. Silver(I) nitrate was obtained from Alfa Aesar, and bromine and
bis(trifluoroacetoxy)iodobenzene were acquired from Sigma Aldrich. Iodobenzene dichloride
was prepared by a previously reported method. 2 8 Reactions were carried out under normal
atmospheric conditions with no precautions taken to exclude moisture or oxygen unless
otherwise stated.
Physical Measurements. NMR measurements were made on a Bruker DPX-400 spectrometer in
the MIT Department of Chemistry Instrumentation Facility. 'H and 1 3C{'H} NMR spectra were
referenced internally to residual solvent peaks, and chemical shifts are expressed relative to
tetramethylsilane, SiMe 4 (6 = 0 ppm). 195Pt{'H}, 19F{1 H}, and 14N{1H} NMR spectra were
referenced externally using standards of K2PtC4 in D20 (6 = -1628 ppm relative to Na 2PtCl6 ),
trifluorotoluene (6 = -63.72 ppm relative to CFCl3 ), and NH 4C1 in 0.1 M HCl (6 = 0 ppm),
respectively. Fourier transform infrared (FTIR) spectra were recorded with a ThermoNicolet
Avatar 360 spectrophotometer running the OMNIC software. Samples were prepared as KBr
disks. Melting points were measured on a Meltemp apparatus and are reported uncorrected.
Electrochemical measurements were carried out utilizing a VersaSTAT3 potentiostat from
Princeton Applied Research accompanied by the V3 Studio software. A three-electrode cell
comprising a glassy carbon (GC) working electrode, a Pt wire auxiliary electrode, and a
Ag/AgC1 reference electrode was used. The electrolyte was 0.1 M (Bu4N)(PF6 ) (TBAP) in NN-
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dimethylformamide (DMF). Under the experimental conditions described, the reversible
ferrocene/ferricenium redox couple occurred at 0.55-0.56 V versus the reference. Elemental
analyses were performed by a commercial analytical laboratory.
Synthesis of cis-[Ptn(NH 3)2(p-OAc) 2Pt"(NH 3)21(NO 3)2, [1](NO 3)2. This compound was
synthesized as previously reported 2 7 with slight modifications. A suspension of cisplatin (1.00 g,
3.33 mmol) and AgNO 3 (1.10 g, 6.48 mmol) in 15 mL of water was stirred for 16 h in the
absence of light at room temperature. The resulting mixture was filtered to remove AgCl. To the
filtrate was added 80% acetic acid (0.250 g, 3.33 mmol). Storage of this solution at 4 'C for 3
days afforded the desired compound as thin brown needles, which were isolated by filtration and
washed with 5 mL of diethyl ether. Yield: 151 mg, 13%. Four additional crops could be isolated
from the filtrate by continued storage at 4 0 C over the course of several weeks. Yield of
additional crops: 270 mg, 24%. Mp 194-200 'C (dec). 'H NMR (DMF-d, 400 MHz): 6 5.07 (br
s, 12H), 1.97 (s, 6H). 13C{'H} NMR (DMF-d7, 100 MHz): 8 185.9, 22.3. 14N{H} NMR (DMF-
d7, 29 MHz): 6 356, -86 (Wi12 ~ 300 Hz). 195Pt'H} NMR (DMF-d 7, 86 MHz): 6 -1401. IR
(KBr, cm '): 3432 m, 3284 m, 1541 s, 1442 s, 1384 vs, 1303 s, 1042 w, 839 w, 704 w, 536 w.
Anal. Calcd. for [1](N0 3)2 , C4Hi8 N6O10 Pt2: C, 6.86; H, 2.59; N, 12.00. Found: C, 6.75; H, 2.59;
N, 11.84.
Synthesis of cis-[C1Pt"(NH3 )2(p-OAc) 2Ptu"(NH3)2 C1](NO 3)2-3DMF, [2](NO 3)2 -3DMF. To a
brown suspension of [1] (NO 3)2 (100 mg, 0.143 mmol) in 3 mL of DMF was added a solution of
PhICl2 (40 mg, 0.15 mmol) in 1 mL of DMF. The brown suspension became a bright-yellow
solution immediately upon the addition of PhICl2. Vapor diffusion of Et 2 0 into this yellow
solution at 4 'C over the course of 16 h afforded bright-yellow crystals. The supernatant was
decanted, and the crystals were rinsed three times with 2 mL of Et 2 0 before being dried in
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vacuo. Yield: 130 mg, 92%. Mp 101-106 'C (dec). 1H NMR (DMF-d 7, 400 MHz): 6 6.44 (t,
12H, 'JNH = 49 Hz), 2.33 (s, 6H). "C{ 1H} NMR (DMF-d 7, 100 MHz): 6 195.2, 22.4. ' 4N{1H}
NMR (DMF-d 7, 29 MHz): 6 355, -65 (W 12 ~ 50 Hz). 195 Pt 'H} NMR (DMF-d 7, 86 MHz): 6 -76
(quintet, 1JptN = 226 Hz). IR (KBr, cm 1): 3443 m, 3097 s, 1648 s, 1585 m 1540 m, 1496 w, 1384
vs, 1289 m, 1106 w, 1044 w, 911 w, 722 w, 665 w. Anal. Calcd. for [2](NO 3)2-3DMF,
C13H39Cl 2N9O 3Pt2 : C, 15.76; H, 3.97; N, 12.73. Found: C, 15.65; H, 3.93; N, 12.56.
Synthesis of cis-[BrPt"(NH3)2(pt-OAc) 2Pt .(NH 3)2BrJ(NO3)2 -3DMF, [3](NO 3)2 -3DMF. To a
brown suspension of [1](N0 3)2 (58 mg, 0.083 mmol) in 2 mL of DMF was added a freshly
prepared 1.23 M solution of Br2 in DMF (75 RL, 0.092 mmol of Br2). The mixture became a
dark-orange-red solution immediately. Vapor diffusion of Et20 into the orange-red solution at 4
'C over the course of 16 h afforded bright-orange crystals. The supernatant was decanted, and
the crystals were washed three times with 5 mL of Et 2O before being dried in vacuo. Yield: 80
mg, 89%. Mp 78-85 'C (dec). 1H NMR (DMF-d7, 400 MHz): 6 6.43 (t, 12H, 'JNH = 44 Hz), 2.31
(s, 6H). 13C{ 1H} NMR (DMF-d 7, 100 MHz): 6 196.2, 22.6. 14N{1H} NMR (DMF-d 7, 29 MHz): 6
355, -67 (W112 ~ 45 Hz). 195Pt{'H} NMR (DMF-d 7, 86 MHz): 6 -216 (quintet, IJPtN = 232 Hz).
IR (KBr, cm 1): 3437 w, 3150 m, 1648 s, 1611 m, 1540 w, 1496 w, 1384 vs, 1352 m, 1286 w,
1107 w, 1043 w, 903 w, 720 w, 662 w. By combustion analysis, [3](NO 3)2 analyzed as a solvate
containing 2.75, rather than three, DMF molecules per formula unit as observed by X-ray
crystallography and 1H NMR spectroscopy. Presumably, a small fraction of DMF was lost from
the lattice under vacuum or during transport of the sample. Anal. Calcd. for [3](NO 3)2 -2.75DMF,
C 12.25H37.25Br2N8 .750 12.75Pt 2: C, 13.86; H, 3.54; N, 11.55. Found: C, 13.85; H, 3.52; N, 11.34.
Synthesis of cis-[(O 2CCF3)Pt"(NH3)2(jp-OAc) 2Pt"(NH3)(t-NH2)]2(NO 3)4 -4DMF,
[4J(NO 3)4-4DMF. To a suspension of [1](N0 3)2 (62 mg, 0.089 mmol) in 1 mL of DMF was
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added a solution of PhI(O2CCF3)2 (39 mg, 0.091 mmol) in 1 mL of DMF. The mixture, initially a
dark-red suspension, became a yellow solution after 10 min at room temperature. Vapor
diffusion of Et2O into this yellow solution afforded yellow-orange crystals after 16 h at room
temperature. The supernatant was decanted, and the crystals were washed three times with 2 mL
of Et2O before being dried in vacuo. Yield: 68 mg, 40%. Mp: >180 'C (gradual darkening),
195-202 'C (dec). IR (KBr, cm 1): 3432 br m, 3122 br m, 1651 vs, 1542 m, 1454 s, 1421 s, 1384
vs, 1301 m, 1267 m, 1190 m, 1138 w, 1106 w, 1083 w, 837 vw, 800 vw, 722 w, 666 vw, 521 vw,
470 vw. Anal. Calcd. for [4](NO 3)4 -4DMF, C24H62F6N 160 2 8Pt4 : C, 15.04; H, 3.26; N, 11.69.
Found: C, 14.97; H, 3.10; N, 11.94.
Reaction of [1](N0 3)2 with XeF2. In a nitrogen-filled glovebox, [1](N0 3)2 (10 mg, 0.0 14 mmol)
was suspended in 1 mL of dry DMF. A solution of XeF2 (3 mg, 0.02 mmol) in 1 mL of dry DMF
was added. A yellow solution formed immediately with a small amount of dark brown
precipitate. The solution was separated from the precipitate by decantation. Vapor diffusion of
Et20 into this solution over 16 h at room temperature under N2 afforded thin yellow needles
suitable for analysis by single crystal X-ray diffraction. Upon drying under vacuum and exposure
to air, the needles decomposed to a brown oily residue.
X-ray Crystallography. Single crystals, mounted in Paratone oil on a cryoloop, were cooled to
100 K under a nitrogen cold stream. A Bruker APEX CCD X-ray diffractometer controlled by
the APEX2 software package 2 9 with a graphite-monochromated Mo Ka radiation source (k =
0.71073 A) was used for data collection. Data were integrated with SAINT 30 and then corrected
for absorption with SADABS. 31 Space-group determination was carried out by analysis of the
metric symmetry of the unit cell and systematic absences in the diffraction pattern using the
program XPREP.3 2 Structures were solved and refined against F2 with the SHELXTL-97
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software package.'33 34 Non-hydrogen atoms were located on difference Fourier maps. Hydrogen
atoms were placed at idealized locations with displacement parameters constrained to be either
1.2 or 1.5 times (for terminal CH 3 or NH3 groups) the thermal parameter of the atoms to which
they were attached. Specific refinement details are provided below, and relevant X-ray
crystallographic data collection and refinement parameters are reported in Table 5.1.
Vapor diffusion of Et2O into a DMF solution of [1](N0 3)2 afforded a mixture of thin
yellow needle-like crystals and orange shards. An orange shard was selected for X-ray
diffraction analysis because the yellow needles were too small to afford appreciable diffraction.
The asymmetric unit consists of the [1]2+ cation, a nitrate anion situated on a general position at
full occupancy, a nitrate anion residing on a crystallographic 2-fold axis, and a nitrate anion
disordered with a water molecule about a crystallographic inversion center. For the nitrate anion
disordered about the inversion center, the bond distances and angles were restrained to be the
same as those of the non-disordered nitrate anion. The occupancy factors of the disordered
nitrate and water atoms were 50:50, as necessitated by the crystallographic inversion center
about which they are disordered. The hydrogen atoms of this half-occupancy water molecule
could not be located on the difference Fourier map and were therefore not included in the final
model. The remaining largest electron density peak (1.32 e-A 3) and hole (-1.53 eA 3) are 0.77
and 0.66 A from Ptl, respectively.
Yellow crystals of [2](NO 3)2-3DMF were grown by vapor diffusion of Et2O directly into
the DMF solution of the crude reaction mixture. The asymmetric unit comprises one molecule of
[2](NO 3)2 and three molecules of DMF. One molecule of DMF is disordered over two
orientations. The bond lengths and angles of the two disordered components were restrained to
be the same as one another, as were the thermal displacement parameters. The site occupancy
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factors of the disordered components refined to a ratio of 71:29. The remaining largest electron
density peak (3.64 e A 3) and hole (-1.83 e-A 3) are 0.77 and 0.64 A from Pt2, respectively.
Orange crystals of [3](NO 3)2 -3DMF were grown by vapor diffusion of Et 20 directly into
a DMF solution of the crude reaction mixture. The asymmetric unit comprises two molecules of
[3](NO 3)2 and six molecules of DMF. One molecule of DMF is disordered over two positions.
The bond lengths and angles of the two disordered components were restrained to be the same as
one another, as were the thermal displacement parameters. The site occupancy factors of the
disordered components were allowed to refine freely and converged at a ratio of 52:48. The
central nitrogen atom of one of the nitrate counterions (N9) gave non-positive definite ellipsoids
upon anisotropic refinement. Attempts to constrain the ellipsoid parameters to match those of
other well-behaved nitrate nitrogen atoms in the structure gave rise to spurious large electron
density peaks and holes in the difference Fourier map near these atoms. In the final model, N9
was therefore refined isotropically without restraints or constraints. We hypothesize that the
difficulty in refining N9 may arise from a small amount of bromide ion at the site of the nitrate
counterion, which would lead to the observed contraction of the N9 thermal displacement
parameter. The remaining largest electron density peak (1.67 e-A -3) and hole (-1.60 e-A 3)
appear at 0.66 A from Pt4 and 0.63 A from Pt2, respectively.
Pale-yellow crystals of [4](NO3)4-4DMF were obtained by vapor diffusion of Et 2 0
directly into a DMF solution of the crude reaction mixture. Half of the tetranuclear complex
cation is related to the other half by a crystallographic inversion center. Also in the asymmetric
unit are the two nitrate counterions and two molecules of DMF. One of the DMF molecules is
disordered over two orientations. Similarity restraints were used to model this disorder and the
site occupancy factors refined to a ratio of 56:44. The axial trifluoroacetate ligands of [4]4+ were
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also disordered. One carbon (C1) atom and one oxygen (02) atom were modeled in different
orientations using the appropriate similarity restraints. The disordered components refined to site
occupancy factors of 52:48. After full anisotropic refinement and placement of the hydrogen
atoms, residual electron density was still present about a crystallographic inversion center. This
electron density was modeled with the SQUEEZE algorithm as part of the crystallographic
program PLATON. 35 Two solvent-accessible voids of 300 A3 with 91 e- were excluded from this
model with SQUEEZE. We hypothesize that this electron density corresponds to disordered
diethyl ether molecules that are readily lost under reduced pressure. The largest remaining
electron density peak (4.85 e-A -3) and hole (-1.76 e-A- 3) were located 1.07 and 0.85 A from Pt2
and Ptl, respectively.
Yellow needles, 5, of the reaction products of [1](NO 3)2 and XeF 2 were obtained by the
vapor diffusion of Et2O into a DMF solution. The X-ray crystal structure revealed an infinite
platinum chain, which propagates down the crystallographic c-axis. Only one nitrate counterion
could be definitely located on the difference map. A large amount of unresolvable electron
density remained in the crystal lattice. This density was modeled with SQUEEZE. The volume of
the void was 1209 A3 and the electron density corresponded to 1062 e~.
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Table 5.1. X-Ray Crystallographic Data Collection and Refinement Parameters.
[1](N0 3)2-0.5H20 [2](NO 3)2-3DMF [3](NO 3)2-3DMF [4](NO 3)4-4DMF 5
formula C4HI 8N 60 10.5oPt 2  C13H 39 C12N 9 0 1 3Pt2  C13H 39Br2N 9O 1 3Pt2  C24H6 2F 6N1 60 28Pt4  C4H 8N 5O 7Pt 2
fw 708.42 990.61 1079.53 1917.26 638.41
space group C2/c P2 1/c P2 1/c C2/c P6522
a, A 19.1794(9) 13.3959(5) 24.2462(12) 35.401(4) 17.7995(9)
b, A 15.7804(7) 10.3272(4) 10.5186(5) 13.8473(14)
c,A 10.8811(5) 25.3699(10) 26.2471(13) 12.8506(13) 11.5444(11)
p, deg 100.4520(10) 121.7120(10) 113.6230(10) 107.367(2)
V, A 3  3238.6(3) 2985.7(2) 6133.0(5) 6012.3(11) 3167.5(4)
Z 8 4 8 4 6
Pcalcd, g'cm-3  2.906 2.204 2.338 2.118 2.008
T, *C -173(2) -173(2) -173(2) -173(2) -173(2)
p(Mo Ka), mm-1  17.320 9.610 11.788 9.384 13.256
O range, deg 1.68-30.10 1.79-29.33 1.83-28.92 1.59-25.13 1.32-27.17
total no. of data 35449 61247 124152 45478 56908
no. of unique data 4748 8166 16123 5366 2354
no. of parameters 233 387 755 424 86
completeness to 0 (%) 99.4 99.7 99.6 99.7 99.7
R1a (%) 2.27 3.72 5.55 7.78 5.21
wR2b (%) 3.83 6.59 7.21 14.86 10.40
R1a (%) for I > 2a 1.82 2.86 3.74 5.36 4.27
wR2b (%) for I > 2y 3.70 6.22 6.66 13.61 10.06
GOFC 1.036 1.119 1.105 1.071 1.139
max, min peaks, eA~3  1.320, -1.529 3.643, -1.828 1.673, -1.599 4.849, -1.761 1.183, -0.868
Flack parameter 0.03(5)
a R1 = EllFI - IFel/ElFol. b wR2 = {E[w(F 2 - Fc2)2 ]/E[w(Fo2)2 ]}" 2 . c GOF = {_[w(Fz -F
p)1/2 where n is the number of data and p is the number of refined parameters.
Computational Studies. Geometries were optimized in the gas-phase starting from coordinates
obtained by X-ray crystallography. Frequency calculations based on optimized geometries were
employed to ensure convergence to local minima on the potential energy surface. For [1]2+ and
[1](N0 3)', geometry optimization required the use of an ultrafine integration grid in order to
achieve convergence at a local minimum. All geometry optimization and frequency calculations
were carried out using the Gaussian03 software package36 with the hybrid functional PBEO.
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The LANL2DZ basis set and effective core potential38 were utilized for platinum atoms, and the
6-31 1+G(d,p) basis set39 was used for the other elements.
Electric field gradient (EFG) parameters and 14N NMR chemical shifts were computed
with the program ORCA 4 0 using optimized geometries obtained from the Gaussian03
calculations. -The PBEO functional was applied for these calculations as well. The all-electron
basis set, def2-TZVP(-f), and its corresponding decontracted auxiliary basis set, def2-TZVP/J, 4 1
were used for all atoms. The zeroth-order regular approximation (ZORA) 42 was applied to
correct for relativistic effects. Solvation effects were modeled with the conductor-like screening
model (COSMO) 4 3 for DMF. Isotropic shielding parameters for 14N nuclei were computed with
the IGLO approach,4 4'45 as implemented in ORCA. The isotropic shielding of NH4' was
calculated at the same level of theory with simulated solvation in water and was used as a
reference to convert other values to ppm.
5.3. Results and Discussion
Synthesis. Treatment of the cis-diamminediaquaplatinum(II) cation with 1 equiv of acetic acid in
water afforded the acetate-bridged dinuclear platinum(II) complex [1] 2+ (Scheme 5.1), as
previously described.2 7 At 4 *C, the nitrate salt of this compound precipitates from aqueous
solution as brown needles. The initial yield of the compound was only 13%. More crops,
however, could be isolated from the filtrate, increasing the total yield to 37%. In aqueous
solution, a mixture of acetic acid and the cis-diamminediaquaplatinum(II) cation gives rise to
multiple species that differ in the binding mode and stoichiometry of the acetate ligand.4 6
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H 3N .,, ' 'P
H3N., ..Cl 1) 4 AgNO 3  H3N O
H3NW 'Cl 2) 2 acetic acid H 3N.,"P .
fine brown needles
[1](NO3)2
Scheme 5.1. Synthesis of [1](NO3)2.
When a solution of [1](NO3 )2 in DMF was allowed to react with slightly greater than 1
equiv of the two-electron-oxidizing agents PhICl2 or Br2 , nitrate salts of the halide-capped
platinum(III) dimers, [212± and [3]2+' respectively, were obtained (Scheme 5.2). Although
partially oxidized chains of [1]2+ have previously been isolated following bulk electrolysis, 4 7
compounds [2]2+ and [3]2+ are the first examples of discrete cis-diammineplatinum(III) dinuclear
complexes bridged by acetate ligands. Previously employed bridging ligands for dinuclear cis-
diammineplatinum(III) complexes are primarily monoanionic nitrogen and oxygen donors,
including a-pyridonate, 4 8 -52 a-pyrrolidonate,53 -" pyrimidines, 56 ~6 0 and amidates. 61-64 Somewhat
analogous carboxylate-bridged dinuclear cis-dimethylplatinum(III) complexes have been
reported,65 -68 and carboxylate-bridged cyclometalated diplatinum(III) complexes have also
recently been described.69 -
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X
- WO (NO3)2H 3N.,,, ..O H3N,1 .0N32H3N (H3NX'- X = Cl, bright yellow crystals
H3N C j> PhI3l2 or Ir H [2](N0 3)2H3N d (NO3)2  H3N 6
H3N"' "O H3N" I 'X X = Br, orange crystalsSx 
_ [3](NO 3)2
Scheme 5.2. Syntheses of [2](N0 3)2 and [3] (NO3)2.
Description of Crystal Structures. Dinuclear platinum(II) cation [1]2+ has previously been
structurally characterized as the SiF6 2- salt.27 Here, crystals of [1]2+ as the nitrate salt were
obtained by vapor diffusion of Et20 into a DMF solution. Two different crystal forms deposited
under these conditions: very fine yellow needles, which were too small for X-ray diffraction
studies, and larger orange shards, which were selected for analysis by X-ray diffraction. The
structure of the orange cation [1]2+ is shown in Figure 5.1, and selected structural features are
summarized in Table 5.2. As expected, the structure is an acetate-bridged dimer. There are two
nitrate counterions per platinum(II) dimer, consistent with a +2 oxidation state of the platinum
ions and indicating the stability of the complex in the presence of oxygen. The distance between
Ptl and Pt2 (atoms labeled in Figure 5.1) is 2.92149(18) A. This value is significantly longer
than those of dinuclear platinum(III) complexes, which generally range from 2.5 to 2.7 A,'
indicating the absence of a formal metal-metal bond between the two d8 metal ions.72 The tilt
angle (t) between adjacent platinum coordination planes is 31.9*, and the average torsion angle
(o) about the Pt-Pt vector is 5.5'. These values for [1]2+ compare favorably to those in the
related a-pyridonate head-to-tail-bridged dinuclear platinum(II) complex
[Pt 2(NH3)4(C 5H4NO)2](NO 3)2 , which are 2.8981(5) A and 28.80, respectively. 73 The torsion
angle in the a-pyridonate complex is 13.0,.73
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2.92149(18) A
3.1324(3) A 3.1523(2) A
Figure 5.1. Structure of [1]2+ (top). Intermolecular interactions between cations are also depicted
(bottom). Thermal ellipsoids are drawn at the 50% probability level.
As indicated in Figure 5.1, dimers of [1]2+ stack in the crystal lattice to form infinite
chains. The Pt-Pt separation between Ptl and its symmetry equivalent, Pt1A, is 3.1523(2) A, and
the corresponding value for the Pt2/Pt2A pair is 3.1324(3) A. Hydrogen-bonding interactions
between oxygen atoms of the bridging acetates and protons of the ammine ligands stabilize the
interaction between Pt2 and Pt2A, for which the torsion angle is 1800 and the N-O distances are
2.97 and 3.00 A. At the Ptl-Pt1A interface, the torsion angle is 41.50 and the nearest N-O
distance is 3.19 A, which rules out hydrogen bonding as a contributor to this interaction. Closed
shell d-d 8 interactions most likely promote this close contact.7 4 76 The structure of the
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previously reported SiF6 2 ~ salt of [1]2+ also includes infinite stacking of platinum(II) dimer
cations,27 which excludes crystal packing as an explanation for the phenomenon
The solid-state molecular structures of [2]2+ and [3]2+ reveal discrete halide-capped cis-
diammineplatinum(III) dimers, with the platinum atoms bridged by two acetate ligands (Figure
5.2). Selected structural features of these and related dinuclear platinum complexes are given in
Table 5.2. The two-electron oxidation of [1]2+ to generate [2]2+ or [3]2+ is accompanied by an
approximate 0.3 A shortening of the Pt-Pt distance and a 100 decrease in the tilt angle,
signifying the removal of two electrons from a strongly metal-metal antibonding orbital (vide
infra). The Pt-Pt distance in [2]2+ is 2.5997(2) A. There are two molecules of [3]2+ in the
asymmetric unit, with Pt-Pt distances of 2.6004(3) and 2.6052(3) A. The small difference in the
Pt-Pt bond lengths between [2]2+ and [3]2+ indicates that the axial ligands have a negligible trans
influence. This result is similar to that for the head-to-tail a-pyridonate-bridged platinum(III)
dimers,4 9 where the Pt-Pt bond lengthens by only 0.014(1) A upon changing axial ligands from
chloride to bromide.5 1 For similar head-to-head a-pyrrolidonate-bridged dimers, the Pt-Pt bond
elongates by 0.024(1) A when chloride is replaced by bromide. 77' 78 For [2]2+ and [3]2+, the trans
influence of the Pt-Pt bond on the axial Pt-ligand bond is clearly noticeable, however. The
Pt-Cl bond lengths in [2]2+ are 2.4321(12) and 2.4017(11) A, >0.1 A larger than typical Pt-Cl
bond distances in most platinum(II) and platinum(IV) structures. A similar effect occurs in [3]2+
where the Pt-Br distances (2.5399-2.5597 A) are greater than typical 2.45 A Pt-Br distances in
other compounds.
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C11
N2,
[2]2+ [3]2+
Figure 5.2. Solid-state molecular structures of the cations [2]2+ (left) and [3]2+ (right). Only one
of the cations in the asymmetric unit of [3]2+ is shown. Thermal ellipsoids are drawn at the 50%
probability level.
The torsion angles in [1]2+ -[3]2+ are all less than 5.50, indicating nearly eclipsed
geometries. The a-pyridonate-bridged platinum(II) complexes exhibit moderate torsion angles
(13.00), which increase upon oxidation to ~28' (Table 5.2). The a-pyrrolidonate-bridged
platinum complexes like [1]2+_[3]2+ remain in eclipsed conformations (o < 50) irrespective of
the oxidation state (Table 5.2). Structurally analogous carboxylate-bridged platinum(III) dimers
with cis-methyl groups instead of ammines exhibit relatively large torsion angles (22-25o).67'68
The small torsion angles of [1]2+-[3]2+ are therefore most likely not a consequence solely of the
bridging acetate ligands. Ammine ligands are much stronger hydrogen-bond donors than unlike
methyl groups. Indeed, significant hydrogen-bonding interactions are present in the crystal
lattices of [1]2+_[3]2+ with DMF and nitrate ions. These hydrogen-bonding interactions may also
stabilize the eclipsed conformations.
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Table 5.2. Relevant Structural Features of [1]2+_[3]2+ and Related Structures from the Literature.
Pt oxidn.
Compound Pt-Pt dist, A Pt-Lxia dist, A T,a deg co,b deg ref
state
[Pt 2(O2CCH3)2(NIH3) 4](NO3)2, [1](N0 3)2  2 2.92149(18) 31.9 5.5 c
[Pt2(O2CCH 3)2(NH3)4](SiF)-4H 20 2 2.9713(8) 36.3 7.2 27
HT-[Pt2(C5H.4NO)2(NH3)4](NO 3)2-2H20 2 2.8981(5) 28.8 13.0 79
HH-[Pt 2(C4H 6NO) 2(NH3) 4](sO4) -H20 2 2.9749 (11) 29.9 4.3 80
[Pt 2C 2( 2CCH3)2(NH3)4 ](NO 3)2-3DMF, 3 2.5997(2) 2.4321(12) 2.4017(11) 19.3 1.4 C
[2](NO 3)2-3DMF
[Pt2Br2(O2CCH3)2(NH3)4](NO3) 2-3DMF, 2.6004(3) 2.5590(7) 2.5465(7) 18.4 3.53 c
[3](NO 3)2-3DMFd 2.6052(3) 2.5597(7) 2.5399(7) 19.6 2.6
HT-[Pt 2Cl2(C5H 4NO) 2(NH3)4](NO3)2  3 2.568(1) 2.444(2) 2.429(4) 19.5 27.4 51
HT-[Pt2Br 2(C5H 4NO)2(NH3) 4](NO 3)2-0.5H20 3 2.582(1) 2.573(1) 2.562(1) 20.5 29.4 51
HH-[Pt 2Cl2(C4H6 NO)2(NH 3)4](SO 4) -2H20 3 2.6235 (13) 2.410 (5) 2.446 (5) 16.3 0.4 77
HH-[Pt2Br 2(C 4H6 NO)2(NH 3)4](NO3)2  3 2.6476 (4) 2.5647 (9) 2.5889 (8) 18.1 1.0 78
[Pt 2(C6 H7N)2(O2CCF3)2(CH3)4] 3 2.557(1) 2.09(2) 2.17(2) 17.6 22 67
[Pt2(C5HsN) 2(O2CCH3)2(CH 3)4] 3 2.529(1) 2.200(11) 15.6 24.8 68
a T is the tilt angle between adjacent platinum coordination planes. " (0 is the average torsion
angle about the Pt-Pt vector. c This work. d The features of both molecules in the asymmetric
unit are reported.
Multinuclear NMR Spectroscopy. Further characterization of [1]2+-[3]2+ was provided by 1H,
3c, 14N, and 195Pt NMR spectroscopy (Table 5.3). The 13C NMR spectra each display two
signals for the inequivalent carbon atoms of the bridging acetate ligands. Although the methyl
group resonance, which occurs near 22 ppm for [1]2+_[3]2+, is not affected by the platinum
oxidation state, the central carboxylate carbon shifts downfield by approximately 10 ppm, from
185.9 to 195.2 and 196.2 ppm, upon oxidation to [2]2+ and [3]2+, respectively.
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Table 5.3. Multinuclear NMR Spectroscopic Data for [1] 2 -[3]2+.a
1H 1C 14 N Pt
compound 6 NH3, ppm IJNH, Hz 6 CH 3 CO2 6 NH 3, ppm 6, ppm 1JNPt, Hz
[1]2+ 5.07 n.o.b 185.9 -86 -1401 n.o.b
[2]2+ 6.44 49 195.2 -65 -76 226
[3]2+ 6.43 44 196.2 -67 -216 232
a All spectra were acquired at room temperature in DMF-d 7 . b Not observed under these
experimental conditions.
The 'H NMR spectra of [1]2-[ 3 ]2+ display sharp singlets for the CH3 group of the
bridging acetate near 2 ppm and broad resonances between 5 and 7 ppm for the coordinated NH 3
groups. Upon oxidation of [1]2+, the methyl group resonance shifts from 1.97 to 2.33 and 2.31
ppm for [2]2+ and [3]2+, respectively, indicating that the electron-deficient platinum(III) center
has an appreciable effect on the electron density at the protons of the methyl group. A similar
effect is observed for the protons of the NH 3 ligands. The greater deshielding effect of the
platinum(III) centers shifts the resonances of these protons from 5.07 ppm in [1]2+ to 6.44 ppm in
[2]2+ and [3]2+. Whereas the resonance appears as a broad singlet for [1]2+, it is a broadened
triplet in [2]2+ and [3]2- (Figure 5.3). The triplet splitting pattern is due to coupling with the
quadrupolar 14N nucleus (I = 1, 99.63% natural abundance). Quadrupolar relaxation by the 14N
nucleus broadens the lines and leads to poorly resolved multinuclear coupling. At constant
temperature and solvent viscosity, the quadrupolar relaxation rate depends on the asymmetry and
magnitude of the electric field gradient (EFG) at the nucleus.81 Because the solvent and
temperature used for all NMR measurements were the same, the ability to resolve H-14N
coupling in [2]2+ and [3]2+ denotes a significant change in the EFG at the coordinated ammines in
the platinum(III) complexes. Values for 1JNH of [2]2+ and [3]2+ are 49 and 44 Hz, respectively,
slightly smaller than those observed for cis-diamminedichloroplatinum(IV) complexes bearing
axial aromatic carboxylate ligands, which range from 53 to 54 Hz.82
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Figure 5.3. NH3 region of the 1H NMR spectra of [1]2+_[3]2+ in DMF-d7 recorded at room
temperature and at a frequency of 400 MHz.
Proton-decoupled 14N NMR spectra were also recorded. 14N NMR spectral analyses of
platinum complexes have been used to study reactions of cisplatin with components of human
blood plasma.83 More recently, this methodology was applied to investigate photoreactive
anticancer platinum(IV) azido complexes. 84 ~8 7 Figure 5.4 shows a comparison of the 14N NMR
spectra of [1]2+_[3]2+ in the NH 3 region. Not shown are sharp signals that appear at 355 ppm, due
to the nitrate counterions for all three complexes. The NH3 signal of [1]2+ shifts downfield upon
oxidation to form [2]2+ and [3]2+, from -86 to -65 and -67 ppm, respectively, consistent with the
higher oxidation state in the latter complexes. The coordinated ammine ligands in platinum(IV)
azido complexes shift even farther downfield, to -- 40 ppm. 84-87 The 14N NMR resonance of the
coordinated NH 3 group in [1]2+ is significantly broader (W112 ~ 300 Hz) than those of the
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platinum(III) complexes [2]2+ and [3]2+ (Wu1 2 ~ 50 and 45 Hz). Because quadrupolar relaxation is
the dominant relaxation mechanism for 14N nuclei,8 8 the sharpening of the signal in [2]2+ and
[3]2+ most likely reflects a decrease in the quadrupolar relaxation rate induced by changing the
EFG upon oxidation, as discussed above. Shoulders are also present in the NH 3 signal of [2]2+
and [3]2+. These shoulders are due to coupling to the 195Pt nucleus (I = 1/2), which is 33%
abundant.
[2](NO3)2
[1](NO3)2
0 -50 -100 -150
S (ppm)
Figure 5.4. 14N{H} NMR spectra of [1]2+_[3]2+ in DMF-d 7 recorded at room temperature and at
a frequency of 29 MHz.
The proton-decoupled 195Pt NMR spectra of [1]2+-[3]2+ are shown in Figure 5.5. The
broad peak for [1]2+ occurs at -1401 ppm, a value similar to those of other platinum(II)
complexes having 0 2N 2 coordination environments. 9 The 195Pt NMR chemical shifts for [2]2+
and [3]2+ are -76 and -216 ppm, respectively, within the region expected for a dinuclear
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platinum(III) complex. 52 The 140 ppm upfield shift of [3]2+ relative to [2]2+ is consistent with the
empirical observation that softer ligands shift 195Pt NMR resonances to more negative values.90
The signals of [2]2+ and [3]2+ appear as quintets, which arise from coupling to two equivalent 14N
nuclei. The presence of such 14N coupling in the spectra of [2]2+ and [3]2+, but not [1]2+, is most
likely a consequence of decreased quadrupolar relaxation at the nitrogen nuclei in the latter.
Chemical shift anisotropy (CSA) of 195Pt plays a large role in its relaxation and attendant NMR
line width.91 ,92 The octahedral coordination geometries of [2]2+ and [3]2+ produce less CSA than
the square-planar geometry of [1]2+. Smaller CSAs for [2]2+ and [3]2+ decrease the line width and
are another factor that enables observation of 14N- 195Pt coupling. The values for 'JNPt for [2]2+
and [3]2+ are 226 and 232 Hz, respectively, larger than that of the platinum(IV) complex
cis,cis,trans-[Pt(NH3)2Cl2(OH)2], 194 Hz,93  and those of several cis-
diamminedichloroplatinum(IV) complexes having axial aromatic carboxylate ligands, which
range from 172 to 179 Hz.8 2
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Figure 5.5. 195pt{iH} NMR spectra of [1]2+_[ 3 ]2+ in DMF-d 7 recorded at
a frequency of 86 MHz.
-1450
room temperature and
Electrochemistry. The cyclic voltammogram of [1]2+ in DMF with 0.1 M TBAP is shown in
Figure 5.6. An irreversible oxidation is observed at 1.20 V vs Ag/AgC1. The return scan shows a
peak at 0.53 V, presumably corresponding to the reduction of the oxidized species obtained on
the forward scan. In contrast to the irreversible oxidation observed for [1]2+, a number of ligand-
bridged dinuclear platinum(II) complexes exhibit reversible oxidations on the cyclic
voltammetry (CV) time scale. 48,5094-96 Even at scan rates as low as 10 mV-s1 and as high as
1000 mV-s- and at -20 *C, the oxidation of [1]2+ remained irreversible.
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Figure 5.6. Cyclic voltammogram of [1](N0 3)2 in DMF with 0.1 M TBAP obtained at a scan
rate of 100 mV-s . The arrows mark the initial potential and scan direction. Potentials are
referenced to Ag/AgCl.
The cyclic voltammograms of [2]2+ and [3]2+, obtained under the same conditions, are
shown in Figure 5.7. The initial scan toward negative potential for [2]2+ reveals a reduction with
a peak potential of 0.12 V. Return scans to positive potentials are marked by weak oxidation
features at 0.90 and 1.40 V. On the second and subsequent cycles, the irreversible reduction peak
broadens and shifts slightly negative, to -0.05 V. At -20 'C and at both fast (1000 mVs-1) and
slow (10 mV-s ) scan rates, no reversibility is observed. The initial reduction peak potential of
[3]2+ is 0.18 V. This peak does not shift after the first cycle or subsequent cycles. The return scan
shows an irreversible peak at 0.90 V that is much more pronounced than those observed for [2]2+.
As with [1]2+ and [2]2+, no reversibility was observed at -20 *C at different scan rates. It is
somewhat surprising that the reduction peak potentials of [2]2+ and [3]2+ are so similar. The axial
halide ligands appear to have little influence on this peak potential. This observation is in
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contrast to a previous electrochemical study on lantern-type pyrimidinethiolate-bridged
platinum(III) dimers, in which complexes bearing axial bromide ligands were reduced at
potentials that were 100 mV more positive than analogous complexes with axial chloride
ligands.97 Also strange is the fact that the return oxidation features are different. Intuitively, it is
expected that the reduction products of [2]2+ and [3]2+ might be [1]2+. Because the return
oxidation does not occur at 1.20 V, as observed in the CV of [1]2+, it appears that different
reduction products are being formed for [2]2+ and [3]2+
EPC = 0.18 V
[3](NO,
0 2 V, -0.05 V 20 pA
Ep =0.90 V
[2](NO )
Epa =1.40 V
2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5
Potential (V)
Figure 5.7. Cyclic voltammograms of [2](NO3)2 (bottom in red) and [3](NO 3)2 (top in black) in
DMF with 0.1 M TBAP obtained at a scan rate of 100 mV-s 1. The arrows mark the initial
potential and scan direction. Potentials are referenced to Ag/AgCl.
To test this hypothesis, [2]2+ and [3]2+ were reduced chemically. These reactions were
followed the reactions by 1H NMR spectroscopy. Reduction with zinc powder produced the
platinum(II) dimer [1]2+ as the major product. In contrast, the use of SnCl 2-2H 20 as the reducing
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agent resulted in the release of the NH 3 ligands as ammonium ions, as evidenced by the presence
of a sharp 1:1:1 triplet centered at 7.68 ppm. These results demonstrate that the reduction
products of [2]2+ and [3]2+ depend on the nature of the reducing agent and suggest that the
electrochemical reduction within the diffusion layer of the electrode could reduce [2]2+ and [3]21-
to species other than [1]2+.
DFT Calculations. The geometries of [1]2+-[3]2+ were optimized in the gas phase using the
hybrid functional PBEO and the 6-311+G(d,p) basis set for atoms other than platinum. The
LANL2DZ basis set and effective core potential were used for the platinum atoms. Table 5.4
compares structural features of the calculated and experimentally determined geometries. At this
level of theory, the Pt-Pt interactions are poorly modeled. This shortcoming is manifest in
computed Pt-Pt distances and tilt angles that are significantly greater than the experimental ones.
For the platinum(III) species, the Pt-Pt separation is overestimated by 0.10-0.14 A, whereas for
[1]2+, this distance exceeds experimental values by 0.64 A. The larger discrepancy between the
computed and experimental Pt-Pt distances for platinum(II) is consistent with a recent
observation that standard hybrid DFT functionals have difficulty in modeling weak d8-d 8
interactions between platinum(II) centers.98 Otherwise, the computed platinum-ligand distances
agree well with experimental values. Notably, the trans influence of the metal-metal bond in
[2]2+ and [3]2+ is recapitulated, as revealed by the long computed platinum-halide distances.
Because the crystal structures of [1]2+_[3]2+ indicate significant hydrogen bonding
between the coordinated ammine ligands and the solvent or counterions, additional geometry
optimizations were carried out, at the same level of theory, in which a nitrate counterion was
explicitly added as a hydrogen-bonding partner for the ammines. The addition of the nitrate
counterion leads to optimized geometries in which the Pt-Pt distances are significantly shorter.
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For [2]2+I and [3]2+, the Pt-Pt distances in these optimized ion pairs are only overestimated by
0.06 and 0.08 A, respectively. The Pt-Pt separation in the nitrate adduct of [1]2+ exceeds
experimental values by 0.22 A. Although still quite large, this result marks a significant
improvement over that computed for the free ion [1]2+ (0.64 A). The presence of the nitrate ion
had little effect on the other platinum-ligand bond distances.
Table 5.4. Comparison of Selected Structural Features of [1]2+_[3]2+ Determined Experimentally
by X-ray Diffraction and Calculated by DFT.a
[112+ex, [1]2+caic [1](NO 3 +cac [2]2 exp [2]2+calc [2](NO 3)caic [3]2+exp [312calc [3](NO3)cai
Pt-Pt 2.921 3.561 3.138 2.600 2.705 2.660 2.603 2.743 2.686
Pt-X 2.427 2.444 2.445 2.552 2.587 2.584
Pt-Oacetate 2.046 2.035 2.052 2.031 2.032 2.048 2.028 2.033 2.050
Pt-Namm.. e 2.024 2.056 2.045 2.024 2.070 2.042 2.022 2.070 2.044
Tb 31.9 70.11 42.5 19.3 32.8 23.7 19.0 33.2 24.0
of 5.5 0.1 1.9 1.4 11.8 1.8 3.1 11.8 1.6
a Experimental values reported are the averages of chemically equivalent distances or angles
found in the asymmetric unit of the X-ray structure. Distances are in A, angles in degrees. b Tilt
angle between adjacent platinum coordination planes in the binuclear unit. C Average twist or
torsion angle about the Pt-Pt vector.
Molecular orbitals relevant to the Pt-Pt bonding interactions of the dimers are shown in
Figure 5.8. The molecular orbitals of the free ions and the nitrate ion pairs of [1]2+_[3]2+ were
qualitatively similar. Because the optimized geometries of the nitrate ion pairs are closer to the
experimental ones than to those of the isolated cations, the molecular orbitals of the ion pairs are
shown. The highest occupied molecular orbital (HOMO) and lowest unoccupied molecular
orbital (LUMO) of [2]2+ and [3]2+ are a and o* orbitals derived from the symmetric and
antisymmetric combination of the dz2 orbitals of the platinum centers. The HOMOs of [2]2+ and
[3]2+ signify the formal Pt-Pt single bond. Furthermore, the HOMOs are antibonding with
respect to the axial ligands, thus giving rise to the long Pt-X axial bond lengths. For [1]2+, which
is reduced by two electrons relative to [2]2+ and [3]2+, the HOMO is the a* orbital. Population of
225
this strongly Pt-Pt antibonding molecular orbital in [1]2+ is consistent with the large Pt-Pt
atomic separation and absence of a formal metal-metal bond. The symmetric combination of the
dz2 orbitals is found to be lower in energy as the HOMO-5.
HOMO LUMO LUMO
-9.791 eV -7.279 eV -7.30 1 eV
HOMO-5 HOMO HOMO
-11.215 eV -10.871 eV -10.479 eV
[1]2+ [2]2+ [3]2+
Figure 5.8. Relevant frontier Kohn-Sham molecular orbitals of [1]2+-[3]2+, optimized as the ion
pair with a single nitrate counterion. The nitrate ions included in the calculation are omitted for
clarity. Isovalues are drawn at 0.04 au.
DFT calculations were further employed to understand the NMR spectral properties of
[1]2+_[3]2+. 14N NMR chemical shifts and EFG parameters of the 14N nuclei were computed for
the optimized geometries of the nitrate ion pair and are collected in Table 5.5. The computed 14 N
NMR chemical shifts ppm, in excellent agreement with the experimentally measured chemical
shift of 355 ppm. Calculated values for the coordinated ammine ligands are approximately 50
ppm farther downfield from experimentally measured values. Given that the known window for
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14N NMR chemical shifts in diamagnetic compounds spans a region of 1100 ppm,88 this
seemingly large 50 ppm deviation represents only a 4.5% absolute error. Importantly, the
calculation successfully predicts the downfield shift of the 14N resonance observed upon the
oxidation of [1]2+ to [2]2+ or [3]2+
The quadrupolar relaxation rate of a 14 N nucleus determines its observed spectral line
width (W 1/ 2). Therefore, the line width is proportional to Ti, the asymmetry of the EFG at the
nucleus, the nuclear quadrupole coupling constant (NQCC), a measure of the magnitude of the
EFG at the nucleus, and Tq, the correlation of the molecule in solution, according to Equation 5.1.
The EFG parameters '9 and NQCC can be readily calculated with DFT methods. The values
computed for the 14 N atoms of the coordinated ammine ligands are listed in Table 5.5. The
asymmetries at the EFG (q) of ammine ligands are similar for all three complexes. The NQCC of
[1](N0 3)f, however, is more than twice as large as the corresponding values for [2](NO 3)* and
[3](NO 3)" and therefore the more important contributor to the large observed W 2 of [1]2+. If the
correlation times are assumed to be equal for the three complexes, the ratio of 14 N NMR line
widths can be calculated from Equation 5.1, using the computed values for 11 and NQCC. This
calculation predicts that, for the platinum(III) complexes, the line widths are equal, whereas the
same signal for the platinum(II) complex is broader by a factor of 6. This value is in agreement
with experimental observations; the W 2 value for [1]2+ (~ 300 Hz) is close to 6 times greater
than those of [2]2+ and [3]2+, which are 50 and 45 Hz, respectively.
Equation 5.1.
W11z0j 1 +77 *(NQCC-r,3 q
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Table 5.5. DFT-Computed Isotropic 14N NMR Chemical Shifts and EFG Parameters for the
Coordinated Ammine Ligands.a
14N Scalc, ppm NQCC, MHz T 2
1 +1 0 (NQCCY
3
[1](NO3)* -29.8 -0.858 0.450 1.05
[2](NO3)* -17.2 -0.400 0.493 0.173
[3](NO3)* -19.0 -0.394 0.585 0.173
a The reported values are averages of those calculated for the four distinct ammine ligands.
Synthesis and Characterization of the Tetranuclear Complex [4](NO 3)4. Treatment of
[1](N0 3)2 in DMF with a slight excess of the hypervalent iodine reagent PhI(O2 CCF 3 )2 , followed
by crystallization via vapor diffusion of Et2 0, afforded an apparently homogeneous crop of
yellow-orange crystalline material. Analysis by X-ray diffraction revealed the compound to be
the amido-bridged tetranuclear platinum compound [4](NO3)4, illustrated in Figure 5.9 and
Scheme 5.3, the interatomic distances and angles of which are summarized in Table 5.6.
CF3
O .. tNH3
NH 3
H3N.,,P '"0 NH3
H3N" (NO 3)2 Phl(O2CCF3)2 0.5 NH2 (NO 3)4H3N.,,"'Pt%.,** DMF H2N."IA"
H3NO' H3Nvi
H3N ,1/t..O'1
H3N*'
0 Y0
CF3
[4](NO 3)4
Scheme 5.3. Synthesis of [4](NO 3)4 .
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Two acetate-bridged diplatinum(III) units are connected by two bridging amido ligands
to form the observed tetranuclear complex. A crystallographic inversion center relates the amido-
bridged dimers. The amido groups could alternatively be assigned as hydroxo ions because the
X-ray scattering power of nitrogen and oxygen are similar. Reasonable and similar thermal
displacement parameters were obtained from isotropic refinements using either assignment, with
insignificant changes in refinement statistics or geometry. The crystal packing was therefore
studied to make the assignment. Both hydrogen atoms of the proposed bridging amido ligands
act as hydrogen-bond donors to a nitrate counterion and a DMF molecule in the crystal lattice. A
hydroxide bridge would hydrogen bond as a donor on one side and an acceptor on the other.
Therefore, our assignment of the bridging atoms as amido groups is most likely correct. The
coordination sphere of the inner two platinum centers (Pt2 and Pt2A) is derived from two oxygen
atoms of bridging acetate ligands in equatorial positions, a nitrogen atom from an ammine ligand
in an equatorial position, and two amido ligands, one in an equatorial position and one in the
axial position. The bridging amido ligand that is coordinated in the axial position is significantly
elongated relative to that in the equatorial position [2.136(10) vs 2.002(9) A]. This elongation of
the axial ligand is due to the strong trans influence of the Pt-Pt bond [Ptl-Pt2, 2.5561(7) A].
The outer two platinum atoms are coordinated to trifluoroacetate ligands in the axial position.
The Pt-O bond is 2.210(9) A. This value is significantly longer than those typically observed for
Pt-TFA bonds in platinum(II) and (IV) compounds, -2.0 A. 99~101 The significant elongation of
this bond may be due to the additive trans influenceio2o3 of the metal-metal bond and the amido
ligand. Longer Pt-TFA bonds of around 2.3 A have been observed in multinuclear complexes
with strong Tl-Pt bonds.104 The [4]4* structure is analogous to those of the a-
pyrrolidonate/amido-bridged tetranuclear platinum(III) complex, HH-
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[(N0 3)(NH 3)2Ptm (C4H6 NO)2Pt"(NH3)(p-NH 2)]2(NO 3)4.-' 5 The difference between this complex
and [4]4* is the presence of acetate rather than a-pyrrolidonate as bridging ligands and
trifluoroacetate instead of nitrate as axial ligands for the outer platinum atoms. In a subsequently
described analogue, the a-pyrrolidonate ligands are oriented in a head-to-tail fashion. 54 The
central bridging ligands were assigned as hydroxo rather than amido.54 Analysis of the CIF file
deposited in the CSD of the head-to-tail structure indicates that the bridging ligand donates two
hydrogen bonds with nitrate counterions, suggesting that these ligands are incorrectly assigned as
hydroxo rather than amido.
NIA
NA N2A
N4A 01A
0 050
t2 t1A
Pt 0503
01 N4
01 ~ N3 06A 4A 03
N1 N2
Figure 5.9. Solid-state molecular structure of [4]4. Ellipsoids are drawn at the 50% probability
level. Unlabeled gray and green ellipsoids correspond to carbon and fluorine atoms, respectively.
Hydrogen atoms and the minor component of disorder in the trifluoroacetate group have been
omitted for clarity.
Table 5.6. Selected Structural Features of [4]4+.a
Ptl-Pt2 2.5561(7) Ptl-05 2.021(8) Pt2-04 2.057(7) Pt2-N4 2.002(9) tb 18.1
Ptl-01 2.210(9) Ptl-N1 2.011(10) Pt2-06 2.037(7) Pt2-N4A 2.136(10) of 1.5
Ptl-03 2.043(8) Ptl-N2 2.006(9) Pt2-N3 2.028(9) Pt2-Pt2A 3.1470(10)
a Atoms are labeled as indicated in Figure 5.9. Numbers in parentheses are estimated standard
deviations in the last significant figures. Interatomic distances are reported in A. br, the tilt angle
in degrees between the coordination planes of Ptl and Pt2. C 0>, the average torsion angle in
degrees about the Ptl-Pt2 vector.
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The 'H and 19F NMR spectra of [4]4± indicate complex solution behavior. Broad, ill-
defined peaks occur between 5.5 and 7.5 ppm in the 'H NMR spectrum of [4]4± in DMF-d7 at 25
0C. These features most likely correspond to protons from the ammine and bridging amido
ligands. The proton chemical shifts of p-NH 2 ligands in platinum(II) complexes range from -1 to
3 ppm depending on the solvent and nature of the peripheral ligands. 106-109 In platinum(IV)
complexes, the protons of these groups resonate farther downfield, between 4.5 and 5.5
ppm."I01 On the basis of the chemical shifts observed for the p-NH2 ligands in [4]4+, it appears
that the metal-metal-bonded diplatinum(III) centers produce deshielding effects similar to those
of the more electron-deficient platinum(IV) centers. The CH 3 resonances of the two inequivalent
bridging acetate ligands appear at 2.58 and 2.30 ppm. Notably, these peaks display shoulders at
2.54 and 2.27 ppm. Also present in the CH3 region are several small peaks between 2.45 and
2.30 ppm that integrate to one-tenth the area of those of the major CH3 resonances. The minor
peaks are present consistently in solutions of crystalline material obtained from different
syntheses. The 19F NMR spectrum of [4]4± at 25 'C similarly displays two major peaks, at
-76.09 and -76.62 ppm, and two minor ones, at -75.72 and -75.80 ppm. The two major peaks
integrate to a ratio of 1:1.4, whereas the minor peaks integrate to a ratio of 0.04:0.06. At 45 'C,
the two major CH 3 resonances coalesce into sharp singlets, losing the shoulders observed at
room temperature (Figure 5.10). The NH region of the 'H NMR spectrum also displays subtle
changes at higher temperatures. The major peaks in the 19F NMR spectrum at 45 'C are
significantly broadened (Figure 5.10), suggesting interconversion between two species. Upon
return of the temperature to 25 'C, the peaks in the 'H NMR spectrum display shoulders again
and the peaks in the 19F NMR spectrum return as sharp singlets, indicating the process to be
reversible. At temperatures greater than 65 'C, the two 19F peaks coalesce completely. At these
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higher temperatures, there is significant decomposition of the starting material, however, as
evidenced by a number of new species in the 1H NMR spectrum upon returning to 25 *C.
45 C
35 OC
25 OC
2.6 0 2 50 2.40 2.3
6 (ppm)
Figure 5.10. Variable-temperature 1H (left) and
45 0C
40 "C
35 *C
30 OC
25 OC
-75.0 -76.0 -77.0 -78.0
6 (ppm)
19F (right) NMR spectra of [4]4+ in DMF-d 7.
The 19F NMR signal of NaTFA appears at -76.00 ppm in DMF-d 7. Therefore, the peak
observed at -76.09 ppm might arise from the TFA ion in solution. The addition of 10 equiv of
NaTFA to a solution of [4]4+ results in coalescence and a slight upfield shift of the CH 3 signals in
the 1H spectra, and the corresponding 19F NMR spectra display a change in the intensities of the
peaks (Figure 5.11). The peak near -76 ppm increases dramatically due to the presence of excess
TFA ion, and the minor peak at -75.80 ppm increases as well. These data suggest that the axial
TFA ligands are labile and that in solution the complex exists as a mixture of different species
bearing different axial ligands. As demonstrated in another control experiment, the addition of 40
equiv of NaNO3 produces no significant changes in either the 1H or 19F NMR spectra, thereby
suggesting that it is most likely DMF that competes with TFA for axial coordination to the
tetranuclear platinum ion.
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S(ppm) S(ppm)
Figure 5.11. 'H (left) and 19F (right) NMR spectra of [4]4± before (bottom) and after (top) the
addition of 10 equiv of NaTFA in DMF-d 7.
The electrochemistry of [4](NO 3)4 in DMF was investigated by CV at a glassy carbon
(GC) working electrode with 0.1 M TBAP as the supporting electrolyte. Cyclic voltammograms
of [4](NO 3)4 are highly dependent on the polishing state of the electrode. With thorough
polishing between scans, fairly reproducible voltammograms were obtained, as shown in Figure
5.12; however, the voltammogram evolved over the course of multiple scan cycles, as indicated
by the arrows of Figure 5.12. The initial scan shows an irreversible reduction comprising several
broad peaks that occur at an onset potential of near 0.4 V and a peak potential of approximately
30 mV. The presence of what appear to be multiple peaks may reflect the presence of multiple
species of [4]4+ in solution or sequential reduction of individual platinum centers. After the initial
reduction of [4]4+, an irreversible oxidation feature appears near 1.2 V. Subsequent cycles lead to
the growth of a reduction feature near 0.5 V and the decay of the initial reduction feature at 30
mV. The oxidation feature at 1.2 V and the reduction at 0.5 V are consistent with those of the
platinum(II) dimer [1]2+ and suggest that [1]2 is an electrochemical reduction product of [4]4+.
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+ 10 equiv NaTFA
The consistent decrease in the peak current upon multiple cycles and the need for stringent
electrode polishing between experiments indicate that other reduction products may be adsorbed
to or deposited on the electrode surface.
10 pA
2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5
Potential (V)
Figure 5.12. Cyclic voltammogram of [4](NO 3)4 in DMF with 0.1 M TBAP as the supporting
electrolyte. The potential is reported relative to Ag/AgCl, and the voltammogram was obtained at
a scan rate of 100 mV-s 1. The red arrow indicates the starting potential and initial scan
direction. The bold red trace is the first scan cycle. The following scans are in black. Changes in
the current as the potential is cycled are indicated by black arrows.
Reaction of [1](N0 3)2 with XeF 2. In an attempt to access a platinum(III) dimer with axial
fluoride ligands, [1](N0 3)2 was treated with a source of solid fluorine, XeF2 . Following
introduction of XeF 2, the brown suspension of [1](N0 3)2 in DMF became a bright yellow
solution. Crystallization by vapor diffusion of diethyl ether gave a homogeneous batch of thin
yellow needles. One of these needles was analyzed by X-ray diffraction. The structure reveals
infinite chains of acetate-bridged platinum dimers that propagate parallel to the crystallographic
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c-axis (Figure 5.13). A column of nitrate counterions also propagate in the same direction. A
large solvent accessible void with diffuse electron density is present in the lattice. This void of
disordered electron density prevented the definitive location of all counterions in the crystal
lattice and, therefore, the oxidation states of the platinum ions. The intradimer Pt-Pt separation is
2.9354(8) A and the interdimer Pt-Pt separation is 3.1435(8) A. These values compare favorably
to those in the confirmed platinum(II) dimer 1 where they are 2.92149(18) and 3.1523(2) A,
respectively. Oxidation of these platinum dimers should decrease the bond lengths as electrons
are removed from a Pt-Pt antibonding orbital. Thus, it appears that treatment of [1](N0 3)2 with
XeF 2 afforded no net oxidation or reaction. Given that an immediate solution color change
occurs after [1](N0 3)2 is treated with XeF 2 and that XeF2 is an extremely strong oxidizing agent,
it is plausible that the initially oxidized platinum(III) product is unstable and reductively
decomposes back to [1](N0 3)2. The reductive decomposition could occur through
disproportionation, photoreduction, or by oxidation of the solvent. Recently, it was reported that
treatment of an acetate-bridged palladium(II) dimer with XeF 2 affords a compound with infinite
palladium chains.11 2 The short 2.72 A Pd-Pd separation confirms the +3 oxidation state of the
palladium ions in the chain. Notably, these chains are thermally unstable. Such thermal
instability may also be a feature of the species formed initially upon oxidation of [1](N0 3)2 with
XeF 2 .
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2.9354(8) A 3.1435(8) A
Figure 5.13. Crystal packing of the infinite Pt chain obtained from the reaction of XeF2 with
[1](N0 3)2 viewed down the crystallographic c-axis with residual electron density in green (top).
Visualization of the Pt chain with relevant Pt-Pt distances labeled (bottom).
5.4. Summary and Conclusions
The oxidative reactivity of the acetate-bridged cis-diammineplatinum(II) complex [1]2+
was explored. Treatment of [1](N0 3)2 with halogen-based oxidants affords the first discrete
diacetate-bridged cis-diammineplatinum(III) complexes, [2](NO 3)2 and [3](NO3)2. Complexes
[1]2+_[3]2+ were fully characterized by multinuclear NMR spectroscopy, X-ray crystallography,
electrochemical methods, and DFT calculations. A novel tetranuclear amido-bridged
platinum(III) species, [4]4*, was also characterized structurally by X-ray crystallography and in
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solution by NMR spectroscopy. The complexes are new additions to the growing family of
dinuclear platinum(III) complexes derived from cisplatin.
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Dicarbamate Complexes
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6.1. Introduction
Having covered chemistry of platinum in the +2 and +3 formal oxidation states in
previous Chapters, in the final chapter of this thesis, we describe new synthetic developments in
the realm of platinum(IV) anticancer prodrugs. Even though all of the clinically approved
platinum-based drugs employ this element in the +2 oxidation state, compounds with platinum in
the +4 oxidation state have become of interest for their potential therapeutic properties. In
particular, they have shown considerable promise both for oral administration and for reduction
of systemic toxicity. 1-3 The orally administered platinum(IV) complex satraplatin progressed as
far as phase III in clinical trials.4 It is hypothesized that the increased stability of these
complexes, due to their low-spin d6 electronic configuration, aids in their survival of the acidic
environment of the gastrointestinal tract before being absorbed into the bloodstream. They
operate by a mechanism similar to that of the first- and second-generation platinum(II)
analogues. An activation step, reduction from platinum(IV) to platinum(II), must occur before
aquation and DNA binding, however (Scheme 6.1).
X
H3N.., t ,..Cl Biological Reducing Agents H 3N.,,,Pt *.Cl
H3N ClH 3N~ ClHN*' I "'C1 ,**' "C
X 2X~
Scheme 6.1. Reductive activation of platinum(IV) prodrugs.
In addition to their kinetic stability, another favorable property of platinum(IV)
complexes relative to their platinum(II) counterparts is the presence of two additional
coordination sites that can be modified to alter their pharmacokinetic properties. By varying the
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two axial ligands, one can predictably alter the redox potential 5-7 and lipophilicity' 9 of the
platinum(IV) complex while leaving the DNA-binding cis-diammineplatinum moiety unaltered.
Furthermore, the axial coordination positions serve as binding sites for other biologically active
ligands, which may have synergistic effects with platinum therapy, as demonstrated by us10-13
and by others. 14~16 The ability to tether platinum(IV) complexes via the axial ligands to various
nanodelivery devices for increased cellular uptake and selectivity1 7-2 5 is another advantage. The
design of new platinum(IV) anticancer complexes, however, is limited by the current synthetic
methodology.2 6 3 2 Most of the newly tested platinum(IV) complexes bear either chloro, hydroxo,
or carboxylato axial ligands. The development of new synthetic methodologies for accessing the
platinum(IV) manifold can expand the range of complexes having novel properties.
The synthesis of platinum(IV) complexes with axial methyl, ethyl, and isopropyl
26
carbamate ligands was described over ten years ago. Since then, their biological properties
have only rarely been explored, and further investigations of the scope of this synthetic
methodology have not been pursued. In this chapter, a modification and an expansion of this
approach through the synthesis of eight new platinum(IV) complexes of both alkyl and aryl
carbamates as well as a brief investigation of their biological activity is reported. Computational
density functional theory (DFT) studies were undertaken to gain a deeper understanding of the
electronic structure of these new complexes. The results presented here indicate that
platinum(IV) carbamates are a promising new class of anticancer drug candidates.
6.2. Experimental Methods
General Materials and Methods. All reactions were carried out under normal atmospheric
conditions. Solvents were used as received without additional drying or purification. All
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isocyanates were used as received from commercial vendors. The compounds cis,cis,trans-
[Pt(NH3)2Cl2(OH) 2], cis,cis,trans-[Pt(NH3)2C 2(O2CCH3)2] (1), and cis-[Pt(NH 3)2C 4] (3) were
synthesized as previously described 34 ,3 5 using cisplatin purchased from Strem Chemicals, Inc., as
the starting material.
Physical Measurements. NMR measurements were recorded on a Bruker DPX-400
spectrometer in the MIT Department of Chemistry Instrumentation Facility at 20 'C with
deuterated dimethyl sulfoxide (DMSO-d6) as the solvent. All NMR chemical shifts (6) are
reported in parts per million (ppm) and referenced as described below. 1H and 13C{'H} NMR
spectra were referenced internally to residual solvent peaks, and chemical shifts are expressed
relative to tetramethylsilane, SiMe 4 (6 = 0 ppm). 195Pt{H} and 19F{1H} NMR spectra were
referenced externally using standards of K2PtCl4 in D20 (6 = -1628 ppm) and trifluorotoluene (6
= -63.72 ppm), respectively. Fourier transform infrared spectra were recorded with a
ThermoNicolet Avatar 360 spectrophotometer running the OMNIC software. Samples were
prepared as KBr disks. Cyclic voltammograms were obtained at room temperature using a
VersaSTAT3 potentiostat from Princeton Applied Research accompanied by the V3 Studio
software. A three-electrode system was used comprising glassy carbon as the working electrode,
a Pt wire as the auxiliary electrode, and a Ag/AgCl reference electrode. Samples were prepared
as 2 mM solutions in N,N-dimethylformamide (DMF) with 0.1 M (n-Bu4N)PF6 as the supporting
electrolyte. Reported values are peak potentials of the irreversible reduction event at a scan rate
of 100 mV-s 1. Under the conditions described here, the reversible ferrocene/ferricenium redox
couple was consistently found between 0.54 and 0.55 V vs Ag/AgCl. Electrospray ionization
mass spectrometry (ESI-MS) measurements were acquired on an Agilent Technologies 1100
series LC-MSD trap. Elemental analyses were carried out by a commercial analytical laboratory.
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Synthesis of cis,cis,trans-[Pt(NH 3)2C 2(O 2CCF3)2] (2). The compound cis,cis,trans-
[Pt(NH 3)2C12 (OH)2] (0.144 g, 0.429 mmol) was suspended in 2 mL of trifluoroacetic anhydride.
The mixture was stirred for 1 h at room temperature, open to air, at which point the volatile
anhydride had evaporated, leaving a white residue. A 2-mL volume of tetrahydrofuran (THF)
was added to the residue, and the resulting yellow solution was filtered through Celite. Pentane
(-10 mL) was layered on top of the THF solution, and the mixture was kept at -40 'C for 1 h to
afford pale-yellow microcrystals of 2. These microcrystals were collected by vacuum filtration
and washed with pentane before being dried in vacuo. Yield: 0.127 g (56%). Mp: 194-196 'C.
H NMR (400 MHz): 6 6.63 (br s, 6H). 1 3C{'H}NMR (100MHz): 6 161.8 (q, 2JCF = 37 Hz),
111.7 (q, 'JCF = 288 Hz). 19F{ 1H} NMR (377 MHz): 6 -73.6. 195Pt{1H} NMR (86 MHz): 6 1182.
IR (KBr, cm- 1): 3426 m br, 3280 s, 3232 s, 3197 s, 3075 m, 1722 vs, 1559 w, 1382 m, 1331 m,
1212 s, 1162 vs, 1034 w, 859 w, 781 m, 739 m, 524 w. Anal. Calcd. for 2, C4H6Cl 2F6 N20 4Pt: C,
9.13; H, 1.15; N, 5.32. Found: C, 9.38; H, 1.21; N, 5.31.
General Synthesis of cis,cis,trans-[Pt(NH3)2C 2(O 2 CNHR)2]. To a suspension of cis,cis,trans-
[Pt(NH 3)2Cl2(OH)2] (0.20 g, 0.60 mmol) in 1 mL of DMF was added a 1-mL DMF solution
containing 4 mol equiv of the isocyanate. The resulting mixture was stirred for 12 h at room
temperature, resulting in the formation of a homogeneous solution. The solution was filtered, and
the desired product was precipitated by the addition of diethyl ether. The solid was collected by
either filtration or centrifugation. To remove residual DMF, the solid was suspended in water for
30 min, isolated by centrifugation, resuspended in ethanol, isolated by centrifugation,
resuspended in diethyl ether, isolated by centrifugation, and finally dried under vacuum.
Compound 4. R = tert-butyl. White solid. Yield: 0.153 g (48%). Mp: 238-245 'C (dec). 1H
NMR (400 MHz): 6 6.65 (br, 6H), 6.05 (br, 2H), 1.17 (s, 18H). 13C{ 1H} NMR (100 MHz): 6
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162.8, 49.4, 29.3. ' 95Pt{'H} NMR (86 MHz): 6 1276. IR (KBr, cm-1): 3387 vs, 3301 m, 3220 s,
2975 m, 2931 w, 1640 vs, 1629 vs, 1505 vs, 1462 m, 1393 w, 1366 m, 1281 vs, 1211 s, 1079 m,
943 m, 788 w, 727 w, 645 w, 569 w, 434 w. ESI-MS (negative-ion mode): m/z 531.1 ([M-H]~,
calcd. 531.1). Anal. Caled. for 4, CioH 26Cl 2N40 4Pt: C, 22.56; H, 4.92; N, 10.52. Found: C,
23.14; H, 4.83; N, 10.65.
Compound 5. R = cyclopentyl. White solid. Yield: 0.240 g (72%). Mp: 208-214 'C (dec). 1H
NMR (400 MHz): 6 6.67 (br, 6H), 6.55 (br, 2H), 3.78-3.71 (m, 2H), 1.68-1.34 (m, 16H).
3 C{I'H} NMR (400 MHz): 6 163.4, 52.7, 32.5, 23.3. ' 95Ptf'H} NMR (86 MHz): 6 1274 (major),
1262 (minor). IR (KBr, cm-1): 3402 s, 3354 vs, 3243 vs, 2959 s, 2869 m, 1629 vs, 1509 vs, 1358
m, 1297 s, 1252 s, 1099 w, 1037 w, 1008 w, 953 w, 782 w, 581 w. ESI-MS (negative-ion mode):
m/z 555.0 ([M-H]-, calcd. 555.1). Anal. Caled. for 5, C12H26Cl2N40 4Pt: C, 25.91; H, 4.71; N,
10.07. Found: C, 25.76; H, 4.66; N, 10.29.
Compound 6. R = cyclohexyl. White solid. Yield: 0.287 g (81%). Mp: 228-233 0C (dec). 'H
NMR (400 MHz): 6 6.67 (br, 6H), 6.47 (br, 2H), 3.19 (br, 2H), 1.71-1.50 (m, 1OH), 1.22-1.02
(m, 1OH). 13 C{1H} NMR (100 MHz): 6 163.0, 50.0, 33.1, 25.3, 24.9. 195Pt{1H} NMR (86 MHz):
6 1276 (major), 1263 (minor). IR (KBr, cm-1): 3375 vs, 3304 m, 3239 s, 2931 s, 2853 m, 1628
vs, 1500 vs, 1244 s, 1035 m, 931 w, 783 w, 724 w, 706 w, 587 w. ESI-MS (negative-ion mode):
m/z 583.0 ([M-H]-, caled. 583.1). Anal. Caled. for 6, C14H30Cl 2N40 4Pt: C, 28.77; H, 5.17; N,
9.59. Found: C, 28.89; H, 5.20; N, 9.44.
Compound 7. R = phenyl. Yellow solid. Yield: 0.214 g (60%). Mp: 171-176 'C (dec). 'H
NMR(400 MHz): 6 9.12 (br, 2H), 7.47 (d, 4H), 7.18 (t, 4H), 6.86 (t, 2H), 6.79 (br, 6H). "C{'H}
NMR (100 MHz): 6 160.7, 140.7, 128.3, 121.0, 118.0. 19sPt{'H} NMR(86 MHz): 6 1265. IR
(KBr, cm-1): 3243 s br, 1654 vs, 1595 s, 1514 s, 1438 s, 1393 s, 1315 s, 1227 s, 1045 m, 1025 m,
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754 m, 691 m. ESI-MS (negative-ion mode): m/z 570.9 ([M-H]-, calcd. 571.0). Anal. Calcd. for
7, C14HI8Cl 2N40 4Pt: C, 29.38; H, 3.17; N, 9.79. Found: C, 29.56; H, 3.07; N, 9.67.
Compound 8. R = p-tolyl. Pale-orange solid. Yield: 0.229 g (64%). Mp: 149-151 'C (dec). 'H
NMR (400 MHz): 6 9.02 (br, 2H), 7.36 (d, 4H), 6.98 (d, 4H), 6.79 (br, 6H), 2.20 (s, 6H).
1'C{ 1H} NMR (100 MHz): 6 160.8, 138.2, 129.7, 128.7, 118.1, 20.4. 195Pt'H} NMR (86 MHz):
6 1264. IR (KBr, cm-1): 3404 s, 3353 s, 3217 br vs, 2924 w, 1663 vs, 1635 s, 1592 m, 1522 vs,
1502 m, 1404 m, 1314 s, 1289 s, 1250 m, 1223 vs, 1041 s, 817 m, 776 m, 740 w, 654 w, 582 w,
510 w. ESI-MS (negative-ion mode): m/z 599.0 ([M-H]-, calcd. 599.1), 1199.0 ([2M-H]~, calcd.
1199.1). Anal. Calcd. for 8, Ci 6H22Cl2N40 4Pt: C, 32.01; H, 3.69; N, 9.31. Found: C, 32.14; H,
3.75; N, 9.51.
Compound 9. R =p-anisole. Pale-orange solid. Yield: 0.190 g (50%). Mp: 115-117 'C (dec). 'H
NMR (400 MHz): 6 8.98 (br, 2H), 7.37 (d, 4H), 6.77 (br d, 1OH), 3.68 (s, 6H).
3C{'H}NMR(100 MHz): 6 160.9, 153.8, 134.0, 119.5, 113.5, 55.1. 195Pt{'H} NMR (86 MHz): 6
1265. IR (KBr, cm- 1): 3223 s br, 2835 w, 1647 vs, 1515 vs, 1410 m, 1298 s, 1223 vs, 1178 m,
1029 s, 827 m, 777 w, 739 w, 652 m, 583 w, 527 w. ESI-MS (negative-ion mode): m/z 630.9
([M-H]~, caled. 631.0). Anal. Calcd. for 9, C16H22Cl2N40 4Pt: C, 30.39; H, 3.51; N, 8.86. Found:
C, 30.45; H, 3.48; N, 8.73.
Compound 10. R = 4-fluorophenyl. Pale-yellow solid. Yield: 0.237 g (65%). Mp: 208-210 'C
(dec). 'H NMR (400 MHz): 6 9.21 (br, 2H), 7.48-7.45 (m, 4H), 7.02 (app t, 4H), 6.78 (br, 6H).
"C{ 1H} NMR(100 MHz): 6 160.7, 156.9 (d, IJCF = 236 Hz), 137.1, 119.5, 114.7 (d, 2 JCF = 22.0
Hz). 19F{lH} NMR (377 MHz): 6 -125.2 (s, 2F). 195Pt{'H} NMR (86 MHz): 6 1265. IR (KBr,
cm-1): 3367 s, 3238 s br, 1657 vs, 1512 vs, 1407 s, 1389 m, 1305 m, 1259 s, 1213 vs, 1157 w,
1101 w, 1037 s, 832 s, 653 m, 584 w, 513 w. ESI-MS (negative-ion mode): m/z 606.9 ([M-H]-,
247
calcd. 607.0), 1216.0 ([2M-H]~, calcd. 1215.0). Anal. Calcd for 10, C 14H1 6Cl 2F2N4 0 4Pt: C,
27.64; H, 2.65; N, 9.21. Found: C, 27.42; H, 2.50; N, 9.02.
Compound 11. R = 1-naphthyl. Pale-orange solid. Yield: 0.093 g (46%, using 0.30 mmol of the
starting material). Mp: 152-157 'C (dec). 1H NMR (400 MHz): 8 9.01 (s, 2H), 8.19-8.17 (m,
2H), 7.88-7.85 (m, 2H), 7.67 (d, 2H), 7.62 (d, 2H), 7.50-7.40 (m, 6H), 6.82 (br, 6H). 13C{'H}
NMR (100 MHz): 6 161.9, 135.5, 133.7, 127.9, 127.5, 125.7, 125.6, 125.2, 123.5, 123.4, 120.6.
195Pt{ 1H} NMR (86 MHz): 6 1269. IR (KBr, cm-1): 3407 s, 3355 s, 3211 s br, 3063 m, 1654 vs,
1566 m, 1490 s, 1410 s, 1341 s, 1247 s, 1101 w, 999 w, 791 m, 772 s, 544 w. ESI-MS (negative-
ion mode): m/z 669.8 ([M-H]-, calcd. 671.1). Anal. Calcd. for 11, C22H22Cl2N40 4Pt: C, 39.30; H,
3.30; N, 8.33. Found: C, 39.44; H, 3.29; N, 8.39.
X-ray Crystallographic Studies. Single crystals were mounted in Paratone oil on a cryoloop
and frozen under a 110 or 100 K KRYOFLEX nitrogen cold stream. Data were collected on a
Bruker APEX CCD X-ray diffractometer with graphite-monochromated Mo Ka radiation (X =
0.71073 A) controlled by the APEX2 software package.3 6 Absorption corrections were applied
using SADABS. 3 7 The structures were solved using direct methods and refined on F2 with the
SHELXTL-97 software package.38 ,39 Structures were checked for higher symmetry using
PLATON. 4 0 All non-hydrogen atoms were located and refined anisotropically. Unless otherwise
stated, hydrogen atoms were placed in idealized locations and given isotropic thermal parameters
equivalent to either 1.5 (terminal CH3 or NH3 hydrogen atoms) or 1.2 times the thermal
parameter of the atom to which they were attached. Structure refinement was carried out using
established strategies. 4 Crystallographic data collection and refinement parameters are shown in
Tables 6.1 and 6.2.
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Colorless plates of 4 suitable for diffraction were grown by slow evaporation of a
concentrated solution of DMSO. Three molecules of DMSO and 4 comprise the asymmetric unit.
One of the three DMSO molecules is disordered over two orientations. This disorder was refined
with the use of similarity restraints on both the geometry and thermal ellipsoids. The ratio of
disordered components refined to 0.3:0.7. The highest residual electron density peak is located
0.09 A from C16A, which is part of the disordered DMSO molecule. The largest residual
electron density hole is located 0.78 A from the platinum atom.
Large, colorless prisms of 5 were obtained by vapor diffusion of water into a DMF
solution. Along with 5, two molecules of DMF are in the asymmetric unit. Validation of this
structure using checkCIF gave rise to an A-level alert regarding the presence of larger than
normal carbon atom thermal ellipsoids. The large ellipsoids arise from unresolved
conformational disorder of the cyclopentyl ring. No attempt was made to model the disorder as
two distinct conformations. The highest residual electron density peak and hole are located 0.80
and 0.78 A from the platinum atom, respectively.
Slow evaporation of a DMSO solution of 6 afforded colorless blocks. The asymmetric
unit includes two molecules of DMSO and a molecule of 6. One of the DMSO molecules was
disordered over two orientations. The disorder was refined with similarity restraints on the
geometry and ellipsoids. The ratio of disordered components refined to 0.17:0.83. A B-level alert
was generated by checkCIF pointing to the presence of large carbon thermal ellipsoids. As with
5, these large ellipsoids can be attributed to a small amount of conformational disorder in the
cyclohexyl ring. The highest residual electron density peak is located 0.80 A from the platinum
atom, and the largest residual electron density hole is located 0.46 A from C10, which is part of
the cyclohexyl ring.
249
Vapor diffusion of water into a DMSO solution of 7 afforded yellow plates suitable for
diffraction. Compound 7 crystallized with two molecules of DMSO, one molecule of water, and
two molecules of the Pt(IV) complex per asymmetric unit. The hydrogen atoms of the water
molecule could be located on a difference Fourier map and were included, constraining the O-H
bond distances to 0.84 A and restraining the thermal ellipsoids to 1.5 times those of the oxygen
atom. As with 5 and 6, an A-level alert was generated by checkCIF regarding larger than normal
carbon ellipsoids. The large carbon ellipsoids involve only one of the four phenyl rings in the
asymmetric unit. Instead of attempting to model the disorder over two sites, the ellipsoids were
allowed to represent the disorder, which involves a slight rotation of the phenyl ring. The highest
residual electron density peak and hole are located 0.94 and 0.75 A from the platinum atom,
respectively.
Pale yellow plates of 8 were grown by vapor diffusion of water into a DMSO solution.
The asymmetric unit comprises two molecules of 8, four molecules of DMSO, and 1.48
molecules of water. Three molecules of DMSO and one water molecules are well ordered. The
hydrogen atoms of the well ordered water molecule could be located on a difference Fourier map
and were included, constraining the O-H bond distances to 0.84 A and restraining the thermal
ellipsoids to 1.5 times those of the oxygen atom. A DMSO molecule is disordered over two
positions. In one of those positions, an additional partially occupied water molecule is also
incorporated into the lattice. The two DMSO molecules were refined with similarity restraints on
their geometries, and the occupancy factor of the water molecule was assigned the same free
variable as the non-clashing disordered DMSO. The occupancy factor of the DMSO/water pair
refined to 0.48, with the single DMSO molecules occupying the lattice the rest of the time. The
hydrogen atoms of the partially occupied water could not be located in the difference Fourier
250
map and are not included in the model. Level A alerts were generated by checkCIF. These alerts
signal the presence of impossibly close contacts between the disordered DMSO molecules in
different unit cells. However, the alerts can be disregarded because the roughly 50:50
components of the disorder must alternate from cell to cell in the lattice in order to prevent
physically impossible close contacts. The highest residual electron density peak and hole are
located 0.89 and 0.59 A from S300, which is part of the disordered DMSO molecules.
Pale yellow needles of 9 were obtained from the vapor diffusion of diethyl ether into an
acetone solution. A molecule of acetone and 9 are present in the asymmetric unit. Structure
refinement proceeded smoothly with no disorder or other issues. The highest residual electron
density peak and hole are located 0.80 and 1.45 A from the platinum atom, respectively.
Vapor diffusion of diethyl ether into a DMF solution of 10 afforded pale yellow needles.
Within the asymmetric unit, two molecules of 10 and seven molecules of DMF are present. Two
of the DMF molecules are disordered over two orientations. Using similarity restraints, both
cases of disorder were refined successfully. The ratio of disordered components refined to
0.42:0.58 and 0.21:0.79. The highest residual electron density peak and hole are located 0.84 and
0.72 A from the Ptl and Pt2, respectively.
Large yellow blocks of 11 were grown by vapor diffusion of water into a DMF solution.
Aside from one molecule of 11, three molecules of DMF also reside in the asymmetric unit. One
of these DMF molecules is disordered over two orientations. The disorder was refined with
similarity restraints, and the ratio of disordered components refined to 0.35:0.65. The highest
residual electron density peak and hole are located 0.85 and 0.74 A from the platinum atom,
respectively.
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Table 6.1. Summary of X-Ray Crystallographic Data Collection and Refinement Parameter for
4-7.
4-3DMSO 5-2DMF 6-2DMSO 7 DMSO-0.5H 20
formula Ci6H 44Cl 2N 40 7PtS 3  C1 8H40Cl2N 6O6Pt C18H4 2Cl2N 40 6PtS2  Ci6H 25Cl2N 40 5 5PtS
fw 766.72 702.55 740.67 659.45
space group P! Pi Pbcn P2 1/c
a, A 8.9361(10) 9.0048(9) 25.5442(17) 11.5530(5)
b, A 10.5917(12) 12.6877(13) 10.7982(7) 31.3292(13)
c, A 16.762(2) 13.2385(14) 20.7211(13) 13.5070(6)
a, deg 89.100(2) 116.484(2)
p, deg 89.454(2) 93.069(2) 109.7380(10)
y, deg 72.258(2) 92.288(2)
V, A3  1510.8(3) 1348.4(2) 5715.5(6) 4601.6(3)
Z 2 2 8 8
pcalcd, g-cm-3  1.685 1.730 1.721 1.904
T, *C -173(2) -173(2) -173(2) -173(2)
p(Mo Ka), mm4  5.066 5.444 5.281 6.458
0 range, deg 2.02-28.25 1.72-29.73 1.59-29.18 1.73-25.11
total no. of data 30171 29870 118407 75374
no. of unique data 7386 7585 7718 8189
no. of parameters 337 304 323 546
completeness to 0 (%) 98.9 98.7 100.0 99.8
Rla (%) 2.91 2.38 4.27 3.44
wR2b (%) 5.50 5.00 5.66 4.96
Rla (%) for I > 2a 2.32 2.17 2.48 2.45
wR2a (%) for I > 2a 5.42 4.92 4.99 4.67
GOFc 1.040 1.039 1.021 1.044
max, min peaks, e-A 3  1.749, -1.229 1.879, -2.044 1.672, -0.787 1.264, -0.733
a RI = JFol - IFII/IFol. b wR2 = {[w(Fe2 - Fc2)2]/C[w(Fo2)2]}m c GOF = {E[w(Fe2 - Fe:)2]/(n
p)}1/2 where n is the number of data and p is the number of refined parameters.
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Table 6.2. Summary of X-Ray Crystallographic Data Collection and Refinement Parameter for
8-11.
8-2DMSO-0.74H 20
C20H 35C12N 406 .7 4PtS 2
769.55
Pi
11.6514(7)
14.7016(8)
18.4270(11)
68.7800(10)
78.9840(10)
84.3020(10)
2886.6(3)
9-acetone
C19H 28Cl2N 40 7Pt
690.44
P2 1/c
18.9166(10)
9.5089(5)
13.7632(7)
92.5790(10)
2473.2(2)
10-3.5DMF
C24.5H 40.5Cl2 F2N 7.50 7.5Pt
864.13
P2 1
18.0923(7)
7.0254(3)
26.4980(11)
104.0310(10)
3267.6(2)
11-3DMF
C3 1 143 C 2N 70 7Pt
891.71
Pi
11.7178(14)
12.0190(15)
13.2152(16)
87.170(2)
77.548(2)
75.264(2)
1757.6(4)
Z 4 4 4 2
pcalcd, g'em-3 1.771 1.854 1.757 1.685
T, C -173(2) -173(2) -163(2) -173(2)
R(Mo Ka), mm 1  5.234 5.935 4.524 4.199
E range, deg 1.49-29.32 2.16-28.74 1.24-28.66 1.58-28.40
total no. of data 60845 51159 68723 35819
no. of unique data 15609 6409 16640 8716
no. of parameters 706 304 903 457
completeness to 0 (%) 98.7 99.7 99.8 98.8
Rla (%) 4.36 2.82 2.83 2.27
wR2b (%) 8.05 4.83 5.70 4.21
Rla (%) for I > 2a 3.16 2.10 2.27 1.91
wR2a (%) for I > 2y 7.18 4.57 5.08 4.09
GOFC 1.029 1.030 1.039 1.037
max, min peaks, e-A3  3.119, -2.625 2.131, -0.468 1.221, -1.191 0.942, -0.712
'RI = EIFoI - IFel/ElFol. b wR2 ={E[w(Fo2 - F c22 ]/E[w(Foz)2 12 c GOF = {I[w(Foz - Fe2)2]/(n
p)}11/2 where n is the number of data and p is the number of refined parameters.
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formula
fw
space group
a, A
b, A
c, A
a, deg
p, deg
y, deg
V, A3
Theoretical Calculations. DFT calculations were performed using the Gaussian 03 (revision
42
DO1) software package. Geometry optimizations, frequency calculations, and molecular orbital
generations were all carried out using the B3LYP functional.43 44 For the light atoms (carbon,
hydrogen, chlorine, nitrogen, oxygen, and fluorine), the 6-31++G(d,p) basis set4 5 was used, and
for platinum, the LANL2DZ basis set and effective core potential46 were used. No solvation
models were employed; the results described for all complexes are in the gas phase. Frequency
calculations were carried out on all optimized geometries to verify the absence of imaginary
values. To determine adiabatic electron affinities, an additional set of geometry optimizations
and energy calculations were performed for the analogous monoanionic platinum(III) complexes
with a doublet spin state. The difference in total electronic energy between the platinum(III)
anion and neutral platinum(IV) complexes is the adiabatic electron affinity of the latter. The
geometry optimization of the one-electron-reduced analogue of 3 gave rise to a structure with an
imaginary frequency. Hence, its adiabatic electron affinity was not computed.
Cell Lines and Culture Conditions. Human A549 (lung carcinoma) and human MRC-5
(normal lung fibroblasts) were grown as adherent monolayers in a growth medium consisting of
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin. The cultures were grown in 25-cm 2 flasks in an incubator at 37 *C
with a humidified atmosphere composed of 5% CO2.
Cytotoxicity Assays. The colorimetric MTT assay was used to determine the cytotoxicity of
cisplatin and compounds 4-11. Trypsinized A549 and MRC-5 cells were seeded into a 96-well
plate at cell densities of 1500 and 2500 cells/well, respectively, in 200 pL of growth medium and
were incubated for 24 h. The medium was then removed, and 200 pL of new growth medium
containing various concentrations of the platinum complexes was added. After 72 h, the medium
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was removed, 200 pL of a 0.8 mg/mL solution of MTT in DMEM was added, and the plate was
incubated for an additional 4 h. The DMEM/MTT mixture was aspirated, and 200 tL of a
mixture of 90% DMSO and 10% glycine buffer, pH 10.5, was added to dissolve the purple
formazan crystals. The absorbance of the plates was read at 570 nm. Absorbance values were
normalized to the platinum-free control wells and plotted as [Pt] versus % viability. IC50 values
were interpolated from the resulting curves. The reported IC 50 values are the averages from at
least three independent experiments, each of which consisted of three replicates per
concentration level. Dilutions of the platinum(IV) compounds in growth medium were prepared
from concentrated solutions (10-20 mM) in DMSO. Cisplatin was diluted from a phosphate-
buffered saline solution (~ 2 mM). Final DMSO concentrations in all cases was 1%, a content
not substantially toxic to cells.
6.3. Results and Discussion
Synthesis and Characterization. The synthesis of platinum(IV) carbamate complexes was
accomplished by treating cis,cis,trans-[Pt(NH3)2Cl2(OH)2] with the desired isocyanate in a DMF
solution (Scheme 6.2). Because the starting complex, cis,cis,trans-[Pt(NH3)2Cl2(OH)2], is largely
insoluble in DMF, the progress of the reaction was monitored visually by observing conversion
of the reaction mixture from a suspension to a homogeneous solution. The synthesis of the
analogous methyl ethyl, and isopropyl carbamate complexes has been reported previously. 2 6 In
this prior study, the authors prepared these complexes by suspending cis,cis,trans-
[Pt(NH 3 )2 Cl2 (OH) 2] in neat isocyanate with no additional solvent. In cases where isocyanate is
expensive or toxic, the use of only a slight excess, as demonstrated in the present work, is a clear
advantage.
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Scheme 6.2. Syntheses of platinum(IV) dicarbamates 4-11.
Platinum(IV) dicarbamates are either white (4-6) or pale-yellow to pale-orange (7-11)
solids. Compounds 7-11 are the first reported platinum(IV) complexes bearing aryl carbamate
ligands and thus extend the scope of the chemistry beyond simple alkyl isocyanates. Compounds
4-11 exhibit good solubility in DMF and DMSO, moderate solubility in THF, acetonitrile, and
acetone, and poor solubility in water and halogenated organic solvents. In solution, the aryl
carbamate complexes, 7-11, decompose to dark-brown solutions when exposed to ambient light
over the course of several hours. The alkyl carbamate complexes, 4-6, remain stable in solution
even in the presence of light. The aromatic substituents of 7-11 most likely play a role in the
256
OH
H3N.,, t, .I Ci
H3NVO' I "Cl
OH
+
photodecomposition of the complexes. In the absence of light, all of the compounds are stable in
solution.
Characterization of compounds 4-11 was accomplished by NMR spectroscopy, IR
spectroscopy, mass spectrometry, elemental analysis, and X-ray crystallography (vide infra).
Elemental analyses of the complexes are in good agreement with expected values, and
electrospray ionization mass spectrometry gave rise to the expected [M-H]~ signals, further
validating the molecular formulas of these compounds. The IR spectra displayed characteristic
C=O stretching frequencies ranging from 1647 to 1663 cm' for the aryl carbamate complexes
and from 1628 to 1629 cmf for the alkyl carbamate complexes. All complexes also display N-H
stretching frequencies derived from the ammine ligands, which appear as a broad series of bands
near 3200 cm-1 .
The 1H, 13C, and 19F (for 10) NMR spectra of the complexes display all expected
resonances. 195Pt and selected 1H NMR chemical shifts are summarized in Table 6.3. The signal
corresponding to the NH proton of the carbamate ligands is observed between 8.97 and 9.21 ppm
for the aryl carbamate complexes, 7-11, and between 6.05 and 6.55 ppm for the alkyl carbamate
complexes, 4-6. This 3 ppm shift reflects significant deshielding of the NH carbamate resonance
relative to the alkyl substituents by the aryl substituents. The proton resonances of the
coordinated ammine ligands appear in all complexes as broad peaks ranging from 6.67 to 6.82
ppm. These values are consistent with ammine coordination to a platinum(IV) center; protons of
ammines coordinated to platinum(II) centers typically lie farther upfield, between 3 and 5 ppm.4 7
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Table 6.3. ' 95Pt and Selected 1H NMR Shifts for 4-11 in DMSO-d at 20 'C.
compound 6 195Pt, ppm 6 'H, carbamate NH, ppm 6 'H, NH3, ppm
4 1276 6.05 6.65
5 1275 (major), 1262(minor) 6.55 6.67
6 1276 (major), 1263 (minor) 6.47 6.67
7 1265 9.12 6.79
8 1264 9.02 6.79
9 1265 8.98 6.77
10 1265 9.21 6.78
11 1269 9.01 6.82
The 195Pt NMR spectra of 7-11 display a single resonance in the range 1264-1269 ppm.
Given that the known window for 195Pt NMR shifts is >15,000 ppm, the small variance in
chemical shifts among these complexes indicates that the peripheral substituents of the aryl rings
have little effect on the magnetic environment of the platinum nucleus. The alkyl carbamate
complex, 4, exhibits a single 195Pt NMR resonance in DMSO-d at 1276 ppm. These chemical
shifts are in the range expected for platinum(IV) complexes 48 -50 and are close to related
platinum(IV) alkyl and aryl carboxylate complexes, which fall between 1000 and 1300 ppm.
Although both the 'H and 13 C NMR spectra of 5 and 6 are consistent with the presence of a
single species in solution, the 195Pt NMR spectra at 20 'C in DMSO-d display two resonances at
approximately 1276 and 1262 ppm in relative intensities of approximately 2:1. As the
temperature of the NMR sample is increased, the two resonances eventually coalesce between 50
and 65 'C, as shown in Figure 6.1 for 5. Consistent with the known temperature dependence of
195Pt NMR chemical shifts, 51 the peaks are shifted downfield at higher temperatures as well.
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Figure 6.1. Variable-temperature 195Pt (left) and 1H (right) NMR spectra of 5 in DMSO-d6 .
This fluxional process could also be monitored by 'H NMR spectroscopy, as shown in
Figure 6.1 for 5. The NH resonance of the carbamate ligand exhibits significant temperature
dependence, shiffing upfield by 0.5 ppm at 80 *C. A small peak in the spectrum near 5.8 ppm
broadens into the baseline at 35 *C. This peak most likely corresponds to the NH resonance of a
minor conformational isomer. The aliphatic region of the 'H NMR spectrum is unaffected by
changes in temperature. The broad peak of the coordinated NH 3 protons is only slightly affected
by an increase in temperature; a small upfield shift occurs and shoulders due to coupling to 14N (I
= 1) become visible. The changes in the 195Pt and 'H NMR spectra as a function of the
temperature are fully reversible; after increasing the temperature to 80 *C, the original spectra
can be obtained at 20 *C.
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As shown in Chart 6.1, three possible conformational isomers exist for the complexes
depending on the orientation of substituents about the C-N bond of the carbamate ligand. It is
not clear why only two of these isomers are observed by 195Pt NMR spectroscopy, but it is
possible that two of the isomers have very similar chemical shifts and are therefore not resolved
as distinct peaks. Another possibility is that one of the conformational isomers is significantly
less stable than the other two and never accumulates in a high enough concentration to be
observed under equilibrium conditions. The use of variable-temperature 195Pt NMR spectroscopy
to distinguish between chemically similar stereoisomers has been reported before.52-55 Our
findings here similarly validate this method as a valuable tool for distinguishing isomers that
could not otherwise be discerned by the more commonly used 1H and 13C NMR spectroscopy.
H'N'R
R% NH
H3N.,1 t ,%.ClPt".
H3N" I 'C
0 0
H N R R 'NH R'N H
anti/anti anti/syn syn/syn
Chart 6.1. Structures of possible isomers of platinum(IV) dicarbamate complexes.
X-ray Crystal Structures. Complexes 4-11 were all characterized by X-ray crystallography and
are the first such structurally characterized platinum carbamate complexes. Relevant bond
distances and angles for the platinum carbamate complexes are listed in Table 6.4, and the
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structures are shown in Figures 6.2 and 6.3. The bond distances are typical; the Pt-Cl bond
lengths are close to 2.3 A and the Pt-O/N distances are -2.0 A. All complexes display the
expected octahedral coordination geometry for platinum(IV). In addition, the structures all have
the same stereochemistry as that of the starting platinum(IV) hydroxo compound (cis,cis,trans),
which is retained upon formation of the carbamate ligands.
Table 6.4. Selected Interatomic Distances (A) and Angles (deg) for 4-11.a
4 5 6 71 81 9 10ll
Pt1-C1l 2.3145(7) 2.3324(6) 2.3075(7) 2.3272(10) 2.3367(9) 2.3187(6) 2.3201(11) 2.3176(6)
Ptl-C12 2.3326(8) 2.3170(6) 2.3151(7) 2.3202(10) 2.3324(9) 2.3271(6) 2.3127(11) 2.3126(6)
Ptl-N1 2.037(2) 2.0423(19) 2.042(2) 1.993(3) 2.034(3) 2.029(2) 2.054(4) 2.0299(17)
Ptl-N2 2.037(2) 2.038(2) 2.041(2) 1.995(3) 2.033(3) 2.038(2) 2.048(3) 2.0349(18)
Ptl-01 2.0117(19) 2.0088(16) 2.026(2) 1.993(3) 2.000(3) 2.0230(18) 2.0209(18) 2.0065(13)
Ptl-03 2.0062(19) 1.9970(16) 2.001(2) 1.995(3) 2.002(3) 2.0113(18) 1.9936(19) 2.0161(13)
N1-Ptl-N2 90.00(10) 90.02(8) 93.17(10) 92.21(13) 89.81(14) 91.70(9) 93.49(10) 92.42(7)
C1l-Ptl-C12 92.57(3) 91.99(2) 91.48(3) 92.68(4) 94.64(3) 90.90(2) 89.24(3) 91.33(2)
01-Ptl-N1 96.54(9) 86.31(7) 97.67(10) 96.66(12) 91.99(13) 91.27(8) 91.90(14) 91.81(6)
01-Ptl-C12 90.12(6) 87.53(5) 90.47(6) 86.18(8) 88.04(9) 88.69(6) 89.58(10) 88.74(4)
03-Ptl-N2 94.89(9) 89.31(8) 93.21(9) 93.15(12) 92.70(13) 91.94(8) 91.40(14) 96.96(6)
03-Pt1-Cl 87.04(6) 88.30(5) 89.64(6) 88.14(8) 87.07(9) 87.92(5) 87.67(9) 84.12(4)
01-Ptl-03 174.06(8) 174.22(7) 174.17(9) 174.94(11) 168.70(11) 174.20(7) 174.72(8) 173.33(6)
a The numbers in parentheses are the estimated standard deviations of the last significant figures.
Atoms are labeled as indicated in Figures 6.2 and 6.3. bTwo molecules per asymmetric unit are
present in the crystal lattice. The parameters shown here are only for one of those molecules.
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4 5 6 7
Figure 6.2. Solid-state molecular structures of 4-7. Ellipsoids are drawn at the 50% probability
level.
8 9 10 11
Figure 6.3. Solid-state molecular structures of 8-11. Ellipsoids are drawn at the 50% probability
level.
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4
A common feature among the eight complexes is the presence of intramolecular
hydrogen bonding between the oxygen atom of the axial carbamate ligands and the equatorial
ammine ligands. Three different geometries are observed for this interaction, as shown in Figure
6.4. In the first geometry, the oxygen atoms lie in a plane bisecting the N-Pt-N angle and
interact with both coordinated ammines equally. This situation occurs for 6, both molecules in
the asymmetric unit of 7, one of the molecules in the asymmetric unit of 8, and 11. The geometry
in which both of the oxygen atoms are twisted to opposite sides and hydrogen bond with the
different ammines is observed only in the case of 5. In the final case, one of the oxygen atoms is
twisted to the side and interacts with only one of the coordinated ammines. This geometry is the
most common hydrogen-bonding motif for this class of compounds and occurs in the remaining
structures.
4 I'02
C1 C12 C C2C C2
N1 t N2 Ni 2
0202 02
Figure 6.4. The three intramolecular hydrogen bonding motifs observed in the crystal structures
of 4 - 11. These three examples are compounds 8 (left), 7 (middle), and 5 (right).
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As discussed above, different conformational isomers, reflecting alternative orientations
of the substituents about the carbamate C-N bond, exist (Chart 6.1). The most commonly
observed isomer is that with a syn/syn ligand orientation, observed for 5, 6, both molecules in the
asymmetric unit of 7, both molecules in the asymmetric unit of 8, and one of the molecules in the
asymmetric unit of 10. The anti/syn isomer occurs in 4, 9, and the other molecule in the
asymmetric unit of 10. The naphthyl carbamate complex 11 crystallized exclusively as the
anti/anti isomer. The occurrence of all three possible isomers throughout the crystal structures of
4-11 reflects a small energy difference between isomers in solution, as observed by NMR
spectroscopy.
Cyclic Voltammetry. The biological activity of platinum(IV) complexes is mediated by their
redox chemistry. In most cases, platinum(IV) complexes, unlike their platinum(II) progeny, do
not bind directly to DNA or other biological nucleophiles.56 The redox potential of platinum(IV)
complexes is therefore believed to be an important factor in their efficacy as antitumor agents.
With this possibility in mind, we studied redox potentials of 1-11 by cyclic voltammetry.
Because of the limited aqueous solubility of 4-11, the cyclic voltammograms were
recorded in DMF using 0.1 M (n-Bu4N)PF6 as the supporting electrolyte. For comparison, the
electrochemical properties of compounds 1-3 were also investigated by cyclic voltammetry in
the same solvent and electrolyte system. As expected for the platinum(IV)/platinum(II) redox
couple, all of the compounds exhibit a single irreversible reduction event in the potential window
of +0.4 to -1.2 V vs Ag/AgCl. The peak potentials (Ep) for these processes obtained at a scan
rate of 100 mV-s- are reported in Table 6.5, and the corresponding cyclic voltammograms are
shown in Figure 6.5. With careful polishing of the glassy carbon working electrode, reproducible
voltammograms were obtained with only minor deviations in the peak potentials. No systematic
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shift in the peak potentials upon multiple cycles was observed, as was observed for 1 when
measured in aqueous solution (see Appendix A).
Because these processes are irreversible, thermodynamic values for the redox potentials
cannot be readily extracted from a single voltammogram. The observed peak potentials reflect a
combination of both the kinetic overpotential and the thermodynamic reduction potential, as
discussed in more detail in Appendix A. Correlations of peak potentials with structure-activity
relationships and reduction kinetics6 of platinum(IV) complexes have been observed. Hence,
although the peak potential is not clearly defined as a thermodynamic or kinetic parameter, it is
still of use for characterizing potential platinum(IV) anticancer agents. For a given set of
equatorial ligands on a platinum(IV) center, the peak potential in water predictably changes as
the axial ligands are varied.5 -7 '5 7 Trifluoroacetate ligands produce the most easily reduced (most
positive peak potential) platinum(IV) complexes, followed by chloride ligands, and then acetate
ligands in that order. Axial hydroxo ligands, although not investigated here, give rise to
platinum(IV) complexes that exhibit peak potentials more negative than those with acetate
ligands. For example, the precursor complex cis,cis,trans-[Pt(NH3)2Cl2(OH)2] is reported to have
a very negative peak potential at -880 mV in aqueous media.57 In moving from water to DMF,
we find here that this general trend still exists for the chloride and carboxylate ligands, as Ep(2)>
Ep(3) > Ep(1). The peak potentials themselves, however, are shifted significantly from those
measured in water. In water, the measured peak potentials of 1 and 3 have been determined by
others to be -640 and -260 mV, respectively, 57 and the peak potential of 2 was measured to be
10 mV. In DMF, these potentials are -720 (1), -350 (2), and -450 (3) mV, indicating that this
solvent change shifts the peak potential by up to 300 mV in the negative direction. Even though
the potentials measured in DMF are shifted significantly from those measured in aqueous
265
solution, a comparison of peak potentials for the carbamate complexes 4-11 to those for 1-3 is
valuable for understanding the relative stability of the complexes in the biological milieu.
0.4 0.0 -0.4 -0.8 -1.2
Potential (V)
-1.6 -2.0
Figure 6.5. Cyclic voltammograms of 1-11. Data obtained for 2 mM solutions of the complexes
in DMF with 0.1 M (Bu 4N)(PF6) as the supporting electrolyte. The scan rate was 100 mV/s.
266
Table 6.5. Peak Reduction Potentials for 1-11 Measured by Cyclic Voltammetry in DMF.
Compound Ep, V vs. Ag/AgCl
1 -0.72 (-0.64)a b
2 -0.35 (0.01)ac
3 -0.45 (-0.2 6 )a b
4 -0.85
5 -0.85
6 -0.82
7 -0.73
8 -0.71
9 -0.72
10 -0.66
11 -0.63
a Values in parentheses are for those measured in aqueous solution. b Ref. 57. C This work
Compounds 7-9 display nearly identical peak potentials near -720 mV. This similarity
indicates that electron-donating groups in the para position of the aryl carbamate ligands have
little effect on the redox potentials of these compounds. Notably, the peak potentials of these
compounds are indistinguishable from that of 1. Thus, the aryl carbamate ligands confer the
same degree of stabilization to the 4+ oxidation state as the acetate ligand. Compound 10
exhibits a higher peak potential at -660 mV. This more positive potential is attributed to the
electron-withdrawing fluorine atom on the aromatic ring of the carbamate ligand, which favors
reduction. The least negative peak potential of the series, at -630 mV, is displayed by the
naphthyl carbamate complex 11. The reason for 11 having a peak potential approximately 100
mV more positive than those of 7-9 is not entirely clear. A possible explanation is that the
increased steric bulk from the large naphthyl group favors ligand dissociation and consequently
reduction. Alternatively, the kinetic component of the peak potential may be increased by a
favorable interaction of the a-aromatic ligands with the glassy carbon electrode during the
electron transfer process. The alkyl carbamates 4-6 have peak potentials between -820 and -850
mV. The alkyl substituents on the carbamate ligand stabilize the 4+ oxidation state by about 100
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mV relative to the aryl substituents. This observation indicates in part that alkyl carbamates are
stronger electron donors and are more capable of stabilizing the electron-poor 4+ oxidation state
than aryl carbamates at least from the heterogeneous electron transfer conditions probed in this
experiment.
Theoretical Calculations. Geometry optimizations were carried out for 1-11 at the DFT B3LYP
theoretical level. For the carbamate complexes, 4-11, geometry optimizations were computed
only for the anti/anti isomers (Chart 6.1). Although no symmetry restraints were placed on the
geometry optimizations, all optimized structures attained nearly perfect C2, symmetry, with the
principal 2-fold axis bisecting the Cl-Pt-Cl and NH 3-Pt-NH 3 angles in the equatorial plane. In
this configuration, intramolecular hydrogen bonding occurs between the oxygen atom of the
carbamate ligands and both of the coordinated ammine ligands, as observed experimentally in
several of the crystal structures.
The frontier Kohn-Sham molecular orbitals (FMOs) of 1-3 are shown in a qualitative
molecular orbital diagram in Figure 6.6. The expected two-over-three d-orbital splitting for a
nearly octahedral transition-metal complex is predicted by these computations. The LUMO and
LUMO+1 are nearly degenerate and are dz2 and dxy a* in character. The HOMO to HOMO-3 are
also close in energy. These orbitals are dx2-y2, dxz, and dyz a*, and Cl 3p nonbonding in character.
The HOMO-LUMO gaps of 1-3 are 4.16, 3.97, and 3.70 eV, respectively. These values
correspond to the magnitude of the d-orbital splitting and reflect the ordering of the acetate,
trifluoroacetate, and chloride ligands in the spectrochemical series.
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dz20* +
dXy -*.
dyr *4
dx2.y2 *
dx n*.
dx2.y2*
3p n.b..
dyz n
dyz i*
d3tAi
Figure 6.6. Qualitative (energies not drawn to scale) Kohn-Sham molecular orbital diagram for 1
(left), 2 (middle), 3 (right). The x-, y-, and z-axes are defined as the bisector of the Cleg-Pt-Cleg
and NH3-Pt-NH 3 angles, the bisector of the Clez-Pt-NH3 angles, and the line comprising the Pt
atom and its two axial ligands, respectively.
The FMOs of 6, 7, and 11 are shown in the qualitative molecular orbital diagram in
Figure 6.7. The FMOs of the other alkyl carbamate complexes, 4 and 5, are qualitatively similar
to those of 6, as are the FMOs of the other aryl carbamate complexes, 8-10, to complex 7. Like
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d 0*
d2 *
dy
dz2 0*I
1-3, the LUMO and LUMO+1 of the carbamate complexes are dz2 and dxy o* in character. The
HOMOs, however, are ligand-localized a orbitals. The presence of these orbitals leads to smaller
HOMO-LUMO gaps for the aryl carbamate complexes which range from 2.52 to 2.99 eV,
compared to those of 1-3. This result is consistent with the observation that 7-11 are sensitive to
light. The smaller HOMO-LUMO gap may render dissociative excited states accessible by the
energy provided by visible light.
d7 zo -
~ - di, ue
3L
-4-3p n b.
Figure 6.7. Qualitative (energies not drawn to scale) Kohn-Sham molecular orbital diagram for 6
(left), 7 (middle), 11 (right). The x-, y-, and z-axes are defined as the bisector of the ClegPt-Cleq
and NH3-Pt-NH 3 angles, the bisector of the Cleq-Pt-NH3 angles, and the line comprising the Pt
atom and its two axial ligands, respectively.
270
The gas-phase adiabatic electron affinities of 1, 2, and 4-11 were computed by
optimizing the geometry of the one-electron reduced platinum(III) species as a doublet anion and
then subtracting its total electronic energy from the neutral platinum(IV) species. The results are
summarized in Table 6.6. The optimized geometries of the platinum(III) species give rise to
stationary points on the potential energy surface, as evidenced by the lack of imaginary
frequencies, except in the case of 3. A comparison of the geometrical parameters of the
calculated platinum(IV) and platinum(III) structures is presented in Table 6.6. Upon reduction to
platinum(III), two mutually trans bonds are elongated significantly, whereas the other bonds are
only altered slightly. This result is expected, for the addition of another electron to the closed-
shell platinum(IV) species would require population of an antibonding orbital. For most cases,
the axial platinum-carbamate bond is lengthened by approximately 0.4 A in the platinum(III)
complex, which is consistent with the conventional view of platinum(IV) reduction depicted in
Scheme 6.1. For 6-8, however, significant bond elongation occurs for the equatorial, mutually
trans platinum-chloride and platinum-ammine bonds. These bonds are elongated by
approximately 0.34 A. This result suggests that in some cases elimination of the equatorial
ligands may be a viable reductive pathway of platinum(IV) and is consistent with experimental
observation of this pathway by others. 58~6 0 The computed gas-phase adiabatic electron affinities
correlate well with the observed peak potentials for reduction. In Figure 6.8, the peak potentials
are plotted as a function of the electron affinity. The relationship is roughly linear (R2 = 0.887),
and as expected, larger electron affinities correlate with more positive peak potentials.
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Table 6.6. The Computed Adiabatic Electron Affinities and the Difference in Computed
Interatomic Distances between the Neutral Pt(IV) Complex and the Anionic Pt(III) Complex.a
Ad, A
Compound Electron Pt-Cll Pt-C12 Pt-N1 Pt-N2 Pt-01 Pt-02
Affinity, eV
1 2.754 0.03021 0.03005 -0.01439 -0.01425 0.39707 0.39701
2 3.791 0.02479 0.02553 -0.02139 -0.02078 0.40872 0.41175
4 2.576 0.02695 0.02698 -0.00836 -0.00832 0.39533 0.39631
5 2.570 0.02719 0.02718 -0.00791 -0.00790 0.39420 0.39422
6 2.321 0.36070 0.03682 -0.01119 0.33653 0.02840 0.02918
7 2.683 0.33739 0.03196 -0.01319 0.33328 0.03518 0.03507
8 2.631 0.33878 0.03234 -0.01287 0.33366 0.03467 0.03458
9 2.901 0.02454 0.02454 -0.00784 -0.00787 0.39023 0.39024
10 3.129 0.02412 0.02419 -0.00897 -0.00884 0.39158 0.39165
11 3.060 0.02305 0.02306 -0.00790 -0.00792 0.39017 0.39028
a Atoms are labeled as shown in Figures 6.2 and 6.3.
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Figure 6.8. Plot of the computed adiabatic electron affinity versus the experimentally measured
reduction peak potentials. The black line is the linear regression of the data.
272
Biological Properties. The cytotoxicities of compounds 4-11 and cisplatin against human lung
carcinoma (A549) and human normal lung (MRC-5) cells were measured by the MTT assay. The
results in the form of 50% growth inhibitory concentrations (IC 50 values) are shown in Table 6.7.
In A549 cells, most of the platinum(IV) carbamates exhibit a level of cytotoxicity that is similar
to that of cisplatin. The IC50 values range from 3 to 6.7 tM, compared to an ICso of 7.0 pM for
cisplatin. Compounds 4 and 5, bearing tert-butyl and cyclopentyl carbamate ligands, showed
greater cytotoxicity than the other compounds, with the IC50 values being 1.0 and 0.6 gM,
respectively. In the noncancerous lung fibroblasts (MRC-5), all of the complexes, except for 4
and 5, were slightly less cytotoxic than cisplatin. The ICso of cisplatin in this cell line was 4.3
gM, and those of 6-11 ranged from 4.8 to 16.0 M. The cytotoxicities of 4 and 5 in the lung
fibroblasts were marked by IC50 values of 2.8 and 2.3 pM, indicating that they are approximately
a factor of two less cytotoxic in the healthy cells compared to the cancerous cells, as observed for
the other carbamate complexes. The results here demonstrate that, like the platinum(IV)
complexes bearing axial chloro, hydroxo, and acetato ligands, this newly synthesized class of
platinum(IV) complexes bearing axial carbamate ligands also contains viable anticancer drug
candidates.
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Table 6.7. Cytotoxicities of Cisplatin and 4-11 in A549 and MRC-5 Cells.
IC50 (pM)a
compound A549 MRC-5
4 1.0 0.3 2.8 ±0.8
5 0.6 0.3 2.3 ± 0.7
6 6.7±2.9 12.7 ±3.5
7 6.7 ±2.1 16.0 ±6.6
8 3.0 ±1.0 5.1 ±1.8
9 5.3 ±2.5 9.3 ±3.2
10 3.7 ±1.2 7.6 ±3.1
11 4.3 ±1.5 4.8 ± 0.3
cisplatin 7.0 2.6 4.3± 1.3
a 50% cell growth inhibitory concentrations as measured by the MTT assay after 72 h exposure.
Values are the average of at least three independent experiments, and the reported errors are the
corresponding standard deviations.
6.4. Summary and Conclusions
The syntheses of eight new platinum(IV) carbamate complexes are described. The
general reactivity of both aryl and alkyl isocyanates with the important platinum(IV) synthon
cis,cis,trans-[Pt(NH3)2Cl2(OH)2] provides a valuable synthetic methodology for the design of
new platinum(IV) complexes with novel properties. It also offers a route for the functionalization
of isocyanate-bearing nanomaterials through the formation of a platinum-carbamate bond. In
contrast to the more common platinum(IV) carboxylate complexes, platinum(IV) carbamates
adopt different isomeric forms depending on the rotational orientation of the ligand, as revealed
by NMR spectroscopy and X-ray crystallography, and their ligand-based orbitals are
intermediate in energy between those of the empty and filled metal d orbitals, as determined by
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DFT calculations. Electrochemical studies of platinum(IV) carbamates display redox potentials
similar to those of platinum(IV) acetates, such as satraplatin. This result suggests that
platinum(IV) carbamate complexes should exhibit stability properties in biological milieu similar
to those of the acetate complexes. The fact that platinum(IV) carbamates display cytotoxicities
similar to or better than that of cisplatin reveals their therapeutic potential. Finally, DFT
computational analyses indicate that the redox potential of platinum(IV) complexes can be
correlated with their computed electron affinities.
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Appendix A
Aqueous Electrochemistry of a Platinum(IV) Prodrug
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A.1. Introduction
As discussed in Chapter 6, platinum(IV) anticancer agents have recently gained interest
as alternatives for clinically used first and second generation platinum(II) analogs.1-3 This
interest stems from their octahedral coordination geometry, which allows for two additional
ligand-binding sites for derivation, and their kinetic inertness, which imparts a greater in vivo
lifetime and the possibility for oral administration. Platinum(IV) anticancer agents are pro-drugs
of platinum(II) complexes. Reduction of platinum(IV) results in loss of two ligands and
formation of a DNA-binding platinum(II) species. The kinetics of this reductive activation step
in vitro and in vivo are of great interest because they dictate whether there is any benefit in
utilizing a platinum(IV) complex over its platinum(II) analog. Premature reduction in the
bloodstream or gastrointestinal tract will lead to a platinum(II) species with its attendant
biodistribution properties. If reduction occurs too slowly, the platinum(IV) complex may be
cleared before it can bind to DNA in tumor tissues.
Various researchers, including us, have utilized cyclic voltammetry as a way to measure
the propensity of a given platinum(IV) complex to be reduced.4 ~" Correlations between
reduction rates and biological activities with cyclic voltammetric data have been found in some
cases ,4,7,14-16 thus validating the methodology as an important tool for characterizing anticancer
platinum(IV) complexes. The change in coordination geometry of a platinum(IV) complex from
octahedral to square-planar upon reduction is reflected by an irreversible reduction peak in the
cyclic voltammogram. Only in a few cases with specially designed ligands have reversible
Pt(IV)/Pt(II) or Pt(IV)/Pt(III) couples been observed. 17'18
Irreversible electrochemical processes, as probed by cyclic voltammetry, are inherently
more complex than reversible ones. For reversible processes, the thermodynamic reduction
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potential of a compound can be determined based on the midpoint of the anodic and cathodic
peak potentials. Since no return oxidation wave is observed in the CVs of platinum(IV)
complexes, the midpoint, and hence the thermodynamic, potential cannot be determined upon
visual inspection of the CV. In the literature, the commonly cited value for Pt(IV) reduction
potentials are the irreversible peak potentials, which depend on scan rate along with other factors
(Equation A.1.). The peak potential is not purely a thermodynamic value. It is, however,
mathematically related to it. The equation describing the peak potential for an irreversible
process is described by Equation A.1, where Ep is the peak potential, E"' is thermodynamic
standard reduction potential, R is the gas constant, T is the temperature, F is Faraday's constant,
a is the transfer coefficient, n. is the number of electrons transferred, Dox is the diffusion
coefficient of the compound being studied, k is the standard rate constant, and v is the scan
rate.19 It is clear from this equation that the rate of electron transfer from the electrode surface to
the platinum(IV) complex (k) affects the Ep observed by cyclic voltammetry.
Equation A.1.
RT r 11 DnFn 1/2Ep = E ' ---- 0.780 + Dnox'/n)n
anaFko \ RT /
The loss of two ligands accompanies the reduction of platinum(IV) to platinum(II). In the
design of new platinum(IV) anticancer constructs, it has been assumed that only the axial ligands
are lost. Axial ligands have been used to attach platinum(IV) pro-drugs to various nanodelivery
devices under the assumption that, upon reduction, cisplatin will be released, leaving the axial
ligands behind (Scheme A. 1).9,10,1,20-2 Recent studies, however, have shown that elimination of
24-both equatorial and axial ligands can occur upon reduction by components of cellular extracts.
26 Furthermore, the products obtained when glutathione was used as a reducing agent were
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glutathione-bound platinum(II) complexes. 2 7 -2 9 These observations have implications for the
design of future platinum(IV) constructs.
Assumed
reduction pathway H3N..,Pt,.Cl
OH H3N WC device
H3N.,"P..Cl
H3N VCl 2 e~
device "PtAlternative H3N*' 'O
possible reduction nanodelivery
pathway device
Scheme A.1. Possible reduction pathways for a platinum(IV)-nanodelivery conjugate.
Here, we describe our investigation of the electrochemical reduction in aqueous solutions
of cis,cis,trans-[Pt(NH3)2Cl2(OAc)2] (1). Although 1 has previously been studies by cyclic
voltammetry in aqueous solutions,'''16 we report further studies here utilizing both a glassy
carbon and platinum working electrode. In contrast to the results obtained in organic solvent, it is
shown that significantly different peak potentials are obtained depending on the nature of the
working electrode in water. Furthermore, it also appears that 1 is reduced by four electrons at the
glassy carbon electrode, thereby forming a layer of platinum metal on the electrode surface.
Additionally, the electrochemical reduction products of 1 were investigated by 'H NMR
spectroscopy after their formation by bulk electrolysis. In accord with previous work,24'25 the
NMR spectroscopic studies suggest that both equatorial and axial ligands are lost upon reduction.
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A.2. Experimental Methods
Compound 1 was synthesized and characterized as previously described.
Electrochemical measurements were carried out utilizing a VersaSTAT3 potentiostat from
Princeton Applied Research accompanied by the V3 Studio software. Three electrode cells were
used for cyclic voltammetry (CV) and chronoamperometry experiments. The working electrode
was either a glassy carbon (GC) or platinum disk (Pt) electrode purchased from Princeton
Applied Research. A platinum wire and Ag/AgCl in saturated NaCl were used as counter and
references electrodes, respectively. Phosphate-buffered saline (PBS) at pH 7.4, which contains
12 mM HP042 and 137 mM NaCl, was used as the electrolytic solution. Before acquiring scans,
solutions were purged with N2 for ~ 5 min, and then kept under a blanket of N 2 during
measurements. The working electrodes were routinely cleaned between experiments by polishing
with alumina paste, rinsing with water, and then sonicating for ~ 2 min in clean water.
Additionally, the glassy carbon electrode was electrochemically activated by holding the
potential at -1 V in a clean PBS solution for 10 min to possibly reduce off C=O functionalities on
the surface. This electrochemical activation step gave similar results to experiments carried out
without it. Hence, this activation was not used routinely for electrode cleaning. Under the
experimental conditions described here, the [Fe"(CN)6 ]4 ~/[Fe"'(CN)6 ]3~ couple was consistently
observed as at +0.22 V. All CVs were obtained at a scan rate of 100 mV/s at ambient
temperature (22-25*C).
Bulk electrolysis experiments were carried out in a three-electrode, two-compartment H-
cell, where the compartments were separated by a fine glass frit. One compartment contained the
working electrode and reference electrode, and the other compartment contained the counter
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electrode. The working electrode was carbon felt, the reference electrode was Ag/AgCl in
saturated NaCl, and the counter electrode was a Pt mesh. The electrolytic solution used was
unbuffered 0.2 M NaNO 3 in water. No buffer was used for these initial experiments in order to
avoid the binding of buffer components to the reduced platinum(II) species. 30,31 Electrolysis was
carried out with magnetic stirring. A concentration of ~10 mM of 1 was utilized. The current was
monitored during the electrolysis and used to determine the endpoint as indicated by its return to
background levels upon the consumption of all electroactive species. Aliquots were removed
from the electrolysis cell during different time points for analysis by 1H NMR spectroscopic
analysis. For 1H NMR spectral analysis, 10% D 20 was added for locking and shimming and 1,4-
dioxane was added as an internal reference (6 = 3.75 ppm). Water suppression was accomplished
by pre-saturation of the HOD signal at a power level of 55 dB.
A.3. Results
Cyclic Voltammetry in Aqueous Solution. The cyclic voltammogram of 1 in pH 7.4 PBS using
a GC working electrode is shown in Figure A. 1. As expected, a single irreversible peak was
observed near -630 mV, consistent with the observations of others.5''' 6 Mutliple CV scans on
the same sample between +1 and -1 V lead to a gradual shift in the peak potential to more
positive values. Eventually, after more than 10 cycles, the peak potential stabilized to a value of
approximately -180 mV. Polishing the electrode with alumina paste and rinsing it with water
returned the peak potential to within 80 mV of the original -630 mV value. Multiple cycles, as
before, shifted the peak potential back to a stable value around -180 mV. This general behavior
is reproducible. Polishing the electrode appears to return it to its original state. The values of the
peak potential themselves, however, varied by up to 80 mV during six different trials.
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1.0 0.5 0.0 -0.5 -1.0 -1.5
Potential vs Ag/AgCI (V)
Figure A.1. Cyclic voltammograms of 1 in pH 7.4 PBS at a scan rate of 100 mV/s using a GC
working electrode. The first cycle is bold and red. Subsequent cycles are black. Black arrows
indicate the features that grew in after multiple consecutive cycles. The red arrow indicates the
initial scan direction.
The cyclic voltammogram of 1 in pH 7.4 PBS obtained using a Pt disk working electrode
is shown in Figure A.2. The CV displays an irreversible peak near -200 mV. Multiple cycles on
the same solution gave rise to poorly overlaid surfaces, but no systematic shift in potential was
observed as occurred for the glassy carbon electrode. The apparent poor signal-to-noise ratio of
this peak may be attributed to the higher background current of the Pt disk electrode, which
begins to catalyze proton reduction at approximately -0.5 V.
284
15 pA
1.0 0.8 0.6 0.4 0.2 0.0 -0.2 -0.4 -0.6
Potential vs Ag/AgCl (V)
Figure A.2. Cyclic voltammogram of 1 in pH 7.4 PBS at a scan rate of 100 mV/s using a Pt disk
working electrode. The black arrow indicates the initial scan direction.
Blank runs using freshly polished GC and Pt disk working electrodes in pH 7.4 PBS are
displayed in Figure A.3. Both electrodes displayed a negative potential limit where the current
increases dramatically. This current increase is most likely due to proton reduction. The onset for
this catalytic feature occurs at -0.5 V for the Pt disk electrode and -1.25 V for the GC electrode.
The lower potential for proton reduction at the Pt electrode is consistent with the well known
utility of platinum as an effective catalyst for this reaction.
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1.0 0.5 0.0 -0.5 -1.0 -1.5 -2.0 -2.5
Potential vs Ag/AgCl (V)
Figure A.3. Cyclic voltammograms of a blank solution of pH 7.4 PBS obtained at a scan rate of
100 mV/s using either a glassy carbon (red) or platinum (black) working electrode.
A GC electrode was modified by running multiple CV cycles on a PBS solution of 1. The
resulting modified electrode was rinsed with water and transferred to a clean solution of pH 7.4
PBS. The blank acquired on the 1-modified glassy carbon electrode is shown in Figure A.4
together with a blank run on a polished glassy -carbon electrode for comparison. The blank shows
the onset of a catalytic current near -0.5 V, similar to that observed for the Pt disk electrode. No
irreversible peak near -180 mV due to 1 in solution was observed. These results suggest that the
reduction of 1 at the glassy carbon electrode results in the deposition of a new material, which
fundamentally alters the electrode surface and gives rise to electrocatalytic activity. A likely
candidate for the nature of the deposited material is metallic platinum.
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100 pAI
Pt
30 pA
1.0 0.5 0.0 -0.5 -1.0
Potential vs Ag/AgCI (V)
Figure A.4. Cyclic voltammograms of a blank pH 7.4 PBS solution obtained at a scan rate of
100 mV/s using either clean glassy carbon electrode (black) or a glassy carbon electrode that has
been modified by repeated CV cycles in a solution containing 1 (red).
Chronoamperometry. Proton reduction was monitored by chronoamperometry (Figure A.5).
The potential was held at -1 V, where proton reduction should occur readily for Pt electrodes,
but to a lesser degree for GC. The current response for a clean GC electrode in pH 7.4 PBS was
approximately 6 pA. The current for a Pt disk electrode stabilized at 60 pA, indicating faster
proton reduction relative to the GC electrode. The GC electrode modified by 1 displayed
efficient proton reduction marked by a current of approximately 70 gA, comparable to that of the
Pt disk electrode. Slow bubble formation was observed at the electrode surface for the Pt disk
and 1-modified GC electrode consistent with the formation of hydrogen gas upon proton
reduction. Polishing the 1-modified GC electrode reduced the observed current to 27 pA. This
result indicates that the adsorbed species can be partially removed by polishing. Additional
polishing and rinses with nitric acid were necessary to restore the current closer to that of the
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1-modified
GC
clean
GC
----------
clean glassy carbon. The apparent difficulty in removing the adsorbed species by conventional
polishing might also explain variances observed in the peak potentials of cyclic voltammograms
of 1 and related platinum(IV) complexes.
0.00020-
Pt
0.00015-
0.00010-
0.00005- 1-modified GC
after polishing
clean GC
0.00000v
0 50 100 150 200 250 300 350 400 450 500 550 600
Time (s)
Figure A.5. Current versus time traces obtained when holding the potential at -1 V vs Ag/AgCl
in a clean pH 7.4 PBS solution using different electrodes.
Bulk Electrolysis and Characterization of Reduction Products. Since the initial peak
potential for the reduction of 1 observed by cyclic voltammetry occurs near -630 mV on a GC
electrode, a bulk electrolysis experiment was carried out by holding the potential constant at a
value of -600 mV. Upon complete consumption of 1, as indicated by the return of the current to
background levels, a grey precipitate had formed. Analysis of the solution by IH NMR
spectroscopy revealed only the presence of free acetate at 8 = 1.90 ppm. The pH of the resulting
solution was between 11 and 12.
Bulk electrolysis experiments at a more positive potential, -0.35 V, were undertaken.
Upon completion of the electrolysis, no visible precipitate had formed. During the course of the
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electrolysis the pH of the solution increased from 4.1 to 10.5. Figure A.6 shows the 1H NMR
spectra of the solution during different time points in the electrolysis. The CH 3 resonance of 1 at
2.10 ppm decayed and three new peaks appeared at 2.00, 1.97, and 1.90 ppm. All three of these
peaks were present at the end of the electrolysis as well. The peak at 1.90 ppm is assigned to free
acetate, whereas the peaks at 2.00 and 1.97 ppm can be assigned to the platinum(II) complexes
cis-[Pt(NH 3)2(OAc) 2] and cis-[Pt(NH 3)2(OAc)(OH 2)] , respectively (Scheme A.2). These
assignments were verified by independent preparation of cis-[Pt(NH 3)2(OAc)2], which exists in
equilibrium with its aquated form, cis-[Pt(NH 3)2(OAc)(OH 2) .32
t=5h
8 = 2.00 ppm
OAc-
t =2 h
t =I h
2.0
a (ppm)
1.5
Figure A.6. 'H NMR spectra of the bulk electrolysis products of 1 at -0.35 V vs Ag/AgCl at
different time points.
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Scheme A.2. Electrochemical reduction pathways of 1.
A.4. Discussion
The peak potential of 1 during the first CV cycle using a GC working electrode observed
in these studies was consistent with previously reported values. Literature values span -570 mV
to -690 mV.5'7'"6 In our studies, we observed values ranging from -560 to -640 mV. The peak
potential measured using a Pt working electrode was found near -200 mV. There is no literature
precedent for cyclic voltammetry of 1 or related platinum(IV) anticancer complexes with a Pt
working electrode. The apparent avoidance of a platinum working electrode by the platinum
anticancer drug development community may stem from the limited potential region in which
the electrode can be used in aqueous solutions. At -0.5 V, the Pt working electrode begins to
catalyze reduction of protons, thus preventing the observation of reduction events at more
negative potentials. The large positive shift in potential in moving from a GC to a Pt working
electrode is noteworthy. Peak potential shifts of up to 600 mV have been observed for
compounds of the formula, trans-[Pt(NH3)4X 2 ]2 + where X is a halide, upon switching from a GC
290
to a Pt electrode.33 This dependence on the composition of the working electrode implies that
electron transfer from the electrode surface to 1 occurs via an inner-sphere mechanism in which
1 is directly in contact with the surface. The different potentials observed may result from
different adsorption energies and kinetics of 1 on the different surfaces. Other researchers have
previously attributed this large shift in potential due to a change in electrochemical mechanism
from an E2C (initial 2-e- transfer followed by a chemical reaction) to an ECE mechanism (1-e~
transfer, chemical reaction, then 1-e transfer) when switching from Pt to GC.3 They propose
that the E2C mechanism operates by a two-electron inner-sphere electron transfer at the Pt
electrode, whereas the ECE mechanism operates by an initial one-electron outer-sphere electron
transfer at the GC electrode.
Multiple CV cycles appear to alter the composition of the GC electrode and the resulting
peak potential readout for 1 (Figure A.1). The observation of the onset of a catalytic current at
approximately -0.5 V and the shift of the peak potential to -0.2 V suggest that the GC electrode
is being converted to a Pt electrode, presumably through electrodeposition of platinum metal
from 1. That the modified electrode itself, rather than a species in solution, was inducing the
catalytic proton reduction current was confirmed by transferring the 1-modified electrode to a
clean PBS solution. Running CV cycles on the clean solution still gave rise to the catalytic
current, which was comparable to that observed for a Pt disk electrode (Figure A.4).
Furthermore, the modified GC electrode showed comparable efficiency to the Pt electrode in
proton reduction when the potential was held at -1 V (Figure A.5). The direct electrodeposition
of platinum from [PtC16 ]2- on carbon-based electrodes is known and has been used for the
formation of adsorbed platinum nanoparticles for catalytic purposes. 34 -4 1 Three redox couples are
invoked to explain the deposition of Pt0 from [PtCl 6]2-
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PtC162- + 4e- + Pt0 + 6C1 (1)
PtCl62- + 2e~ + Pt"C12 + 2C- (2)
Pt"C142 +2e~ + Pt'+ 4Cr~ (3)
The standard reduction potentials at 25 0 C for the three couples are 0.74, 0.72, and 0.76 V versus
NHE for (1), (2), and (3), respectively.4 2 The similarities of all three couples indicate that all
three processes occur within a narrow potential window. Hence, they would most likely not be
resolved as individual peaks in a cyclic voltammetry experiment. Although the corresponding
couples for 1 are not known, a similar phenomenon may explain the apparent observation of
platinum deposition and only the presence of a single peak in the cyclic voltammogram
Bulk electrolysis studies were carried out to investigate the reduction products of 1.
Reduction at -0.6 V led to the formation of a black precipitate, and only free acetate ion was
observed by IH NMR spectroscopy. The black precipitate may be platinum black fonned upon
reduction from Pt(IV) to Pt(0). The observation of only free acetate by 1H NMR spectroscopy is
consistent with such an hypothesis. Additionally, the relatively basic pH measured at the end of
electrolysis might be to due to the release of ammonia from the platinum coordination sphere
upon full reduction. The electrolysis at -0.35 V appears to reduce 1 by only two electrons,
because the platinum(II) compounds cis-[Pt(NH3)2(OAc) 2] (2) and cis-[Pt(NH3)2(OAc)(OH2)]*
(3) remained in solution after the current returned to background levels. Cisplatin most likely is
also formed. However, owing to rapid proton exchange of the coordinated ammine ligands,
cisplatin cannot be detected by 1H NMR spectroscopy. The use of 195Pt NMR spectroscopy to
detect cisplatin was precluded by the low concentrations employed for these studies. The
increase in pH of the solution is not fully understood. Free acetate ion is expected to increase the
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pH only slightly. The compounds cis-[Pt(NH 3)2(OAc) 2] and cis-[Pt(NH 3)2(OAc)(OH 2)] +
observed after electrolysis probably arise from the cis elimination of the chloride ligands upon
the reduction of 1 (Scheme A.2). Alternatively, both axial acetate ligands could be lost and then
exchange with the chloride ligands of cisplatin. Given the lability of the acetate ligand on
platinum(II) complexes, this pathway is disfavored. The observation of cis elimination here is
consistent with literature.24 ,2 4 3
A.5. Summary and Conclusions
Significantly different peak potentials for the reduction of 1 are observed depending on
the nature of the working electrode. This difference is assumed to be a result of different
heterogeneous rate constants, k (Equation A.1), for electron transfer from the electrode surface
to 1. Different k values could result from different mechanisms of electron transfer at the
electrode surface. Inner-sphere electron transfer mediated by bridging halide ligands has been
documented for platinum(IV) complexes at the surface of electrodes.3334446 The relative
energies of such surface-bound halide-bridged intermediates and the rates at which they form
would certainly be different depending on the composition of the surface. The large errors (up to
100 mV)14 in observed peak potentials measured in aqueous solution might be a reflection of the
sensitivity of the inner-sphere platinum reduction event to the nature of the electrode surface.
Cyclic voltammetry at a GC electrode in aqueous solution leads to a four-electron
reduction of 1 and deposition of metallic platinum. The electrodeposition of Pt(IV) on carbon-
based electrodes has been observed previously.34 4 1 One explanation for this phenomenon is that
the 2-e~ and 4-e- reduction events occur at similar potentials such that CV cannot resolve them.
Another possibility is that the overpotential required for the 2-e- reduction of platinum(IV) is
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greater than the potential required for the 4-e~ reduction. Thus, by the time a current response is
observed in the CV, the potential is sufficiently reducing to form platinum metal
The bulk electrolysis of 1 occurs with both cis and trans elimination of two ligands. This
observation may have implications for the design of future platinum(IV) anticancer agents. In the
case of 1, the axial ligands are acetates. Since acetate is a fairly labile ligand for platinum(II), the
resulting cis-diamminediacetatoplatinum(II) complex should still readily bind to DNA. On the
other hand, if cis halide elimination were to occur for cct-[Pt(NH 3)2Cl2(OH) 2], the inert complex,
cis-[Pt(NH 3)2(OH) 2] would result. The products observed in this study, however, were the result
of reduction at an electrode surface. The product distribution should depend on the mechanism of
reduction and therefore the chemical nature of the reducing agent. As has been shown recently,
reduction of platinum(IV) complexes with ascorbic acid yields different products than those
obtained by the reduction with glutathione. 29
The reduction of platinum(IV) complexes to platinum(II) and platinum(0) should be
thermodynamically favored for most reducing agents, because the standard reduction potentials
for these processes are quite positive (+0.68 to 1.18 V versus NHE).4 7 As with the aquation of
cisplatin, the reduction of platinum(IV) appears to be a kinetically controlled process. In most
cases, the reduction of platinum(IV) proceeds through inner-sphere electron transfer mechanisms
via a ligand-bridged activated complex. 4 8 -5 3 The rate-determining step in these cases is formation
of this ligand-bridged activated complex. For outer-sphere electron transfer reactions of
platinum(IV), the rate-determining step is a one-electron transfer and would therefore be dictated
by the Pt(IV)/Pt(III) redox couple. Outer-sphere electron-transfer reactions of platinum(IV) are
much slower than inner-sphere reactions, 54 and therefore likely play only a minor role in the
biological setting. The heterogeneous electron transfer kinetics at an electrode surface are
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fundamentally different from the homogeneous reduction reactions that occurs in the biological
setting. However, useful correlations between the electrochemical peak potential and
homogeneous reduction rates and anticancer activity have been noted.4 '7'14 -6 The observed
correlation between electrochemical peak potential and reduction rate by ascorbic acid 14 may
arise due to similar halide-bridged intermediates either at the electrode surface or at an oxygen
atom of ascorbic acid. There are several cases, however, in which this correlation is not
present,53,ss confirming that heterogeneous electron-transfer kinetics at the electrode surface do
not always predict the homogeneous electron transfer kinetics in solution. Correlations of the
biological activity with peak potential may relate to the electronic properties of the platinum(IV)
centers. Electronic properties of medicinal compounds, typically in the form of a Hammett
parameter, can often be related to biological activity in structure-activity relationships. 56 Because
the peak potential in organic solvent correlates with computed electron affinity,13 and in part
with LUMO energy,57 this property may also be useful for modeling and predicting anticancer
activity of platinum(IV) complexes. The measured peak potential also correlates in some cases
with the lipophilicity of the platinum(IV) complexes.5 8 Hence, relationships between peak
potential and biological activity may be due to differences in lipophilicity between the
compounds.
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Appendix B
Targeting the Mitochondria with Platinum Anticancer Agents using
Mitochondria-Penetrating Peptides
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B.1. Introduction
The biological target of the widely used anticancer drug cisplatin is nuclear DNA.' There
is ample evidence to support this hypothesis, the most convincing of which is the observation
that cells with decreased nuclear DNA repair capacities are hypersensitive to cisplatin.2 4
Nevertheless, the electrophilic properties of cisplatin and its aquated analogues enable this and
related platinum-based drugs to bind to a wide range of intracellular nucleophiles, such as
proteins,5 RNA,6 and phospholipids. 7 The importance, if any, of these off-target binding
interactions on the mechanism of action of platinum-based drugs remains poorly understood.
Because of their central role in mediating apoptosis, mitochondria are actively being
explored as a potential anticancer drug targets. 8 -11 The mitochondria contain their own circular
DNA (mtDNA).12 It is therefore of interest to consider the degree to which platinum-based drugs
bind to mtDNA and how these mtDNA lesions affect their overall mechanism of action. Previous
studies revealed that greater quantities of cisplatin bind to mtDNA than to genomic DNA
extracted from mammalian cells. 3"14 The role of the mtDNA adducts is debated in the literature.
On one hand, mitochondrial DNA damage by cisplatin in various tissues has been implicated as a
mediator for the toxic side effects of the drug, including neuropathy, 5 ototoxicity,16 and
developmental toxicity. 17'18 In contrast, other studies have proposed that the mitochondrial and
not nuclear DNA is the critical target of cisplatin in potentiating its anticancer activity.19,20 The
mitochondria also appear to play in role in mediating cellular resistance to cisplatin. Cisplatin-
resistant cell lines have elevated mitochondrial membrane potentials,2 '2 2 sustain less damage to
mtDNA when treated with cisplatin,2 3 and exhibit substantially less mitochondrial uptake of
cisplatin 2 4 compared to the non-resistant parent lines. Taken together, the abovementioned
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results indicate a complicated role of the mitochondria in mediating the cellular response to
cisplatin.
To investigate more precisely the importance of the mitochondria as a target for
platinum-based chemotherapy, it would be advantageous to have a platinum complex that
selectively localizes to this organelle. The use of cell-penetrating peptides (CPPs) 5'2 1 to direct
the platinum complex through the cell membrane into the desired organelle provides a viable
strategy for preparing such a construct. In particular, mitochondria-penetrating peptides
(MPPs),7 a subclass of CPPs, can be utilized. MPPs are typically short peptide sequences
comprising alternating lipophilic and cationic residues. Here, we describe our preliminary
investigations of a platinum(II) complex conjugated to the N-terminus of an MPP with the
sequence rFxrFxrFxr, where r is d-arginine and Fx is l-cyclohexylalanine. This work is a
collaborative effort with the lab of Professor Shana 0. Kelley at the University of Toronto. The
chemistry described provides a general route to Pt-peptide conjugates that are attached to leaving
group ligands. The biological activity of this construct in wild-type and cisplatin-resistant A2780
ovarian cancer cells is presented.
B.2. Experimental Methods
General Materials and Methods. Small-molecule synthesis was carried out under normal
atmospheric conditions with no precautions to exclude moisture or air. Cisplatin was purchased
from Strem Chemicals and used as received. HATU (O-(7-azabenzotriazol-1-yl)-N,N,N','-
tetramethyluronium hexafluorophosphate) was purchased from Oakwood Chemicals and used as
received. Succinylacetone (Hsuccac) was synthesized from ethyl acetate and levulinic acid as
previously described. 2 8 Peptides were synthesized and provided in the solid-state, attached to
Rink Amide resin, by the Kelley lab.
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Physical Measurements. NMR spectra were acquired on a Bruker DPX-400 spectrometer in the
MIT Department of Chemistry Instrumentation Facility (DCIF). 1H and 13C NMR spectra were
referenced to residual protons or the carbon nucleus of the deuterated methanol (1H 6 = 3.31
ppm, 13C 6 = 49.1 ppm), and signals are reported versus TMS. For 1H NMR spectra acquired in
D2 0, signals were referenced to an internal standard of 1,4-dioxane (6 = 3.75 ppm). 195 Pt NMR
spectra were referenced externally to a standard of K2PtCl 4 in D20 (6 = -1628 ppm). For FTIR
spectra, samples were prepared as KBr disks and data was recorded with a ThermoNicolet
Avatar 360 spectrophotometer running the OMNIC software. Electrospray ionization mass
spectrometry (ESI-MS) measurements were acquired on an Agilent Technologies 1100 series
LC-MSD trap. Solutions used for biological studies were dissolved in MilliQ water (or PBS for
cisplatin) and sterile filtered. The platinum concentrations of the solutions were determined by
graphite-furnace atomic absorption spectroscopy (GFAAS) using a Perkin-Elmer AAnalyst600
spectrometer. Elemental analyses were performed by a commercial analytical laboratory.
Synthesis of [Pt(succac)(NH 3)2](NO 3). Cisplatin (500 mg, 1.67 mmol) and AgNO 3 (552 mg,
3.25 mmol) were stirred together in 10 mL of H2 0 in the absence of light at room temperature
for 16 h. The resulting mixture was filtered to remove AgCl. To the filtrate, a solution of NaOH
(67 mg, 1.7 mmol) and succinylacetone (269 mg, 1.70 mmol) in 5 mL of H20 was added
dropwise. After stirring at rt for 5 h, the resulting solution was concentrated to dryness at 60 'C
under reduced pressure to afford an orange oil. This oil was dissolved in 3 mL of H20, acidified
with three drops of 25% HNO 3. Acetone (50 mL) was added, and the resulting turbid white
suspension was stirred for approximately 3 min, resulting in the deposition of an oily orange-
brown residue. The turbid supernatant was decanted and mixed with 50 mL of a 1:1 (v/v)
mixture of acetone and diethyl ether. Upon stirring at rt for approximately 5 min, an orange-
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brown residue deposited again. The cloudy supernatant was decanted and poured directly into
150 mL of diethyl ether. The mixture was stored at -40 'C for 1.5 h and filtered to collect a
white solid. The white solid was washed with 2 x 10 mL diethyl ether and then dried in vacuo.
Yield: 203 mg (28%). Mp 159-164 'C (dec). 'H NMR (400 MHz, MeOD-d 4): 6 5.65 (s, 1H),
4.44 (br s, 6H), 2.58 (t, 2H), 2.44 (t, 2H), 1.88 (s, 3H). "C NMR (100 MHz, MeOD-d 4): 6 186.5,
186.3, 176.7, 102.7, 35.1, 31.0, 26.1. 95Pt NMR (86 MHz, MeOD-d 4): 6 -1570. IR (KBr, cm 1):
3432 m, 3285 s, 1708 m, 1563 s, 1524 s, 1384 vs, 1356 s, 1309 s, 1202 w, 1175 m, 1039 w, 807
w, 645 w. ESI-MS (+ mode, MeOH): m/z 386.1 (calcd. for [Pt(succac)(NH 3)2]*: 386.1). Anal.
Calcd. for C7Hi 5N30 7Pt: C, 18.75; H, 3.37; N, 9.37. Found: C, 19.04; H, 3.38; N, 9.27.
Synthesis of Pt-MPP, [Pt(succac)(NH 3)2]-r(Fir)3-CONH 2. A 50-pmol portion of solid FMOC-
r(Fxr)3 on Rink Amide resin was placed in a fritted 2.5-mL Torviq disposable syringe and
swelled with 2 mL of anhydrous DMF for 1 h. The N-terminal FMOC group was removed by
treating the resin with a solution of 25% 4-methylpiperidine in DMF (v/v) for a period of 30 min,
and the deprotected resin was washed with 5 x 1.5 mL of DMF. A mixture of 90 mg (200 pmol)
[Pt(NH 3)2(succac)]NO 3 and 76 mg (200 ptmol) HATU was dissolved in 1.5 mL of 10% NN-
diisopropylethylamine (DIPEA) in DMF (v/v) and immediately added to the deprotected resin.
The reaction vessel was shaken at rt for 60 min, and the solution was then expunged from the
syringe. The resin was washed sequentially with 5 x 1.5 mL of DMF and 5 x 1.5 mL CH2 Cl 2 and
then dried in vacuo. The dry resin was treated with a TFA/water/triisopropylsilane 95/2.5/2.5%
(v/v) solution for 90 min to cleave Pt-MPP from the Rink Amide resin. Pt-MPP was precipitated
from the cleavage solution with diethyl ether. The resulting solid Pt-MPP was separated by
centrifugation and purified by semi-preparative HPLC with a C18 reverse-phase column (9.4 mm
x 250 mm). A two-solvent system (A = 0.1% TFA (v/v) in H 20; B = 0.1% TFA (v/v) in
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acetonitrile) was employed for purification according to the following protocol: isocratic flow,
10 % B, 0-5 min; gradient, 10-50% B, 5-35 min. The flow-rate was kept constant at 3 mL min-'
throughout the purification. Fractions from sequential runs containing Pt-MPP were pooled and
lyophilized. The purity of the final product was assessed via analytical HPLC (C18, 4.6 mm x 250
mm), according to the following protocol: after a 5 min isocratic wash (10 % B), a linear
gradient of 10-50% B was run over 30 min (35 min total) at a flow rate of 1 mL min'. HPLC, tr
= 23.8 min, >95% pure. ESI-MS (pos. ion mode): m/z 1583.8 ([M+HTFA]*, calcd. 1583.8),
1469.8 ([M]+, calcd. 1469.8), 735.3 ([M+H]2+, calcd. 735.4), 490.5 ([M+2H] 3+, calcd. 490.3),
368.1 ([M+3H] 4-, calcd. 368.2). 195Pt NMR (86 MHz, D20): 8 -1591 ppm.
Synthesis of Pt-MPP(TAMRA), [Pt(succac)(NH 3)2]-r(Fxr)3K(5/6-carboxytetramethyl-
rhodamine)-CONH 2. A 50-gmol portion of solid FMOC-r(Fxr) 3K(5(6)-TAMRA) on Rink
Amide resin was labeled with 200 gmol (90 mg) of [Pt(NH 3)2(succac)]NO 3 using the procedure
described above for the preparation of Pt-MPP. The purity of the two isomers (5 and 6) of Pt-
MPP(TAMRA) were assessed via analytical HPLC (C18, 4.6 mm x 250 mm), according to the
same protocol as for Pt-MPP. The 5-isomer (tr = 26.5 min) was found to be >95% pure based on
the integrated chromatogram. The 6-isomer (tr = 25.7 min) was judged to be 94% pure based on
the integrated chromatogram and not deemed sufficiently pure for further biological studies.
Characterization for 5-isomer: ESI-MS (pos. ion mode): m/z 1005.7 ([M+H]*, calcd. 1005.5.),
670.8 ([M+2H] 2+, calcd. 670.9), 503.3 ([M+3H] 3+, calcd. 503.4). 195Pt NMR (86 MHz, D2 0): 6 -
1589 ppm.
X-ray Crystallography. Single crystals of succinylacetone and [Pt(succac)(NH 3)2](NO3) were
grown from hexanes/Et20 and MeOH/Et 2O, respectively. Crystals were selected and mounted in
n-paratone oil on a cryoloop, frozen under a 100 K KRYO-FLEX nitrogen cold stream. A Bruker
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APEX CCD X-ray diffractometer with graphite-monochromated Mo-Ka radiation (X = 0.71073
A) controlled by the APEX2 software package 2 9 was utilized for data collection. Data were
corrected for absorption with SADABS. 30 The SHELXTL-97 software package3 1,3 2 31 ,32was used
to solve the structures with direct methods and further refine them against F 2. All non-hydrogen
atoms were located on the difference map and refined anisotropically. The enol and carboxylic
acid hydrogen atoms of succinylacetone were located on the difference map and semi-freely
refined with constraints on the O-H distances (0.84 A) and isotropic thermal displacement
parameters of the hydrogen atoms (1.5 times that of the oxygen atoms to which they are
attached). The carboxylic acid hydrogen atom of [Pt(succac)(NH 3)2 ](NO3) was also located and
refined similarly. Other hydrogen atoms were placed at calculated positions and isotropic
displacement parameters were constrained to be either 1.2 or 1.5 (terminal hydrogens) times
those of the atoms to which they are bound. Crystallographic data collection and refinement
parameters are collected in Table B. 1.
Cell Culture. A2780 and A2780CP70 (ovarian wild-type and cisplatin-resistant) cell lines were
obtained from Fox Chase Cancer Center and cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were incubated in a
humidified atmosphere containing 5% CO 2 at 37 'C.
Cytotoxicity Assays. The colorimetric MTT assay was used to assess cytotoxicity. In a 96-well
plate, 2000 cells per well were seeded in 100 ptL of growth medium and allowed to attach
overnight. The growth media was then aspirated and replaced with 100 pL of growth medium
containing varying concentrations of the platinum complexes. Six wells were used per
concentration level. After 72 h, the platinum-containing media was aspirated and replaced with
200 pL of RPMI-1640 containing 0.67 mg/mL MTT. The cells were further incubated for 4 h.
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The MTT solution was removed, and the resulting purple formazan crystals were dissolved in
100 ptL of 25:1 mixture of DMSO and aqueous ammonia. The absorbance was measured at 550
nm. The absorbance values were normalized to the Pt-free wells (100% cell viability) and are
plotted versus platinum concentration. From the resulting curves, 50% growth inhibitory
concentration (IC 50) values were determined by interpolation. These experiments were repeated
at least three times, and the reported IC50 values are the averages of these trials with the error
estimated from the resulting standard deviations.
Table B.1. X-ray Crystallographic Data Collection and Refinement Parameters for
Succinylacetone and [Pt(succac)(NH 3)2](NO3).
succinylacetone [Pt(succac)(NH 3)2 ](NO 3)
formula C 7H 100 4  C 7 H 15N 3 0 7Pt
fw 158.15 448.31
space group P2 1/c P2 1/c
a, A 21.050(4) 5.1808(3)
b, A 6.5228(14) 9.5216(6)
c, A 5.2953(11) 25.5478(16)
P, deg 90.273(3) 91.4100(10)
V, A3  727.1(3) 1259.88(13)
Z 4 4
pcalcd, g-cm-3 1.445 2.364
T, 0C -173(2) -173(2)
t(Mo Ka), mm-1 0.119 11.168
9 range, deg 1.93-29.40 1.59-28.77
completeness to 0 (%) 99.8 100
total no. of data 14465 24630
no. of unique data 2002 3257
no. of parameters 107 169
no. of restraints 2 1
Rla (%) (all data) 3.73 3.23
wR2b (%) (all data) 10.70 4.52
R a (%) (I > 2ay) 3.53 2.30
wR2b (%) (I > 2a) 10.49 4.25
GOFC 1.070 1.029
max, min peaks, e-A 3  0.510, -0.195 1.850, -0.905
a RI =IFol - IFe/IFol. b wR2 = {X[w(Fo2 -F 2)2]/E[w(F 2) 2]} 2. c GOF = {E[w(Fo2 - Fe2)2]/(n
p)}1/2 where n is the number of data and p is the number of refined parameters.
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Cell Imaging Studies. A2780 and A2780CP70 cells were seeded in an imaging dish in 2 mL of
growth medium. At ~ 60% confluency, the cells were imaged. The growth media was swapped
with premixed media containing 1 or 10 gM of the Pt-MPP(TAMRA) construct, and the cells
were allowed to incubate with the dye for 1 h. The organelle dyes, Mito-tracker Green and
Hoechst 33258, were added to the cells at 1.25-2.5 ptM concentrations and allowed to incubate
for 30 min. At the end of the incubation period, the media was aspirated, and the cells were
washed with 3 x 1 mL PBS and submerged in 2 mL of dye-free DMEM for imaging. The
imaging experiments were performed using a Zeiss Axiovert 200M inverted epifluorescence
microscope equipped with an EM-CCD digital camera (Hamamatsu) and a MS200 XY Piezo Z
stage (Applied Scientific Instruments). The light source was an X-Cite 120 metal-halide lamp
(EXFO) and the fluorescence images were obtained with an oil-immersion objective at 63x
magnification. The microscope was operated by the Volocity software program of Perkin-Elmer.
Colocalization of the dyes was investigated with using the program ImageJ 34 , using a previously
described protocol.3 s
B.3. Results and Discussion
Synthetic Strategy. Conjugates of platinum-based anticancer agents and peptides have
previously been prepared and characterized, the first of which was reported in 2000.36 These
conjugates can be categorized based on the attachment point of the peptide to the platinum agent,
which occurs either at the non-leaving group ligand (amine) of a platinum(II) complex, 36-4 5
leaving group ligand (carboxylate) of a platinum(II) complex, 46 or through the axial ligands of
platinum(IV) complex.47~51 By attaching a peptide to the non-leaving group ligands of a platinum
anticancer agent, the reactivity of the platinum complex with DNA is altered,52 and the nature of
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the resulting DNA adducts and cellular responses are also presumably different from the parent
drug. Different amine ligands, as in the case of oxaliplatin, give rise to platinum anticancer
complexes with different spectra of activity and resistance profiles. Although desirable for the
preparation of new platinum chemotherapeutics, these features are not preferred if one is seeking
to investigate only how the change in cellular localization, directed by a conjugated peptide,
affects biological activity of an anticancer agent. For our purposes then, the MPP could either be
attached to the leaving group ligand of a platinum(II) complex or to an axial ligand of a
platinum(IV) complex. Platinum(IV) complexes need to be reduced to platinum(II) before
binding to DNA or other cellular targets can occur.5 3 ,54 Two ligands are lost upon reduction. The
commonly held notion that two axial ligands are exclusively eliminated upon reduction has been
challenged by recent studies, which show that equatorial chloride ligands can also be lost.
55
'
56
Hence, the reduced product is not necessary reflective of the parent platinum(II) agent.
Furthermore, the reduction kinetics of platinum(IV) complexes are also dependent on the nature
of the cell line used,57 and some platinum(IV) compounds are reduced immediately by
components of the cellular growth medium.58
Because of the abovementioned complications for the other two approaches, we sought to
use a leaving group ligand as an attachment point for the MPP. The work discussed in Chapter 4
demonstrated the utility of p-diketonate ligands as leaving groups in platinum anticancer
agents. 59 Hence, we sought a ligand that contained both a p-diketonate unit for coordination to
platinum(II) and a carboxylic acid or amine functionality for conjugation to a peptide via
standard coupling chemistry. The compound succinylacetone, which can be prepared in one step
from commercial reagents without the need for column chromatography, 2 8 met both of those
criteria and was selected for further studies.
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Synthesis and Characterization of [Pt(succac)(NH 3)2](NO 3). The synthetic route utilized for
the preparation of [Pt(succac)(NH 3)2](NO 3) is one that was described in Chapter 4 for other cis-
diammine(p-diketonate)platinum(II) complexes.5 9 As shown in Scheme B. 1, the diaqua analog of
cisplatin was treated with the deprotonated succinylacetone to obtain the expected product. The
previously reported workup protocol for this class of compounds, which calls for the evaporation
of the aqueous solution, dissolution of the resulting residue in methanol, and precipitation of the
product with diethyl ether, failed to give pure material. Instead, brown solids were typically
obtained that did contain the desired product, as evidenced by ESI-MS, but of insufficient purity
for further use and studies. We hypothesize that the difficulty in isolating pure material arises
from the free carboxylic acid on the succinylacetone ligand, which can also coordinate to
platinum(II), forming a number of undesired byproducts. To access pure compound, an
alternative workup protocol was devised. A concentrated aqueous solution of the reaction
mixture was acidified with HNO3 to ensure full protonation of the carboxylic acid group. A
series of precipitations was carried out using acetone, an acetone:ether mixture, and diethyl ether.
The first two precipitations afforded oily orange-brown residues and white slightly turbid
supernatant. Pure compound could be isolated from the supernatant upon the addition of further
volumes of diethyl ether as a white solid. Presumably, the major impurities have lower solubility
in these acetone:water mixtures than the desired compound.
N03
Na H3NwPtv,0.-.-'
H3NHPt20I + 2 A 2 H3NptOH2 (NO3)2 +o 0 H20 H3N O
H3 N' 'C1 - 2 AgCI (s) H3N' OH2j OH
0 HO
[Pt(succac)(NH 3)21(NO 3)
Scheme B.1. Synthesis of [Pt(succac)(NH 3)2](NO 3).
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Elemental analysis and ESI-MS are in accord with the proposed formula. Multinuclear
NMR spectroscopy further established the purity and identity of the compound. The 1H and 13C
NMR spectra display all expected resonances for the proposed structure of this compound.
Notably, the NH 3 protons of the coordinated ammine ligands, which readily exchange with protic
or deuteric solvents, could be observed in MeOD-d4 as a broad feature at 4.44 ppm if spectra
were acquired within half an hour of preparation of the NMR sample. The observed chemical
shift of 4.44 ppm is in the expected region for NH 3 protons coordinated to platinum(II).6 0 The
195Pt NMR spectrum of [Pt(succac)(NH 3)2](NO3) shows a single broad peak centered at -1570
ppm. This resonance is shifted downfield by approximately 20 ppm from the related complex,
[Pt(acac)(NH 3)2](SO4)o.s.5 9 Although for 19'Pt NMR spectroscopy, which spans a chemical shift
region of 13,000 ppm,61 ,62 this 20 ppm shift is relatively minor, it is still outside the bounds of
the expected error for this measurement (1-5 ppm). Hence, the free carboxylic acid of
[Pt(succac)(NH 3)2](NO3) has a subtle effect on the coordination sphere of the platinum center,
possibly by an intra- or intermolecular hydrogen-bonds with the coordinated ammine ligands, as
observed in the solid-state crystal structure (vide infra).
Succinylacetone and [Pt(succac)(NH 3)2 ](NO 3) were both characterized
crystallographically. These solid-state molecular structures are shown in Figure B.1.
Succinylacetone crystallizes as its enol tautomer, as verified the disparate C-O bond distances,
which are indicative of one single C-O bond and one double C=O bond. Furthermore, the
hydrogen atom of the enol could be definitively located on the difference map. The crystal
structure of [Pt(succac)(NH 3)2 ](NO 3) confirms the expected coordination of the succac ligand
through the p-diketonate unit rather than the carboxylic acid. The hydrogen atom of the
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carboxylic acid was located on the difference map as well. The delocalized nature of the p-
diketonate ligand is ascertained from the similar C-O and C-C bond distances that comprise the
six-member chelate ring. A network of hydrogen bonds span the crystal lattice of
[Pt(succac)(NH 3)2](NO3). The terminal carboxylic acid does not engage in carboxylic acid dimer
interactions, but instead forms hydrogen bonds with an ammine ligand of a neighboring complex
and a nitrate counterion.
04
1.3300(13)-i
02
03
1.289(4)
Figure B.1. Solid-state molecular structures of succinylacetone (top) and
[Pt(succac)(NH 3)2](NO 3) (bottom). Bond distances displayed in the figure are in Angstroms. For
[Pt(succac)(NH 3)2](NO3 ), the nitrate counterion has been omitted for clarity. Ellipsoids are
drawn at the 50% probability level. Selected interatomic distances (A) and angles (0) for
[Pt(succac)(NH 3)2](NO3): Ptl-01, 1.994(3); Ptl-02, 1.992(3); Ptl-N1, 2.029(3); Ptl-N2,
2.021(3); 01-Ptl-02, 95.46(10); Nl-Ptl-N2, 91.43(13); 01-Ptl-N1, 85.74(12); 02-Ptl-N2,
87.37(12).
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Preparation of Pt-MPP and Pt-MPP(TAMRA). The Pt-MPP conjugates were prepared
directly on the solid-phase resin (Rink Amide). The resins, which contained the MPP and the
TAMRA-labeled MPP attached via the C-terminus, were soaked in a DMF solution containing
an excess of [Pt(succac)(NH 3)2](NO3) preactivated with the coupling reagent HATU. The resin
was then washed, and the peptides were cleaved form the solid-phase support with 95% TFA.
Preparative HPLC allowed isolation of the expected Pt-conjugates in greater than 95% purity.
Conjugation to an analogous peptide labeled with the carboxytetramethylrhodamine (TAMRA)
fluorophore was also carried out for later use in fluorescence cell imaging studies. The TAMRA
dye was attached by an amide bond via the amine side-chain of an additional lysine residue. The
TAMRA-labeled peptide was provided as a mixture of isomers, which differed in the attachment
point of the peptide to the bottom ring of the TAMRA dye (5 or 6 position). Only one of the
isomers was successfully isolated with >95% purity. The final constructs, Pt-MPP and Pt-
MPP(TAMRA), are shown in Chart B. 1.
Pt-MPP
0
04,0-N- rF rF rF r-4XH NH,
H3N NH3
Pt-MPP(TAMRA)
N- rFxrFxrFxrK 04H NH,
0+0G
HIN Ni t
HN
0
CHo2Co O r
Chart B.1. Schematic drawing of the two Pt-peptide constructs reported herein.
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The conjugates were characterized by ESI-MS and NMR spectroscopy. The mass spectra
displayed m/z peaks of the +1, +2, and +3 ions, which were all marked by isotopic fine structure
characteristic of the six naturally abundant isotopes of platinum. 195Pt NMR spectra in D20 could
be obtained for both constructs as well. As shown in Figure B.2, both species display a single
resonance near -1590 ppm. These values are identical to that of [Pt(acac)(NH 3)2](SO4)0 .5 , which
is found at -1593 ppm. 5 9 Hence, the diammine(p-diketonate) coordination sphere of the platinum
atoms is retained in the peptide-conjugates, even after cleavage from the resin with 95% TFA. 'H
NMR spectra were also obtained. Diagnostic peaks for the proton at the y-position of the p-
diketonate ligand were found at 5.68 and 5.61 ppm as sharp singlets for Pt-MPP and Pt-
MPP(TAMRA), respectively. Furthermore, the CH3 resonances of the succinylacetone ligand
were located at 1.88 and 1.83 ppm for the labeled and unlabeled constructs. The aromatic region
of the 'H NMR spectrum of Pt-MPP(TAMRA) displayed all the expected signals for the
TAMRA dye. Based on previous NMR studies of isomerically pure TAMRA dyes,6 3 the
aromatic signals are assigned as shown in Figure B.3. The singlet of Hf in CD 30D resonates at
7.97 ppm for the 6 isomer of carboxytetramethylrhodamine and at 8.73 ppm for the 5 isomer. 63
Hence, our construct contains isomerically pure 5 isomer as drawn in Chart B.l. because this
resonance is observed at 8.63 ppm.
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Figure B.2. 95Pt NMR spectra of Pt-MPP (left) and Pt-MPP(TAMRA) (right) in D20.
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Figure B.3. Aromatic region of the 'H NMR spectrum of Pt-MPP(TAMRA) in D20.
Cytotoxicity Studies. For cytotoxicity studies, the wild-type and cisplatin-resistant ovarian
cancer cell lines A2780 and A2780CP706 were used. In addition to testing cisplatin and Pt-
MPP, [Pt(acac)(NH 3)2](SO4)o.5 and [Pt(succac)(NH 3)2 ](NO 3) were also investigated. These two
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complexes were used as peptide-free controls. Their ligand substitution kinetics are expected to
be more comparable to that of Pt-MPP because the three constructs all employ similar p-
diketonate leaving group ligands. The results of these assays using a 72 h incubation period are
summarized in Table B.2, where IC50 values are collected, and displayed in Figure B.4, which
shows several representative dose-response curves. In Table B.2, resistance factors (R.F.'s),
which are defined as the ratios of IC 50 values of the resistant to sensitive cell lines, are given as
well.
Table B.2. IC 50 Values and Resistance Factors (R.F.'s) Measured After a 72 h Incubation Period.
Compound IC 50 (pM)a R.F.b
A2780 A2780CP70
cisplatin 0.60 ±0.08 5.2 ±1.4 8.7+2.6
Pt-MPP 7.5 ± 0.3 5.0 ± 1.4 0.7 ± 0.2
[Pt(acac)(NH 3)2](SO 4)o.5 13.9 ± 1.9 122 ± 10. 8.8 ± 1.4
[Pt(succac)(NH 3)2](NO 3) 220 40 855 ±35 3.9 ± 0.7
a Values are the average from at least independent experiments and reported errors are the
standard deviations. b R.F. = resistance factor, defined as ICso(resistant)/ICso(sensitive)
Cisplatin effectively kills A2780 cells at submicromolar concentration levels. In the
resistant line, however, the IC50 value increases by almost one order of magnitude.
[Pt(acac)(NH 3)2](SO4)o.5 is less effective than cisplatin with IC50 values in both cell lines that are
approximately 20 times greater. The least cytotoxic compound tested is [Pt(succac)(NH 3)2](NO 3)
as indicated by its ICso values, which are greater than 200 piM in both cell lines. In the wild-type
cell line, the Pt-MPP is less cytotoxic than cisplatin, but more so than [Pt(acac)(NH 3)2](SO4)o.s.
In the resistant cell line, however, Pt-MPP is equitoxic with cisplatin. Additionally, the resistance
factor of this construct is 0.7 ± 0.2, thus indicating that it avoids traditional cisplatin resistance
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mechanisms in this cell line. The conjugation of the MPP, therefore, increases the efficacy of the
[Pt(-diketonate)(NH 3)2]* structure and circumvents cellular resistance.
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Figure B.4. Representative dose-response curves for the treatment of A2780 (black squares) and
A2780CP70 (red circles) cells lines with (A) cisplatin, (B) [Pt(acac)(NH 3)2](SO4). 5, (C)
[Pt(succac)(NH 3)2](NO3), and (D) Pt-MPP.
Cell Imaging Studies. Imaging studies of the TAMRA-labeled Pt-MMP were carried out in both
resistant and sensitive A2780 cell lines. Both 1 and 10 pM incubation concentrations were used
for these studies. Representative images for both cell lines and concentrations are shown in
Figures B.5 and B.6, and Pearson's correlation coefficients, describing the degree of
colocalization of Pt-MPP(TAMRA) with the organelle dyes, are collected in Table B.3.
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Figure B.5. Images of A2780 cells treated with (A) 1 or (B) 10 pM Pt-MPP(TAMRA) for 1 h
visualized by (i) DIC, (ii) blue channel (Hoechst 33258), (iii) green channel (Mito-tracker green),
and (iv) the red channel (TAMRA). Scale bar = 32 pM.
Figure B.6. Images of A2780CP70 cells treated with (A) 1 or (B) 10 pM Pt-MPP(TAMRA) for
1 h visualized by (i) DIC, (ii) blue channel (Hoechst 33258), (iii) green channel (Mito-tracker
green), and (iv) the red channel (TAMRA). Scale bar = 32 gM.
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Table B.3. Pearson's Correlation Coefficients (PCC) for Colocalization of Pt-MPP(TAMRA)
and the Organelle Dyes.
Cell Line, Concentration Mitochondrial PCC Nuclear PCC
A2780, I pM 0.36 ± 0.08 -0.03 ± 0.04
A2780, 10 pM 0.45 ± 0.08 0.0 ± 0.03
A2780CP70, 1 IM 0.40 ± 0.18 0.03 L 0.06
A2780CP70, 10 pM 0.53 ± 0.13 0.0 ± 0.01
For both cell lines, Pt-MPP(TAMRA) shows moderately good localization to the
mitochondria as judged by Pearson's correlation coefficients for overlap with the mitochondrial
dye. Pearson's correlation coefficients range from -1 to 1, where 1 indicates a perfect co-
localization and -1 signifies opposite localization. The extent of the localization appears to be
dependent on the concentration of construct with better mitochondrial localization observed at
the 10 pM concentration level. Additionally, these results clearly show that Pt-MPP(TAMRA)
does not go the nucleus; Pearson's correlation coefficients for overlap with the nuclear stain are
all effectively 0. Some punctate staining was observed in the red channel. Several of these
intense, sharp signals occur in extracellular locations. The precise origin of these punctate
features remains uncertain, but they could arise from precipitation of the peptide, possibly due to
aggregation. In the absence of these signals, the Pearson's correlation coefficients for
mitochondrial localization should increase.
B.4. Conclusions and Ongoing Work
Cellular resistance to cisplatin can arise at one or many different points during the
operative lifetime of the drug. Pre-target resistance occurs as a result of either decreased cellular
uptake or increased intracellular sequestration by off-target nucleophiles such as glutathione.
6 5
When cisplatin locates and binds to DNA, on-target resistance pathways, which includes
increased repair of platinum-DNA adducts, take effect.65 Post-target pathways occur if the cell
fails to trigger apoptosis or other cell death pathways in response to DNA damage induced by
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cisplatin. 65 The mechanisms of cisplatin resistance in the A2780CP70 cell line have been the
subject of many investigations. From these previous reports, it appears that many of the
abovementioned factors contribute to cisplatin resistance in this cell line. Post-target resistance,
however, is not important because A2780CP70 cells can activate the apoptotic cell death
pathway.6 6 Additionally, cellular uptake does not appear to be responsible for this resistance
either because at short exposure times (1-4 h) cisplatin is taken up to almost equal extents in the
wild-type and resistant cell lines.24 6 7 On the other hand, the resistant cell line does exhibit
increased glutathione levels by comparison to the sensitive line, which suggests that
sequestration of the active drug by these thiols could be a contributing factor to the resistance. 64
Further studies found that the resistant cell line can more efficiently remove Pt-DNA cross-
links,68-70 and that resistance can be overcome by inhibiting the nucleotide excision repair
pathway.7 1
Given these known resistance mechanisms in A2780CP70 cells, the question naturally
arises as to how Pt-MPP can circumvent them whereas the other platinum agents tested in our
study cannot. Because both cisplatin and our Pt-MPP constructs contain the same non-leaving
group unit, {Pt(NH 3)2} , the nature of the resulting DNA adducts and the cellular response to
them should be identical. Hence, an on-target circumvention of resistance can be ruled out.
Additionally, the similar structure of our construct to that of [Pt(acac)(NH 3)2](SO 4)0 .5 suggests
that both species should be equally susceptible to deactivation by glutathione. Therefore, a
difference in this off-target mechanism of resistance is most likely not operable. Two other
possibilities exist; either the Pt-MMP construct exhibits enhanced cellular uptake in the resistant
cell line and/or it is hitting a completely different target that is not susceptible to the same
resistance mechanisms as the conventional platinum target, nuclear DNA. The cell localization
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studies using the TAMRA-labeled conjugate indicate that the construct localizes to the
mitochondria to a much higher extent than the nucleus. This result suggests that the platinum
may be avoiding traditional resistance pathways by targeting the mitochondria. This conclusion,
however, assumes that the TAMRA dye and additional lysine residue do not significantly alter
the cellular distribution properties of the original construct. Caution must be used in invoking
such an assumption because large dyes can significantly alter the localization properties of
metal-peptide conjugates.72 Preliminary organelle fractionation studies using cells treated with
the unlabeled Pt-MPP, however, do indicate a subtle increase in mitochondrial uptake of Pt as
measured by GFAAS, corroborating these fluorescence imaging studies.
The preliminary results of this investigation can be compared to those of another system,
where the anticancer, DNA-alkylating agent chlorambucil was attached to an MPP. 73 Like our
platinum conjugate, the chlorambucil-MPP construct exhibited good cytotoxicity in
chlorambucil-resistant cell lines. Additionally, the chlorambucil-MPP conjugate, in contrast to
Pt-MMP, was significantly more cytotoxic than the parent drug, chlorambucil, in all cell lines
tested. The lower toxicity of Pt-MPP compared to cisplatin most likely arises from slow ligand
substitution kinetics imparted by the p-diketonate ligand. It may be more appropriate to compare
the anticancer activity to [Pt(acac)(NH 3)2]*, which should have similar aquation and DNA-
binding kinetics. For this comparison, it is clear that attachment of the MPP leads to an increase
in activity, consistent with the chlorambucil-MPP studies.73
Work carried out by our collaborators in the University of Toronto has revealed some
additional interesting aspects of this construct. The polymerase chain reaction (PCR) was carried
out using mitochondrial and genomic DNA extracted from cells treated with Pt-MPP. Results of
this study indicate that Pt-MPP impedes PCR of mitochondrial DNA to a greater extent than
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genomic DNA in comparison to those from cisplatin-treated cells. Therefore, it appears that Pt-
MPP damages mitochondrial DNA more effectively than cisplatin. Additionally, cell cycle
analysis revealed that cisplatin arrests cells in the G2 phase, consistent with literature reports,74
whereas Pt-MPP leads to no alteration or arrest of the cell cycle. These results support the
hypothesis that Pt-MPP attacks a different target than cisplatin.
In summary, the conjugation of platinum anticancer compound to an MPP creates an
agent that is able to circumvent traditional cisplatin-resistance mechanisms, most likely by
interacting with a target different from genomic DNA. We demonstrated the utility of the
complex, [Pt(succac)(NH 3)2](NO3), for attachment to an MPP via standard solid-phase peptide
synthetic methods. A number of other CPPs can also conceivably used as well thus indicating
that [Pt(succac)(NH 3)2](NO 3) will have a greater utility for making novel anticancer platinum
compounds.
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Appendix C
Synthesis and Characterization of Several Novel Platinum
Complexes
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C.1. Introduction
In this final appendix, several novel platinum compounds that were synthesized and
characterized during the course of this thesis work are described. The structures of these
compounds, along with their abbreviated names, are shown in Chart C. 1.
Complexes with DCA Ligands. The first set of compounds presented here was inspired by
work in our lab on mitaplatin, cis,cis,trans-[Pt(NH3)2Cl2(DCA)2] where DCA = dichloroacetate.1
Like mitaplatin, the compounds presented here, cis-[Pt(NH 3)2(DCA)2] and cis-
[Pt(NH 3)2(DCA)4], are coordinated to DCA. DCA is an inhibitor of pyruvate dehydrogenase
kinase (PDK).2 A result of inhibition of PDK is the switching of the cancer cell metabolic
pathway from aerobic glycolysis, which occurs in the cytosol, (Warburg Effect) to oxidative
phosphorylation, which takes place in the mitochondria. This shift restores normal mitochondrial
function and decreases the mitochondrial membrane potential, allowing apoptosis-inducing
factors (ALFs) to escape this organelle and trigger apoptosis.3 ,4 Mitaplatin, a combination of
cisplatin and 2 equiv of DCA, exhibits selectivity for killing cancerous over non-cancerous cells
lines, presumably because of the ability of DCA to target the unique cancer metabolic pathway.
We were interested to determine whether cis-[Pt(NH3)2(DCA)2] and cis-[Pt(NH 3)2(DCA)4]
would display similar anticancer properties and set out to prepare them.
Using BIPhMe for Platinum Chemistry. The bidentate ligand 2,2'-bis(1-
methylimidazolyl)phenylmethoxymethane, or BIPhMe, was reported by our lab over 20 years
ago.5 Since then, this ligand has been used for the preparation of multinuclear Fe, Mn, and Zn
complexes. 5'6 The compound [Pt(BIPhMe)C 2] was pursued because related platinum(II)
bis(imidazole) complexes bind to nucleobases and exhibit in vitro anticancer activity.7 10 It was
hypothesized that [Pt(BIPhMe)Cl 2] might also have anticancer properties.
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Amide-Coupling to Functionalize Platinum(II) Complexes. The amide-coupling chemistry of
[Pt(edma)C 2] discussed in Chapter 3 was used to tether several biologically active molecules to
the platinum(II) core.
Nitroimidazoles are well known hypoxia-targeting and radio-sensitizing agents." These
agents undergo a 4-electron reduction selectively in hypoxic tissue to form electrophilic
hydroxylamines, which can alkylate DNA or other targets.12 Several platinum-nitroimidazole
complexes were previously reported.13~16 These constructs, however, contain a direct bond
between the nitrogen atom of the nitroimidazole and the platinum(II) center. This bond can
potentially disrupt functions of both the platinum(II) center and the nitroimidazole group. Here, a
nitroimidazole was attached remotely to the [Pt(edma)C12] core. The utility of this complex,
nitro-Pt, may lie in its ability, by virtue of the nitroimidazole group, to selectively target hypoxic
tumor tissue.
Nitrogen mustards comprise a well studied class of anticancer agents17 that operate by
forming interstrand DNA cross-links. Modified versions of the clinically used nitrogen
mustards, mustine and chlorambucil, were covalently attached to [Pt(edma)C12] via amide bond
coupling. The presence of both the platinum(II) unit, which forms primarily 1,2-intrastrand
DNA-cross-links, and the nitrogen mustards, which prefer to form interstrand cross-links, was
proposed to lead to a potent DNA-damaging cytotoxic agent.
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Chart C.1. Compounds presented in this appendix.
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C.2. Experimental Methods
Materials and Methods. The compounds, cis-[Pt(DMSO) 2Cl2],1 9 cis-[Pt(NH3 )2(OH)4 ],2 2-(2-
methyl-5-nitro-1H-imidazolyl)ethylamine dihydrochloride,2 1 , N1 ,N-bis(2-chloroethyl)propane-
1,3-diamine dihydrochloride,2 2  and 4-(3-aminopropyl)-NN-bis(2-chloroethyl)aniline
dihydrochloride,2 3 were prepared as previously reported. BIPhMe, synthesized by known
methods,5 was kindly provided by Mr. Eric Victor. Other materials and reagents were purchased
from commercial vendors and used as received. Solvents were analytical grade, but otherwise
not rigorously dry. Reactions were carried out under normal atmospheric conditions.
Physical Measurements. NMR spectra were acquired on a Bruker DPX-400 spectrometer in the
MIT Department of Chemistry Instrumentation Facility (DCIF). 1H and 13C NMR spectra were
referenced to residual protons or the carbon nucleus of the solvent, and signals are reported
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versus tetramethylsilane, Me 4Si (6 = 0). 195Pt NMR spectra were referenced externally to a
standard of K 2PtCl 4 in D20 (6 = -1628 ppm). For FTIR spectra, samples were prepared as KBr
disks and data were recorded with a ThermoNicolet Avatar 360 spectrophotometer running the
OMNIC software. Electrospray ionization mass spectrometry (ESI-MS) measurements were
acquired on an Agilent Technologies 1100 series LC-MSD trap. Elemental analyses were carried
out by a commercial analytical laboratory.
Synthesis of cis-[Pt(DCA)2(NH 3)21. A mixture of cisplatin (0.10 g, 0.33 mmol) and Ag2 SO 4
(0.10 g, 0.32 mmol) was suspended in 13 mL of distilled H2 0 and stirred for 12 h in the absence
of light. The resulting mixture was filtered through a pad of Celite on a glass frit to remove solid
AgCl and yield a colorless filtrate containing cis-[Pt(NH 3)2(H 2 0) 2](SO 4). An aqueous solution of
Ba(DCA)2, prepared by mixing Ba(OH) 2-8H 20 (0.10 g, 0.73 mmol) and dichloroacetic acid
(0.10 g, 0.78 mmol) in 2 mL of H20, was added dropwise with vigorous stirring. A white
precipitate, presumably insoluble BaSO 4, formed immediately, and the mixture was left to stir at
room temperature. After 3 h, the mixture was filtered, and the colorless filtrate was lyophilized to
yield an off-white powder (0.16 g, 99%). IR (KBr, cm-1): 3425 m sh, 3276 s br, 1660 vs, 1356 s,
1217 m, 819 m, 787 m, 738 m, 669 m. 1H NMR (400 MHz, DMSO-d6 with NaDCA added): 6
6.46 (2H, s), 4.79 (6H, br s). ESI-MS (neg. and pos. ion mode): m/z 356.9 ([M-DCA]*, calcd.
356.0), 612.8 ([M+DCA]-, calcd. 612.8).
Synthesis of cis-[Pt(DCA) 4(NH 3)2]. cis-[Pt(OH) 4(NH 3)2] (0.24 g, 0.80 mmol) was suspended in
10 mL of CH2 C12 . Dichloroacetic anhydride (0.96 g, 4.0 mmol) in 10 mL of CH 2Cl 2 was added,
and the mixture was stirred at room temperature for 1.5 h, resulting in the formation of a
homogeneous pale yellow solution. The CH2 Cl 2 was removed under reduced pressure to give a
thick yellow oil. Upon the addition of 25 mL of H 20 followed by vigorous stirring and
327
sonication, a white precipitate formed. The precipitate was collected by filtration and washed
with 5 mL of Et2O. Yield: 0.38 g, 63%. IR (KBr, cm-1): 3568 m, 3497 w, 3231 m br, 1679 vs,
1559 w, 1324 s, 1196 s, 953 m, 818 s, 783 m, 748 m, 673 w. 'H NMR (400 MHz, DMSO-d): 6
6.94 (6H, br s), 6.62 (2H, s), 6.53 (2H, s). 13 C{'H} NMR (100 MHz, DMSO-d): 6 169.8, 169.7,
66.6, 64.8. 195Pt{'H} NMR (86 MHz, DMSO-d): 6 2076. ESI-MS (neg. ion mode): m/z 739.0
([M-H]-, calcd. 738.7).
Synthesis of [Pt(BIPhMe)C 2]. To a suspension of cis-[Pt(DMSO)C 2] (0.118 g, 0.279 mmol)
in 2 mL MeOH, a solution of BIPhMe (80 mg, 0.28 mmol) in 1 mL of MeOH was added
dropwise. After stirring for 16 h at rt, the resulting suspension was filtered to collect the product
as a pale yellow solid. The material was washed with 2 x 3 mL MeOH and 2 x 3 mL diethyl
ether, prior to drying in vacuo. Yield: 134 mg, 88%. 1H NMR (400 MHz, DMF-d 7): 6 8.10 (d,
2H), 8.00 (d, 2H), 7.58 (t, 2H), 7.51 (d, 2H), 7.47 (t, 1H), 3.71 (s, 6H), 3.19 (s, 3H). 13C{H}
NMR (100 MHz, DMF-d 7): 6 140.1, 136.7, 129.5, 129.4, 126.8, 125.3, 124.7, 81.0, 53.1, 36.1.
195 Pt{H} NMR (86 MHz, DMF-d 7): 6 -2170. ESI-MS (pos. ion mode): m/z 570.9 ([M+Na]*,
calcd. 571.0), 1118.9 ([2M+Na]*, calcd. 1119.1).
Synthesis of Mustl-Pt. To a solution of [Pt(edma)C12] (300 mg, 0.781 mmol) in 6 mL of DMF
was added a solution of 1,1'-carbonyldiimidazole (131 mg, 0.809 mmol) in 6 mL of DMF. The
resulting mixture was stirred at 60 'C for 10 min and then sparged with N2. At room temperature,
a solution of N,N-bis(2-chloroethyl)propane-1,3-diamine dihydrochloride (220 mg, 0.809
mmol) in 9 mL of DMF was added in a dropwise manner. The resulting mixture was stirred at
room temperature for 16 h, and then concentrated to a volume of -3 mL under vacuum at 60 'C.
The concentrated solution was filtered through Celite, and the desired compound was
precipitated by the addition of 10 mL of H20. The pale yellow solid was collected by filtration
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and washed sequentially with 2 x 5 mL of water, 2 x 5 mL of ethanol, and 2 x 5 mL of diethyl
ether before being dried under vacuum. Yield: 148 mg (33%). 'H NMR (DMF-d 7, 400 MHz): 6
8.13 (t, 1H), 6.07 (br s, 1H), 5.47 (br s, 2H), 4.17 (d, 1H), 3.66 (t, 4H), 3.60 (dd, 1H), 3.27 (q,
2H), 3.30 (br m, 1H), 2.89 (t, 4H), 2.77 (br m, 2H), 2.66 (t, 2H), 2.50 (br m, 1H), 1.65 (in, 2H).
"'C{'H} NMR (DMF-d, 100 MHz): 6 168.0, 57.8, 56.4, 55.2, 52.0, 47.3, 42.8, 37.3, 27.7.
195 'H} NMR: 6 -2338. ESI-MS (MeOH, pos. ion mode): m/z 586.9 ([M+Na]*, calcd. 587.0),
1151.9 ([2M+Na]*, calcd. 1153.1 (100%), 1152.1 (99.7%)). Anal. Calcd. for CnlH 24Cl4N4OPt: C,
23.37; H, 4.28; N, 9.91. Found: C, 23.22; H, 4.20; N, 9.72.
Synthesis of Must2-Pt. To a solution of [Pt(edma)C12] (227 mg, 0.591 mmol) in 5 mL of DMF
was added a solution of 1,1 '-carbonyldiimidazole (101 mg, 0.62 mmol) in 5 mL of DMF. The
resulting mixture was stirred at 60 'C for 10 min and then sparged with N 2. At room temperature,
a solution of 4-(3-aminopropyl)-NN-bis(2-chloroethyl)aniline dihydrochloride (216 mg, 0.62
mmol) in 8 mL of DMF was added in a dropwise manner. The resulting mixture was stirred at
room temperature for 16 h, and then concentrated to a volume of -3 mL under vacuum at 60 'C.
The concentrated solution was filtered through Celite, and the desired compound was
precipitated by the addition of 10 mL of H20. The pale yellow solid was collected by filtration
and washed sequentially with 3 mL of water, 2 x 3 mL of ethanol, and 2 x 3 mL of diethyl ether
before being dried under vacuum. Yield: 237 mg (63%). 'H NMR (400 MHz, DMF-d): 6 8.19
(t, 1H), 7.11 (d, 2H), 6.75 (d, 2H), 6.09 (br s, 1H), 5.49 (br s, 2H), 4.19 (d, 1H), 3.78 (s, 8H),
3.64 (m, 1H), 3.22 (in, 2H), 3.05 (br m, 1H), 2.78-2.69 (br m, 2H), 2.57-2.53 (br m, 3H), 1.79-
1.72 (in, 2H). "C{'H} NMR (100 MHz, DMF-d): 6 168.0, 145.0, 130.1, 129.7, 112.5, 55.8,
55.25, 53.1, 47.3, 41.5, 38.9, 32.0, 31.7. 195Pt {H} NMR: 6 -2338. ESI-MS (pos. ion mode): m/z
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641.1 ([M+H]*, calcd. 641.1). Anal. Calcd. for C17H 28Cl 4N40Pt: C, 31.84; H, 4.40; N, 8.74.
Found: C, 32.09; H, 4.10; N, 8.71.
Synthesis of Nitro-Pt. To a solution of [Pt(edma)C12] (300 mg, 0.781 mmol) in 6 mL of DMF
was added a solution of 1,1.'-carbonyldiimidazole (128 mg, 0.790 mmol) in 6 mL of DMF. The
resulting mixture was stirred at 60 0 C for 10 min and then sparged with N 2. At room temperature,
a solution of 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylamine dihydrochloride (197 mg, 0.810
mmol) in 8 mL of DMF was added in a dropwise manner. The solution was concentrated to 6
mL under vacuum at 60 *C and then filtered. The addition of 14 mL of water precipitated the
desired compound as a pale yellow solid, which was collected by centrifugation and washed
sequentially with 5 mL of H 20, 2 x 5 mL of ethanol, and 2 x 5 mL of diethyl ether, before being
dried under vacuum. Yield: 220 mg (53%). 1H NMR (DMF-d7 , 400 MHz): 6 8.45 (t, 1H), 8.00
(s, 1H), 6.06 (br s, 1H), 5.45 (br s, 2H), 4.56-4.42 (m, 2H), 4.18 (d, 1H), 3.77 (m, 1H), 3.60-3.50
(m, 1H), 2.90 (br m, 1H), 2.69 (br m, 2H), 2.51 (s, 3H), 2.37 (br m, 1H). "C{ 1H} NMR (DMF-
d7, 100 MHz): 6 168.9, 151.9, 139.3, 133.3, 57.8, 54.9, 47.3, 45.9, 38.6, 13.9. 195Pt{ 1H} NMR: 6
-2343. ESI-MS (MeOH, pos. ion mode): m/z 558.9 ([M+Na]*, calcd. 559.0), 1094.8 ([2M+Na]*,
calcd. 1095.1). Anal. Calcd. for CioH18Cl2N60 3Pt: C, 22.40; H, 3.38; N, 15.67. Found: C, 22.58;
H, 3.42; N, 15.46.
X-Ray Crystallography. Single crystals were mounted in Paratone oil on a cryoloop and frozen
under a 110 K KRYO-FLEX nitrogen cold stream. Data were collected on a Bruker APEX CCD
X-ray diffractometer with graphite-monochromated Mo-Ka radiation (X = 0.71073 A) controlled
by APEX2 software package. 24 Empirical absorption corrections were applied using SADABS. 25
The structures were solved using either direct methods or Patterson methods and refined on F2
26,27using the SHELXTL-97 software package. Structures were checked for higher symmetry
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using PLA TON.2 8 All non-hydrogen atoms were located and refined anisotropically. In general,
hydrogen atoms were placed in idealized locations and given isotropic thermal parameters
equivalent to either 1.5 (NH3 protons) or 1.2 times the thermal parameter of the atom to which
they are attached. X-ray crystallographic data collection and refinement parameters are collected
in Table C.1.
A water molecule crystallized in the lattice with cis-[Pt(NH 3)2(DCA)2]. The hydrogen
atoms were located on the map and refined semi-freely with constraints on the O-H distances
and hydrogen atom thermal displacement parameters. The hydrogen atoms of the ammonia
ligands were also found and refined in a similar manner. A water molecule was also present in
the lattice with [Pt(BIPhMe)Cl 2]. The hydrogen atoms, however, could not be discerned from the
difference Fourier map and were therefore omitted from the final model. The inability to find
these hydrogen atoms is somewhat consistent with the apparent lack of hydrogen bonds, which
might give long-range crystallographic order and directionality of the water molecule, within the
crystal lattice.
Two molecules of cis-[Pt(NH 3)2(DCA)4] crystallized in the asymmetric unit along with
one molecule of water. The hydrogen atoms of the water molecules were located and refined as
described above. Two DCA ligands of one complex and three of the other one in the asymmetric
unit exhibited significant orientational disorder, primarily involving the chlorine atoms. The
refinement of this disorder was aided by similarity restraints of the interatomic distances and
angles of the disordered components. The directionality and magnitude of the thermal
displacement parameters of these disordered ligands were also restrained. Despite these efforts to
satisfactorily refine the disorder, the final model contained several chlorine and carbon atoms
with ellipsoids that were abnormally large or oblate, resulting in the generation of several Level
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A, B, and C CheckCIF alerts. Additionally, four solvent-accessible voids with unidentifiable
residual electron density remained in the unit cell on the 4 site symmetry special positions. The
SQUEEZE algorithm of PLATON 2 8 was employed to account for this diffuse electron density.
Each of these voids was 174 A3 in volume and contained density equivalent to 55 electrons. This
density is proposed to arise from 5.5 disordered water molecules.
Table C.1. X-Ray Crystallographic Data Collection and Refinement Parameters for cis-
[Pt(NH3)2(DCA)2]-H 20, cis-[Pt(NH3)2(DCA)4]-6H 20, and [Pt(BIPhMe)Cl 2]-H 20.
cis- cis-[Pt(NH 3)2(DCA)4]-6H 20 Pt(BIPhMe)Cl 2]-H20.
[Pt(NH 3)2(DCA)2].H20
formula C4HioC14N20 5Pt C8H1 1C18N 20s.5oPt C16HI8Cl2N40 2Pt
fw 503.03 749.88 564.33
space group Pi I41/a P2 12121
a, A 6.7906(11) 25.2649(5) 10.8521(5)
b, A 9.4294(15) 12.4965(6)
c, A 11.1410(18) 27.8478(11) 13.3279(6)
a, deg 68.628(2)
p, deg 75.903(2)
y, deg 72.458(2)
V, A 3  626.20(17) 17775.7(9) 1807.44(15)
Z 2 32 4
pcalcd, g-cm-3 2.668 2.242 2.074
T, 0C -163(2) -163(2) -173(2)
p(Mo Ka), mml' 12.062 7.316 8.077
0 range, deg 1.99-26.37 1.61 -28.70 2.23 -29.66
total no. of data 11439 187020 37973
no. of unique data 2567 11496 5073
no. of parameters 169 655 230
completeness to 99.9 100.0 99.8
E) (%)
RI"(a%) 1.42 3.19 1.67
wR2 (%) 3.51 7.09 3.24
Rla (%) for I > 1.39 2.80 1.56
2(y
wR2a (%) for I > 3.50 6.88 3.20
2a
GOF 1.173 1.031 1.039
max, min peaks, 1.126, -0.756 2.884, -2.100 0.458, -0.609
e-A 3
Flack parameter 
-0.014(4)
RI = EIFoI - IFcII/IFoI. cwR2 = {E~w(F02 -F 2)2]/[w(Fo2 )2]}. C GOF = {E[w(F.2 - Fe )2]/(n
-p)}/2 where n is the number of data and p is the number of refined parameters.
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C.3. Results and Discussion
New Analogues of Mitaplatin. The platinum(II) version of mitaplatin, cis-[Pt(NH 3)2(DCA)2],
was prepared using methods that are well established for the synthesis of cis-
diam(m)inedicarboxylatoplatinum(II) complexes. 29 Briefly, cis-[Pt(NH 3)2(OH)2](SO 4), obtained
in situ from cisplatin and Ag2 SO 4 in water, was treated with Ba(DCA)2, formed from
Ba(OH)2 8H 20 and dichloroacetic acid. Insoluble BaSO 4 results and the water-soluble product
can be recovered by removal of the solvent after filtration.
Lyophilization was necessary because rotary evaporation at 60 'C decomposed the
material, giving insoluble platinum black. Additionally, there were occasional instances in which
lyophilization of the filtrate gave a pale-green powder with the strong smell of dichloroacetic
acid. Because of this olfactory clue, it is believed that a certain amount of decomposition
occurred due to the presence of excess acid. The green color could also possibly arise from
photoreduced Ag, carried over from the first step of the reaction. Samples of cis-
[Pt(NH 3)2(DCA)2] prepared in this manner are consistently contaminated with free DCA,
possibly as the counterion of residual Ba2+ ions. Because of the high solubility of cis-
[Pt(NH 3)2(DCA) 2] in most polar solvents, attempts to remove excess DCA by washing with
water or alcohols resulted in dissolution of most of the product. Hence, the preparation of this
compound still needs optimization. The 1H NMR spectrum in DMSO-d indicates the presence of
two species in solution in addition to residual DCA; a major peak at 6.48 ppm and a minor one at
6.28, both sharp singlets. The addition of excess NaDCA, however, leads to the disappearance of
the minor peak and an increase in the major one. Therefore, it is proposed that cis-
[Pt(NH 3)2(DCA)2] is in equilibrium with its monosolvated form, cis-[Pt(NH3)2(DMSO)(DCA)]*.
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The addition of excess DCA can shift this equilibrium to cis-[Pt(NH 3)2(DCA)2 ], as observed by
1H NMR spectroscopy.
The solid-state molecular structure of cis-[Pt(NH3)2(DCA)2], shown in Figure C.1,
reveals the expected square-planar coordination geometry that is characteristic of platinum(II)
complexes. A molecule of water is also present in the crystal lattice. The orientations of the
carbonyl groups of the DCA ligands are nearly perpendicular to the coordination plane, obviating
any intramolecular hydrogen bonding with the coordinated ammine ligands. Instead, they form
hydrogen bonds with the water molecule and the ammine ligands of neighboring complexes in
the lattice.
C4
C13
03 N1
Ptl
01
01 N2
Figure C.1. Solid-state molecular structure of cis-[Pt(NH 3)2(DCA)2]. Ellipsoids are drawn at the
50% probability level. The water molecule in the asymmetric unit is omitted for clarity. Selected
distances (A) and angles (*): Ptl-Ol, 2.036(2); Ptl-03, 2.0309(19); Ptl-N1, 2.013(2); Ptl-N2,
2.040(3); 01-Ptl-03, 87.04(8); N1-Ptl-N2, 90.46(11); 01-Ptl-N2, 93.56(10); 03-Ptl-N1,
88.73(9).
The preparation of the tetrakis(DCA) complex, cis-[Pt(NH3)2(DCA)4], was accomplished
by treating cis-[Pt(NH 3)2(OH)4] with an excess of dichloroacetic anhydride in CH 2Cl 2 . After an
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hour, the suspension of cis-[Pt(NH 3)2(OH)4] converts to a homogeneous solution, signaling
completion of the reaction. This general protocol for the preparation of cis-
diamminetetracarboxylatoplatinum(IV) complexes is previously reported. 30 ,1  1H NMR
spectroscopy of the complex is consistent with the presence of two inequivalent (axial and
equatorial) DCA ligands that resonate at 6.62 and 6.53 ppm. The 195Pt NMR spectrum reveals a
single resonance at 2076 ppm, consistent with the formulation of the complex as a Pt(IV) species
with an N2 0 4 coordination sphere.
The solid-state molecular structure of cis-[Pt(NH 3)2(DCA)4] is shown in Figure C.2. Only
one of the molecules that is present in the asymmetric unit is shown. Both molecules in the
asymmetric unit exhibited conformational disorder of the DCA ligands, giving rise to some
poorly behaved thermal ellipsoids. The immediate coordination sphere of the platinum(IV)
center, however, is not directly involved in this disorder. The structure reveals the expected
octahedral geometry that is characteristic for complexes of platinum(IV). The ammine ligands
are arranged in a cis orientation, indicating that the stereochemistry of the starting material, cis-
[Pt(NH 3)2(OH) 4], is retained.
335
Figure C.2. Solid-state molecular structure of cis-[Pt(NH 3)2(DCA)4]. Only one molecule in the
asymmetric unit is shown. Only major components of the disordered DCA ligands are shown.
Green, red, and grey ellipsoids correspond to chlorine, oxygen, and carbon atoms respectively.
Ellipsoids are drawn at the 50% probability level. Selected distances (A) and angles (0): Ptl-O1,
2.018(3); Ptl-03, 2.023(3); Ptl-05, 2.003(3); Ptl-07, 1.998(3); Ptl-N1, 2.034(3); Ptl-N2,
2.025(3); N1-Ptl-N2, 88.46(13); 01-Ptl-03, 83.05(10); 05-Ptl-07, 169.68(11).
Preparation of [Pt(BIPhMe)C 21. The synthesis of [Pt(BIPhMe)Cl 2] was accomplished by the
treatment of cis-[Pt(DMSO) 2Cl2] with BIPhMe in MeOH. This protocol is analogous to that
described in Chapter 2 for the preparation of dichloroplatinum(II) complexes of modified di-2-
pyridylmethane ligands. The 1H NMR spectrum of [Pt(BIPhMe)C12] indicates that the complex
has Cs symmetry in solution. Even though the BIPhMe ligand forms a six-membered chelate ring
and the substituents on the bridgehead carbon atom are inequivalent, only one conformational
isomer is observed in DMF-d 7 at room temperature. This result is in contrast to that for the di-2-
pyridylmethane complexes described in Chapter 2, for which both exo and endo conformers
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were detected under similar conditions. The 195Pt NMR shift of [Pt(BIPhMe)C 2] is -2170 ppm,
similar to those observed for the complexes of Chapter 2, which range from -2057 to -2199
ppm.
The structure of [Pt(BIPhMe)Cl 2] is shown in Figure C.3. A notable difference between
this structure and those of the di-2-pyridylmethane complexes is the greater planarity of the
chelate ring. The average root-mean-square deviation (RMSD) of the atoms comprising this ring
and from the best-fit plane is 0.153 A for [Pt(BIPhMe)Cl 2]. For [Pt(Ts-dpm)C 2] and [Pt(Ds-
dpm)C12), these values are 0.341 and 0.358 A, respectively. The larger values for the dpm
compounds arise from the distorted boat-like conformation of the chelate ring. The greater
planarity observed for [Pt(BIPhMe)C12] may explain the inability to detect the conformational
exo and endo isomers.
c N2
N1
Pt1
C12
Figure C.3. Solid-state molecular structure of [Pt(BIPhMe)Cl 2]. Ellipsoids are drawn at the 50%
probability level. A water molecule in the asymmetric unit is omitted for clarity. Selected
distances (A) and angles (*): Ptl-Cll, 2.3078(7); Ptl-C12, 2.2977(7); Ptl-N1, 2.010(2); Ptl-N2,
2.010(2); Cll-Ptl-Cl2, 88.70(2); N1-Ptl-N2, 88.29(8); Cll-Ptl-N1, 92.25(6); C12-Ptl-N2,
90.92(6).
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Nitroimidazole- and Nitrogen Mustard-Platinum Conjugates. The amide-coupling chemistry
described in Chapter 3 was used to attach a nitroimidazole group and two different nitrogen
mustards to a diaminedichloroplatinum(II) core. The synthetic protocol was essentially
unchanged from that described in Chapter 3, demonstrating the scope of this reaction.
Furthermore, all compounds were obtained as analytically pure material, suitable for biological
studies. Preliminary cytotoxicity assays with mustl-Pt and must2-Pt revealed approximate IC50
values of 80 and 2 tM, respectively, in HeLa cells. Because of solubility issues, however, DMF
was used as a cosolvent, and dose-response curves never reached concentrations that completely
killed all cells. Hence, this assay needs to be repeated. The nitroimidazole complex was not
tested because our lab does not currently have an established protocol for culturing cells under
hypoxic conditions. The hypoxia-targeting properties of the nitroimidazole, therefore, could not
be assessed. A potential pitfall of these and related compounds is the modification of the non-
leaving group ligands, which may negatively affect the DNA-binding properties of the
complexes. The use of succinylacetone as a leaving group, as described in Appendix B, may
provide a more favorable method to make functionalized platinum complexes.
C.4. Summary
The synthesis and characterization of several new platinum complexes are reported. The
Pt-DCA complexes represent new additions to a growing class of dual-threat platinum anticancer
agents. [Pt(BIPhMe)Cl 2] is the first platinum complex bearing the BIPhMe ligand. Nitro-Pt,
mustl-Pt, and must2-Pt illustrate the utility of the amide-coupling chemistry described in
Chapter 3 for the preparation of novel bifunctional platinum anticancer agents.
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